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The expression and role of KLF4 in psoriasis
K Kim, H Kim and J Yoon Department of Dermatology, Hallym University Sacred Heart
Hospital, Anyang, Republic of Korea
Krüppel-like factor 4 (KLF4) is a transcription factor that regulate a diverse array of cellular processes,
including development, differentiation, proliferation and apoptosis. The role of its function regard-
ing keratinocytes has been widely studied, yet its exact role or function has not been elucidated.
The objective of the study was to investigate the epidermal expression level of KLF4 in normal healthy
donor skin and psoriatic lesional and non-lesional skin, and determine its roles of KLF4 in psoria-
sis. We compared the epidermal expression level of KLF4 in normal healthy donor skin and psori-
atic lesional and non-lesional skin immunohistochemically and measured the epidermal level of
KLF4 with RT-PCR. We also performed epidermal proliferation after knocking down of KLF4, using
siRNA to evaluate the growth of keratinocyte in HaCaT cells. The entire epidermis, especially the
suprabasal layer of the psoriatic epidermis showed increased KLF4 expression compared to the
normal, non-lesional skin. After treatment, the expression level in the suprabasal layer of the pso-
riasis skin was decreased. The epidermal level of KLF4, as measured by RT-PCR, was increased after
the treatment of the psoriasis skin and the proliferation of HaCaT cells was changed by knocking-
down the KLF4 mRNA. In conclusion, these data demonstrates that KLF4 can be an important reg-
ulator in epidermal proliferation and can be associated with epidermal proliferation disorders, includ-
ing psoriasis.
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Inflammatory gammadelta T cells collaborate with Th17 cells to maintain psoriasiform der-
matitis in the CD18hypo PL/J mouse model
MV Gatzka,1 H Hainzl,1 T Peters,1 K Singh,1 A Tasdogan,2 M Wlaschek1 and K Scharffetter-
Kochanek1 1 Dept. of Dermatology and Allergic Diseases, Ulm University, Ulm, Germany and
2 Dept. of Immunology, Ulm University, Ulm, Germany
Background: The contribution of Interleukin-17 (IL-17) to the pathogenesis of psoriasis is substan-
tiated by the clinical efficacy of antibodies against the common IL-12/IL-23 subunit p40, like Ustek-
inumab, suppressing IL-17 and Th1 cytokine production. To further address the significance of IL-
17 producing T cell subsets in psoriasis, CD18hypo PL/J mice, developing a psoriasiform dermatitis
at 12-14 weeks of age as a consequence of reduced expression of CD18/β2 integrin to 2-16 % of
wildtype levels, were systematically analyzed for the presence of gammadelta and CD4+ T cell
subsets in blood, lymphnodes and skin and the effect of blocking different targets within the IL-23/IL-
17 axis. Results: Severity of CD18hypo PL/J psoriasiform dermatitis generally correlated with a loss
of skin-resident Vγ5+ T cells and concurrent skin infiltration with inflammatory γδTCR-low express-
ing Vγ4+ and Vγ6+ T cells preceded by an increase of IL-23R+ Vγ4+ T cells in local lymphnodes in
this psoriasis mouse model. Both, γδ T cells and Th17 cells contributed to IL-17 production in situ
and in in vitro restimulation experiments. Injection of diseased CD18hypo PL/J mice with anti-γδTCR-
, -IL-17, and -IL-23 antibodies resulted in an almost complete resolution of skin inflammation and
eliminated pathological Vγ4+ T cells. In peripheral blood and skin sections from psoriasis patients,
we observed a variable increase in IL-17+ gammadelta T cells that correlated with a reduction of
CD18 levels compared to age-matched healthy subjects. Conclusion: These results for the first time
demonstrate a critical role of skin-infiltrating inflammatory gammadelta T cells in a complex psori-
asis model as well as a role for wildtype CD18 expression levels in suppression of pathological gam-
madelta T cells and suggest the need for individualized therapy of psoriasis patients depending on
the skin infiltrate.
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Blocking von Willebrand factor (VWF) attenuates cutaneous immune-complex (IC)-vasculi-
tis
C Hillgruber,1 AK Steingräber,1 B Pöppelmann,1 SW Schneider2 and T Goerge1 1 Dept. of
Dermatology, University of Münster, Münster, Germany and 2 Dept. of Dermatology,
University of Heidelberg, Mannheim, Germany
Von Willebrand factor (VWF), a key player in hemostasis, is increasingly recognised as a pro-inflam-
matory protein. Here, we found a massive accumulation of VWF in skin biopsies of patients suffer-
ing from immune-complex (IC)-mediated vasculitis (ICV). To clarify the role of VWF in IC-mediated
inflammation, we induced experimental ICV either in mice treated with VWF-blocking antibodies
or in VWF–/– mice. Interference with VWF led to a significant inhibition of the cutaneous inflam-
matory response. We confirmed the major findings in irritative contact dermatitis, a second model
of cutaneous inflammation. In vivo imaging of cutaneous inflammation in the dorsal skinfold cham-
ber revealed unaffected leukocyte rolling upon anti-VWF treatment. However, we identified that
reduced leukocyte recruitment is accompanied by reduced vascular permeability. While VWF-medi-
ated neutrophil recruitment to the peritoneum was described to require the VWF-receptor on platelets
(GPIbα), the VWF-GPIbα axis was dispensable for cutaneous inflammation. As assessed in tail bleed-
ing assays we could exclude interference of VWF-blockade with hemostasis. Of particular impor-
tance, anti-VWF treatment was effective both in prophylactic and therapeutic administration. Thus,
VWF represents a promising target for the treatment of ongoing IC-mediated inflammation as e.g.
in rheumatoid arthritis or leukocytoclastic vasculitis.
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Autoimmunity against epidermal antigen by Th17 cells induces psoriasis-like skin inflamma-
tion
S Nishimoto,1,2 H Takahashi,2 M Amagai2 and A Yoshimura1 1 Department of Microbiology and
Immunology, Keio University School of Medicine, Tokyo, Japan and 2 Department of
Dermatology, Keio University School of Medicine, Tokyo, Japan
Psoriasis is a chronic inflammatory skin disease, in which IL-23/IL-17 axis is critical in the
immunopathogenesis. Although psoriasis has been considered as an autoimmune disease, the direct
evidence for its autoimmunity is missing. Moreover, it is unknown what kind of skin pathology can
be induced by autoreactive T cells with Th17 phenotype when they attack the skin. Here we show
that Th17-type autoimmune response against physiological epidermal antigen induces psoriasis-like
skin inflammation. To obtain autoreactive CD4+T cells against epidermal antigen, we utilized
desmoglein 3-specific T cell receptor transgenic (Dsg3H1) mouse, then polarized them into Th17
cells with IL-6, IL-23 and TGF-β or Th1 cells with IL-12 in vitro. When they were adaptively trans-
ferred into Rag2-/- mice, the recipient mice with Th17- Dsg3H1 T cells developed dermatitis with
scale on their ear and tail. The histological examination of the lesional skin revealed that acantho-
sis, parakeratosis and neutrophilic infiltration in the epidermis and dermis resembling a histopathol-
ogy of psoriasis. These pathologies were not observed when Th1- Dsg3H1 T cells, or wt Th17 T cells
were transferred. Furthermore, the mRNA of neutrophil-attractive chemokines (CXCL1, 2, 3, 5), pso-
riasis related cytokines (IL-1β, TNF-α, IL-23, IL-36) and S100a8, S100a9, which were characteristi-
cally high in psoriasis skin, were significantly up-regulated in the skin of mice transferred with Th17-
Dsg3H1 T cells. Because IFN-γ producing T cell populations emerged from the transferred Th17-
Dsg3H1 T cells at D14, we further explored critical cytokines contributing to the psoriasis-like phe-
notype. IFN-γ-/- Dsg3H1 Th17 cells induced the phenotype, whereas anti-IL-17 or IL-12/23 p40
blocking antibody diminished the pathology, indicating that Th17 type cytokines, but not IFN-γ, are
essential. These results demonstrated that cutaneous psoriasis-like immunopathology can be induced
by Th17 T cells self-reactive to epidermal antigens.
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IL-17 expression in dermatitis herpetiformis and bullous pemphigoid
A Zebrowska,1 M Wagrowska-Danilewicz,2 M Danilewicz,2 O Stasikowska-Kanicka,2 A Cynkier,1
A Sysa-Jedrzejowska1 and E Waszczykowska1 1 Department of Dermatology and Venereology,
Medical University of Lodz, Lodz, Poland and 2 Laboratory of Nephropathology, Medical
University of Lodz, Lodz, Poland
Dermatitis herpetiformis (DH) and bullous pemphigoid (BP) are skin diseases associated with
eosinophilc and neutrophilic infiltrations. Although cytokines are critical for the selective attraction
and activation of various leukocyte subsets in the inflammatory process, there are single findings
concerning concentration of IL-17 in autoimmune bullous disease. Skin biopsies were taken from
10 patients with DH, 14 with BP and from 10 healthy subjects. The localization and expression of
IL-17 in skin lesions and perilesional skin was studied by immunohistochemistry. Moreover the
serum concentration of IL-17 was measured by immunoassays. Expression of IL-17 in the epider-
mis and in inflammatory influxed cells in dermis was detected in skin biopsies from BP and DH
patients. Expression of IL-17 was statistically higher in epidermis and infiltration cells in specimens
from BP patients than DH patients. Examined interleukin expression was detected in perilesional
skin of all BP patients but it was much lower than in lesional skin. The expression of examined IL-
17 was not observed in biopsies from healthy people. Serum level of IL-17 was statistically higher
in BP and DH groups as compared to control group. Our results provide the evidence that IL-17
may play an essential role in activating and recruiting eosinophils and neutrophils, which ultimately
contribute to the tissue damage in DH and BP. Our data suggest that the IL-17 pattern expression
directly contributes to the cellular infiltration in DH and BP.
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Tofacitinib has no clinically significant effects on cells controlling chronic viral infection and
reactivation
F Valenzuela,1 KA Papp,2 D Pariser,3 S Tyring,4 R Wolk,5 M Buonanno5 and H Valdez5 1 University
of Chile, Santiago, Chile, 2 Clinical Res. Inc. and Probity Medical Res. Inc, Waterloo, ON,
Canada, 3 Pariserderm, Norfolk, VA, 4 CCS, Webster, TX and 5 Pfizer Inc, Groton, CT
Systemic psoriasis therapies have been associated with viral reactivation (eg CMV, zoster, PML). To
evaluate the effects of tofacitinib on lymphocyte subpopulations, and CMV and EBV viral loads (VL),
T cell subpopulations and VL were prospectively examined in a Phase 2b, 12-week study. In a dou-
ble-blind randomized controlled trial, the effects of tofacitinib 2, 5, and 15 mg BID on T helper
(CD4+), T cytotoxic (CD8+), B (CD19+), and NK (CD16/56+) lymphocyte counts and serial CMV
and EBV VL were compared with placebo in patients with moderate to severe chronic plaque pso-
riasis. 197 patients participated (49 in each tofacitinib arm; 50 in the placebo arm). Most patients
were male (63%), mean age 44 years and mean baseline PASI score was 21. After 12 weeks of
treatment, 25, 41, 67, and 2% of patients in the 2, 5, 15 mg BID and placebo arm, respectively,
achieved a PASI75 response. At Week 12 there was a dose-dependent decrease in median NK cells
in the tofacitinib arms (-27, -24, and -52 cells/mm3) and an increase in median number of B cells
(+51, +65, +89 cells/mm3). There was no change in CD8+ T cells. An initial increase at Week 4 in
CD4+ T cells in the tofacitinib arms (+36, +86, +129 cells/mm3) returned towards baseline at Week
12. Median (Q25, Q75) CMV VL was 0 (0,0) at baseline with no change observed through Week
12 in any group. Baseline EBV VL was 0 (0, 0.95), 0 (0, 1), 0 (0, 0.85), 0 (0, 1.3) in the 2, 5, 15 mg
BID and placebo arm. Median changes through Week 12 were 0 (0, 1.25), 0 (0, 0.6), 0.7 (0, 0.9),
and 0 (-1.1, 0). For CMV, 11, 7, 34, and 4% of patients with an undetectable VL at baseline had a
detectable VL on follow-up. For EBV, these values were 44, 20, 48, and 23% in the tofacitinib 2, 5,
15 mg BID and placebo arm. To facitinib was associated with dose-dependent decreases in NK
cells and increases in B cells. No meaningful change occurred in T lymphocytes (CD4+ or CD8+)
and EBV or CMV VL.
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Analysis on spatio-temporal distribution of platelets in cutaneous inflamed sites of mouse
contact dermatitis
J Daito,1 Y Harada,2 R Tamagawa-Mineoka,1 P Dai,2 T Takamatsu2 and N Katoh1 1 Department of
Dermatology, Kyoto Prefectural University of Medicine, Kyoto, Japan and 2 Department of
Pathology and Cell Regulation, Kyoto Prefectural University of Medicine, Kyoto, Japan
Platelets have an important role in skin inflammation as well as hemostasis and thrombosis. We
have recently reported that activated platelets induce leukocyte recruitment into the dermis by form-
ing platelet-leukocyte aggregates via P-selectin in cutaneous inflammatory reaction. However, pre-
cise behaviors of platelets in cutaneous inflamed sites have not been verified. The purpose of our
study was to examine spatio-temporal distribution of platelets in cutaneous inflamed sites of murine
contact dermatitis. We performed immunohistochemical study and in vitro imaging to reveal the
kinetics of platelets and leukocytes in murine model of hapten-induced contact dermatitis. Platelets
increased and adhered to leukocytes within the vessels at 4 hr after elicitation. Both CD62P and
PF4 were expressed on the surface of platelets at 4 hr. After 8 hr from challenge, shattered CD41-
positive platelets were observed both within and outside vessels. At 24 hr, many leukocytes were
surrounded by shattered CD41-positive platelets. CD62P and PF4 were not expressed on shattered
CD41-positive platelets at 24 hr. The number of leukocytes attached by CD41-positive platelets was
most increased at 8 hours and the cells attached by CD41-positive platelets were increased outside
vessels as the time passed. In vitro imaging showed that activated platelets attached to the leuko-
cytes and surrounded their cell membranes. We conclude that platelets adhere with leukocytes in
the vessels and are phagocytosed by leukocytes during extravasation.
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Decreased expression of IL-17 pathway genes in blood in patients with plaque psoriasis treated
with the anti-IL-17A monoclonal antibody, ixekizumab
JG Krueger,1 ER Dow,2 E Nantz,2 WJ Komocsar,2 P Banerjee,2 C Leonardi,3 GS Cameron,2
S Banerjee2 and RW Hoffman2 1 The Rockefeller University, New York, NY, 2 Eli Lilly &
Company, Indianapolis, IN and 3 St. Louis University School of Medicine, St. Louis, MO
Changes in expression of IL-17 pathway genes in whole blood mRNA after treatment of patients
with plaque psoriasis with the anti-IL-17A monoclonal antibody, ixekizumab, were investigated in
a small Phase 1 mechanism of action study and in a larger Phase 2 study (1, 2). Analysis in 40 patients
randomized in the double-blind placebo-controlled Phase 1 study demonstrated significant decreases
in blood mRNA expression for the IL-17 pathway genes: neutrophil gelatinase associated lipocalin
(N-GAL) (p<0.0005), IL-17 receptor subunit A (IL-17RA) (p<0.005), and matrix metallopeptidase 9
(MMP9) (p<0.06) with ixekizumab treatment but not with placebo. In the 142 subjects randomized
in the double-blind placebo-controlled Phase 2 study (2), changes in blood mRNA expression with
ixekizumab treatment replicated those observed in the Phase 1 study: N-GAL (p<5.0e-5), IL-17RA
(p<5.0e-6), and MMP9 (p<5.0e-6). There were no statistically significant changes in circulating white
blood cell or neutrophil numbers with respect to gene expression or treatment. Also, lymphocyte
and neutrophil-specific mRNA did not broadly correlate with treatment response. Thus, significant
specific decreases in blood mRNA expression of key IL-17 pathway genes, N-GAL, IL-17RA, and
MMP9, were observed after ixekizumab treatment in both studies and further confirmed in the sec-
ond randomized, placebo-controlled trial. Ongoing and future flow cytometric studies may deter-
mine if circulating cell subsets can be identified as potential sources of these mRNA transcripts and
help explain the molecular mechanisms underlying these findings. Finally, regardless of their cel-
lular source, these mRNA biomarkers may serve, individually or in combination, as useful bio-
markers for measuring response to treatment with ixekizumab.
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Germline autoreactivity of VH1-46 antibodies to desmoglein 3 may explain their predomi-
nance in pemphigus vulgaris
MJ Cho,1 AS Lo,3 EJ Choi,1 AR Nagler,1 X Mao,1 CB Rubin,1 MR Posner,2 LA Cavacini3 and
AS Payne1 1 Univ. of Pennsylvania, Philadelphia, PA, 2 Mt. Sinai School of Med., New York,
NY and 3 Harvard Med. School, Boston, MA
Pemphigus vulgaris (PV) is a potentially fatal blistering disease caused by autoantibodies (autoAbs)
to desmoglein 3 (Dsg3). A better understanding of how autoAbs develop could improve PV ther-
apy by more specifically targeting the pathogenic autoAbs or the cells that produce them. Toward
this end, we cloned human anti-Dsg3 Abs (scFv or IgG) from four PV patients using phage display
(n=2) or heterohybridoma (n=2) technologies. We identified VH1-46 anti-Dsg3 Abs from all 4 patients,
comprising 5 unique heavy chain complementarity determining region (CDR) 3 sequences. No VH1-
46 anti-Dsg Abs were identified in a phage display library from an unaffected individual. All 5 Abs
caused suprabasal blisters in human skin explants. F706 IgG4 and F779 IgG1 bound epitopes in
the Dsg3 EC1 domain, while 3.2, 4.2, and PVE4-8 scFv bound Dsg3 EC3. Expression of mono-
clonal variable regions as scFv, IgG1, and/or IgG4 did not affect epitope specificity. Surprisingly,
most VH1-46 Abs did not show evidence of antigen-driven positive selection by focused binomial
testing of replacement to silent mutation patterns. To determine if somatic mutations are required
for Dsg3 binding, we reverted mutated Abs to their germline (GL) amino acid sequences. 4.2 GL
and PVE4-8 GL still bound Dsg3 by ELISA and immunofluorescence, with approximately 25-fold
decrease in relative affinity. Analysis of mutation patterns in F706 GL and F779 GL, which lost
Dsg3 binding, revealed homologous acidic amino acid CDR mutations. Site-directed mutagenesis
indicated that these CDR1-2 acidic amino acid mutations are necessary and sufficient for Dsg3 bind-
ing. Our data indicate that VH1-46 autoAb gene usage is predominant in PV, which may be due to
germline autoreactivity of some VH1-46 Abs and/or acidic amino acid mutations in the CDRs that
confer Dsg3 binding. Additionally, somatic mutation patterns suggest that pathogenic Abs may
mature through an extrafollicular plasmablast pathway.
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The total antioxidant capacity in pemphigus vulgaris patients is decreased compared to healthy
controls and bullous pemphigoid patients
AA Shah, K Seiffert-Sinha and AA Sinha Dermatology, University at Buffalo and Roswell Park
Cancer Institute, Buffalo, NY
Excessive oxidative stress (oxidant/antioxidant imbalance) has been increasingly recognized as a
potential triggering factor in autoimmunity. This may be particularly relevant in the skin, which is
constantly exposed to both physical and chemical elements, exogenously (stress, pollutants, UV
light) and endogenously (infections, inflammation). Pemphigus vulgaris (PV) is a potentially life
threatening autoimmune blistering skin disease whose exact etiology is not known. While genetic
factors and immune disturbances are relevant to disease development, the role of environmental
factors, including oxidative stress, has been largely unexplored. In this study, we evaluated the total
antioxidant capacity (TAC) in PV patients compared to healthy controls and bullous Pemphigoid
(BP) subjects. Serum was obtained from 47 PV patients, 25 controls, and 18 BP patients and tested
for TAC by ELISA. We found a statistically significant decrease in TAC when comparing all PV patients
vs. all controls (p<0.001) and vs. all BP patients (p<0.001). These results were confirmed after age/sex-
matching in PV vs. controls (n=40; p<0.01) and PV vs. BP (n=36; p<0.001). Furthermore, PV patients
with active disease had significantly lower TAC than age/sex-matched PV patients in remission (n=18;
p<0.05), and PV patients in remission had significantly lower TAC than age/sex-matched control
subjects (n=34; p<0.01). We found no significant differences in TAC comparing PV patient sub-
groups classified based on flare status, therapy regimen, gender, age, or disease duration. Overall,
our data indicates that there is increased oxidative stress in PV that is distinct from other bullous
diseases, such as BP, and is more pronounced when active lesions are present. The reasons for
these differences remain to be determined. Future longitudinal studies tracking individual patient’s
TAC levels over the course of disease may help to better understand the relationship between antiox-
idants and disease activation/manifestation.
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Memory regulatory T cells require IL-7 and not IL-2 for their maintenance in skin
I Gratz, H Truong, A Abbas and M Rosenblum UCSF, San Francisco, CA
Thymic Foxp3-expressing regulatory T cells (Tregs) are activated by peripheral self antigen to increase
their suppressive function, and a fraction of these cells survive as memory Tregs (mTregs). Memory
Tregs persist in non-lymphoid tissue after cessation of self antigen expression and have enhanced
capacity to suppress autoimmune responses when antigen is re-expressed. Because of the impor-
tance of these cells in regulating inflammation in tissues, we have begun to define their character-
istics and the signals required for their generation and maintenance. We show that this population
expresses well-defined effector memory T cell markers and localizes to hair follicles in skin. The
cells express high levels of both IL-2Rα and IL-7Rα, suggesting that IL-2, IL-7, or both are required
to establish and maintain these cells. Using a genetic deletion approach, we show that IL-2 is required
to generate mTregs from naïve CD4+ T cell precursors in vivo. However, IL-2 is not required to main-
tain these cells in the skin and skin-draining lymph nodes (SDLNs). Conversely, IL-7 is essential for
maintaining mTregs in skin in the steady state. These results further elucidate the fundamental biol-
ogy of mTregs and suggest strategies for inducing and maintaining immune homeostasis in periph-
eral tissues.
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Epitope mapping of Tcell responses to NC16a in bullous pemphigoid shows strong associa-
tion with Th2 responses with specific IL-4 responses and IgE to NC16a
AD Ormerod,1 WJ Pickford,1 V Gudi,1 AH Haggart,1 BJ Lewis,1 R Herriot2 and RN Barker1 1
Division of Applied Medicine, University of Aberdeen, Aberdeen, United Kingdom and 2
Aberdeen Royal Infirmary, Aberdeen, United Kingdom
The aim of this study was to map the fine specifity of T cell responses to NC16a in patients with bul-
lous pemphigoid and healthy controls. PBMC from a total of 29 bullous pemphigoid patients and
14 matched controls were tested for proliferative and cytokine responses to recombinant NC16a
and a complete panel of 21 overlapping 10 mer peptides spanning this region of BPAg2. IgE anti-
bodies were detected using ELISA in 16 patients and 11 controls. Proliferative responses to NC16A
and the peptide panel in the patients with active disease were similar in frequency and magnitude
to those in healthy donors, and included late responses typical of naive cells in about 60% of each
group. There was a significant increase in patients responses to NC16a for IL-4 (p=0.026 Mann Whit-
ney) compared to controls and similarly for 5 of the 21 peptides (p<0.05). Factor analysis used as
a reductionist approach strongly identified factors that separate responses to the peptide panel dis-
cretely into IL-4, IFNγ and IL-10 or TGFβ. Factors segregating IL-4 responses from TGFβ were pre-
dicted by whether the subject was a patient or control, while factors separating IL-4 versus IL-10
were predicted by a disease stage with active blistering or in remission. Finally, we confirmed a sig-
nificant upregulation of IgE responses to BP180 in patients compared to controls (p=0.004 Mann-
Whitney U test) with IgE against BP180 showing good specificity and sensitivity for BP in receiver
operating characteristics (ROC) curves. There are complex patterns of T cell phenotype and fine
autoreactive specificity in responses to NC16A, found in patients and normal controls. However,
specific IL-4 and IgE responses show the strongest associations with pemphigoid, suggesting an
important contribution of Th2 cells to pathogenesis.
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The α7 nicotinic acetylcholine receptor – An emerging target for anti-inflammatory and antifi-
brotic treatment strategies in dermatology
A Stegemann,1 A Sindrilaru,2 SA Grando,3 K Scharffetter-Kochanek,2 TA Luger1 and M Böhm1 1
University of Münster, Münster, Germany, 2 University of Ulm, Ulm, Germany and 3
University of California, Irvine, CA
Nicotinic acetylcholine receptors (nAchRs) are cell surface receptors that are widely expressed in
a variety of tissues including skin. Although nAchRs are well appreciated as mediators for nicotine
(the addictive component of cigarettes) their potential as therapeutic targets is only recently emerg-
ing. We show that tropisetron, an approved antiemetic agent previously characterized as a sero-
tonin antagonist, acts in human dermal fibroblasts (HDF) via α7nAchR to suppress transforming
growth factor (TGF)-β1-mediated expression of collagen and myofibroblast markers. In HDF from
patients with systemic sclerosis tropisetron likewise elicited such salutary effects. The relevance of
these findings was confirmed in a mouse model of scleroderma. Tropisetron not only prevented but
also reversed an already established skin fibrosis. To address whether tropisetron has also promis-
ing biological effects in a completely different experimental setting, we wondered whether cytokine
signalling in human epidermal keratinocytes, key cells of inflammatory skin diseases like psoriasis,
is also affected by the drug. Here, tropisetron even in nanomolar concentrations attenuated tumor
necrosis factor (TNF)-α-mediated expression of both interleukin (IL)-6 and IL-8. This anti-inflam-
matory effect was again mediated via α7nAChRs and appeared to be independent of TNF-α-medi-
ated generation of oxidative stress or NF-κB activation. In summary, our findings strongly encour-
age further studies on the functional role of α7nAchRs in inflammatory and fibrotic skin diseases
including therapeutic exploitation of drugs specifically targeting these receptors.
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Inhibitors TrkA, TrkB and TrkC are effective in models of atopic dermatitis and allergic skin
disease
SW Andrews, D Wright, K Bouhana, PA Lee and LE Burgess Array BioPharma, Boulder, CO
To elucidate the role of the neurotrophin / Trk pathway on signs and symptoms associated with aller-
gic skin disease, an orally available Trk inhibitor was evaluated in the NC/NGA mouse model of
Atopic Dermatitis (AD). As follow-up, a topical compound screen using the fluorescein isothy-
ocyanate (FITC)-induced contact hypersensitivity model was used to further understand the effects
of Trk inhibition on cytokine expression typically associated with allergic skin disease. Atopic Der-
matitis Model: NG/Nga mice exhibiting signs and symptoms of AD were treated with ARRY-470, a
potent, selective, orally bioavailable inhibitor of the Trk pathway at doses of 30 mg/kg BID for 4
weeks and evaluated for measures of disease severity and histologic changes in disease progression
relative to topical Protopic as a control. Contact Sensitivity Model: BALB/c mice sensitized and chal-
lenged with FITC, were treated topically with a panel of Trk inhibitors and evaluated for changes in
ear thickness and up-regulation of inflammatory cytokines relative to a topical steroid control. In
the NC/Nga model, oral ARRY-470 caused a 41% (p < 0.01) decrease in itch bouts, a 61% (p <
0.01) reduction in total itch scores and trends toward improvements in symptoms (oozing, hemor-
rhage, edema, erythema) and skin histopathology (inflammation, epithelial necrosis, epidermal
hyperplasia, orthokeratotic hyperkeratosis, parakeratotic hyperkeratosis) relative to vehicle control.
In the FITC contact hypersensitivity model, topical Trk inhibitors reduce ear swelling 37 - 44% (p <
0.01), IL-4 production 46 – 68% (P = 0.001) and resulted in a 60 - 91% (p < 0.01) reduction of
other key cytokines associated with atopic dermatitis (IFN-γ, TNF-α, IL-1, IL-4, IL-12, KC). These
results demonstrate the effectiveness of Trk inhibition in reducing the signs, symptoms, histologic
presentation and cytokine up-regulation associated with atopic dermatitis. Both oral and topical
Trk inhibitors have been identified and warrant further investigation as potential new treatment
options for allergic skin disease.
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IgG4 is the dominant subclass in Egyptian pemphigus vulgaris sera
M Saleh,1,2 M Amagai1 and J Yamagami1 1 Dermatology, Keio University School of Medicine,
Tokyo, Japan and 2 Dermatology, Cairo University School of Medicine, Cairo, Egypt
Pemphigus is a tissue-specific autoimmune disease targeting the cell-cell adhesion molecules,
desmogleins (Dsgs). It is more common in certain ethnic groups: Ashkenazi Jews and those of Mediter-
ranean origin. Pemphigus is mainly classified into pemphigus vulgaris (PV) and pemphigus folia-
ceous (PF). Since there is accumulating evidence of the pivotal role of IgG in blister formation,
autoantibodies have been thoroughly analyzed. IgG4 was reported as predominant subclass in sev-
eral populations. In Egypt PV is more common than PF. In this work we sought to identify IgG sub-
class distribution among Egyptian PV patients. The sera of 50 PV patients who were treated during
2012 were utilized. Thirty nine were females and 11 were males. Forty three patients were muco-
cutaneous, 3 were mucosal and 4 were cutaneous PV. Seven of the sera were from patients before
starting treatment. Six sera were from complete remission on therapy patients. IgG4 was present in
45 (90%), IgG1 was present in 34 (68%) and IgG3 was present in 5 (10%) of the sera. The patients
were classified into 3 groups. Group A: pemphigus disease area index (PDAI) ≥25, group B: PDAI
24-14 and group C: PDAI <14. In group A: 11/11 sera had IgG4, 9/11 sera had IgG1 and 3 sera had
IgG3 anti-Dsg3 antibodies. In group B: 4/4 sera had both IgG4 and IgG1 anti-Dsg3 antibodies. In
group C: 30/35 sera had IgG4, 21/35 sera had IgG1 and 2/35 sera had IgG3 antibodies. On com-
paring the IgG subclass of the patients who did not start treatment and patients who were already
under treatment, IgG4 subclass was the predominant subclass before and after treatment. IgG4
subclass was present in 3/6 sera who were in complete remission on therapy while IgG1 was pres-
ent in low OD in the other 3 sera. No difference was observed in IgG subclass pattern between
mucosal, mucocutaneous and cutaneous PV. These results indicate that IgG4 is the predominant
subclass in Egyptian PV patients before, during therapy and in some cases in clinical remission.
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Oral Streptococcus is one of immunopathological trigerring factors in aphthous ulceration
including Behcet’s disease
F Kaneko,1 A Togashi,2 E Nomura3 and K Nakamura4 1 Dermatology, Southern TOHOKU
Research Institute for Neuroscience, Koriyama, Japan, 2 Dermatology, Southern TOHOKU
Research Institute for Neuroscience, Koriyama, Japan, 3 Dermatology, Southern TOHOKU
Research Institute for Neuroscience, Koriyama, Japan and 4 Dermatology, Saitama Medical
University, Irumagun, Japan
There may be some difficulties to differentiate Behcet disease (BD) and recurrent aphthous stom-
atitis (RAS) from other aphthous lesions including herpes simplex virus (HSV) infection. “Pathergy
test” has been thought as one of auxiliary diagnostic benefits for BD for long time, albeit less sen-
sitivity. The prick reaction by streptococcal antigens is highly diagnostic for BD patients though the
standard antigens are unable to be routinely provided, because the patients have hyper-reactivity
against streptococci. More simply specific diagnostic ways should be considered. The prick with
neat and filter-sterilized saliva (S- and FS-prick) was performed on the skin of the patients, because
oral streptococci are contained in saliva. The skin reactions were measured in diameter 48 hours
after prick and the biopsy was performed from the skin reaction to analyze immunohistologically.
In 9 out of 10 BD patients (90%), the S-prick reaction was intensely observed and 3 out of 5 RAS
patients (60%) showed relatively weak reaction. None of other patients and healthy controls
responded to the prick. As no reaction appeared by the FS-prick, the response by S-prick might be
due to oral streptococci in the patients. Salivary culture revealed streptococcal colonies in MS agar.
Histology of the pricked skin-site displayed predominant infiltration of CD4+T cells and mono-
cyte/macrophage lineage resembling to the vascular reaction of erythema nodosum-like eruption
in BD patients. The S-prick is helpful in diagnosis for BD and RAS. The results suggest that the pos-
itive pathergy reaction of BD patients might be due to cutaneous microorganisms having cross-
immunity to oral streptococci and that may provide a direct evidence for triggering action in the
underlying immunopathology of the two oral disease conditions.
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TLR2-ligands promote Th2-mediated dermatitis through IL-4 mediated suppression of IL-10
S Kaesler, T Volz, Y Skabytska, K Chen, U Hein, E Guenova, M Röcken and T Biedermann
Dermatology, Eberhard Karls University Tuebingen, Tuebingen, Germany
Innate immunity is the first line of defense at surface organs like the skin and plays a crucial role in
the subsequent shaping of adaptive immunity. However, the contribution of innate immune signals
in the modulation of already ongoing adaptive immune responses remained largely uncharacter-
ized. An ideal disease to investigate how innate immune signals interact with the adaptive immune
system is atopic dermatitis (AD), because AD is Th-cell mediated with IL-4 dominating acute lesions
and covered with Staphylococcus aureus providing potent innate signals activating Toll-like-recep-
tor (TLR) 2. We investigated Th2-cell mediated dermatitis with or without TLR2 activation in a mouse
model of AD using adoptive transfer of Th2 cells. We show here that this Th2-cell mediated der-
matitis is self limiting, depends on IL-4, is mediated by cutaneous MHC II+ cells and is strongly
enhanced and sustained by TLR2 activation. Further analyses revealed that combinative sensing of
innate TLR2 ligands and adaptive IL 4 leads to dermatitis exacerbation and persistence through
suppression of IL-10. This demonstrates how innate signals transform transient Th2-cell mediated
inflammation into persistent dermatitis as seen in chronic human AD. Moreover, these data provide
another rationale for targeting IL-4 in AD patients, a therapeutic approach currently under devel-
opment.
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Characterization of inflammation in keratinocyte Dlx3-deficient murine skin
J Kim,1 Y Ogawa,2 E Palazzo,1 M Udey2 and M Morasso1 1 Developmental Skin Biology Unit,
NIAMS/NIH, Bethesda, MD and 2 Dermatology Branch, NCI/NIH, Bethesda, MD
The homeobox transcription factor Dlx3 is involved in the terminal differentiation of keratinocytes
(KCs), and mutations in Dlx3 are associated with tricho-dento-osseous syndrome characterized by
abnormal hair, teeth and bone. We previously reported that epidermal depletion of Dlx3 in vivo
(K14cre;Dlx3kin/f mice; cKO) led to IL-17-associated skin inflammation and that the skin of cKO
mice showed a psoriasis-like phenotype and gene expression profile. Our current work addresses
the kinetics of inflammation in K14cre;Dlx3kin/f skin. Initially (postnatal day 1; P1 to P7), cKO skin
exhibited non-T cell-predominant skin inflammation with many macrophages, while γδT cells pro-
ducing IL-17A were prominent at later times. IL-17A-producing skin T cells were already more abun-
dant at P7 in cKO relative to WT skin, and at P21 cKO skin contained 15x more IL-17A-producing
cells than WT skin, with 80% of IL-17A-producing cells being γδT cells. Half of these IL-17A-pro-
ducing γδT cells were Vγ4-bearing γδT cells. Although Dlx3 and K14 are also expressed in thymic
epithelial cells, depletion of Dlx3 from thymic epithelial cells did not appear to influence the gen-
eration and development of Vγ4+ cells, because the number of thymic Vγ4+ cells and IL-17A-pro-
ducing Vγ4+ cells were comparable in P7 WT and KO thymus. RNA-seq data showed that at P1,
cKO epidermis contained abundant transcripts corresponding to genes that are known to recruit
non-T cells (CCL4, NCF1), providing a partial explanation for the early recruitment of macrophages.
Expression of other inflammation-related genes (including Ccl9, Ccl12 and Csf1r) was upregulated
in the dermis. We propose that absence of Dlx3 in keratinocytes leads to overproduction of
chemokines and cytokines that results in enhanced recruitment of macrophages into skin, perhaps
followed by heightened production of IL-23 and/or IL-1 leading to the accumulation of IL-17A-pro-
ducing Vγ4+ cells in the dermis. Epidermal Dlx3 may be an important regulator of skin inflamma-
tion in health and disease.
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Mechanisms of keratinocyte mitochondrial damage in pemphigus vulgaris
M Kalantari-Dehaghi, Y Chen, W Deng, PH Wang and SA Grando University of California,
Irvine, CA
Current understanding of pathophysiology of pemphigus vulgaris (PV) does not explain acantholy-
sis in patients lacking desmoglein antibodies. We have previously shown that PV IgGs enter ker-
atinocytes (KCs) and specifically bind to a number of mitochondrial proteins, which is associated
with mitochondrial damage triggering apoptosis and leading to acantholysis. Protein microarray
demonstrated that mitochondrial proteins most commonly targeted in PV are involved in oxidative
phosphorylation, O2 respiration, production/inactivation of reactive oxygen species (ROS), and tri-
carboxylic acid cycle. In this study, we sought to identify changes in the vital mitochondria func-
tions in KCs treated with the sera from PV patients and healthy donors. PV sera significantly increased
proton leakage from KCs, suggesting that PV IgGs increase ROS production and reduce the ability
of KCs to respond to stress. Indeed, measurement of intracellular ROS production by the c-H2DCFDA-
AM dye labeling of cultured KCs showed a drastic increase of cell staining in response to treatment
by PV sera, which was confirmed by FACS analysis. Exposure of KCs to PV, but not normal, sera
also caused dramatic changes in the mitochondrial membrane potential detected with the JC-1
dye. The obtained results thus demonstrated that anti-mitochondrial antibodies produced by PV
patients can disrupt the electron transfer chain, resulting in a loss of electrochemical gradient
across the inner membrane, increase ROS production and reduce the ability of KCs to respond to
stress. These changes can trigger the mitochondria mediated intrinsic apoptosis. The obtained results
explain, in part, the mechanism of therapeutic action of mitochondria-protecting drugs, such as
nicotinamide, minocycline and cyclosporine, in PV patients and suggest novel avenues for devel-
opment of personalized therapies based on the pharmacological correction of mitochondrial abnor-
malities in individual PV patients.
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Pemphigus vulgaris autoantibody profiling by proteomic technique
M Kalantari-Dehaghi,1 G Anhalt,2 M Camilleri,3 P Felgner,1 K Leiferman,4 M Pittelkow,3 J Zone4
and S Grando1 1 University of California, Irvine, CA, 2 Johns Hopkins University, Baltimore,
MD, 3 Mayo Clinic, Rochester, MN and 4 University of Utah, Salt Lake City, UT
Pemphigus vulgaris (PV) is a mucocutaneous blistering disease characterized by IgG autoantibod-
ies against stratified squamous epithelium. Current understanding of PV pathophysiology does not
explain the mechanism of acantholysis in patients lacking desmoglein antibodies, which justifies a
search for novel targets of pemphigus autoimmunity. We tested 264 pemphigus and 138 normal
control sera on the multiplexed protein array platform containing 701 human genes encompassing
many known keratinocyte cell-surface molecules and members of protein families targeted by organ-
non-specific PV antibodies. The top 10 antigens recognized by patients’ sera were proteins encoded
by the DSC1, DSC3, ATP2C1, PKP3, CHRM3, COL21A1, ANXA8L1, CD88 and CHRNE genes. The
most common combinations of target antigens included at least one of the adhesion molecules
DSC1, DSC3 or PKP3 and/or the acetylcholine receptor CHRM3 or CHRNE with or without the
MHC class II antigen, DRA. To identify the PV antibodies most specific to the disease process, we
sorted the data based on the ratio of patient to control frequencies of antigen recognition. The fre-
quency of antigen recognition by patients that exceeded the control by 10 and more times were the
molecules encoded by the CD33, GP1BA, CHRND, SLC36A4, CD1B, CD32, CDH8, CDH9, PMP22
and HLA-E genes as well as mitochondrial proteins encoded by the NDUFS1, CYB5B, SOD2, PDHA1
and FH genes. The highest specificity to PV showed combinations of autoantibodies to the calcium
pump encoded by ATP2C1 with C5a receptor plus DSC1 or DSC3 or HLA-DRA. These results iden-
tified new targets of pemphigus autoimmunity. Novel autoantibody signatures may help explain
individual variations in disease severity and treatment response and serve as sensitive and specific
biomarkers for new diagnostic assays in PV patients.
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Impaired Notch-MKP-1 signalling in hidradenitis suppurativa: An approach to pathogenesis
by evidence from translational biology
BC Melnik University of Osnabrück, Dermatology, Environmental Medicine and Health
Theory, Osnabrück, Germany
Recent findings in familial hidradenitis suppurativa (HS) demonstrated loss-of-function mutations
of components of the γ-secretase (GS) complex leading to decreased protease cleaving activity,
which may compromise canonical Notch signalling. Appropriate Notch signalling is of pivotal impor-
tance for maintaining the inner and outer root sheath of the hair follicle and skin appendages. This
approach to the pathogenesis of HS is primarily supported by circumstantial evidence derived from
translational biology. Impaired Notch signalling is proposed to be the major pathogenic mecha-
nism of HS. Deficient Notch signalling switches the fate of outer root sheath cells resulting in con-
version of hair follicles to epidermal cysts. Epidermal cyst rupture with release of keratin fibres may
activate the innate immune system. Impaired Notch signalling may compromise apocrine gland
homeostasis. Damage-associated molecular pattern molecules released either by ruptured epider-
mal cysts and less maintained apocrine glands may stimulate TLR-mediated innate immunity. All
aggravating factors of HS, smoking, obesity, skin occlusion and androgens, further promote inflam-
mation by release of proinflammatory cytokines derived from activated monocyte/macrophages.
Inappropriate Notch signalling may not only initiate inflammation in HS but may leads to insuffi-
cient feedback inhibition of overstimulated innate immunity. Regular Notch signalling via induc-
tion of MAPK phosphatase-1 (MKP-1) terminates TLR-MAPK-signalling in macrophages and IL-23
secreting DCs, the key players for Th17 cell polarization. Thus, impaired Notch signalling links HS
to other Th17-driven comorbidities. All major therapeutic interventions in HS appear to attenuate
increased MAPK activation of innate immune cells due to impaired Notch-mediated feedback reg-
ulation of innate immunity.
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The role of M1/M2 macrophages in HSV-induced Behçet’s disease mouse model
S Sohn,1,2 M Anower,1 J Shim,1,2 B Choi,1 H Kwon1 and D Bang3 1 Lab Cell Biol Inst Med Sci,
Ajou University, Suwon, Republic of Korea, 2 Brain Korea Program, Ajou University, Suwon,
Republic of Korea and 3 Dept Dermatol, Yonsei University, Seoul, Republic of Korea
The exact mechanism of the inflammatory changes occurring during the development of the Behçet’s
disease (BD) remains unclear. We aimed to investigate the role of classical (M1) and alternative (M2)
activation of macrophage in herpes simplex virus (HSV)-induced BD mouse model. The classical
versus alternative activated macrophage ratio (M1/M2 ratio) was calculated by analyzing the sur-
face markers CD16/32 and CD23 as M1 and M2 markers, respectively by flow cytometry. mRNA
expression of IFN-γ and IL-6 as M1 and Arginase 1, FIZZ-1 and MHC-II as M2 markers were ana-
lyzed by RT-PCR. The cytokines IL-17, IL-6 and IL-4 levels were also assessed in serum by ELISA. In
BD mice, M1 phenotype was up-regulated and increased M1/M2 ratio compared to asymptomatic
BD normal (BDN) and normal healthy mice. For M1/M2 phenotypic transformation in vivo normal
mice, recombinant interferon-gamma (rIFN-γ) significantly increased M1/M2 ratio (1.74±0.42) com-
pared with recombinant interleukin-4 (rIL-4) (0.83±0.20) or the phosphate buffered saline (PBS)
treated control (0.66±0.34). In this study, BD mice treated with rIL-4 decreased M1/M2 ratio (1.2±0.3)
compared to PBS (2.4±2.9) or rIFN-γ (2.1±2.3) treated groups and also ameliorated the BD symp-
toms accompanied with down-regulation of IL-17 and IL-6, and up-regulation of IL-4. Furthermore,
treatment with colchicine and pentoxifylline decreased the M1/M2 ratio and improved the symp-
toms in BD mice. Therefore, a shift in the population of macrophages is a pathologic factor and
modulation of macrophage phenotypes could be an effective therapeutic approach for treatment of
BD in future.
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Detection of pathological cleavage sites and neoepitopes on collagen XVII, a major autoanti-
gen for bullous pemphigoid
W Nishie, H Ujiie, K Izumi and H Shimizu Department of Dermatology, Hokkaido University
Graduate School of Medicine, Sapporo, Japan
In bullous pemphigoid (BP), the most common autoimmune blistering disease, IgG autoantibodies
(autoAbs) target hemidesmosomal transmembrane collagen XVII (COL17). IgG autoAbs from BP
patients preferentially react with the juxtamembranous extracellular NC16A domain of COL17;
however, it is still uncertain why and how the NC16A domain yields high antigenicity. In this study,
we showed that cleavage of COL17 at non-physiological sites within the NC16A domain plays an
important role in the generation of neoepitopes targeted by autoAbs. We first identified cleavage
sites on recombinant COL17 that had been treated with plasmin as a candidate pathological pro-
tease, which is known to exist in BP lesional skin as well as in BP blister fluid. Mass spectrometry
analysis revealed the major amino-terminal cleavage sites of cleaved 120kD extracellular polypep-
tides to be Ser508. Interestingly, ELISA studies with short peptides corresponding to the cleavage site
demonstrated that certain IgG autoAbs of BP patients reacted with the epitopes that were evoked
after the cleavage at Ser508; in contrast, no IgG autoAbs reacted with the epitopes associated with
the physiological cleavage site Gln525. These results suggest that non-physiological cleavage of COL17
within the NC16A domain plays a role in the generation of autoantigen for BP. A final question is
whether the neoepitopes that were evoked after the cleavage at Ser508 are actually present in lesional
skin of BP. To address this, we generated cleavage-site-specific antibodies targeting the amino-ter-
minal Ser508 that correctly target the neoepitopes at this cleavage site. The cleavage-site-specific anti-
bodies revealed that COL17 is actually cleaved at Ser508 and that neoepitopes are generated in vivo
in the lesional skin of certain BP patients. In conclusion, this study showed that non-physiological
ectopic cleavage of COL17 within the NC16A domain plays a distinct role in the pathomechanism
of autoimmunity to COL17 in BP.
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Selective blocking of the interaction of extracellular cyclophilins with CD147 reduces recruit-
ment of leukocytes during inflammation
C Schiene-Fischer,2 M Malesevic,2 D Gutknecht,1 JC Simon1 and A Saalbach1 1 Dermatology,
University Leipzig, Leipzig, Germany and 2 Unit for Enzymology of Protein Folding, Max-
Planck-Institut, Halle/Saale, Germany
Extracellular cyclophilins (eCyp) have been identified as a novel class of chemotactic mediators.
Here, using a newly-generated inhibitor of cyclophilins (MM284), a cell-impermeable, non-immuno-
suppressive CsA derivative, the physiological importance of eCyp for the recruitment of leukocytes
during inflammation was analyzed. The cell-impermeability and its inability to affect calcineurin
activity or NF-AT activation are indicative for a lack of T cell mediated immunosuppressive activity
of this compound. The biological effect of MM284 to inhibit eCyp activity was shown by a dose-
dependent inhibition of migration of different leukocyte subsets towards CypA. Use of mutant
CypA derivates lacking its enzymatic activity revealed that the enzymatic active site of CypA is essen-
tial for its chemotactic activity. Inhibition of leukocytes recruitment during inflammation in a mouse
model of experimental induced peritonitis and delayed-type-hypersensitivity model by blocking
eCyp with MM284 revealed the physiological impact of eCyp in the regulation of inflammation.
Using leukocytes from CD147-deficient mouse we showed that this eCyp-mediated migration of
leukocytes is exclusively mediated by CD147. Indeed, CD147-/- leukocytes were unable to migrate
towards CypA. Consistently, the extravasation of leukocytes during inflammation was significantly
decreased in CD147-/- mice compared to wildtype littermates. Failure of inhibition of migration
and inflammation by blocking eCyp by MM284 in CD147-/- mice proved that the action of eCyps
in inflammation is exclusively mediated by their interaction with CD147. Taken together, eCyps
might be useful therapeutic targets for reducing inflammatory diseases associated with leukocyte
recruitment into tissue.
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CX3CL1/fractalkine and its receptor CX3CR1 regulate atopic dermatitis by controlling effec-
tor T cell retention in inflamed skin
D Staumont-Sallé,1,2,3 N Hornez,3 C Lavogiez,3 A Kanda,2 C Mionnet,4 J Prawitt,1,2 S Fleury,1,2
E Bouchaert,1,2 A Lazzari,4 E Delaporte,2,3 N Glaichenhaus,4 B Staels,1,2 V Julia4 and
D Dombrowicz1,2 1 U1011, Inserm, Lille, France, 2 University of Lille 2, Lille, France, 3
Dermatology, University Hospital of Lille, Lille, France and 4 UMR 6097, CNRS, Nice, France
Introduction: We previously demonstrated that CX3CL1/fractalkine and its receptor, CX3CR1, reg-
ulate allergic asthma by controlling Th2 lymphocyte survival within inflamed lungs. As increased
CX3CL1 and CX3CR1 levels have been observed in human atopic dermatitis (AD), we have inves-
tigated their role using a murine model of AD. Materials and methods: We used an experimental
model of AD obtained by repeated epicutaneous sensitization against a protein antigen (LACK), in
CX3CR1-deficient mice and their wild type counterparts. We next investigated the efficacy of a
FKN antagonist AT to inhibit the LACK-induced pathology in WT animals. To decipher the mecha-
nisms accounting for the role of CX3CR1 expression by T helper cells in skin inflammation, we mon-
itored the recruitment, the survival and the proliferative capacities of both CX3CR1-proficient and
CX3CR1-deficient LACK-specific Th1 and Th2 cells upon co-injection into WT mice that were exposed
to LACK. Results : CX3CR1-deficient mice were impaired in their ability to develop AD. This defect
was associated with decreased antigen-specific -IgG2a and -IgE concentrations. These results were
confirmed by blocking CX3CL1/CX3CR1 interactions in wild type mice. As previously observed
upon systemic sensitization, CX3CR1-deficiency does neither affect antigen presentation nor T cell
proliferation in vivo upon skin sensitization. However, unlike asthma, CX3CR1 expression regulated
retention and not survival of effector T lymphocytes in the inflammatory skin in this model of AD.
Conclusion: Our results reinforce CX3CR1 and CX3CL1 as promising therapeutic targets in AD.
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A novel mouse model for a blistering skin disease
T Hurskainen,1,2 N Kokkonen,1,2 J Jackow,3 R Sormunen,4 J Moilanen,1,2 S Löffek,3 R Soininen,4
CW Franzke,3 L Bruckner-Tuderman3 and K Tasanen1,2 1 Dermatology, University of Oulu, Oulu,
Finland, 2 Clinical Research Center, Oulu University Hospital, Oulu, Finland, 3 Dermatology,
University of Freiburg, Freiburg, Germany and 4 Biocenter Oulu, University of Oulu, Oulu,
Finland
Collagen XVII/BP180 is an important component of hemidesmosomes that are multiprotein struc-
tures connecting epithelial cells into the underlying basement membrane. Bullous pemphigoid
(BP) is the most common autoimmune blistering skin disease with a characteristic of skin itching
and a blister formation in the epidermal basement membrane zone. Nearly all BP-patients carry
inflammation triggering autoantibodies against juxtamembraneous extracellular NC16A domain of
collagen XVII. The molecular mechanisms causing the production of autoantibodies and the devel-
opment of blisters are, however, unclear. To analyze in more detail the multiple functions of the
NC16A domain we have recently generated a transgenic mouse line with a deletion in correspon-
ding NC14A region of murine collagen XVII. Newborn ΔNC14A mice have no visible phenotypic
changes distinct from the wild type. However, in histological analysis, subepidermal microblisters
were found in the skin of newborn ΔNC14A mice. ΔNC14A mice grow normally and have normal
breeding, pregnancy and birth. Interestingly, although the major epitope of autoantibodies is miss-
ing ΔNC14A mice begin to scratch and develop erosions at the age of around two months. Histo-
logical analysis of scratching mice revealed development of blisters and accumulation of inflam-
matory cells in their skin. The more detailed analysis of ΔNC14A mouse skin with transmission
electron microscopy showed rudimentary and malformed hemidesmosomes, loose basement mem-
brane and accumulation of vesicles at the cell membrane. Thus the phenotype of ΔNC14A mouse
has features of both inherited (spontaneous blisters in junctional epidermolysis bullosa) and acquired
(delayed itching, blistering and inflammation in BP) blistering skin disease and therefore provides
a feasible model for studies concerning the role of collagen XVII in these disorders.
125
Aryl hydrocarbon receptor deficiency in skin exacerbates psoriatic inflammation
P Di Meglio,1 JH Duarte,1 H Ahlfors,1 ND Owens,2 H Müller,1 Y Li,1 F Villanova,3 I Tosi,3 K Hirota,1
M Gilchrist,2 FO Nestle,3 U Mrowietz4 and B Stockinger1 1 Molecular Immunology, NIMR,
London, United Kingdom, 2 Systems Biology, NIMR, London, United Kingdom, 3 St. John’s
Institute of Dermatology, King’s College London and NIHR Biomedical Research Centre,
London, United Kingdom and 4 Psoriasis-Center, University Medical Center Schleswig-
Holstein, Kiel, Germany
Psoriasis is a chronic inflammatory skin disease resulting from the interaction of genetic and envi-
ronmental factors. Cross-talk between innate, adaptive and epithelial/stromal cells, such as ker-
atinocytes and fibroblasts, underpins the pathological response in this disease. More than 40 dis-
ease-associated loci have been identified to contribute to psoriasis. Environmental risk factors on
the other hand remain less well-defined on a mechanistic basis. The Aryl hydrocarbon receptor (AhR)
is a ligand-activated transcription factor responsive to environmental stimuli that is essential for the
maintenance of intestinal barrier integrity. The wide expression of AhR in several skin cell types
suggests a role for AhR signalling at this barrier organ. Here, we combine the imiquimod-induced
mouse model of psoriasiform inflammation with the analysis of psoriasis patient skin biopsies, to
investigate the role of AhR in psoriasis. AhR deficiency in the non-hematopoietic compartment
resulted in a more severe psoriasiform phenotype, with increased acanthosis, neutrophils infiltra-
tion and expression of pro-inflammatory mediators. Moreover, exposure of psoriasis skin biopsies
to either AhR agonist or antagonist modulated psoriasis-related genes, with AhR agonist reducing
their expression in lesional skin, and AhR antagonist up-regulating these genes in non-lesional
skin. Taken together, our results suggest that AhR has a critical role in dampening skin immune
responses and that lack of AhR in non-hematopoietic cells exacerbates dysregulated cross-talk
between innate and adaptive cells in psoriasis.
124
Microbial diversity and cutaneous inflammation are predictive for the clinical course of exper-
imental epidermolysis bullosa acquisita
CT Ellebrecht,1,2,3 G Srinivas,4 K Bieber,2 D Banczyk,1 S Künzel,4 K Kalies,1 CM Hammers,1,2,3
JF Baines,4,5 D Zillikens,2 RJ Ludwig2 and J Westermann1 1 Anatomy, University of Lübeck,
Lübeck, Germany, 2 Dermatology, University of Lübeck, Lübeck, Germany, 3 Dermatology,
University of Pennsylvania, Philadelphia, PA, 4 Max Planck Institute for Evolutionary Biology,
Plön, Germany and 5 Institute for Experimental Medicine, Christian-Albrechts-University, Kiel,
Germany
Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering skin disease, characterized by
binding of autoantibodies to type VII collagen (COL7) at the dermal-epidermal junction (DEJ). Dis-
ease induction by immunization with a recombinant fragment of COL7 results in autoantibody pro-
duction in 100% of SJL/J mice. Interestingly, however, 20% of these mice develop no skin disease
after immunization despite of detectable autoantibodies. The combination of autoantibody pro-
duction and absence of skin blisters in the context of the same genetic background and identical
environmental conditions has not been studied yet. We hypothesized, that the lack of skin blister-
ing despite of autoantibody production was associated with a distinct immunological and micro-
bial pattern before break of tolerance. To assess this hypothesis we investigated skin samples before
disease induction. Determining the cutaneous expression of CD11c, KC and TNFα before immu-
nization with type VII collagen, lack of skin blisters after disease induction could be predicted with
a probability of >80%. Additionally, absence of skin blisters was associated with a higher diversity
in the skin microbiome assessed before immunization. Our results suggest that both microbial diver-
sity and sub-clinical cutaneous inflammation, preceding the break of tolerance, govern the clinical
phenotype of experimental EBA in genetically predisposed mice, thus providing potential tools for




Th17, Th22 and regulatory T cell responses in early atopic dermatitis lesions and atopic patch
tests
BJ Lewis,1 F Meredith,2 LG Lawson,2 RN Barker1 and AD Ormerod1 1 Division of Applied
Medicine, University of Aberdeen, Aberdeen, United Kingdom and 2 Dermatology, Aberdeen
Royal Infirmary, Aberdeen, United Kingdom
Recent studies suggest that Th17 cells participate in atopic dermatitis to a lesser degree than psori-
asis and towards Th22 cells contributing more to inflammation in the skin lesions. The aim of this
study was to investigate the participation of cells of the Th17/Th22 lineage and regulatory Tcells in
early AD lesions, clinically uninvolved AD skin and examine their dynamics in atopic patch tests.
Punch biopsies were taken from 12 patient’s involved and uninvolved skin and from 3 patients
APTs each at 3 timepoints. Skin was disaggregated with viable cells and peripheral blood mononu-
clear cells stained for enumeration by FACS. From APT (n=3) lymphocyte cultures were stimulated
and measured for cytokine responses by multiplex bead array. IL-17, IL-22, IL-23R and FOXP3
were all significantly increased in involved and uninvolved AD skin compared to peripheral blood.
Within the Th17 lineage (IL-23 receptor positive cells) IL-17 was reduced in involved skin compared
to IL-22 and there were significantly more IL-22+, IL-17- cells in lesional skin consistent with a
population of Th22 cells. In atopic patch tests (APT) there was an influx of IL-17 cells at 24 hours
and at 72 hours Th17 cells fell while FOXP3 and Th2 cells increased. Cytokine responses in cells
derived from APT, showed brisk responses with IL-13, IL-6, IL-1β and interferonγ, TNFα and a weaker
IL-17 response to Der P1 stimulation. The Th17 lineage participate in early AD lesions and APT.
These cells are preferentially recruited to uninvolved and involved skin. Involved skin is charac-
terised by predominantly IL-22 secreting (Th22) cells.
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TL0-1 phototherapy in psoriasis increases the ratio of Th1:Th2 cells, and the numbers of reg-
ulatory T cells, in lesions and peripheral blood
IS Kotb,1,2 BJ Lewis,1 N Darwish,2 HA Salem,2 S El-Mongy,2 RN Barker1 and AD Ormerod1 1
Division of Applied Medicine, University of Aberdeen, Aberdeen, United Kingdom and 2
Department of Dermatology, Andrology and STDs, Mansoura University, Mansoura, Egypt
An imbalance between effector and regulatory Tcell (Tregs) subsets may be key in psoriasis patho-
genesis. Treg cells have also been reported to be deficient in numbers and/or functionally inactive
in lesional psoriatic skin. This study aimed to determine the effect of narrow band TL0-1 light treat-
ment, on the numbers of Th1, Th2, Th17 and Tregs in the blood and skin of psoriatic patients, and
to correlate any immunologic changes with the clinical response. Ten (7M, 3F), treatment-naïve
patients with mild to moderate psoriasis were recruited (mean age 46.7yr; mean baseline PASI 7.24).
PBMC and lymphocytes from psoriatic lesional skin were phenotyped by flowcytometry, identify-
ing ex vivo cell populations as Th1 (CD4+T-bet+), Th2 (CD4+GATA-3+), Th17 (CD4+CCR4+CCR6+IL-
23R+) and Treg (CD4+CD25+CD127loFoxP3+). In baseline samples of PBMC and biopsy respec-
tively, the mean proportions of each CD4+ subset, were Th1, 1.25% & 2.72%; Th17 5.62% & 18.70%;
Th2, 0.92% & 2.82%; and Treg, 2.75% & 1.42%. After 6 weeks of TL0-1 treatment, mean PASI had
decreased to 1.9, and significant changes (p<0.001, paired t test) occurred in Th1, Th2 and Treg pop-
ulations. In blood and skin respectively, Th1 cells decreased to 0.54% & 1.01%, Th2 cells increased
to 1.77% & 6.13%, and Treg cells increased to 7.96% & 8.45%. Th17 cells showed non-significant
respective decreases to 3.44% & 13.8%. The increase in lesional Tregs was significantly correlated
(r=0.5) to the clinical improvement represented by PASI score. The clinical response of psoriatic skin
to TL0-1 therapy is associated with reductions in the ratios of Th1:Th2 cells, and increased frequency
of Treg cells. Augmenting immunoregulatory responses therefore appears desirable and may account
for the remittive effect of phototherapy.
128
Challenges of systemic IL-17A quantification in patients treated with secukinumab, an anti-
IL-17A antibody
C Calonder, R Helbaj, S Spindeldreher and P Lloyd Preclinical Safety, Novartis Institutes for
BioMedical Research, Basel, Switzerland
The quantitative assessment of systemically low-abundant and often small cytokines is challenging,
even more so when other molecules like endogenous binding proteins and/or the drug, in this case
a therapeutic antibody targeting the cytokine, are present in the biological matrix. We demonstrate
this with the example of IL-17A, a homodimeric cytokine of 2x17kD, which is present at sub-picogram
/ mL concentration in serum of healthy humans and for which we’ve developed and validated a lig-
and binding assay on the MesoScale Discovery (MSD) platform. A Sandwich assay format was
selected to quantify total IL-17A, meaning free IL-17A and IL-17A bound to Secukinumab, and a
sensitivity of 25 pg/mL was achieved. The assay was based on a single tool antibody, a human IgG1,
which binds to a different epitope on IL-17A than the drug and therefore does not interfere with
Secukinumab binding to IL-17A. The homo-dimeric structure of the analyte allowed use of the
same tool antibody for capture and detection of IL-17A, except that as detection agent the tool anti-
body derived Fab-fragment was selected for the assay. This format prevented a potential specificity
issue caused by the presence of anti-human IgG antibodies in a patients’ serum which would be
capable to bridge between capture and detection full length IgGs and in such cases lead to false-
positive results. The assay was fully validated and is currently used to analyse clinical samples. The
reliable quantification of a drug’s target is important to assess target engagement, to measure dura-
tion of target modulation after drug administration and to provide reliable data sets for pharmaco-
kinetic/pharmacodynamic modelling. For clinical programs, reliable pharmacodynamic, pharma-
cokinetic and immunogenicity data are essential and their integrated interpretation is key in terms
of safety and efficacy. In this case study, we describe the successful development of a challenging
pharmacodynamic assay.
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Treatment with clodronate liposomes or cyclosporine have minor effects on imiquimod-
induced skin inflammation in mice
E Hsia, E Santori, K Held, K Manley, L Andrews-Jones and M Stern Allergan, Irvine, CA
Though not completely understood, the pathogenesis of psoriasis involves an increased presence
of activated T-cells (Th1 and Th17) and dendritic cells (DCs) in lesional skin. Topical application of
imiquimod (IMQ) has been shown to induce psoriasis-like inflammatory skin lesions in mice, and
this has been proposed as a model for psoriasis. To explore the development of T-cell responses
during IMQ-induced skin inflammation, antigen-presenting cells (APCs) were depleted with clo-
dronate liposomes (CL). BALB/c mice were pre-treated with CL or control PBS liposomes (PBSL) by
intradermal or i.p. injection prior to once daily treatment of 5% IMQ for 6 days. Skin inflammation
was assessed by visual examination of erythema, induration, and scaling and histology. APC and T-
cell populations in the inguinal lymph nodes (ILN) and spleen were assessed by FACS. In mice
treated with CL by i.p. injection, there was a significant decrease in the number and frequency of
CD11b+ macrophages and CD11c+ DCs in both ILN and spleen, as compared to PBSL-treated mice.
Similar trends were observed with intradermal administration of CL, but were not as robust. Sys-
temic CL treatment also reduced the number of activated CD4+ and CD8+ T cells, and Treg cells.
Furthermore, splenocyte Th1 and Th17 populations were modestly reduced following systemic CL
treatment. However, despite these changes in APCs and activated T cells by CL treatment, no sig-
nificant changes in skin erythema, induration, and scaling were observed. To further understand the
role of activated T cells in this model, we treated mice orally with cyclosporine A (CsA), a potent
suppressor of T-cell activation, concomitantly with 2.5% IMQ for 9 days. While a high dose of CsA
(100 mg/kg) inhibited IMQ-induced splenomegaly (p=0.012, vs. untreated) and delayed the onset
of scaling (p=0.023 at Day 5, vs. untreated), it did not prevent the development of IMQ-induced
inflammatory skin lesions. Taken together, these data suggest that APCs and activated T-cells do not
play a major role in IMQ-induced psoriasis-like skin inflammation.
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Role of the SDF-1/CXCR4 axis in two different mouse models of chronic skin inflammation
S Zgraggen,1 R Huggenberger,1 A Ochsenbein,1 S Proulx,1 K Kerl,2 D Aebischer1 and M Detmar1
1 ETH Zurich, Zurich, Switzerland and 2 University Hospital Zurich, Zurich, Switzerland
There is some evidence, that the SDF-1/CXCR4 axis may be involved in the pathogenesis of several
inflammatory diseases. However, it is not known whether this chemokine axis also plays a role in
inflammatory skin diseases. Based on our finding of an increased number of CXCR4 positive cells
in lesional psoriatic skin compared to normal human skin, we evaluated in two different mouse
models of chronic cutaneous inflammation the relevance of the SDF-1/CXCR4 interaction. We found
that CXCR4 and SDF-1 were significantly up-regulated during inflammation in the skin of the
established keratin 14 (K14) VEGF-A transgenic (tg) mouse model as well as in the skin of Imiquimod
treated mice. To investigate the functional importance of the SDF-1/CXCR4 axis in vivo, we inhib-
ited CXCR4 signaling by AMD3100, a specific CXCR4 antagonist. The treatment significantly reduced
inflammatory edema formation in the inflamed ear skin of both mouse models. In the K14 VEGF-A
tg mice we found that in the inflamed ear skin, CXCR4 was only expressed on blood vessels but not
on lymphatic vessels and that inflammatory angiogenesis was significantly reduced by inhibiting
CXCR4 signaling. Furthermore, incubation with AMD3100 inhibited SDF-1 induced chemotaxis of
CXCR4+ splenocytes in vitro. Taken together, these results demonstrate that inhibition of the
CXCR4/SDF-1 axis might serve as a novel strategy to treat patients with inflammatory skin disorders
such as psoriasis.
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Efficacy of targeting Janus kinase pathways by tofacitinib in a human psoriatic lesional skin
xenograft transplantation model
H Ma,1 K Stenderup,2 C Rosada,2 L Napierata,1 K Masek-Hammerman,3 M Hegen,1 TN Dam4 and
JD Clark1 1 Immunoscience Research Unit, Pfizer Inc, Cambridge, MA, 2 Department of
Dermatology, Aarhus University Hospital, Aarhus, Denmark, 3 Drug Safety Research &
Development, Pfizer Inc, Cambridge, MA and 4 Department of Dermatology, Roskilde
Hospital, Roskilde, Denmark
Tofacitinib is a novel Janus kinase (JAK) inhibitor that has demonstrated efficacy in psoriasis clini-
cal trials. Tofacitinib preferentially inhibits signaling by JAK3 and/or JAK1 with functional selectiv-
ity over JAK2. Inhibition of JAK1 and JAK3 blocks the common gamma chain signal for cytokines
including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Inhibition of JAK1 also attenuates signaling by
additional pro-inflammatory cytokines, such as type I interferons and IL-6. Together these cytokines
are important to lymphocyte function and differentiation and therefore regulate multiple aspects of
the immune response. To understand the mechanisms whereby tofacitinib improves psoriasis, we
employed a human psoriatic lesional skin xenotransplantation model. Here we demonstrated that
tofacitinib treatment of CB.17 SCID mice engrafted with human psoriatic skin reduced clinical signs
of psoriasis in the grafts when compared to grafted skin from mice that received vehicle only. His-
tologic analysis confirmed the clinical data: epidermal thickness, parakeratosis, angiogenesis,
granulocyte and lymphocyte scores, and the number of cells expressing pSTAT3 were significantly
decreased (p<0.005) in grafts from mice treated with tofacitinib relative to vehicle-treated mice.
Gene expression analysis of the psoriatic skin revealed that tofacitinib also significantly down
modulated various cytokines, chemokines, receptors and signaling factors including CTSC, CXCL1,
IL-12RB1, and IL-15 (p<0.05). The inhibition of IL-6 and IL-21 signaling may be responsible for the
reduction in IL-12RB1 subunit which is shared by both IL-23 and IL-12 receptor complex. These
results contribute to our understanding of the underlying mechanism of the efficacy observed in the
positive psoriasis clinical trial for tofacitinib.
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Cytokine-induced insulin resistance in endothelial cells contributes to the pathogenesis of
psoriasis and its co-morbidities
K Woth,1 S Diehl,1 V Lang,1 W Boehncke2 and C Buerger1 1 Department of dermatology,
Universityhospital, Frankfurt a.M., Germany and 2 Service de dérmatologie, Hôpital
Universitaire, Geneva, Switzerland
Psoriasis is a chronic inflammatory skin disease, which shows also a systemic dimension. This is
represented by its co-morbidities such as the metabolic syndrome, diabetes and cardiovascular dis-
eases. Due to the various similarities between a psoriatic and an artherosclerotic plaque, we hypoth-
esize that a common pathomechanism is underlying these formations. A possible link might be rep-
resented by inflammation-driven insulin resistance, as under healthy conditions insulin is both cardio
protective and anti-inflammatory. We could previously show that “psoriatic cytokines” (IL-1β, IL-
17, IL-22, IL-23 and TNF-α) can induce insulin resistance in primary dermal microvascular endothe-
lial cells which was measured by the insulin-dependent phosphorylation of PKB. Moreover we could
demonstrate that JNK is the key kinase in mediating insulin resistance by using chemical inhibitors
and siRNA mediated knockdown. In order to investigate the functional consequences of insulin
resistance, we examined the expression of adhesion molecules which are involved in the process
of transendothelial migration of lymphocytes. The expression of these molecules on the cell surface
is repressed by insulin and altered under conditions of insulin resistance. Furthermore we investi-
gated the rolling and adhesion of lymphocytes on the endothelial cell layer under static and flow
conditions. We could show that both processes are altered under insulin-resistant conditions. There-
fore we suggest that under conditions of systemic inflammation as in psoriasis the disturbed insulin
response contributes to the pathogenesis of psoriasis and its co-morbidities by regulating the pres-
entation of adhesion molecules on the endothelial surface and thereby contributing to lymphocyte
extravasation. Therapeutic approaches interfering with the altered insulin response in psoriasis might
by very effective by targeting both the dermal as well as the cardiovascular dimension of psoriasis.
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Integration of lyoplate based flow cytometry and computational analysis for standardized bio-
marker discovery in inflammatory skin diseases
F Villanova,1,2 P Di Meglio,1,2,3 M Inokuma,4 N Aghaeepour,5 E Perucha,6 J Mollon,7 L Nomura,4
M Hernandez-Fuentes,6,2 A Cope,8 S Heck,2 V Maino,4 G Lord,6,2 RR Brinkman5,9 and FO Nestle1,2
1 St. John’s Institute of Dermatology, King’s College London, London, United Kingdom, 2 NIHR
GSTT/KCL Comprehensive Biomedical Research Centre, Guy’s & St. Thomas’ NHS Foundation
Trust, London, United Kingdom, 3 Molecular Immunology, National Institute for Medical
Research, London, United Kingdom, 4 Biological Research & Development, BD Biosciences,
San Jose, CA, 5 Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada, 6 MRC
Centre for Transplantation, King’s College London, London, United Kingdom, 7 Division of
Genetics and Molecular Medicine, King’s College London, London, United Kingdom, 8
Academic Department of Rheumatology, King’s College London, London, United Kingdom and
9 Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada
Discovery of immunological biomarkers for monitoring immune-mediated inflammatory diseases
is an important unmet clinical need. In this study we establish a novel framework for immunolog-
ical biomarker discovery, comparing a conventional (liquid) flow cytometry platform (CFP) and a
unique lyoplate-based flow cytometry platform (LFP) in combination with advanced computational
data analysis. Peripheral blood mononuclear cells from healthy volunteers were stimulated and
stained using either liquid or lyophilized reagents for the analysis of different T cell subsets and
their cytokine production. We found increased detection of cytokines (IFN-γ and IL-10) and acti-
vation markers (Foxp3 and CD25) by using LFP compared to CFP. Moreover fluorescent intensity
of cells stained with lyophilized antibodies was increased compared the liquid counterpart. LFP
allowed medium-throughput processing of samples, and saved acquisition time keeping a compa-
rable intra- and inter-assay variability compared to CFP. Automated computational analysis applied
to the same data set identified novel immunophenotypes, such as CD25+ and FoxP3+ cells, previ-
ously not identified via manual analysis. Our results establish a new flow cytometry platform for
standardized and rapid immunological biomarker discovery with wide application to inflamma-
tory skin diseases.
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Development of an ELISA for detection of soluble Thy-1 and its application in evaluation of
pulmonary involvement in patients with systemic sclerosis
M Schmidt,1 A Saalbach,1 D Gutknecht,1 S Christoph2 and F Kollert2 1 Department of
Dermatology, Venerology and Allergology, Medical Faculty of the Leipzig University, Leipzig,
Germany and 2 Department of Rheumatology and Clinical Immunology, University Medical
Center, Freiburg, Germany
Recently, we described Thy-1 as an activation-associated molecule on human dermal microvascu-
lar endothelial cells. In contrast, human dermal fibroblasts exhibit a constitutively high expression
of Thy-1. Since Thy-1 is a glycosylphosphatidylinositol-anchored glycoprotein it might be shedded
from the cell surface. Indeed, treatment of fibroblasts with phospholipase C causes the cleavage of
membrane bound Thy-1 and the generation of soluble Thy-1 (sThy-1), which can be detected by
Western blot. Soluble receptors such as sVCAM-1, sICAM-1 are able to regulate or block important
immunological or biological interactions. Therefore, an enzyme-linked-immunosorbent assay (ELISA)
was established to determine sThy-1 in serum and biological fluids such as wound fluid or synovial
fluid. Since it is discussed that expression of Thy-1 is associated with a fibrotic phenotype of fibrob-
lasts, sThy-1 was detected by ELISA in the serum of patients with systemic sclerosis (SSc), a fibrotic
disease with unknown etiology. Therefore sThy-1 concentrations were measured in 76 patients
with SSc compared to 31 healthy volunteers. Soluble Thy-1 levels were significantly increased in
the sera of SSc patients compared to healthy controls. Moreover, sThy-1 levels were enhanced in
SSc patients with pulmonary involvement including pulmonary arterial hypertension (PAH) or pul-
monary fibrosis compared to SSc patients without pulmonary involvement. Taken together, Thy-1
can be cleaved from the cell surface and sThy-1 can be detected by ELISA. In sera of SSc patients
sThy-1 is increased supporting data from mouse models showing an association of Thy-1 expres-
sion and the development of fibrosis. Finally, enhanced levels of sThy-1 in sera of SSC patients with
pulmonary involvement suggest a potential value of sThy-1 as a marker for the presence of PAH in
SSc.
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Contact of Treg to dendritic cells (DC) is guided by Treg-derived adenosine, inducing directed
migration and recruitment of adhesion molecules in DC via adenosine A2A receptors
S Ring, A Pushkarevskaya, A Enk and K Mahnke Ruprecht Karls University, Heidelberg,
Germany
In cocultures, dendritic cells (DC) and regulatory T cells (Treg) form aggregates within 2h. The DC/Treg
interaction was specific, as even in presence of CD4+ T-cells aggregates developed only between
Treg and DC. Molecules involved were ICAM-1, connexins, as well as LFA-1, all of which accu-
mulated in the plasma membrane at the contact zone between Treg and DC, indicating formation
of a defined “synapse”. Analysis of the migratory behavior of individual cells in the cocultures showed
increased motility of the DC in presence of Treg as opposed to conventional CD4+ T cells (Tcon).
As Treg, in contrast to Tcon, express the adenosine-producing ectonucleotidase CD39, we next asked
whether blockade of CD39 affect the aggregation. Indeed, the addition of the CD39 antagonist POM-
1 caused a complete inhibition of the chemotactic activity of Treg on DC and prevented formation
of aggregates. To identify the source of adenosine in DC–Treg cocultures, we generated bone mar-
row derived DC and isolated Treg from CD39KO and wt mice and set up mixed cocultures. CD39KO
DC were still able to aggregate with Treg, whereas CD39KO Treg did not interact with wt DC.
Moreover, CD39KO Treg did not stimulate motility and directed migration of DC towards Treg. To
identify the responsible adenosine receptor(s), we preincubated DC with antagonists for the four
known adenosine receptors (A1, A2A, A2B and A3) and cocultured them with Treg. These experi-
ments revealed that specifically the adenosine A2A receptor antagonist blocked the adenosine-
induced motility of DC and formation of clusters with Treg. In contrast, all other adenosine recep-
tor antagonists showed no effects. Thus, our data indicate that adenosine produced by Treg exerts
chemotactic activity on DC by engaging A2A receptors and as a result Treg-DC aggregates develop.
This interaction may render DC less stimulatory and may provide an additional means by which
Treg suppress immunologic functions.
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Serum IgA reactivity against GroEL of Streptococcus sanguinis and human hnRNP A2/B1 in
patients with Behçet’s disease
S Cho,1 Z Zheng,1 K Ahn,2 M Choi,1 S Cho,1 D Kim,1 H Lee3 and D Bang1 1 Department of
Dermatology and Cutaneous Biology Research Institute, Yonsei University College of
Medicine, Seoul, Republic of Korea, 2 Specialization Research Center, Hallym University
Hangang Sacred Heart Hospital, Seoul, Republic of Korea and 3 Department of Biostatistics,
Yonsei University College of Medicine, Seoul, Republic of Korea
Infectious agents, especially Streptococcus sanguinis (S. sanguinis) and herpes simplex virus, have
long been postulated to be major triggering factors for Behçet’s disease (BD). The aim of this study
was to identify an anti-S. sanguinis antigen reacting with serum IgA antibody in BD patients. We
detected a target protein by proteomics analysis and evaluated serum IgA reactivity of 100 BD
patients against the identified streptococcal target protein and human hnRNP A2/B1. Homologous
epitope sequences between the streptococcal target protein and human hnRNP A2/B1 were also
evaluated. Four protein bands were detected by immunoprecipitation, and chaperonin GroEL was
identified by a proteomics analysis. Reactivity of serum IgA against recombinant S. sanguinis GroEL
was detected in 73 of 100 BD patients (73%) and in 21 of 70 healthy controls (30%). In addition,
reactivity of serum IgA against human recombinant hnRNP A2/B1 was present in 79 of 100 BD
patients (79%) and in 8 of 70 healthy controls (11.4%). Among the eight distinctive epitopes with
significant homology between S. sanguinis GroEL and human hnRNP A2/B1, the serum IgA reac-
tivity of BD patients was markedly higher with epitope 3 (hnRNP A2/B1 peptide 33-46 and GroEL
peptide 57-70) and epitope 6 (hnRNP A2/B1 peptide 177-188 and GroEL peptide 347-358). In
conclusion, we identified a S. sanguinis GroEL protein as a target of serum anti-S. sanguinis IgA
antibody reactivity in BD patients. In addition, BD patients exhibited serum IgA reactivity against
homologous epitope regions between S. sanguinis GroEL and human hnRNP A2/B1.
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The lipohormesis: A new concept to fight aging by a lipostructure-like activity
C Bezivin1 and E Loing2 1 R&D, Lucas Meyer Cosmetics, Champlan, France and 2 R&D, Lucas
Meyer Cosmetics, Québec, QC, Canada
Age-related modification of the facial structure due to lipoatrophy is one of the new concerns of
consumers over the age of 50. Indeed subcutaneous adipose tissue is responsible for the plump
aspect of the face but with aging, this fat pads progressively melts. A lipofilling-like cosmetic ingre-
dient therefore must activate adipose tissue growth by acting on several factors of adipocytes metab-
olism including activation of adipogenesis, activation of lipogenesis and inhibition of lipolysis. To
act on all these parameters at the same time, a key factor has been identified, the HIF1A (Hypoxia
Inducible Factor) which represent a new target for the control of adipose tissue growth. We demon-
strated that an ionosome of ornithine is able to induce this hormetic factor, which mimics a hypoxia,
and so to activate a biocontrolled expansion of adipose tissue. The mechanism of this ingredient
has been discovered by a kinetics gene expression study which has underlined a first transient
stress induction following by the expression of different genes implied in the physiological growth
of adipose tissue (expression of genes controlling adipogenesis, increase of fatty acids storage, glu-
cose oxidation, lipogenesis…). The results of this gene expression study have been confirmed in
vitro on human adipocytes culture by the measurement of the fatty acid release. Indeed a dose
dependent-decrease (-11% at 0.05% and -29% at 0.2% of the ornithine ionosome) of the non-
esterified fatty acids has been observed for the ornithine ionosome. The efficiency of the ionosome
of ornithine (2% in a basic cream compared to a placebo cream control) has been evaluated by a
clinical study on the nasogenian fold which demonstrated a significant decrease in the wrinkle depth
(-9.5% vs +3.2% for the placebo control) and in the skin roughness (-5.9% vs + 3.1% for the placebo
control) after only 30 days of treatment. This new mechanism of action, the lipohormesis has been
described and validated as a key target in the treatment of skin structural disorders caused by age-
related lipoatrophy.
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Vasoconstriction and anti-inflammatory properties of the alpha adrenergic receptor agonist
brimonidine
D Piwnica, C Rosignoli, S Cazareth, M Schuppli-Nollet, A Jomard and J Aubert Research,
Galderma, Sophia Antipolis, France
The transient and non-transient facial erythema of rosacea is the most prevalent and also the most
difficult manifestation of the disease to treat. The alpha-adrenergic receptor agonist brimonidine is
an alpha-2 selective agonist that is currently under regulatory review as the most advanced prom-
ising new therapy for the facial erythema of rosacea, whereas oxymetazoline, a non-specific alpha
agonist, is currently in clinical development for the same indication. These compounds are thought
to reduce erythema through vasoconstriction of cutaneous blood vessels. To investigate the effects
of brimonidine on vasoconstriction in humans, the contraction of isolated human cutaneous arter-
ies and veins was monitored using wire myography. Interestingly, brimonidine was more potent
and selective than oxymetazoline on small cutaneous arteries, less than 200μm (which represent
the larger vessels in the dermis). In addition, brimonidine was very active on veins, in which vasodi-
latation appears to have a major incidence in skin redness. Additionally, to investigate the effect of
brimonidine on skin inflammation, ears of mice were topically treated with brimonidine and fol-
lowing topical application of arachidonic acid (ARA), ear swelling was measured as an indicator of
inflammation. After a single topical application, 0.2% brimonidine reduced ARA-induced ear edema
in mice by up to 80.8% (p<0,01), demonstrating a strong anti-inflammatory effect. Finally, the pro-
filing of brimonidine on more than 200 targets confirmed the high specificity towards alpha-adren-
ergic receptors and especially alpha-2 subtypes. Taken together, these data suggest that brimonidine
has both vasoconstrictive and anti-inflammatory properties, both of which would be beneficial in
the treatment of rosacea. Moreover, we show that the action of brimonidine is highly selective with
respect to the molecular targets and blood vessel diameters, a property that may be desirable from
a safety point of view in the context of daily chronic treatment.
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Herpes simplex virus 1 antibodies in patients with pemphigus vulgaris are increased com-
pared to healthy controls
P Senger,1 M Hoffman,1 G Singh,1 D Murro,2 K Seiffert-Sinha1 and AA Sinha1 1 Dermatology,
University at Buffalo and Roswell Park Cancer Institute, Buffalo, NY and 2 Georgia Health
Sciences University, Augusta, GA
Pemphigus vulgaris (PV) is an autoimmune skin disorder characterized by painful blisters in the
skin and/or mucous membranes. Although a strong genetic link has been established, the exact eti-
ology of PV remains uncertain. Environmental factors, in addition to genetic components, are believed
to contribute significantly to disease pathogenesis and etiology. Specifically, the role of the herpes
simplex virus (HSV) and its influence on disease has been explored in multiple studies, but on lim-
ited numbers of patients and with inconsistent results. In order to more definitively explore the rela-
tionship between HSV1 and PV, we compared the relative levels of the HSV1 IgG antibody in
serum of PV patients (active, n=56 and remittent, n=38) and healthy controls (n=50) by ELISA, the
largest such evaluation thus far. Index values were calculated for each patient/control group. The
average index values of PV patients, regardless of disease phase (1.24±0.99), were found to be sig-
nificantly higher than controls (0.86±0.72) (p=0.018, t-test). These differences were largely attrib-
utable to patients in the active phase of disease; the average index value of active patients (1.38±1.03)
was found to be significantly higher than that of controls (p=0.007), while there was no significant
difference was measured between remittent patients (0.99±0.80) and controls (p=0.415). We did
observe a trend towards significance when comparing active vs. remittent patients (p=0.087). Our
data support a potential link between HSV and PV manifestation and expression. Further research
is needed to determine whether HSV is causally linked to PV pathogenesis or represents an epiphe-
nomenon of disease, and to determine potential mechanisms by which HSV might influence clin-
ical disease manifestation.
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Over-expression of AIRE and lack of Dsg1 expression in thymoma associated with a PF patient:
An implication for novel mechanisms of autoimmune development
A Tsuchisaka,1 S Kaneko,2 M Furumura1 and T Hashimoto1 1 Dermatology, Kurume University,
Kurume, Japan and 2 Dermatology, Shimane University, Izumo, Japan
Thymomas are tumors of thymic epithelial cells and about 40% patients with thymoma show
parathymic syndromes, including myasthenia gravis and other autoimmune diseases. In this study,
we attempted to detect autoantigens of pemphigus in thymoma tissues. We collected various tissue
samples of 7 thymomas, 1 thymic carcinoma and 2 persistent thymus. One thymoma patient was
complicated with pemphigus foliaceus (PF) showing IgG autoantibodies exclusively to desmoglein
(Dsg) 1, which is one of desmosomal cadherins and known as PF antigen. We first examined expres-
sion of various desmosomal cadherins, i.e., Dsg1-3 and desmocollins (Dscs) 1-3, by immunoblot-
ting (IB) using extracts from thymomas. This study revealed that Dsgs and Dscs were expressed in
variable extents in individual tumors, with some negative results. Intriguingly, the extracts from the
PF thymoma showed much stronger reactivity with Dsgs and Dscs, except for Dsg1, than the extracts
from other tumors. These results were confirmed by immunofluorescence (IF) and immunohisto-
chemical (IHC) analyses. The autoimmune regulator (AIRE) promotes the expression of self-anti-
gens in the thymus, but is reported to be absent in thymomas. Because we speculated that PF thy-
moma expressed AIRE, which was responsible for the abnormally higher expression of various
antigens, we also examined AIRE expression in thymic tumors by IB and IHC analyses. Surprisingly,
reactivity with AIRE was detected only in PF thymoma, but no or weak reactivity in other tissues.
From these results, we suggest that ectopic expression of AIRE in thymomas may induce aberrant
expression of various self-antigens. In our PF case, Dsg1 expression might be suppressed by over-
expression of other desmosomal cadherins by unknown mechanisms, and the lack of Dsg1 expres-
sion may cause PF development.
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GARP modifies T cell activation and differentiation in vitro and in vivo
SA Hahn,1 HF Stahl,2 H Jonuleit1 and A Tuettenberg1 1 Department of Dermatology, University
Medical Center of the Johannes Gutenberg University, Mainz, Germany and 2 Boehringer
Ingelheim Pharma GmbH & Co. KG, Research Germany, Biberach an der Riss, Germany
CD4+CD25+Foxp3+ regulatory T cells (Treg) prevent the activation of autoaggressive T cells in the
context of autoimmune diseases such as psoriasis. One major activation maker on Treg is GARP
(glycoprotein A repetitions predominant) which binds and activates latent TGF-β a well known sup-
pressor of inflammatory T cell activation. To investigate the potential role of GARP as a therapeutic
drug to treat inflammatory disorders we generated soluble GARP protein (sGARP) and analyzed the
functional assignment of sGARP in the differentiation and activation of human CD4+ T cell. Here
we show that sGARP significantly upregulates Foxp3 and suppresses the proliferation and effector
cytokine production such as IFN-γ and IL-2. These effects are only verifiable in resting and naïve
CD4+CD45RA+ T cells but not in differentiated CD4+CD45RO+ T cells. Furthermore, repetitive stim-
ulation of naïve cordblood-derived CD4+ T cells in presence of sGARP induce their differentiation
into adaptive regulatory T cells which suppress the activation of differentiated T effector cells in
coculture. To investigate whether sGARP is able to modulate unwanted T cell-mediated inflamma-
tion in vivo, we used sGARP in a pre-clinical humanized mouse model of graft-versus-host diseases
(GvHD). Repetitive applications of sGARP prevent GvHD onset and T cell-mediated destructive
inflammation including strong inhibition of autoaggressive skin inflammation. Taken together, our
results indicate a crucial role for GARP in the modulation of peripheral tolerance and open the pos-
sibility to use sGARP as an immune modifier in the treatment of transplantat rejection and inflam-
matory disorders such as T cell-mediated autoimmunity and allergic diseases.
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Genetic support for a role for the NLRP1 inflammasome in psoriasis
A Ekman,1 D Verma,1 C Bivik,1 M Fredrikson2 and C Enerbäck1 1 Ingrid Asp Psoriasis Research
Center, Division of Cell biology and Dermatology, Department of Clinical and Experimental
Medicine, Faculty of Health Science, Linköping University, Linköping, Sweden and 2 Division
of Occupational and Environmental Medicine, Department of Clinical and Experimental
Medicine,, Faculty of Health Science, Linköping University, Linköping, Sweden
Psoriasis is an immune-mediated skin disease. NLRP1 is part of the NLRP1 inflammasome, a cytoso-
lic multiprotein complex that cleaves pro-interleukin (IL)1β and pro-IL-18 to their biologically active
forms. Single nucleotide polymorphisms (SNPs) in the NLRP1-coding gene may contribute to the
dysregulated immune response in psoriasis. We investigated the role of four SNPs in NLRP1:
rs6502867, rs8079034, rs878329 and rs12150220. In a well-defined, family-based patient sample
comprising 1,847 individuals from 478 families and 802 healthy controls, genotypes for selected
single nucleotide polymorphisms (SNPs) in NLRP1 were determined by TaqMan Allelic Discrimi-
nation. Transmission Disequilibrium Test was used to determine if there was a preferential trans-
mission of NLRP1 allele to patients with psoriasis and a case-control comparison was performed to
determine if the genotypes were more highly represented in psoriasis patients than in healthy con-
trols. Plasma levels of IL-1β and IL-18 were measured in age- and gender-matched psoriasis patients
and healthy controls using a Luminex cytokine assay. A significant increase in the transmission of
the NLRP1 rs8079727 and rs878329 alleles was demonstrated (p=0.006 and p=0.033, respectively).
In the case-control comparison, the genotypes rs6502867, rs878329 and rs12150220 were found
to be significantly overrepresented (p<0.0005 for each) in psoriasis patients. A higher level of IL-18
was seen in plasma from psoriasis patients. An increased susceptibility risk for psoriasis in the pres-
ence of NLRP1 rs6502867, rs878329 and rs12150220 polymorphisms was observed along with an
increased transmission of the NLRP1 rs8079727 and rs878329 polymorphisms.
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The role of PPARγ in the control of sebogenesis in vitro. Prospective for novel treatment of
acne
A Mastrofrancesco,1 M Ottaviani,1 D Kovacs,1 M Ludovici,1 C Zouboulis,2 E Camera1 and
M Picardo1 1 S Gallicano Dermatologic Institute, Cutaneous Physiopathology, Rome, Italy and
2 Dessau Medical Center, Depts. of Dermatology, Venereology, Allergology and Immunology,
Dessau, Germany
Acne has a multifactorial pathogenic mechanism wherein increased sebum and inflammation play
a central role. Evidence suggests that dietary glycemic load and insulin signaling play an important
role in the sebaceous gland activity and skin inflammation influencing sebum composition and
low glycemic diet seems to ameliorate clinical manifestations. A growing body of findings indi-
cates that peroxisome proliferators-activated receptor gamma (PPARγ), which regulates lipid and
glucose metabolism, controls lipogenesis even in sebaceous gland cells. We demonstrated that a
newly designed PPARγmodulator (GMG-43AC) exerts anti-inflammatory activity in stimulated sebo-
cyte cell line (SZ95) and normal human keratinocytes. In this study we investigated the role of GMG-
43AC on the regulation of the sebaceous lipid synthesis induced by insulin on SZ95 focusing on
intracellular pathway. GMG-43AC significantly reduced the sebaceous lipid synthesis evaluated by
the Nile Red and GC-MS assay. On insulin-stimulated SZ95 the reduction of SREBP nuclear tran-
scription factor and target genes such as Fatty Acid Synthase, Stearoyl-CoA Desaturase 1 and HMG-
CoA reductase at mRNA level was detect. The specific PPARγ inhibitor GW9662 abolished the effect
of GMG-43AC on the lipogenic genes. The insulin activated MAPK/extracellular regulated kinase
(ERK1/2) and phosphatidylinositide 3-kinase-Akt pathways were down-modulated by GMG-43AC.
These results highlighted the ability of GMG-43AC to counteract sebogenesis induced by hyperin-
sulinemic stimulus offering the possibility for a new promising drug for the treatment of acne.
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Apoptosis has a role in the disturbed homeostasis of epidermal keratinocytes in psoriasis
C Bivik, M Carlström and C Enerbäck Ingrid Asp Psoriasis Research Center, Department of
Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University,
Linköping, Sweden
Psoriasis is a chronic inflammatory skin disease, affecting about 3% of the population. Hyper pro-
liferation of epidermal keratinocytes and incomplete terminal differentiation lead to a thick layer of
cornified cells, called psoriatic plaque. The homeostasis of cells is regulated by processes includ-
ing both proliferation and apoptosis. However, apoptotic cell death has been given very limited
attention in psoriasis. In this study, we investigated the apoptotic process in UV irradiated cultured
keratinocytes established from psoriatic skin punch biopsies (both involved and uninvolved skin
areas) as well as from healthy control skin. The results demonstrated significantly higher viability of
UVB exposed cells established from both involved and uninvolved psoriatic skin compared to healthy
controls. To see whether the observed UV resistance was due to inhibited apoptosis, caspase-3 activ-
ity assays were performed. The results clearly demonstrated different apoptotic response between
the samples. The control cells showed a marked caspase-3 activity following UV exposure, while
in keratinocytes from both involved and uninvolved psoriatic skin the activity was significantly dimin-
ished. Western blot analyses of cytosolic fractions displayed higher cytochrome c level in ker-
atinocytes from healthy control cells compared to psoriatic keratinocytes following UVB irradiation.
In conclusion, our data suggest a dysregulated apoptotic process in psoriatic keratinocytes, which
may contribute to the disease pathogenesis. Interestingly, keratinocytes from uninvolved psoriatic
skin did also demonstrate UV resistance compared to healthy control cells. Furthermore, the exper-
iments identify the position for dysregulation to be located upstream of cytochrome c release in the
mitochondrial pathway.
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Keratinocytes from patients with atopic dermatitis express high levels of histamine 4 recep-
tor which mediate histamine induced proliferation
F Glatzer,1 M Gschwandtner,1,2 S Mommert,1 T Werfel1 and R Gutzmer1 1 Dermatology and
Allergy, Medical School Hannover, Hannover, Germany and 2 Dermatology, Medical
University of Vienna, Vienna, Austria
Atopic dermatitis (AD) is a common disease which affects up to 20 % of the population and clearly
lowers the quality of life. The involved pathophysiologic mechanisms of this disease are not fully
understood until now. Hyperproliferation of keratinocytes, resulting in acanthosis is one important
observation in AD. Also elevated levels of histamine are observed in lesional skin. The focus of our
study was the analysis of histamine effect on the proliferation of human keratinocytes, especially
with regard on histamine 4 receptor (H4R). We isolated outer root sheath keratinocytes from healthy
donors and from patients with AD and determined H4R expression with real-time PCR was used.
Proliferation was evaluated by in vitro cell proliferation assay and by scratch assays. We observed
higher H4R mRNA expression on keratinocytes from patients with AD compared with non-atopic
donors. These keratinocytes responded to stimulation with histamine or with an H4R agonist with
a significant higher proliferation compared with non-stimulated control cells. The observed upreg-
ulation of proliferation was blocked by pre-incubation with the specific H4R-antagonist JNJ7777120.
Furthermore the incubation of AD keratinocytes with histamine or a specific H4R agonist led to a
faster closure of scratching wounds. The H4R antagonist JNJ7777120 reversed this histamine and
agonist effect. In summary we describe a high H4R expression on keratinocytes from AD patients
and define a functional role on these cells. The stimulation of keratinocyte proliferation through
histamine via H4R may represent a mechanism that contributes to the observed epidermal hyper-
plasia in patients with AD. These findings contribute to the thesis that H4R antagonists may repre-
sent a novel approach for the treatment of AD.
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From the skin to the bone: Pro-osteoclastogenesis inflammatory march
A Balato, A Raimondo, S Lembo, M Schiattarella, M Mattii, R Di Caprio, N Balato and F Ayala
Dermatology, University Federico II, Naples, Italy
Up to 30% of psoriasis (Ps) patients develop psoriatic arthritis (PsA): in approximately 80% of
cases, arthritis follows Ps in a mean period of 10 years. Pro-inflammatory mediators involved in the
pathogenesis of both disease, including interleukin (IL)-33, osteopontin (OPN) and tumor necrosis
factor (TNF)-α are increased in the synovium as well as in the skin and contribute to osteoclasto-
genesis and bone erosion. The aim of this study was to assess the ability of pro-inflammatory medi-
ators such as IL-33, OPN and TNF-α to induce skin prompted osteoclastogenesis. Ex vivo skin
organ cultures from healthy donor were stimulated with IL-33, OPN, TNF-α and gene expression
of RANKL, IL-6, IL-33, OPN, TNF-α, ST2L, OPG, IL-4, IL-13 and IL-10 was analyzed. Culture
supernatants were harvested and used to stimulate healthy donor PBMCs. After 15 days, we per-
formed osteoclasts identification through tartrate resistant acid phosphatase (TRAP) staining and
osteoclasts activity assessment through TRAF6, NFATC1 and Cathepsin K gene expression. Our
results showed that pro-osteoclastogenesis mediators RANKL, IL-6, IL-33, OPN and TNF-α were
overexpressed in ex vivo skin organ cultures stimulated with recombinant IL-33, OPN and TNF-α
in a time, but not dose, dependent manner. Conversely, anti-osteoclastogenesis factors such as OPG,
IL-4, IL-13 and IL-10 were downregulated respect to unstimulated skin. Osteoclasts overdifferenti-
ated when healthy PBMCs were cultured with supernatants from stimulated skin. Similarly the acti-
vation markers of mature osteoclasts, TRAF6, NFATC1 and Cathepsin K, were enhanced. Our results
suggest the possibility of a “pro-osteoclastogenesis march” induced by cutaneous pro-inflamma-
tory mediators.
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Anti-inflammatory and anti-pruritic effects of topical kappa-opioid receptor agonist WOL071-
007 in murine models of skin inflammation
M Soeberdt, U Knie and C Abels Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld,
Germany
Small molecule kappa-opioid receptor (KOR) agonists have been widely investigated as potential
analgesics and for the treatment of pruritus. However, effects in the central nervous system are
accompanied by sedation, dysphoria or diuresis. In this study we investigated anti-pruritic and anti-
inflammatory effects of a novel KOR agonist WOL071-007 following topical administration in vivo.
In the topical arachidonic acid (AA)-induced ear swelling model in mice WOL071-007 at 0.1 to 3
mg/ear and vehicle (acetone/ethanol (1:1)) were each administered 30 min before and 15 min after
AA (5 mg/ear). WOL071-007 at 0.3, 1 and 3 mg/ear caused significant (p<0.05) reduction of ear
swelling relative to vehicle. Moreover, WOL071-007 at 0.1, 0.3, 1 and 3 mg/ear was associated with
significant (p<0.05) inhibition of scratching in a dose-dependent manner. In addition, WOL071-007
was tested in a mouse model of oxazolone-induced dermatitis. Mice were challenged on days 5
and 7-12. On days 7-18, vehicle and WOL071-007 (0.02 to 2.5 mg in 20 μl acetone/ethanol (1:1))
was daily applied on right ear 3 h prior oxazolone challenge on days 7-12. Dosing continued with-
out oxazolone through day 18. WOL071-007 at 2.5 mg caused significant (p<0.05) reduction of
ear swelling on days 9-14. Lower doses of WOL071-007 showed little or no effect. Histological
analysis showed dose dependent effects of WOL071-007 on ear thickness, epidermal thickness
and dermal infiltrate. Effects of the 0.1 and 0.5 mg doses were slightly weaker compared to 0.6 mg
hydrocortisone. Topical application of a selective and potent KOR agonist showed significant anti-
inflammatory effects in a dermatitis model. Thus, KOR agonists should be further investigated as
treatment for inflammatory skin diseases.
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IL-33 effects in psoriasis: The induction of pro-inflammatory cytokines via keratinocyte and
mast cell activation 
A Balato, S Lembo, M Mattii, M Schiattarella, R Di Caprio, L Di Costanzo, N Balato and F Ayala
Dermatology, University Federico II, Naples, Italy
Interleukin-33 (IL-33) is the most recent addition to the IL-1 family. It has been shown to function
as a ligand for the IL-1 receptor-related protein ST2. Although originally defined as an inducer of
Th2-mediated responses, IL-33 was recently found to be involved in arthritis as well as in psoriasis,
typical Th1/Th17-mediated diseases. The aim of our study was to investigate the role of IL-33 in
psoriasis pathogenesis through its ability to promote inflammation via mast cells (MCs) and ker-
atinocytes (KCs) activation. From in vivo findings, IL-33 resulted elevated in lesional and non lesional
skin but not in the serum of psoriasis patients. IL-33 has been shown to be present in the nucleus
as well as in the cytoplasm and in the tight junctions of psoriatic KCs; moreover extracellular secre-
tion was induced by TNF-α in immortalized KCs. HaCaT cells, human MCs line (HMC-1) and pri-
mary KCs overexpressed IL-33 after TNF-α stimulation, but not after IL-17. TNF-αwas able to induce
IL-6, MCP-1, VEGF and the addition of IL-33 reinforced these increases. TNF-α and IL-33 combi-
nation was also able to induce IL-6 and MCP-1 in ex vivo cultured healthy skin specimens. Our
study provides evidence that IL-33 may have a role in psoriasis biology, and that its pathway may
involve KCs and MCs.
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GATA-3 cleavage by DNAzymes as therapeutic approach for the treatment of allergic skin
diseases
U Purath,1 R Ibrahim,2 A Turowska,1 U Homburg,1 F Runkel,3 T Schmidts,3 D Dobler,3 H Renz,2
H Garn2 and A Mueller1 1 sterna biologicals GmbH & Co. KG, Marburg, Germany, 2 Research
Division of Clinical Chemistry and Molecular Diagnostics, Hospital of the University,
Marburg, Germany and 3 University of Applied Sciences, Giessen, Germany
GATA-3 represents the central regulatory molecule in the differentiation and activation of Th2 cells
and is necessary and sufficient for Th2 cytokine expression in CD4-positive T cells. Thus, it repre-
sents the master transcription factor in the development of allergic immune reactions making it a
promising target for therapeutic intervention. We have developed a meanwhile patented GATA-3
specific DNAzyme – called hgd40. In general, DNAzymes are catalytically active single-stranded
DNA molecules that consist of two binding domains flanking a central catalytic domain. They rep-
resent a particular class of antisense molecules combining the superior specificity of antisense mol-
ecules with an inherent catalytic activity which makes them an attractive tool for the specific inter-
ference with disease-causing target molecules. In the present study we tested the potential inhibitory
efficacy of hgd40 formulated in a newly developed water-in-oil-in-water (W/O/W) emulsion in a
model of oxazolone-induced allergic contact dermatitis in mice designed to induce prolonged skin
swelling reactions thereby enabling the analysis of treatment effects on T cell-mediated pathome-
chanisms. Treatment with topically applied hgd40 significantly and dose dependently reduced
oxazolone-induced skin swelling reactions. Infiltration of inflammatory cells into the skin was also
reduced by treatment with hgd40. No adverse effects due to hgd40 or the emulsion were detected,
while treatment with dexamethasone, though very effective with respect to skin swelling and infil-
tration, showed clear adverse effects like scaling and skin atrophy. Taken together, W/O/W-formu-
lated DNAzyme hgd40 represents a new and promising therapeutic concept for the topical treat-
ment of allergic skin diseases.
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Dermal CARD14 expression in psoriasis
JL Harden,1 K Pierson,1 M Suárez-Fariñas,1 A Chiricozzi,1,2 R Goldbach-Mansky,3 A Bowcock4 and
MA Lowes1 1 Department for Investigational Dermatology, The Rockefeller University, New
York, NY, 2 Department of Dermatology, University of Rome Tor Vergata, Rome, Italy, 3
Translational Autoinflammatory Disease Section, NIH/NIAMS, Bethesda, MD and 4
Department of Genetics, Division of Human Genetics, Washington University School of
Medicine, St. Louis, MO
Mutations in the casapase recruitment domain, family member 14 (CARD14) gene have recently
been described in some psoriasis patients, and explain psoriasis susceptibility locus 2 (PSORS2).
CARD14 is a multi-domain scaffold protein that regulates NF-κB activation. Psoriasis-associated
CARD14 alterations lead to enhanced NFkB signaling and up-regulation of many NF-kB responsive
genes including cytokines such as IL8 and CCL20. Previously published immunohistochemistry data
from our group demonstrated that CARD14 is expressed mainly in epidermal keratinocytes, but is
also in scattered dermal cells. In order to identify which dermal cells express CARD14 we utilized
double and triple immunofluoroscence staining of frozen sections of psoriasis lesions. Dermal
CARD14 expression was not found to co-localize with CD3+ (T-cells), CD11c+ (Dendritic cells),
or CD163+ (Macrophages). However, CARD14 did co-localize with vimentin+ cells, and also with
most CD31+ endothelial cells. Triple immunofluroscence staining confirmed that CARD14 was
expressed in vimentin+CD31+ endothelial cells. This finding is particularly interesting, as overac-
tive NFkB signaling in endothelial cells may result in upregulation of cell adhesion molecules and
chemokines, contributing to the recruitment and infiltration of pathogenic immune cells. Future
studies will elucidate how CARD14 contributes to psoriasis pathogenesis, as well as the contribu-
tion of dermal endothelial cells in this disease.
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An IL-1β inhibitor diacerein blocks the pro-inflammatory and atherogenic effects of IL-1β on
epidermal and endothelial cells
H Zhang,1 L Bao1 and L Chan1,2 1 Dermatology, UIC, College of Medicine, Chicago, IL and 2
Medical Service, JB VA Medical Center, Chicago, IL
Psoriasis, the prototypic inflammatory skin disease, is associated with atherosclerosis and cardio-
vascular co-morbidities. IL-1β, a marker of inflammation, is known to be up-regulated in psoriasis
and is a key pro-inflammatory cytokine inducing atherosclerosis. We ask the question of how IL-1β
contributes to the skin and the cardiovascular pathophysiology and whether an IL-1β inhibitor, diac-
erein, could reverse these effects on a cellular level. In our experiment, human HaCat keratinocytes
and primary coronary artery endothelial cells were untreated, treated with IL-1β, or treated with
combined IL-1β and diacerein. The mRNA levels were determined by reverse transcription-PCR
method. IL-1β up-regulates in HaCat cells several genes that encodes for pro-inflammatory pro-
teins such as CCL11, CCL19, CCR1, CYBB, and LY75. Diacerein fully reversed these up-regulations.
A comprehensive picture of atherosclerosis gene up-regulation in endothelial cells by IL-1β was
assayed with an atherosclerosis PCR microarray. Genes with at least 2-fold up-regulation or down-
regulation by IL-1β and with a P-value of less than 0.05 were identified. Specifically, IL-1β signifi-
cantly up-regulated 20 endothelial cell atherogenic genes including CCL2, CCL5, CD44, CSF-1,
CSF2, ICAM-1, LDL receptor, SELE, TNF, and VCAM-1. Diacerein provided partial to full inhibition
of IL-1β activity in endothelial cells, bringing down IL-1β up-regulation for all of the 20 genes. Sur-
prisingly, diacerein also displayed an intrinsic protective effect on the cardiovascular system. While
IL-1β had no effect on these atherogenic genes in endothelial cells, diacerein down-regulated APOB,
CDH5, FABP3, FN1, IL-1R1, ITGA5, ITGA-X, MSR-1, PDGF-B, and PTGS-1 by 3, 2, 5, 7, 2, 2, 3,
20, 9, and 5 folds respectively. Together, our data provides cellular evidences that IL-1β could sig-
nificantly contribute to skin inflammation and vascular atherosclerosis and that diacerein could par-
tially or fully reverse these inflammatory and atherogenic effects.
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FOXP3 promotes the degradation of EZH2 methyltransferase: A novel mechanism for FOXP3
as a suppressor gene in lymphoid malignancies?
Z Shen1 and L Chen2 1 Department of Dermatology, Southwest Hospital, Third Military
Medical University, Chongqing, China and 2 Department of Dermatology, Daping Hospital,
Third Military Medical University, Chongqing, China
FOXP3 (forkhead box P3) was first considered as a key transcription factor in regulatory T cells. Now
its expression has been demonstrated not restricted to the normal lymphocyte lineage and it can be
expressed by some lymphoid malignancies, including some lymphoma cells. Published evdences
suggested FOXP3 as a tumor suppressor in these lymphoid malignancies. But the mechanism by
which FOXP3 play its roles as a suppressor gene is not determined. In this study, we mainly utilized
cell culture, ELISA, and Western blot methods. We first observed that there was an inverse correla-
tion in various conditions between FOXP3 and histone methyltransferase EZH2 (enhancer of zeste
homolog 2, a central epigenetic regulator in malignancies). We found that FOXP3 could decrease
EZH2’s promotion of cell growth and colony formation in MT2 cells. Next, we demonstrated that
FOXP3 could downregulate EZH2 protein level. This downregulation depended on not only the
amount, but also the nuclear localization of FOXP3. EZH2 could not be downregulated in cells with
cytoplasmic retention of FOXP3. Finally, we demonstrated FOXP3 promoted EZH2 protein degra-
dation through K48-linkage ubiquitination by enhancing E3 ligase Praja1. Our study provides a new
mechanism for FOXP3 in chromatin remodeling as an EZH2 inhibitor and supports FOXP3 as a
tumor suppressor in lymphoid malignancies.
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Key immune modulatory effects exerted by calcipotriol in combination with corticosteroid
on human immune cells
P Lovato, H Norsgaard and M Røpke LEO Pharma, Ballerup, Denmark
Psoriasis is a chronic inflammatory skin disorder characterized by hyperproliferation of keratinocytes
and dermal infiltration of neutrophils, dendritic cells (DC) and activated CD4+ T-cells (Th1, Th17
and Th22) and CD8+ T-cells (Tc1, Tc17 and Tc22), which secrete soluble messengers, e.g. inter-
leukin(IL)-17 and TNFα, that promote skin inflammation. Recent experimental and clinical data
strongly suggest that IL-17, IL-23 and TNFα are, indeed, central cytokines in driving the pathogen-
esis of psoriasis. The calcipotriol/betamethasone dipropionate two-compound gel is widely used
for topical treatment of psoriasis vulgaris, however the mechanism behind the high efficacy of this
treatment has not been studied in detail. The objective of this study was to investigate and compare
the immune modulatory effects of betamethasone dipropionate (BDP), calcipotriol, and the cal-
cipotriol/BDP combination on i) IL-23 secretion by human DC and ii) differentiation and activity of
human Th17 and Tc17 cells in vitro. Compared to vehicle control or mono-treatments, the combi-
nation of calcipotriol and BDP strongly inhibited the expression of IL-23 by human DC and impacted
both the differentiation and activity of human T cells. In particular, the two components were com-
plementary in enhancing the immune modulatory activity affecting both maturation and biological
functions by: i) inhibition of IL-6, IL-23 and TNFα expression by BDP; ii) inhibition of IFNγ, IL-8,
IL-17 and IL-22 expression by calcipotriol; iii) enhanced anti-inflammatory effect of BDP by cal-
cipotriol; iv) reversal of steroid-mediated inhibition of IL-4, IL-5, IL-10 and IL-13 production by cal-
cipotriol; v) highly significant effect of calcipotriol in differentiating DC and T cells. These data
highlights the beneficial and complementary effects of calcipotriol and betamethasone dipropionate
combination in suppressing the endogenous release of cytokines associated with psoriatic inflam-
mation and in inducing an immune modulatory cytokine profile in contrast to the broader immuno-
suppressive effect observed with corticosteroid mono-therapy.
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Recombinant anti-collagen VII Fab fragments which compete against autoantibodies in patients
with epidermolysis bullosa acquisita
H Qiao,1,2 H Ujiie,2 R Abe,2 Q Li,1,2 R Moriuchi,2 JR McMillan,2 H Shimizu2 and G Wang1 1
Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
and 2 Department of Dermatology, Hokkaido University Graduate School of Medicine,
Sapporo, Japan
Epidermolysis bullosa acquisita (EBA) is an acquired blistering skin disease caused by autoantibodies
against type VII collagen (COL7). Complement activation triggered by the deposition of those autoan-
tibodies is considered to be essential for the pathogenesis of EBA. The cartilage matrix protein (CMP)
subdomain of COL7 within the NC-1 domain is reported to contain the pathogenic epitopes of
EBA. In EBA diseases, F(ab’)2 fragments from pathogenic autoantibodies thatlack the Fc portion nec-
essary to activate complement, fail toinitiate disease progression. These dataindicate that prevent-
ing complement activation by blocking normal autoantibody binding to the corresponding target
skin antigens is a viable candidate therapeutic strategy for treating these diseases.The purpose of
this study is to provide a new strategy for thetreatment of antibody-mediated EBAusing recombi-
nant Fabs to block complement activation induced by pathogenic autoantibodies. In order to develop
a disease specific treatment for EBA, we tried to generate Fab antibody fragments against the CMP
domain of COL7 which block the binding of EBA autoantibody and prevent complement activa-
tion. Recombinant Fab fragments were generated from antibody repertoires of an EBA patient using
a phage display method. We obtained three Fab clones that were highly specific to the CMP domain.
These Fab fragments did not activate complements in vitro. They showed a marked competitive abil-
ity to inhibit the binding of EBA autoantibodies to the CMP domain in vitro. These results suggest
that those Fab fragments block the pathogenic epitope of EBA and may reduce the disease activity
by inhibiting the complement activation.
155
CD22 expression is required for development of pristane-induced lupus model in mice
Y Hamaguchi,1 T Matsushita,1 M Hasegawa,1 K Takehara,1 T Tedder2 and M Fujimoto1 1
Dermatology, Kanazawa University, Kanazawa, Japan and 2 Immunology, Duke University
Medical Center, Durham, NC
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by autoan-
tibody production and the involvement of most organs including skin. In addition to the contribu-
tion of T cells, recent studies have revealed a critical role of B cells in SLE development. CD22 is a
member of the sialoadhesion subclass of the immunoglobulin superfamily. CD72 is a type II trans-
membrane glycoprotein and a member of the calcium-dependent lectin superfamily. Both CD22
and CD72 are expressed on the cell surface of immature and mature B cells and provide negative
feedback pathways to downregulate B cell antigen receptors (BCR) signaling. Although CD22-defi-
cient (CD22-/-) mice show increased calcium signaling in their conventional B cells but do not
develop autoimmunity, CD72-deficient (CD72-/-) mice modulate peripheral B cell tolerance and
developed autoimmunity. Using CD22 and CD72 double-deficient (CD22-/-/72-/-) mice, we
addressed whether CD22 and CD72 have redundant functions. CD22-/-/72-/- mice showed decreased
number of peripheral B cells and increased frequency of peritoneal B1a cells. CD22-/-/72-/- mice
showed increased serum IgM levels. CD22-/-/72-/- mice showed a diminished immune response to
thymus-independent type I antigen but almost normal immune response to thymus-dependent anti-
gen. In pristane-induced lupus model, wild type and CD72-/- mice exhibited increased urine pro-
tein. However, CD22-/- mice exhibited minimal increased urine protein and CD22-/-/72-/- mice did
not show increased urine protein, even lower than pristane-treated wild type mice. These results
show that CD22 expression may be required to develop autoimmunity in pristane-induced lupus
model.
156
IMO-3100, an antagonist of Toll-like receptor (TLR) 7 and TLR9, demonstrates clinical activ-
ity in psoriasis patients with 4 weeks of treatment in a phase 2a trial
AB Kimball,1 J Krueger,2 T Sullivan3 and RD Arbeit3 1 Dermatology, Massachusetts General
Hospital, Boston, MA, 2 The Rockefeller University, New York, NY and 3 Idera
Pharmaceuticals, Inc., Cambridge, MA
IMO-3100 is novel oligonucleotide antagonist that inhibits TLR7/TLR9-mediated induction of Th1,
Th17, and inflammasome pathways; it also ameliorates pathology in preclinical models of autoim-
mune diseases including psoriasis. IMO-3100 was evaluated in a randomized, double-blind, placebo-
controlled trial of patients with moderate-to-severe plaque psoriasis designed to evaluate prelimi-
nary safety and provide initial clinical proof-of-concept for this novel therapeutic approach. 44
patients were randomized to receive 4 once-weekly injections (Days 1, 8, 15, and 22) of IMO-
3100 at 0.16 or 0.32 mg/kg or placebo. Assessments of clinical response at Days 29, 36, and 57
included the Psoriasis Area Severity Index (PASI). Biopsies of psoriasis plaques were obtained on
Days 1 and 29. Among the 40 clinically evaluable patients, median baseline PASI was 16.3 (range:
10.4, 35.8). Median PASI changes relative to Day 1 were: at Day 15, -10%, -9%, and -6% for the
placebo, 0.16-mg/kg, and 0.32-mg/kg cohorts; at Day 29, -12%, -32% (p<0.02), and -12%; and at
Day 36, -12%, -28% (p<0.03), and -22%, respectively. Plaque induration scores decreased con-
currently (e.g., Day 29 changes of 0%, -35% (p<0.02), and -13%). Clinical improvement was sus-
tained, consistent with inhibition of cytokine induction; at Day 57, PASI decreases of 35% to 90%
were observed in 12 (48%) of 25 patients treated with IMO-3100 compared with 0 of 12 placebo
recipients (p<0.005). Median epidermal thickness change in biopsy samples was +7.7% in placebo
treated patients and -6.4% in IMO-3100 treated patients (p=0.21). IMO-3100 was well tolerated
and no serious adverse events were reported during this trial. This proof of concept study provides
the first demonstration of a therapeutic effect for a TLR7/TLR9 antagonist in autoimmune disease.
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Eccrine sweat stimulates the release of IL-8 via IL-1 from epidermal keratinocytes as a dan-
ger signal
H Okazaki, X Dai, M Murakami, Y Hanakawa, M Tohyama, Y Shirakata and K Sayama
Dermatology, Ehime University Graduate School of Medicine, Toon, Japan
Eccrine sweat is secreted onto the skin surface and is not harmful to normal skin. However, if the
epidermal barrier is disrupted, as in atopic dermatitis (AD), eccrine sweat can be a potent exacer-
bating factor. Although eccrine sweat contains a number of minerals, proteins, and proteolytic
enzymes, it is unknown how it causes skin inflammation. Thus, we hypothesized that eccrine sweat
stimulates keratinocytes directly, as a danger signal. Eccrine sweat was collected from healthy vol-
unteers after 30 min of exercising and was desalted, lyophilized, re-constituted, and filtered. Nor-
mal human keratinocytes were cultured under serum-free conditions and stimulated with concen-
trated sweat for 6 or 24 h. Cytokine production was analyzed by real-time PCR using total RNA and
an ELISA of the culture supernatants. IL-8 mRNA expression was enhanced about 30-fold and IL-
1βmRNA was increased more than 10-fold by sweat. Supernatant IL-8 protein was also significantly
induced by sweat. Western blot analysis showed activation of NF-κB, ERK, and JNK signaling in
keratinocytes. Furthermore, pretreatment with an IL-1R antagonist blocked sweat-induced IL-8 pro-
duction, indicating that IL-1 is a major factor in the sweat-induced release of IL-8. Next, we con-
firmed the presence of IL-1α and IL-1β in sweat from healthy volunteers by ELISA; the mean con-
centrations of IL-1α and IL-1β were 1344 and 351 pg, respectively, in 1 mg of sweat protein. Thus,
we showed that eccrine sweat contains significant amounts of IL-1α and IL-1β, which are biologi-
cally active and can stimulate epidermal keratinocytes to release IL-8. As sweat is extruded onto the
skin surface, there is no direct contact with keratinocytes in normal skin. However, under condi-
tions with a defective cutaneous barrier, as in AD, IL-1 in sweat may come into direct contact with
epidermal keratinocytes, resulting in their activation. In conclusion, eccrine sweat is a danger sig-
nal for epidermal keratinocytes and is strongly associated with the pathogenesis of AD.
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Leucine-rich α-2 glycoprotein is an innovative biomarker for psoriasis
H Nakajima, K Nakajima, M Takaishi, M Tarutani and S Sano Kochi Medical School, Nankoku,
Japan
Psoriasis is systemic inflammatory disease, characterized by aberrant activation of Th 17 cells that
mainly target skin. The advent of biological agents led to a marked improvement in the treatment
of psoriasis. Nevertheless, these agents are not effective for all patients with psoriasis and current
biomarkers are not helpful to select a relevant biologics for individual patients. Thus, there is a
requirement for the development of alternative biomarkers that can predict treatment response and
evaluate the disease activity during therapy. Leucine-rich-α-2 glycoprotein (LRG) is an approxi-
mately 50kDa glycoprotein in which 20% of amino acid residues are leucines. Although the phys-
iological function of LRG is still unknown, serum levels of LRG were reported to be significantly
higher in patients with autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, Behçet
disease and ulcerative colitis. We investigated serum LRG levels in psoriasis patients and normal
controls. Significantly increased LRG levels were found in psoriasis patients compared with con-
trols. Serum LRG levels correlated with the PASI score whereas CRP did not correlate with the PASI.
Moreover, by analyzing before and after anti-TNF therapy, the serum LRG levels showed the supe-
riority over CRP in the sensitivity for remission of psoriasis. We also found up-regulated expression
of LRG both in human psoriatic lesions and in psoriasis-like lesions of K5.Stat3C transgenic mice,
a representative mouse model of psoriais. Furthermore, tape-stripping on the back skin in K5.Stat3C
mice led to up-regulation of LRG not only in the lesional skin but also in the liver, suggesting that
LRG might link the inflamed skin to systemic inflammation. These data provide a reliable clinical
utility of LRG to screen psoriasis activity and support the notion that psoriasis links to systemic
inflammation.
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Development of endogenous cannabinoid receptor modulating compounds as anti-inflam-
matory agents for skin disease
B Kim,1 B Park,1 J Jeon,1 H Kim,2 S Ahn,3 S Hong,4 S Jeong1 and S Lee5 1 Division of Applied
Research, NeoPharm Co., Ltd., Daejeon, Republic of Korea, 2 Department of
Dermatology/Atopy and Asthma center, Seoul Medical Center, Seoul, Republic of Korea, 3
Department of Dermatology, Wonju College of Medicine, Yonsei University, Wonju, Republic
of Korea, 4 Department of Dermatology, College of Medicine, Dankook University, Cheonan,
Republic of Korea and 5 Department of Dermatology, Yonsei University College of Medicine,
Seoul, Republic of Korea
Many inflammatory mediators, including cytokines(interleukin, TNF), inflammatory proteases, arachi-
donic acid metabolites and histamine are released by mast cell activation. However, little is known
about the endogenous modulators for mast cell activation and their mechanism. Endogenous cannabi-
noids found in peripheral tissues, such as palmitoylethanolamide (PEA), have been proposed as hav-
ing autacoid activity, which can down-regulate mast cell activation and local inflammation. Based
on the chemical structure of cannabinoid receptor regulators(agonist/antagonist), about 30 com-
pounds were synthesized and their modulating activity on human cannabinoid receptor 1 (CB1R)
and 2 (CB2R) were screened using CB1R or CB2R transfected CHO cell line, respectively. Among
the compounds, a few potential CB1R agonists were screened and further investigated on mast cell
activation model. Using a cultured rat mast cell line, effect of selected compounds on FceRI-induced
histamine and beta-hexosaminidase release were measured. As a result, newly synthesized CB1R
agonists down-regulated the release of mediators by IgE activation or intracellular calcium eleva-
tion in mast cells. Furthermore, inhibitory effect on histamine release was also observed in mast
cells activated by protease-activated receptor (PAR)-2 agonists. Taken together, CB1R agonists can
down-regulate the mast cell activation, and might be a used for relieving inflammatory symptoms
mediated by mast cell activation, such as atopic dermatitis, psoriasis, contact dermatitis or chronic
urticarial.
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New mouse model to investigate the neurogenic facial flush associated with subtypes I and
II of rosacea
C Nonne, S Wise, A Jomard and M Rivier Research, Galderma R&D, Sophia-Antipolis, France
Dysfunctional cutaneous vasculature and neuronal dysregulation have been proposed to partici-
pate in the transient flush or permanent facial erythema found in both Subtype I and Subtype II
Rosacea patients. Histopathological studies have revealed oedema, vasodilation, and infiltrates of
leukocytes in the facial skin of patients. These characteristics may be related to neurogenic inflam-
mation, a process in which inflammation is triggered by the peripheral nervous system. The aim of
this study was to set up animal models of neurogenic inflammation and subsequent flushing rele-
vant to Rosacea. Neurogenic skin inflammation can be induced by capsaicin which activates the
vanilloid type 1 receptor (TRPV1) leading to the release of neuropeptides (CGRP, SP ...) with vasodila-
tory properties. In Hairless rats, we induced a neurogenic flush by systemic activation of TRPV1 with
a subcutaneous injection of capsaicin 30 mg/kg. The flush was measured in blood plasma by the
release of CGRP neuropeptide at 60 and 90 minutes (increase of 6 to 10 pg/ml respectively). Intra-
venous injection of αCGRP in Hairless rat also induced a global facial flush as measured on the
skin using the laser Doppler perfusion imaging. Two CGRP-receptor antagonists, CGRP8-37 and
BIBN4096 i.v., were able to block the CGRP-flush. The facial CGRP-flush was also performed in
the mouse, where the topical pre-treatment of the mouse ear with a CGRP-receptor antagonist,
MK3207 3 % in ethanol, showed a high decrease of CGRP-induced flushing, as measured by laser
Doppler perfusion imaging. Another vasodilator neuropeptide, PACAP, was also tested in Hairless
rat: only the intravenous injection of PACAP27, and not PACAP38, induced a facial flush. We have
developed new preclinical models that will be useful to investigate the vascular component of neu-
rogenic skin disorders such as Rosacea and may identify new therapeutic candidates for such indi-
cations. Of particular interest, the mouse model of CGRP-induced vasodilatation will be useful to
evaluate topically applied pharmaceutical agents.
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Genetic modification of HLA-DR linked with the PSMB8 mutation in Nakajo-Nishimura syn-
drome
K Kunimoto,1 F Furukawa,1 H Ida2 and N Kanazawa1 1 Dermatology, Wakayama Medical
University, Wakayama, Japan and 2 Medicine, Kurume University School of Medicine,
Kurume, Japan
Nakajo-Nishimura syndrome (NNS; OMIM#256040, ORPHA2615) is a recently-defined hereditary
autoinflammatory disorder characterized by recurrent inflammatory attacks with fever and/or skin
eruptions and progressive lipomuscular atrophy. This disease is caused by a unique mutation of the
PSMB8 gene, which not only impairs an enzymatic activity of the encoding β5i subunit, but also
disturbs formation of the immunoproteasome complex. Although immunoproteasome is involved
in formation of antigenic peptides presented on MHC class I, no obvious symptoms with immun-
odeficiency have been reported in NNS patients. Rather, some patients show detectable autoanti-
bodies while growing-up. By flow cytometry, unexpectedly, expression of HLA-DR was exclusively
undetectable on the NNS patients-derived immortalized B cells, whereas expression of HLA-ABC
was intact. HLA-DR expression was also undetectable on the patients’ peripheral blood B cells and
monocytes. By further analyses of the patients-derived immortalized B cells, HLA-DR expression
was detected in close contact with the plasma membrane by intracellular staining with another anti-
body recognizing its intracellular portion, whereas its expression was still undetectable by intra-
cellular staining with the former antibody. Thus, HLA-DR was undetectable with a specific mono-
clonal antibody in NNS. As the clone can be used for blocking the mixed leukocyte reaction, a
predictable modification of HLA-DR might affect its interaction with T cell receptor. By sequence
analyses of the HLA-DR gene, the homozygous c.46G>C transition causing the Val16Leu substitu-
tion was observed commonly and specifically in all examined NNS patients. As the PSMB8 gene is
located in the MHC class II region and the strong founder effect was reportedly observed in the
patients’ genome, it is possible that the HLA-DR mutation is linked with the PSMB8 mutation and
contribute to the complex phenotype of NNS.
162
TGF-β under non-inflammatory cytokine milieu converts naive CD4+ T cells into thymic-
type Helios+ regulatory T cells
T Nomura,1 K Sugita,2 N Hayatsu,3 K Saitou,1 A Kitoh,1 Y Miyachi1 and K Kabashima1 1
Department of Dermatology, Kyoto University, Kyoto, Japan, 2 Department of Dermatology,
University of Occupational and Environmental Health, Kitakyushu, Japan and 3 RCAI, RIKEN,
Yokohama, Japan
CD4+Foxp3+ regulatory T (Treg) cells control various immune responses including contact hyper-
sensitivity, and maintain homeostasis of cutaneous immune system. Adoptive therapy using Treg
cells has been proposed to control cutaneous immune diseases. However, clinical use of Treg cells
is hampered by contaminated quasi-Treg cells, which abandon their suppressive function by losing
Foxp3. Helios, an Ikaros family transcription factor, is a good marker to identify thymic-type Treg
cells, which express Foxp3 constitutively and are recognized as bona fide Treg cells. In this study,
we aimed to convert naive CD4+ T cells into thymic-type Treg cells that express Helios. To address
this issue, we screened optimal condition for conversion in vitro by monitoring the expression of
Helios and Foxp3 as their markers. Stimulation with plate-bound anti-CD3ε in the presence of
TGF-β/IL-2 converted naive CD4+ T cells into induced-type Treg cells which express Foxp3 but not
Helios. Contrary, conversion by anti-CD3ε/CD28 conjugated microbeads with TGF-β/IL-2 resulted
in Helios expression in half of the converted (Foxp3+) cells. The latter conversion was dependent
on TGF-βR signaling because SB431542, a TGF-βR inhibitor, abrogated the expression of both Helios
and Foxp3. Furthermore, IFN-γ induced Helios but inhibited Foxp3 expression while IL-4 inhibited
both Helios and Foxp3. Thus, we conclude that TGF-β under non-inflammatory cytokine milieu con-
verts CD3ε/CD28-stimulated naive CD4+ T cells into thymic-type Treg cells. Th1-cytokines seem to
engender Helios+ non-regulatory T cell subset whose function and fate remain unexplored. On the
other hand, Th2-cytokines interfere conversion. These findings will be exploitable for controlling
immune response in the skin.
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Molecular mechanisms of Sema3A gene regulation in human epidermal keratinocytes
Y Kamata,1 M Tominaga,1 A Kamo1 and K Takamori1,2 1 Institute for Environmental and Gender
Specific Medicine, Juntendo University Graduate School of Medicine, Urayasu, Japan and 2
Department of Dermatology, Juntendo University Urayasu Hospital, Urayasu, Japan
An increase in epidermal nerve density is considered to be one of the major causes of antihista-
mine-resistant pruritus, suggesting that the lesional skin is itch sensitive. Previously, we reported a
potential contribution of semaphorin 3A (Sema3A) to modulation of epidermal innervation in atopic
dermatitis (AD) and dry skin. Interestingly, psolaren ultraviolet-A therapy (PUVA) reduced epider-
mal hyperinnervation in AD by normalization of abnormal Sema3A expression in epidermis. How-
ever, the regulatory mechanisms of endogenous Sema3A have not been investigated in detail. There-
fore, this study was performed to analyse the regulatory mechanisms of Sema3A in normal human
epidermal keratinocytes (NHEK). The 5’-flanking region of Sema3A gene (approx. 1.4 kb) was cloned
from human genomic library using a Genome Walker. Next, we identified a number of putative tran-
scriptional factor binding sites by using TFSEARCH. Moreover, our assays using luciferase expres-
sion plasmids containing sequentially deleted fragments of the 5’-flanking region of Sema3A proved
to be a critical region for Sema3A promoter activity within -144 bp from the transcription start site.
We next examined the luciferase activity in proliferating or differentiated NHEK in calcium con-
centration dependence. The promoter activity of Sema3A-1.4kb was dose-dependently up-regulated
by CaCl2 in the differentiated NHEK (15-fold, p<0.001). Interestingly, the promoter activities were
down-regulated by change to low calcium (0.15 mM) from high calcium medium (1.4 mM). In addi-
tion, Sema3A promoter activity was increased in the presence of proinflammatory cytokines such
as TNF-α (3-fold, p<0.01) and IFN-γ (2.5-fold, p<0.05), whereas unaffected with IL-4. Thus, our data
may imply a unique regulatory mechanism of Sema3A in association with the epidermal calcium
gradients and proinflammatory cytokines.
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Histamine H4 receptor antagonists exhibit insufficient anti-pruritic and anti-inflammatory
effects on mite extract ointment-induced mouse model of atopic dermatitis
M Tominaga,1 A Kamo,1 O Negi,1,2 S Tengara,1 Y Kamata,1 A Noguchi1 and K Takamori1,2 1
Institute for Environmental and Gender Specific Medicine, Juntendo University Graduate
School of Medicine, Urayasu, Japan and 2 Department of Dermatology, Juntendo University
Urayasu Hospital, Urayasu, Japan
Histamine H1 receptor (H1R) antagonists are commonly used to treat patients with atopic dermati-
tis. However, the treatment is usually ineffective against pruritus. Recent studies using mouse
model of pruritus have demonstrated that histamine H4receptor (H4R) is also involved in histamine-
dependent itch. This study was performed to examine the effects of different H4R antagonists,
JNJ7777120 and JNJ28307474, on itch and skin inflammation in NC/Nga mice, which is a model
for atopic dermatitis. Atopic dermatitis-like symptoms were induced in NC/Nga mice by repeated
application of Dermatophagoides farinae body (Dfb) ointment. Mice that scored over 5 for dermatitis
severity were treated by either intraperitoneal injection with control vehicle or the H4R antagonists
(at 10 mg/kg or 30 mg/kg) once every 2 days for 3 weeks. No significant improvement of dermati-
tis was observed in the Dfb ointment-induced mice treated by either of these H4R antagonists. In
addition, neither inhibited scratching behaviour. Indeed, the number of scratching bouts signifi-
cantly increased by treatment with 30 mg/kg JNJ28307474. There was no significant difference in
locomotion activity between the H4R antagonist treated-mice and the vehicle treated-mice. There-
fore, these results suggest that these H4R antagonists are insufficient for anti-pruritic and anti-inflam-
matory effects on Dfb ointment-induced atopic dermatitis model.
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CISH suppresses IL-17-induced CCL20 production from epidermal keratinocytes via inhibi-
tion of the Src/MEK/ERK pathway
M Tohyama, Y Shirakata, Y Hanakawa, X Dai, H Okazaki, M Murakami, K Hashimoto and
K Sayama Department of Dermatology, Ehime University Graduate School of Medicine,
Ehime, Japan
IL-17 is a mediator of innate immunity that plays an important role in skin infection. CCL20/MIP-
3α recruits IL-17-producing cells, and, in turn, IL-17 induces CCL20 production from epidermal
keratinocytes. Although IL-17-producing cells exist in the lesional skin of patients with atopic der-
matitis (AD), skin infections are frequently complicated, suggesting that the IL-17 axis is disturbed
in AD. Previously, we showed that IL-4 enhanced the expression of cytokine-inducible SH2-con-
taining protein (CISH), a member of the SOCS/CIS family, in epidermal keratinocytes. We exam-
ined whether Th2 cytokines suppress IL-17-induced CCL20 production via CISH. The Th2 cytokines
IL-4/IL-13 suppressed IL-17-induced CCL20 production by 50% in cultured human epidermal ker-
atinocytes. To clarify the role of CISH, CISH was expressed in keratinocytes using adenoviral vec-
tors. CISH expression significantly suppressed IL-17-induced CCL20 production. Next, we analyzed
IL-17 signaling, including IκB-ζ, a member of the nuclear IκB family involved in IL-17 signaling in
keratinocytes. IL-17 phosphorylated ERK, p38, and JNK and increased IκB-ζ expression. MEK/ERK
inhibitors or the knockdown of IκB-ζ strongly suppressed CCL20 expression. However, CISH expres-
sion had no effect on IκB-ζmRNA expression, indicating that IκB-ζ is not involved in the CISH path-
way. On the other hand, IL-17-induced ERK phosphorylation was significantly attenuated by CISH.
Moreover, IL-17 induced Src family phosphorylation, and a Src inhibitor suppressed IL-17-induced
ERK phosphorylation and CCL20 production. Thus, CISH suppressed IL-17-induced CCL20 pro-
duction by inhibiting the Src family/MEK/ERK pathway. Because the number of IL-17-producing cells
and CCL20 expression are lower in AD than in psoriasis, we analyzed CISH expression in lesional
skin. CISH expression was enhanced in AD, but suppressed in psoriasis. Decreased numbers of IL-
17-producing cells, due to CISH, may disturb antimicrobial defenses in AD.
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Low frequency of IgG autoantibodies specific to the precursor form of desmoglein 1 and 3
in patients with sporadic pemphigus
J Yamagami,1 MA Saleh,1,2 M Ohyama,1 T Hachiya,3 K Kuroda3 and M Amagai1 1 Dermatology,
Keio University, Tokyo, Japan, 2 Dermatology, Cairo University, Cairo, Egypt and 3 Medical
Biological Laboratories Co. Ltd., Nagoya, Japan
Desmoglein (Dsg) is synthesized in the endoplasmic reticulum as a precursor (preDsg) with a propep-
tide and is assembled into desmosomes as a mature form (matDsg) on the cell surface after the
propeptide is cleaved. Our previous study showed patients with endemic form of pemphigus foli-
aceus (PF) in Tunisia had antibodies (Abs) against matDsg1 as well as preDsg1 while healthy indi-
viduals in the same area had Abs only against preDsg1, suggesting that anti-preDsg1 Abs may pre-
cede the development of pathogenic anti-matDsg1 Abs. To investigate whether Japanese patients
with sporadic form of pemphigus have anti-preDsg Abs, we examined 50 sera from patients with
pemphigus vulgaris (PV) and 45 sera from PF on ELISAs coated with mammalian recombinant preDsg
or matDsg. While all PV and PF sera reacted with matDsg3 and matDsg1, respectively, 90% (45/50)
of PV also reacted with preDsg3 and 93% (42/45) of PF also reacted with preDsg1. The average
binding inhibition rate to preDsg by absorption with matDsg was 91% in Dsg3 in PV sera and 86%
in Dsg1 in PF sera, indicating low frequency of anti-preDsg specific antibodies in pemphigus patients.
In contrast, the average binding inhibition rate to matDsg by absorption with preDsg was only 54%
in Dsg3 in PV and 37% in Dsg1 in PF, suggesting high frequency of antibodies against epitopes
masked by prosequence. These findings imply that prosequence-cleavage-dependent epitopes will
provide an important clue to develop an assay to accurately evaluate the disease activity and to
understand the mechanisms of blister formation in pemphigus.
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Th17-induced CXCL10 sustains proteases release during early blistering in bullous pemphigoid
S Le Jan,1 J Plee,1,4 D Vallerand,1 A Dupond,2 E Delanez,1 A Durlack,3 P Bernard1,4 and
F Antonicelli1 1 Dermatology, University of Reims, Reims, France, 2 Biochemistry, University
of Reims, Reims, France, 3 Histopathology, University hospital, Reims, France and 4
Dermatology, University hospital, Reims, France
Background: Binding within the dermal-epidermal junction (DEJ) of autoantibodies against BP180,
the major auto-antigen in bullous pemphigoid (BP), results in subepidermal blistering. Although pro-
teases involved in DEJ degradation have been clearly identified, the mechanisms linking inflam-
matory cells to protease expression still need to be specified. Objective: The purpose of this study
was to define the cytokines expressed at the subepidermal blister lesion site, and then determine
the biological mechanisms linking inflammation to matrix degradation. Population: Thirty one con-
secutive patients with BP from 2009 to 2011 and 16 age matched controls were included. Serum
samples, blister fluids, and skin biopsies specimens were collected at time of diagnosis when pos-
sible. Results: This study showed that CXCL10 level was increased in serum from BP patients com-
pared to controls, and still higher in BP blister fluids. Levels of Th17 associated cytokines IL-17, IL-
22 and IL23 were significantly larger in blister fluids compared to both BP and control serum whereas
TGFβ and IL-6 were increased in BP serum and blister fluids respectively. Orientation of lympho-
cytes towards Th17 differentiation with either TGFβ, IL-6 and IL-23, or with serum and blister flu-
ids from BP patients was associated with an upregulation of CXCL10 mRNA expression. In turn,
CXCL10 increased proteases (MMP-9, HLE) secretion from both PBMC and PMN isolated from BP
patients. Mass spectrometry showed that extracellular matrix degradation led to PGP generation that
favored PMN recruitment and activation. Conclusions: In BP, Th17 differentiation under the control
of IL-1β, IL-6 and IL-23, and characterized by IL-17 and IL-22, also expressed high level of CXCL10.
Enhanced proteases secretion by PBMC and PMN upon CXCL10 favors DEJ degradation, and cre-
ated an amplifying loop owing to the generation of PGP, a matrix issued chemoattractant for PMN.
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A novel necroptosis pathway of annexin A1/ FPR1 interaction in severe cutaneous adverse
drug reactions
N Saito, H Qiao, T Yanagi, S Shinkuma, A Suto, Y Fujita, S Suzuki, T Nomura, H Nakamura,
H Shimizu and R Abe Dermatology, Hokkaido University Graduate School of Medicine,
Sapporo, Japan
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening cutaneous
adverse drug reactions involving keratinocyte death. The mechanism of keratinocyte death in SJS/TEN
remains unclear. Recently, an alternative mechanism of cell death has been discovered: necropto-
sis, which is programmed necrosis mediated by receptor-interacting proteins (RIPs). Here we show
that SJS/TEN are necroptosis-mediated diseases induced by the newly discovered pathway of annexin
A1 and formyl peptide receptor1 (FPR1) interaction. We found that the dead keratinocytes in SJS/TEN
lesions showed morphological necrosis. The supernatant from the causative-drug-stimulated periph-
eral blood mononuclear cells (PBMCs) of patients with SJS/TEN induced the death of SJS/TEN ker-
atinocytes, whereas the supernatant from patients with ordinary drug-induced skin reactions (ODSRs)
and healthy controls did not. The keratinocytes from ODSR patients and healthy controls were
unaffected by either SJS/TEN or ODSR supernatant. These cytotoxicities were blocked by RIP1
inhibitor (Necrostatin-1) or knockdown of RIP3 with siRNA but not by pan-caspase inhibitor. Mass
spectrograph analysis identified annexin A1 as a key mediator of keratinocyte death from the fact
that depletion of annexin A1 prevented such death. Furthermore, blocking of FPR1, which is a recep-
tor of annexin A1, inhibited keratinocyte death. In addition, annexin A1 and FRP1 expression were
both detected in the SJS/TEN lesions; in contrast, fairly low expression was detected in the non-
lesional SJS/TEN skin or in ODSR lesions. Finally we developed an SJS/TEN therapy that targets
necroptosis using a necroptosis blocker (necrosulfonamide: NSA) in SJS/TEN model mice. These
data clearly indicate that necroptosis is a promising target for SJS/TEN treatment and that NSA is a
therapeutic candidate. These new insights into SJS/TEN pathogenesis are expected to prompt clin-
ical prevention and drug development.
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Keratinocyte-specific loss of Phospholipase C δ1 results in aberrant activation of IL-23/IL-17
axis and skin inflammation
Y Nakamura, K Kanemaru and K Fukami Laboratory and Genome and Biosignals, School of Life
Sciences, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan
Phosphoinositide turnover is an important intracellular signal transduction system. Phospholipase
C (PLC) is a key enzyme in phosphoinositide turnover. PLC hydrolyzes phosphatidyl inositol 4, 5-
bisphosphate and generates two lipid second messengers, diacylglycerol and inositol 1, 4, 5-trispho-
sphate, leading to protein kinase C (PKC) activation and mobilization of calcium ion from intracel-
lular stores. Since one PLC isozymes, PLCδ1 is abundantly expressed in keratinocytes, we generated
keratinocyte-specific PLCδ1 knockout mice. Loss of PLCδ1 in keratinocytes resulted in a decrease
in overall PLC activity of more than 90% in epidermis, indicating that PLCδ1 is a dominant PLC iso-
form in epidermis. Epidermis of keratinocyte-specific PLCδ1 knockout mice showed marked increase
in interleukin (IL)-23 expression. Forced activation of PLC downstream effectors restored normal
expression of IL-23 in epidermal sheets, strongly suggesting that insufficient activation of PLC down-
stream effectors causes IL-23 upregulation. IL-17, a downstream target of IL-23, was also upregu-
lated in skin of keratinocyte-specific PLCδ1 knockout mice. Aberrant activation of IL-23/IL-17 axis
is observed human inflammatory skin diseases, including psoriasis. Interestingly, keratinocyte-spe-
cific PLCδ1 knockout skin showed some aspects of human psoriasis, such as acanthosis, hypervas-
cularization, Stat3 activation, and IL-36 upregulation. In addition, PLCδ1 protein was decreased in
epidermis of patient with psoriasis. Taken together, our results indicate that keratinocyte-specific
loss of PLCδ1 results in aberrant activation of IL-23/IL-17 axis and skin inflammation.
171
Activation of inflammasome is related to S100A9 induction and is involved in chronic inflam-
mation of the skin with atopic dermatitis
M Yamamoto,1,2 K Inoue,2 M Sawane,2 T Maeda,1 R Tsuboi1 and T Hibino2 1 Department of
Dermatology, Tokyo Medical University, Tokyo, Japan and 2 Shiseido Innovative Science
Research & Development Center, Yokohama, Japan
Previously we reported a positive feedback loop between S100A8/A9 and proinflammatory cytokines
in human keratinocytes. Knockdown of the newly identified S100A9 receptor, EMMPRIN, abolished
this reaction, indicating involvement of S100A9-EMMPRIN interaction in chronic inflammation. In
addition, recent investigations suggested a role of inflammasome in the initiation of inflammation.
In the present study, we tried to analyze inflammatory responses induced by S100A9 and inflam-
masome. First we examined effects of air exposure on cultured keratinocytes. This treatment strongly
up-regulated S100A9 expression. Interestingly it promoted immediate release of ATP up to 70% of
its total contents, which leads to the inflammasome activation. We checked mRNA expression of
23 kinds of its components after air exposure. Some of the NOD-like receptor (NLR) family mem-
bers markedly increased at 24-48 h. Specific siRNAs to the up-regulated NLRs significantly sup-
pressed S100A9 induction. We generated involucrin promoter-driven S100A9 transgenic (Tg) mice
with HR-1 background. A characteristic feature of this Tg was elevated levels of transepidermal water
loss. Ear swelling of TNCB-treated Tg mice continued to increase even after 24 h, whereas that of
the wild mouse decreased after 24 h. Active caspase-1 specific antibody showed caspase-1 activa-
tion at the granular layer. We also examined localization of S100A9, EMMPRIN, and active cas-
pase-1 in the skin with atopic dermatitis (AD). Although all of these molecules were hardly detectable
in the normal skin, they showed strong up-regulation and co-localization in the granular layer of
the lesional skin with AD. These lines of evidence indicate a close connection between S100A9-
EMMPRIN and inflammasome systems in the initiation and chronicity of the inflammation. These
systems would be involved in the pathogenesis of AD.
173
CD4, but not CD8, T cells are required for induction of experimental epidermolysis bullosa
acquisita
H Iwata,1 K Bieber,1 B Tiburzy,2 N Chrobok,3 K Kalies,3 A Shimizu,4 S Leineweber,5 A Ishiko,4
E Schmidt,1 D Zillikens,1 J Westermann,3 K Seeger,5 R Manz2 and R Ludwig1 1 Dermatology,
University of Lübeck, Lübeck, Germany, 2 Systemic Inflammation Research, University of
Lübeck, Lübeck, Germany, 3 Anatomy, University of Lübeck, Lübeck, Germany, 4
Dermatology, Toho University, Ota-ku, Japan and 5 Chemistry, University of Lübeck, Lübeck,
Germany
In autoimmune bullous dermatoses (AIBD), autoantibodies induce blisters on skin and/or mucous
membranes. Using animal models for AIBD, mechanisms of autoantibody production and blister-
ing have been relatively well characterized. However, the role of T cells in the pathogenesis of
these diseases has not been investigated in detail. Epidermolysis bullosa acquisita (EBA) is an AIBD
associated with antibodies to type VII collagen (COL7). The majority of EBA sera recognize the NC1
of COL7, including the von Willebrand Factor A2 (vWFA2) domain. In an active mouse model of
EBA induced by immunization with a GST-COL7 fusion protein, disease induction depended on
both the genetic background of the mice and a Th1 polarization in draining lymph nodes (dLN).
Furthermore, upon immunization, nude mice did not produce autoantibodies or skin lesions. Yet,
it has remained unclear if, and if yes, which T cell subsets are required for EBA induction. Here, we
established a novel disease model of EBA by immunization with vWFA2 (lacking GST). While all
tested mouse strains developed autoantibodies, disease manifestation was exclusively observed in
mice carrying the H2s haplotype. In immunized mice, T cells specific for this antigen were later
detected in dLN. Anti-vWFA2 autoantibodies located at the lamina densa by immunoelectron
microscopy, bound to dermal side of salt-split skin and induced skin blisters when passively trans-
ferred. When depleted at the time of immunization, absence of CD8 T cells had little to no effect,
while depletion of CD4 T cells significantly delayed autoantibody production and disease onset.
Collectively, we demonstrate the pathogenic relevance of antibodies targeting the vWFA2 domain
of COL7 and show the requirement of CD4 T cells to induce autoimmunity.
172
Bullous pemphigoid autoantibodies induce skin fragility in neonatal mice in a complement-
independent manner
T Sasaoka, H Ujiie, W Nishie, A Shibaki, H Nakamura and H Shimizu Depertment of
Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Bullous pemphigoid (BP), the most common autoimmune blistering disorder, is caused by autoan-
tibodies against type XVII collagen (COL17). In BP lesional skin, deposition of autoantibodies as
well as complement-activation and inflammatory cell infiltration are seen; however, the extent to
which complement-activation contributes to blister formation in BP is still controversial. To finally
clarify the necessity of complement in blister formation in BP, we produced C3-deficient COL17-
humanized mice. Interestingly, autoantibodies from BP patients induce skin fragility in neonatal C3-
deficient COL17-humanized mice, off course, without complement deposition. To further address
the amount of NC16A-binding IgG and blister formation, we generated hybridomas that produced
monoclonal mouse IgG1 (mIgG1: high affinity to NC16A and low ability for complement activa-
tion) and IgG2c (mIgG2c: low affinity to NC16A and high ability for complement activation) anti-
bodies against the human NC16A domain of COL17. Low-dose mIgG1 induced skin fragility in
injected neonatal COL17-humanized mice associated with faint deposition of C3. High-dose mIgG2c
induced weak deposition of IgG and distinct deposition of C3, but showed low potential to induce
skin fragility in injected mice. These results indicate that the amount of NC16A-binding IgG relates
more directly to the induction of skin fragility than complement deposition does. Treatment with
mIgG1 depleted the amount of COL17 in cultured keratinocytes more than treatment with mIgG2c
did, suggesting that COL17-depletion by IgG-binding correlates with skin fragility. In summary, this
study shows BP autoantibodies can induce skin fragility in a complement-independent manner.
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Serine protease inhibitor attenuates PAR-2 triggered inflammatory response and keratin 1
expression in human primary keratinocytes
CM Okamura,1 Y Niki,1 S Takeuchi,1,3 C Nishigori,3 L Declercq,2 DB Yarosh2 and N Saito1 1 Kobe
Skin Research Department, Biosignal Research Center, Kobe University, Kobe, Japan, 2 Basic
Science Research, Estée Lauder Companies, Melville, NY and 3 Division of Dermatology, Kobe
University Graduate School of Medicine, Kobe, Japan
Protease-activated receptor-2 (PAR-2) is a member of G protein-coupled receptors that are acti-
vated by serine proteases such as trypsin and tryptase. PAR-2 controls melanosome indigestion and
phagocytosis of keratinocytes. Soybean trypsin inhibitor (STI), a known inhibitor of PAR-2, has
been shown to inhibit melanosome phagocytosis by keratinocytes. Although PAR-2 activation stim-
ulates inflammatory response and inhibits differentiation in keratinocytes, the effect of STI on inflam-
mation and differentiation has not been reposted. In this report, we have investigated the anti-inflam-
matory effect of STI in human primary keratinocytes. In addition, we report the influence of STI on
keratinocyte differentiation after phagocytosis. First of all, we confirmed that cyclooxygenase-2
(COX-2) expression was upregulated by incubation of human primary keratinocytes with PAR-2 ago-
nist peptides, SLIGKV (H-Ser-Leu-Ile-Gly-Lys-Val-OH), melanosomes or fluorescent microspheres.
The upregulation of COX-2 expression was suppressed by incubation with STI. STI treatment also
decreased the basal level of COX-2 expression in keratinocytes. In concert with COX-2 expression,
STI treatment suppressed basal and PAR-2-triggered prostaglandin E2 (PGE2) release. Furthermore,
we found that incubation of keratinocytes with melanosomes increase the expression of keratin 1,
early marker of differentiation. The upregulation of keratin 1 after melanosome indigestion was
suppressed by STI treatment. Our data indicate that inhibition of PAR-2 by STI suppresses inflam-
matory response and differentiation after melanosome phagocytosis of human primary keratinocytes.
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Activin A inhibits antigen-induced allergy in murine epicutaneous sensitization
M Kypriotou,1 D Rivero,1 M Huber,1 H Acha-Orbea,2 S Werner3 and D Hohl1 1 Service of
Dermatology, Beaumont Hospital CHUV, Lausanne, Switzerland, 2 Department of
Biochemistry, University of Lausanne, Lausanne, Switzerland and 3 Department of Biology,
Institute of Molecular Health Sciences, ETH Zurich, Zurich, Switzerland
Activin A, a member of the TGFβ superfamily, is involved in physiological processes such as cell
differentiation, tissue homeostasis, wound healing, reproduction, and in pathological conditions,
such as fibrosis, cancer and asthma. Activin enhances mast cell maturation, as well as regulatory T-
cell and Langerhans cell differentiation. In this study we investigated the potential role of activin in
epicutaneous sensitization with ovalbumin, notably with respect to its effect on known Th2-polar-
isation. For this purpose, transgenic mice overexpressing activin in keratinocytes and their wild-type
controls were sensitized epicutaneously with ovalbumin. Skin biopsies were analyzed with regard
to histopathological features and mRNA expression of pro-inflammatory and Th1/Th2 cytokines,
and Ig levels were measured in the serum. Unexpectedly, transgenic mice were more susceptible
to inflammation compared to wild-type littermates after tape-stripping and vehicle or OVA appli-
cation. Thus, Il1β and Tslp mRNA levels were increased and neutrophils accumulated at the site of
the treatment. However, activin overexpressing animals were protected from allergic reactions,
because Th2-cytokine expression and OVA-specific IgE levels remained low compared to WT ani-
mals. We conclude that activin protects from antigen-induced skin allergy through modulation of
the immune response. These findings highlight the role of activin in cutaneous sensitization and in
skin homeostasis.
www.jidonline.org   S29
IID13_Abstracts-5  3/25/13  3:00 PM  Page S29
ABSTRACTS | Auto-Immunity & Inflammation
175
Increased sensitivity to stratum corneum neutralization favors the development of dermati-
tis in flaky-tail mice
T Sakai, Y Hatano and S Fujiwara Dermatology, Oita University, Yufu, Japan
Neutralization of the stratum corneum (SC) pH adversely impacts the epidermal function, includ-
ing permeability barrier homeostasis. In addition, substantial permeability barrier abrogation causes
cutaneous inflammation. Conversely, maintenance of the SC acidity prevents the development of
barrier abnormalities and downstream immune dysfunction. Neutralization of the SC is induced by
a variety of stimuli, including scratching, use of soap and skin inflammation. Thus, the homeosta-
sis of the SC acidity is important to help maintain healthy skin. We herein investigated the impact
of impaired homeostasis of the SC acidity on the emergence of an atopic dermatitis (AD)-like con-
dition using flaky-tail mice. The flaky-tail mice have been known to preferentially exhibit AD-like
dermatitis with or without exposure to induction stimuli, such as haptens or allergens, compared
to wild type mice. We revealed that the SC acidity was maintained in flaky-tail mice with an increase
in the expression levels of sPLA2 and NHE1, which might compensate for a decrease in urocanic
acid due to a loss-of-function mutation in the filaggrin gene, as previously reported by Fluhr et al.
Our physiological examinations revealed that the homeostatic function to maintain the SC acidity
in flaky-tail mice was not as robust as that in wild type mice when exposed to neutralization stim-
ulation due to application of a superbase, 1,1,3,3-Tetramethylguanidine (TMG). In fact, although
upregulated expression of both sPLA2 and NHE1 was induced after the application of TMG in wild
type mice, this was not observed in flaky-tail mice. In addition, a consecutive two-week daily
application of TMG induced substantial skin inflammation with elevation of the serum IgE levels in
flaky-tail mice, but not in TMG-treated wild type mice or vehicle-treated flaky-tail mice. These results
suggest that an impaired homeostatic reaction following insults to the SC acidity might be involved
in the emergence of AD-like dermatitis in flaky-tail mice, providing new insight into the pathogen-
esis of AD.
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The T regulatory cell/T helper 17 cell ratio is reduced in the gut of patients with dermatitis
herpetiformis
E Antiga,1 I Pierini,1 G Baroni,2 E Del Bianco,1 B Bianchi,1 D Renzi,3 S Di Lollo,2 AS Calabrò,3
P Fabbri1 and M Caproni1 1 Department of Critical Care, Section of Dermatology, University of
Florence, Florence, Italy, 2 Department of Critical Care, Section of Pathologic Anatomy,
University of Florence, Florence, Italy and 3 Department of Clinical Pathophysiology, Section
of Gastroenterology, University of Florence, Florence, Italy
In the present study we investigated regulatory T cells (Tregs) and T helper 17 cells (Th17) in the gut
of patients with dermatitis herpetiformis (DH), the specific cutaneous manifestation of celiac dis-
ease (CD). Six patients with DH were enrolled and duodenal samples were collected before gluten-
free diet. Markers of Tregs (CD4, CD25, FOXP3) and of Th17 (RORγt, IL-17, IRF-4) were investi-
gated by immunohistochemistry. As controls, samples of 4 patients with CD without skin involvement,
3 patients with CD and psoriasis, as well as from 4 healthy subjects (HS) were collected. Few FOXP3+
Tregs were detected in the gut of patients with DH, CD, CD and psoriasis, and HS. Interestingly, no
statistical significant differences were found in the FOXP3+/CD4+ cell ratio between the four groups
of patients. By contrast the numbers of RORγt+, IL-17+ and IRF4+ lymphocytes were higher in
patients with DH, CD, CD and psoriasis compared to those found in HS (p < 0.001 for all the groups).
Interestingly, the Tregs/Th17 ratio, calculated as the ratio between FOXP3+ and RORγt+ cells, was
significantly lower in patients with DH with respect to patients with CD and patients with CD and
psoriasis (DH vs CD: p = 0.01; DH vs CD and psoriasis: p = 0.02). In conclusion, our data demon-
strated that Th17 cells are involved in the pathogenesis of intestinal lesions in patients with DH and
in patients with CD. However, patients with DH showed a different lymphocytic pattern with a
decreased Tregs/Th17 ratio than patients with CD, suggesting in the former a more evident relative
defect of Tregs, that could be involved in the phenotypic differences of the two diseases.
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The loss of Piasy activates IL23 expression from keratinocyte in response to IL17 and TNFα,
a positive feedback mechanism for Th17 activation in psoriasis
Y Liu, D McClanahan, S Persaud, Y Wang and B Ehst Dermatology, Oregon Health & Science
University, Portland, OR
Psoriasis is a chronic inflammatory disease with genetic predisposition. There is a vicious circle of
uncontrolled inflammation which involves the interplay between keratinocyte hyperproliferation
and immunocyte infiltration and activation. Although keratinocytes are generally considered to be
downstream of a psoriatic immunoresponse, evidence is accumulating to suggest that keratinocytes
may play active roles in psoriasis pathogenesis. We previously found that the expression of CCL20,
a psoriatic chemokine essential for the recruitment of Th17 cells, is down-regulated by PIASy (Pro-
tein Inhibitors of Activated Stats) in keratinocytes. More recently, we have shown that imiquimod-
induced psoriasis-like phenotypes were significantly enhanced in PIASy-deficient mice in a gene
dosage dependent manner. More importantly, PIASy deficiency resulted in robust expression of IL-
23 from primary keratinocytes in response to combined treatment with TNFα and IL-17A. As IL-23
is essential for Th17 activation, PIASy inactivation provides a molecular basis for forming a vicious
cycle of IL-23 overproduction from keratinoctyes and IL17 and TNFα cytokine overproduction
from Th17 cells that contributes to constitutive Th17 activation in psoriasis. Biochemically, we have
identified NF-κB and STAT3 as the targets negatively regulated by PIASy. More importantly, we
have identified 2 functional PIASy single nucleotide polymorphisms (SNP) that compromise its
ability to inhibit NF-κB and STAT3. As NF-κB and STAT3 are the major contributors in the inflam-
mation circuitry of psoriasis, the inactivation of PIASy provides a novel mechanism for uncon-
trolled inflammation in psoriasis pathogenesis. The analysis of the PIASy molecular pathway in pso-
riasis will not only help us understand the molecular basis of aberrant inflammation in psoriasis,
but also may provide new molecular and cellular targets for psoriasis prognosis, prevention and
therapy.
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Fumaric acid attenuates the eotaxin-1 expression in TNF-α-stimulated fibroblasts by sup-
pressing p38 MAPK-dependent NF-κB signaling
K Roh,1 E Jung,1 J Lee,1 J Lee2 and D Park1 1 Biospectrum LIfe Science Institute, Seongnam,
Republic of Korea and 2 Dermatological Health Management, Eulji University, Seongnam,
Republic of Korea
Eotaxin-1 is a potent chemoattractant for eosinophils and a critical mediator during the develop-
ment of eosinophilic inflammation. Fumaric acid is an intermediate product of the citric acid cycle,
which is source of intracellular energy. Although fumaric acid ameliorates psoriasis and multiple
sclerosis, its involvement in eotaxin-1-mediated effects has not been assessed. In this study, we inves-
tigated the effects of fumaric acid on eotaxin-1 expression in a mouse fibroblast cell line. We found
that fumaric acid significantly inhibited tumor necrosis factor-α-induced eotaxin-1 expression. This
fumaric acid effect was mediated through the inhibition of p38 MAPK-dependent NF-κB signaling.
We also found that fumaric acid operates downstream of MEKK3 during TNF-α-induced NF-κB sig-
naling, which upregulated eotaxin-1 expression. In addition, fumaric acid attenuated expression of
CCR3, an eotaxin-1 receptor, and adhesion molecules that play important roles in eosinophil bind-
ing to induce allergic inflammation. Taken together, these findings indicate that inhibiting TNF-α-
induced eotaxin-1 expression by fumaric acid occurs primarily through suppression of NF-κB sig-
naling, which is mediated by inhibiting p38 MAPK and suggest that fumaric acid may be used as a
complementary treatment option for eotaxin-1-mediated diseases.
179
Anti-alpha-2-macroglobulin-like-1 autoantibodies are detected frequently and may be path-
ogenic in paraneoplastic pemphigus
N Ishii,1 S Numata,1 K Teye,1 D Tsuruta,1 R Sogame,1 H Koga,1 Y Natsuaki,1 A Tsuchisaka,1
T Hamada,1 T Karashima,1 T Nakama,1 M Furumura,1 C Ohata,1 T Kawakami,2 I Schepens,3
L Borradori3 and T Hashimoto1 1 Dermatology, Kurume University School of Medicine, and
Kurume University Institute of Cutaneous Cell Biology, Fukuoka, Japan, 2 Dermatology, St.
Marianna University School of Medicine, Kawasaki, Japan and 3 Dermatology, Inselspital,
Bern University Hospital and University of Bern, Bern, Switzerland
Paraneoplastic pemphigus (PNP) shows autoantibodies mainly to plakin and desmosomal cadherin
family proteins. We have recently identified alpha-2-macroglobulin-like-1 (A2ML1), a 170 kDa
broad range protease inhibitor, as a novel and unique PNP antigen. In this study, we first tested a
large number of PNP sera by various methods to assess how frequently anti-A2ML1 autoantibod-
ies are detected in PNP. Forty (69.0%) of 58 PNP sera recognized A2ML1 recombinant protein
expressed in COS7 cells by immunofluorescence (IF) and/or immunoprecipitation/immunoblotting
(IP/IB). IP/IB showed higher sensitivity than IF. In addition, 22 (37.9%) PNP sera reacted with A2ML1
by IB of cultured normal human keratinocytes (NHKs) under non-reducing condition. Statistical
analyses using various clinical and immunological data showed that the presence of anti-A2ML1
autoantibodies was associated with early disease onset and absence of ocular lesions. Next, to inves-
tigate the pathogenic role of anti-A2ML1 antibody, we performed additional in vitro functional stud-
ies using anti-A2ML1 polyclonal antibody and cultured NHKs. Addition of anti-A2ML1 polyclonal
antibody to culture media decreased NHK cell adhesion examined by dissociation assay, and
increased plasmin activity detected by casein zymography, suggesting that anti-A2ML1 antibody
may decrease NHK cell adhesion through plasmin activation by inhibition of A2ML1. This study
demonstrated that autoantibodies to A2ML1 are frequently and specifically detected and may play
a pathogenic role in PNP.
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Indomethacin inhibits eosinophil migration to prostaglandin D2: Proposal of a mechanism of
action for eosinophilic pustular folliculitis
A Hirai,1,2 N Kataoka,2 T Satoh1 and H Yokozeki2 1 Department of Dermatology, National
Defense Medical College, Tokorozawa city, Japan and 2 Department of Dermatology,
Graduate School, Tokyo Medical and Dental University, Tokyo, Japan
Eosinophilic pustular folliculitis (EPF) is an inflammatory skin disease characterized by pruritic fol-
licular papulopustules that tend to form in an annular configuration, accompanied by blood and
tissue eosinophilia. EPF is usually resistant to topical corticosteroids; but responds well to systemic
administration of indomethacin. However, the mechanism of therapeutic effect remains unclear.
One of the unique characteristics of indomethacin is that, unlike other non-steroidal anti-inflam-
matory drugs, it is a potential agonist of CRTH2, a receptor for prostaglandin (PG)D2. In this study,
we investigated the pharmacological actions of indomethacin on eosinophil migration. Eosinophils
exhibited chemotactic responses to both PGD2 and indomethacin through CRTH2 receptors. Pre-
treatment of eosinophils with indomethacin greatly inhibited eosinophil migration to PGD2 and,
to a much lesser extent, to eotaxin (CCL11). Indomethacin also cancelled a priming effect of Δ12-
PGJ2, a plasma metabolite of PGD2, on eosinophil chemotaxis to eotaxin. Indomethacin down-
modulated cell surface expression of both CRTH2 and CCR3. A number of hematopoietic-type PGD
synthase (+) cells were observed within the cellular infiltrate in the dermis of EPF. Moreover, hair
follicle epithelium and epidermal keratinocytes around eosinophilic pustules together with the
eccrine apparatus of palmoplantar lesions of EPF were immunohistochemically positive for lipocalin-
type PGD synthase. Thus, PGD2-CRTH2 interaction may be involved in the pathogenesis of EPF
and indomethacin appears to exert therapeutic effects via homologous and heterologous desensi-
tization of eosinophil CRTH2 and CCR3, respectively, by agonistic effects on CRTH2.
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Epicutaneous application of Toll-like receptor 7 agonists leads to systemic autoimmunity in
wild-type mice: A new model of SLE
M Yokogawa, M Takaishi, K Nakajima, S Kataoka, Y Terada and S Sano Kochi University,
Nankoku, Japan
Recent studies have shown that Toll-like receptor (TLR) 7 plays a critical role in development of
autoimmunity in patients with systemic lupus erythematosus (SLE) as well as lupus-prone mice. Here
we report that topical treatment of wild-type mice with the TLR7/8 agonist imiquimod (IMQ) three
times weekly on ear skins leads to fatal autoimmune disease by 15 weeks of the regimen. IMQ-
treated mice from different genetic backgrounds developed anemia, glomerulonephritis, hepatitis,
pericarditis, and increased skin photosensitivity to UVB irradiation. They showed elevated autoan-
tibodies to double stranded (ds) DNA and lupus-like glomerulonephritis within 4 weeks of topical
IMQ treatment, while intraperitoneal administration of IMQ caused less severe disease. Deletion
of plasmacytoid dendritic cells (pDCs) reduced the anti-dsDNA titers and ameliorated the glomeru-
lonephritis, suggesting that pDCs are essential for IMQ-induced autoimmunity. Topical treatment
with R848, another TLR7/8 agonist, also led to severe autoimmune disease in wild-type mice. Fur-
thermore, Tlr7 deficient mice, but not Tlr9 deficient mice, were protected from IMQ-induced autoim-
munity, further supporting the key role of TLR7 signaling. This protocol provides a novel inducible
lupus model in wild-type mice, and underscores the skin as the primary organ that allows TLR7 ago-
nists to initiate systemic autoimmune disease, SLE.
183
Continuous mechanical contraction induces inflammatory factors in human epidermal ker-
atinocytes
T Gomi, T Hinokitani, M Shishido and K Yo Dermatological R&D, POLA Chemical Industries,
Inc., Yokohama, Japan
Human skin is subject to mechanical stress due to factors such as muscle movement, gravity, and
physical contact. Secretion of inflammatory cytokines induced by NF-kB signaling has been reported
to occur in endothelial and epidermal cells subjected to cyclic or continuous mechanical stretch-
ing. Moreover, the stretch-activated calcium ion channel (SAC) has been implicated in this process.
As cells were subjected to mechanical stretching in these studies, the effect of physical contraction
remains unclear. Thus, the aim of this study was to determine the inflammatory effect of continu-
ous physical contraction on epidermal keratinocytes. Normal human epidermal keratinocytes (NHEK)
were seeded into collagen-coated silicon chambers and incubated for 24 hours at 37 °C. Subse-
quently, NHEK were subjected to 33% continuous uniaxial contraction and incubated for a further
6 or 24 hours before harvesting for total RNA purification. The mRNA expression of 84 common
cytokines and chemokines in harvested cells was examined using RT2 Profiler PCR array system.
Results showed that continuous contraction significantly upregulated expression of not only inflam-
matory cytokines such as IL-1α, IL-6, TNFα, but also neutrophil/leucocyte chemotactic factors includ-
ing CXCL1, CCL2 and IL-8. ELISA was used to confirm findings at a protein level. Notably, most of
these factors are involved in inflammation and are downstream targets of NF-kB signaling. Our find-
ings suggest that continuous contraction of NHEK results in mechanotransduction via activation of
SAC.
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Valrubicin reduces inflammation in activated human keratinocytes and leukocytes
S de Fønss,1 E Hauge,1 L Rottbøll,1 SM Andersen,1 E de Darkó,2 K Stenderup1 and C Rosada1 1
Deparment of Dermatolgy, Aarhus University Hospital, Aarhus, Denmark and 2 Valderm ApS,
Lyngby, Denmark
Valrubicin alleviated psoriasis xeno-transplanted onto the back of immunodeficient mice. The effect
was attributed to a reduction of keratinocyte hyper-proliferation; a characteristic of psoriasis. A sim-
ilar reduction in hyper-proliferation was observed in human squamous cell carcinoma cell lines and
tumor development inhibition has been demonstrated in a murine skin carcinogenesis model. Both
psoriasis and skin cancer present an inflammatory component. Valrubicin showed an effect in an
acute and a chronic murine inflammation model; however, the impact source of the effect of val-
rubicin on inflammation in human tissue is still unknown. An understanding of valrubicin’s role in
inflammation, in human tissue, is of utmost importance to fully appreciate valrubicin’s potential as
future treatment of hyper-proliferative and inflammatory skin diseases. The aim of the present study
was to investigate valrubicin’s effect on inflammation in human tissue by employing activated human
keratinocytes and leukocytes; cell types that are both present in the skin. Primary human keratinocytes,
isolated from four healthy volunteers, and HaCaT cells were activated with 12-O-tetrade-
canoylphorbol 13-acetate (TPA) followed by exposure to valrubicin for 2 hrs. Valrubicin treatment
significantly reduced the mRNA expression levels of the inflammatory cytokines IL-1β, IL-8, and
TNF-α. Leukocytes as peripheral blood mononuclear cells (PBMCs) were isolated from patients with
severe plaque psoriasis and activated with staphylococcal enterotoxin B (SEB) and IL-2. Similarly,
the 2 hrs valrubicin exposure significantly reduced the mRNA expression levels of the inflamma-
tory cytokines IL-1β and IL-8. In conclusion, the present data confirm an anti-inflammatory effect
of valrubicin in human tissue that may partly explain valrubicin’s beneficial effect in psoriasis and
skin tumor development. The anti-inflammatory effect suggests a possible role for valrubicin to treat
other inflammatory skin diseases.
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GM-CSF modulates both innate and adaptive immune responses in autoantibody-mediated
organ-specific autoimmune disease
U Samavedam,1 H Iwata,1 S Müller,1 FS Schulze,1 A Recke,1 E Schmidt,1,2 D Zillikens1 and
RJ Ludwig1 1 Department of Dermatology, University of Lübeck, Lübeck, Germany and 2
Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany
Aberrant cytokine responses are linked to pathogenesis of autoimmune diseases. Autoimmune bul-
lous dermatoses (AIBD) are prototypical organ-specific autoimmune diseases, characterized by
autoantibodies against cutaneous structural proteins, leading to blistering. In experimental epider-
molysis bullosa acquisita (EBA), an AIBD with autoantibodies to type VII collagen (COL7), we
noted elevated serum concentrations and an increased cutaneous expression of GM-CSF, but not
G-CSF. In line, induction of experimental EBA was impaired in GM-CSF deficient mice or after neu-
tralizing GM-CSF. Functionally, GM-CSF enhanced reactive oxygen species release from immune-
complex-activated neutrophils and controlled neutrophil migration into the blood and skin. Treat-
ment of mice with already established immunization-induced EBA with anti-GM-CSF improved the
skin blistering. Interestingly, decreased serum levels of anti-COL7 autoantibodies were observed in
GM-CSF-deficient mice after immunization. In these mice, we also noted a reduced neutrophil
recruitment into peripheral lymph nodes. An identical effect was evoked by neutrophil depletion
during immunization in wild type mice. Combination of both, depletion of neutrophil granulocytes
in GM-CSF deficient mice, led to an even stronger inhibition of autoantibody production. This indi-
cates that the role of GM-CSF as cytokine and neutrophil granulocytes as players of the innate
immune system have overlapping and distinct functions in autoantibody generation. Concluding
from these results, targeting GM-CSF may be a promising therapeutic strategy for autoantibody-
mediated diseases.
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Drug induced EBV reactivation in DRESS syndrome triggers a B lymphocyte dependent IL-10
secretion
B Janela,1 D Picard,2 M Vaillant,2 P Joly,2 S Calbo2 and P Musette2 1 Singapore Immunology
Network, Agency for Science, Technology and Research, Singapore, Singapore and 2 INSERM
U905, Rouen University Hospital, Department of Dermatology, Rouen, France
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe drug-induced reaction
that involves both the skin and the viscera. Observations have evidenced herpesvirus reactivations
in DRESS. Activated EBV specific cytotoxic CD8+ T cells have been previously identified as major
actors in the pathophysiology of DRESS. In addition, DRESS inducer drugs exclusively induce an
increased production of EBV virus in B-LCL lines derived from DRESS patients. As for other her-
pesvirus, EBV biology is associated with an immune evasion strategy, based on a protein named
BCRF1, also known as viral IL10 (vIL-10), which is 84% homologous to the human IL-10 (hIL-10).
We then measured IL10 secretion levels in DRESS patients and assessed the origin of IL10 secre-
tion in DRESS patients. Forty DRESS patients were included in a prospective and multicentric study.
We analyzed the presence of IL-10 by ELISA, microarrays, FACS and Quantitative-PCR which allowed
us to quantify and distinguish hIL-10 from vIL-10. We also characterized in vitro the effect of DRESS
inducer drugs on vIL-10 and hIL-10 production by B-LCL derived from DRESS patients or healthy
controls. Our results show that DRESS patients have increased serum total IL-10 concentrations at
the onset of the disease, mainly secondary to increased vIL10. IL-10 is not secreted by CD4+ T cells
but DRESS patient have B cells which, under stimulation, produce 2.33 times more IL-10 than B
cells from healthy controls. In vitro, DRESS inducer drugs disrupt the IL-10 balance in B-LCL from
DRESS patient by decreasing hIL-10 and increasing vIL-10 both at the RNA and protein level. In
conclusion, DRESS patients have increased total IL10 levels, mainly related to an increase of vIL10
production, as suggested by the effect of DRESS drug inducers on the EBV production and on the
vIL10 levels. These findings give new insights in the understanding of the pathophysiology of DRESS.
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Protective role of anti-inflammatory complex on human skin cells
M Pasikowska, R Debowska, B Marczak and I Eris Cosmetic Laboratories Dr Irena Eris, Centre
for Science and Research Dr Irena Eris, Warsaw, Poland
Skin is under constant exposure to environmental factors such as UV-radiation, allergens or chem-
icals. Skin cells’ damages accumulate with age are resulting in chronic inflammation, oxidative
stress and DNA damage. Immunological changes include increased production and circulation of
pro-inflammatory cytokines such as Interleukin-6 (IL-6), Interferon gamma (IFN-γ) and Tumor necro-
sis factor alpha (TNF-α), leading to a low-grade chronic inflammation. This state has been regarded
as a background for many age-related human diseases. Therefore the aim of this study was to eval-
uate the anti-inflammatory effect of two molecules and their complex on the level of IL-6 in super-
natants of human skin keratinocytes challenged with UVB-radiation. Investigated substances are
amino acid TioP and phenolic acid RA. Both compounds are a powerful natural protectors of the
cellular membrane due to theirs antioxidizing and anti-free radical properties. Different concen-
trations of each compound and complex were analyzed. ELISA test for IL-6 antibodies showed
decrease level of the cytokine in each tested combination. A single treatment with TioP or RA
exhibited anti-inflammatory effect, however the strongest inhibition of IL-6 production induced by
UVB was demonstrated for the complex TioP-RA, 7mM and 60 mg/ml, respectively. Moreover,
TioP-RA complex was found to enhance viability of keratinocytes after UVB exposure (MTT assay).
Taken together, these results showed that both tested compounds reveal synergic effect on UV-
induced skin cells inflammation. Knowing the antioxidant properties of both molecules and iden-
tifying their strong anti-inflammatory action, suggest that these substances may protect skin from
chronic inflammation as well as have potential application in the ‘inflammaging’ filed.
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Epidermal cFLIP is a critical regulator of skin homeostasis and protects from TNF-induced
keratinocyte apoptosis
D Panayotova-Dimitrova,1 M Feoktistova,1 B Kellert,1 M Ploesser,1 A Marx,2 S Porubsky,2
M Hupe,1 F Jensen,4 A Zenclussen,4 P Geserick,1 Y He3 and M Leverkus1 1 Section of Molecular
Dermatology, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany, 2
Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany, 3 Duke University
Medical Center, Durham, NC and 4 Medical Faculty, Otto-von-Guericke University,
Magdeburg, Germany
Key proteins within cell death signalling platforms are FADD, caspase-8, and cellular FLICE-inhibitory
protein (cFLIP). Mice that constitutively lack any of these molecules die at early embryonic age.
Recently, epidermis-specific deletion of either FADD or caspase-8 resulted in development of a
severe inflammatory skin disorder. The role of cFLIP for the control of inflammatory and cell death
pathways in the skin is unknown. We have generated mice lacking cFLIP in the epidermis. Strik-
ingly constitutive epidermal-specific deletion of cFLIP using keratin 14 (K14)-dependent Cre-expres-
sion led to embryonic death around E10. To overcome the limitations of embryonic lethality, we
generated mice with skin-specific inducible postnatal deletion of cFLIP. Shortly after tamoxifen appli-
cation, cFLIP expression was abrogated in adult skin of cFLIPfl/fl-K14CreERtam mice. Loss of cFLIP
resulted in severe alteration and macroscopically detectable inflammation of the skin in tamoxifen-
treated animals, but not in control animals. Histological, immunohistological and in vitro analysis
revealed rapid caspase activation and apoptotic, but not necroptotic cell death in the skin or cul-
tured keratinocytes. Interestingly apoptosis was dependent on autocrine TNF production triggered
by loss of cFLIP in the epidermis. In vitro and in vivo inhibition experiments using TNF-R2-Fc fusion
protein revealed the critical role of TNF, but not TRAIL or CD95L, for epidermal cell death. Taken
together our data demonstrate the critical importance of cFLIP for the integrity of the epidermis and
for constitutive silencing of skin inflammation.
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Clinical and immunologic prognostic factors of bullous pemphigoid: A multicenter, prospec-
tive study of 120 patients
F Fichel,1 C Barbe,1 P Joly,2 C Bedane,3 P Vabres,4 F Aubin,5 F Truchetet,6 C Michel,7 J Jegou,8
F Grange,1 F Antonicelli9 and P Bernard1 1 Reims University Hospital, Reims, France, 2 Rouen
University Hospital, Rouen, France, 3 Limoges University Hospital, Limoges, France, 4 Dijon
University Hospital, Dijon, France, 5 Besançon University Hospital, Besançon, France, 6 Metz-
Thionville Hospital, Thionville, France, 7 Mulhouse Hospital, Mulhouse, France, 8 Chalons
Hospital, Chalons, France and 9 Champagne Ardenne University, Reims, France
Background: Although predisposing factors for bullous pemphigoid (BP) have been recently estab-
lished, no clinical or immunologic factors have been identified to predict disease outcome yet.
Objective: To identify potential clinical and immunologic risk factors for BP relapse during the first
year of treatment. Patients and Methods: In this prospective, multicenter, open study, 120 patients
were included. Clinical data were recorded at baseline; 36 patients (30%) had an associated demen-
tia and 100 were treated by superpotent topical corticosteroids. Baseline and follow-up visits were
planned at days 0, 60, 90, 150, 210, 270 and 360 to record disease activity and collect blood sam-
ples for BP180/230 ELISA values measurement. Results: During the 1-year follow-up, 35 (29.2%)
patients relapsed, 31 of them still were under therapy. Although BP180 and BP230 ELISA values
were similar at baseline between relapsing and non-relapsing patients, their values decreased less
rapidly between days 0 and 60 in relapsing patients (p=0,0004 and 0,05, respectively). In multi-
variate analysis, factors at baseline independently associated with relapse were an extensive dis-
ease at inclusion (Hazard ratio (HR) 2.4, 95% confidence interval (CI) 1.2-4.8) and an associated
dementia (HR 2.1, 95% CI 1.0-4.2). Conclusions: The present study demonstrates that superpotent
topical corticosteroids induce a dramatic, early decrease of anti-BP180/230 autoantibodies. A slight-
est decrease of these autoantibodies, as well as extensive disease or dementia at baseline, were rel-
evant to predict BP clinical relapse within the first year of treatment.
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Disease flare and progression in cutaneous lupus erythematosus: A longitudinal study of CLE
YC Chang,1,2 KJ Propert,3 S Sirignano,4 B Chong4 and VP Werth1,2 1 Dermatology, Perelman
School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2 Dermatology,
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, 3 Biostatistics, Hospital of the
University of Pennsylvania, Philadelphia, PA and 4 Dermatology, UT Southwestern, Dallas, TX
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated clini-
cal tool that measures Cutaneous Lupus Erythematosus (CLE) disease activity and responsiveness.
Clinically significant “flare” in CLE disease activity has not yet been determined, which may be
important when looking at changes in disease activity over time. In addition, longitudinal analyses
of disease activity in terms of CLASI have not yet been conducted. Our study had two aims: 1) to
determine how to best use the CLASI to define clinical “flare,” and 2) to objectively evaluate CLE
disease course in terms of average disease activity (area under the curve/year), overall progression
(best-fit slope), and variability (flares/year). Using ROC analysis to optimize specificity and sensi-
tivity, clinical “flare” between visits was defined as mean signed and percentage increase in CLASI
of 4 and 40%, respectively. We studied 96 patients in a longitudinal retrospective analysis with at
least 2 years follow-up. A majority of patients had mild disease activity [CLASI 0-9] (74%) and sta-
ble disease course (67%), defined by slope <2, over an average of 3.3 years. Those with mild dis-
ease activity tended to have stable disease, fewer flares per year, and better quality of life on aver-
age than those with moderate-severe disease. Higher percentage of those with moderate-severe
disease (64% vs 33%), especially those who remained stable or worsened, were current smokers.
A higher percentage of patients who worsened in disease activity were male (58%) compared to
improved or stable disease. Longitudinal studies of CLE have been difficult in the past due to lack
of validated clinical tools and databases, and this serves as a foundation to objectively analyzing
longitudinal data using CLASI.
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The limitations in measuring improvement in disease activity in patients with mild cutaneous
lupus erythematosus
YC Chang,1,2 KJ Propert3 and VP Werth1,2 1 Dermatology, Perelman School of Medicine at the
University of Pennsylvania, Philadelphia, PA, 2 Dermatology, Philadelphia Veterans Affairs
Medical Center, Philadelphia, PA and 3 Biostatistics, Hospital of the University of
Pennsylvania, Philadelphia, PA
The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a reliable and val-
idated clinical tool that can be used to classify Cutaneous Lupus Erythematosus (CLE) patients into
groups according to disease severity and to demonstrate clinically significant improvement in dis-
ease activity. It is probable that a patient’s baseline disease severity influences the magnitude of
change in clinical outcome measures seen in clinical improvement. This retrospective cohort study
analyzed data from 270 patients in the CLE database to determine how to best measure clinically
significant improvement in the subset of CLE patients with mild disease (based on CLASI activity
score of 0-9) by analyzing changes in CLASI activity score as well as the Physician Global Asses-
ment (PGA), patient visual analogue scale (VAS), and Skindex-29+3. We found that there is a small
but significant difference in the change in CLASI activity scores between the clinical response and
non-response groups using the PGA as an external outcome measure in patients with mild CLE.
However, there are no significant differences in change in Skindex 29 subscores or VAS itch and
pain scores between the clinical response and non-response groups. In addition, in patients with
mild CLE, neither changes in Skindex-29 subscores nor changes in patient VAS scores (itch, pain,
fatigue, skin health) correlated with changes in CLASI, and changes in Skindex-29 did not correlate
with changes in VAS scores. Recent studies have demonstrated CLASI responsiveness in patients
with baseline mild disease using the established definition. This study suggests that patients with
mild CLE disease activity may demonstrate improvement in disease based on a decrease in CLASI
score that is not detectable by other external outcome measures.
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Effects of topical rapamycin versus tacrolimus in atopic dermatitis-like mouse model
MI Abd el-latif,1 M Tanaka,2 M Wataya-Kaneda,2 H Murota2 and I Katayama2 1 dermatology,
Cairo University, Cairo, Egypt and 2 dermatology, Osaka University, Osaka, Japan
Background: Sirolimus (Rapamycin), is an immunosuppressant drug belongs to macrolides, used to
prevent rejection in organ transplantation. It was discovered that rapamycin had potent immuno-
suppressive and antiproliferative properties.Unlike tacrolimus; the potent topical treatment for atopic
dermatitis (AD); rapamycin is not a calcineurin inhibitor. However, it has a similar suppressive effect
on the immune system. Rapamycin inhibits the response to IL-2 and thereby blocks activation of T-
and B-cells. In contrast, tacrolimus inhibits the production of IL-2. Thereby, it might be assumed
that rapamycin has therapeutic potential in AD through inhibition of IL-2 response. Methodology:
NC/Nga mice, which are commonly used as an AD model, were treated topically with 4% sodium
dodecyl sulfate (SDS)/ dermatophagoides farinae (DF) extract ointment to induce AD like lesions,
twice weekly for 4 weeks. The mice were treated topically twice a week with rapamycin (0.03%,
0.1%, and 0.2%), rapamycin vehicle or tacrolimus (TR) in the last 2 weeks. Results: as expected the
local rapamycin concentration was coinciding with concentration used with significant difference
between both 0.1%, and 0.2% and 0.03% rapamycin. The difference in the dermatitis score before
and after treatment was however significant in 0.03% rapamycin treated group compared to vehi-
cle treated group. This was associated with significant decrease in the mean epidermal thickness in
the same group. Also there was a significant decrease in the dermal lymphocyic infiltrate. However
the differences in the serum IgE level, as well as the mast cell infiltration were not significant. The
effects of 0.03% rapamycin treated group on the dermatitis score, and lymphocytic infiltrate were
comparable to tacrolimus treated group and were significant with regard to the epidermal thick-
ness. Conclusion: 0.03% topical rapamycin is effective in treatment of NC/NGA mice induced der-
matitis. Topical rapamycin might be an effective therapeutic target for topical AD treatment.
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Simvastatin decreases skin T-cell infiltration and prevents epidermal depigmentation in a
mouse model of vitiligo
M Rashighi,1 P Agarwal,1 KI Essien,1 ML Frisoli,1 H Pazoki-Toroudi2 and JE Harris1 1 Department
of Medicine, Division of Dermatology, University of Massachusetts Medical School,
Worcester, MA and 2 Center for Research & Training in Skin Diseases & Leprosy, Tehran
University of Medical Sciences, Tehran, Islamic Republic of Iran
Our goal was to test the efficacy of simvastatin as a novel treatment for vitiligo. Vitiligo is an autoim-
mune disease that results in depigmentation of the epidermis and is caused by CD8+ T cell destruc-
tion of melanocytes, a process that is critically dependent on IFN-γ expression in affected skin. IFN-
γ signals through STAT1, inducing the expression of chemokines required for T cell infiltration of
the skin in vitiligo. Simvastatin attenuates STAT1-mediated transactivation in vitro, and one group
reported a patient with both vitiligo and hypercholesterolemia who developed rapid repigmenta-
tion following treatment with high-dose simvastatin. These data led to our hypothesis that simvas-
tatin could be used as a potential treatment for vitiligo. To test this hypothesis, we used a mouse
model of vitiligo that develops focused epidermal depigmentation through adoptive transfer of
melanocyte-specific T cells. We found that intraperitoneal simvastatin reduced severity of vitiligo
by 4-fold (p = 0.003), and reduced the ability of CD8+ T cells to migrate to ear and tail by 50-fold
and 27-fold respectively (p = 0.0001, p = 0.0008), despite having no effect on the total numbers of
CD8+ T cells in blood, spleen or skin-draining lymph nodes. Similar to neutralization of IFN-γ, short-
term treatment of mice with established disease resulted in a reduction of CD8+ T cells in ear by
18-fold (P = 0.015), suggesting that simvastatin acts directly in the skin to suppress chemokine pro-
duction, rather than systemically to prevent T cell activation. Therefore, simvastatin may prevent
the infiltration of autoreactive CD8+ T cells into the skin in vitiligo by disrupting IFN-γ signaling.
Based on these observations, we are currently recruiting subjects for a double-blinded, placebo-
controlled clinical trial to test high-dose simvastatin as a new treatment for patients with vitiligo.
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Allelic and copy number variations in human Fcγ receptor genes are strongly associated with
susceptibility to autoimmune blistering diseases (AIBD)
A Recke,1,11 G Vidarsson,2 RJ Ludwig,1,11 M Freitag,1,11 S Möller,1,11 R Vonthein,3 J Schellenberger,1
O Haase,1,11 S Görg,4 A Nebel,5 S Schreiber,5 R Gläser,6,11 S Benoit,7,11 M Sárdy,8,11 R Eming,9,11
M Hertl,9,11 D Zillikens,1,11 I König,3 E Schmidt1,10,11 and S Ibrahim1,11 1 Dept. of Dermatol., Univ.
Lübeck, Lübeck, Germany, 2 Sanquin Res. Inst., Amsterdam, Netherlands, 3 Inst. of Med.
Biometry and Statistics, Univ. Lübeck, Lübeck, Germany, 4 Dept. of Transfusion Med., Univ.
Lübeck, Lübeck, Germany, 5 Inst. of Clin. Mol. Biol., Univ. Kiel, Kiel, Germany, 6 Dept. of
Dermatol., Univ. Kiel, Kiel, Germany, 7 Univ. Würzburg, Würzburg, Germany, 8 Univ. Munich
(LMU), Munich, Germany, 9 Univ. Marburg, Marburg, Germany, 10 CCIM, Univ. Lübeck,
Lübeck, Germany and 11 German AIBD Study Group, Germany, Germany
AIBD are prototypic autoantibody-mediated diseases, some of which – as bullous pemphigoid (BP)
– are dependent on Fcγ receptors (FcγR). FcγR show frequent allelic and gene copy number varia-
tions, which may affect their functions and influence susceptibility to systemic autoimmunity. To
unravel the relevance of FcγR genetic polymorphism in AIBD, we investigated FcγR expression lev-
els and functional impact on neutrophils in an ex vivo immune complex-mediated ROS release
assay with 150 blood donors. We then studied association with susceptibility to BP and pemphi-
gus vulgaris/foliaceus (PV/PF) in 170 BP patients, 100 PV/PF patients and 388 controls. Ex vivo, ROS
release was increased with FcγRIIIb gene copies (19±8.9%/copy, p=0.038), but paradoxically
decreased by the FcγRIIc open reading frame (ORF) allele (-11.9±4.2%/copy,p=0.004). FcγRIIIb
mRNA levels rose with gene copy number (p=4.7e-9), while FcγRIIb mRNA expression was depend-
ent on the FcγRIIc ORF allele (p=1.7e-10). Susceptibility to BP was associated inversely to this:high
gene copy number of FcγRIIIb reduced (logHR -0.75±0.24/copy,p=0.0016) and high copy numbers
of FcγRIIc increased disease risk (logHR 0.63±0.2/copy,p=0.002). In contrast, risk for PV/PF was
associated with promotor polymorphisms in FcγRIIb (logHR -0.74±0.393/copy,p=0.05) and with
FcγRIIc ORF/stop variation (logHR 0.41±0.151/copy,p=0.012). These association patterns suggest
different etiologies for BP and PV/PF and correspond to different roles of FcγR in tissue damage and
loss of tolerance.
195
Mast cell-deficient kitw-sh/w-sh mice as a photodermatosis model
N Schweintzger,1,2 A Gruber-Wackernagel,1 E Reginato,1,2 G Mayer,2 I Bambach,2 A Limon-
Flores,3,4 S Ullrich,3 S Byrne3,5 and P Wolf1 1 Research Unit for Photodermatology, Department
of Dermatology,, Medical University of Graz, Graz, Austria, 2 Center for Medical Research,
Medical University of Graz, Graz, Austria, 3 Department of Immunology, UT MD Anderson
Cancer Center, Houston, TX, 4 Escuela Nacional de Ciencias Biológicas-IPN, Mexico City,
Mexico and 5 Infectious Diseases and Immunology, Sydney Medical School,, The University
of Sydney, Sydney, NSW, Australia
Polymorphic light eruption (PLE) patients are thought to show a resistance to the immunosuppres-
sive effects of sunlight. This includes a reduced infiltration of neutrophils and macrophages into the
skin and an impaired migration of Langerhans cells to the draining lymph nodes upon UV expo-
sure. The mechanisms leading to these immunological disturbances remain to be determined. To
elucidate a potential involvement of mast cells we made use of a mast cell-deficient mouse model
(KitW-sh/W-sh). Mast cell-deficient mice and their wild-type controls were exposed to a range of
single UVB doses or underwent a chronic UVB regime over 4 weeks, mimicking photohardening
therapy similar to that given to PLE patients. Our results indicated that KitW-sh mice displayed a
reduced UVB tolerance phenotype compared to their controls, determined by measurement of hyper-
plasia, cellular infiltration and inflammation of the skin. Mast cell-deficient mice showed an exces-
sive scratching behaviour immediately after UVB irradiation that was entirely absent in wild-type
mice. In addition, KitW-sh mice exhibited a reduced FoxP3 mRNA expression, accompanied by
diminished numbers of regulatory T-cells (Tregs) in different lymphoid organs after single UVB
dosages. Protection from UVB-induced scratching was dependent on mast cells because engraft-
ment of wild type mast cells into KitW-sh/W-Sh attenuated the scratching. Taken together these
results suggest that i) the KitW-sh mouse model is useful to study the pathogenesis of photoder-
matoses (such as PLE) and ii) mast cells linked to the function and levels of Tregs may be involved.
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Neutrophils orchestrate their own recruitment in immune complex-induced inflammation
by C5aR and FcγR signaling
CD Sadik,1,2 ND Kim1 and AD Luster1 1 Center for Immunology and Inflammatory Disease,
Massachusetts General Hospital/Harvard Medical School, Boston, MA and 2 2Department of
Dermatology, Allergy, and Venereology, UKSH, Lübeck, Germany
Neutrophil recruitment into peripheral tissues is a hallmark of immune complex-induced inflam-
mation. Two pathways by which immune complexes may activate neutrophils include complement
fixation, resulting in the generation of C5a, and direct engagement of Fcγ receptors (FcγRs). While
both pathways exert vastly overlapping effects on neutrophils in vitro, the dual requirement for
both pathways in several mouse models of immune complex-induced inflammation, including
autoantibody-induced inflammatory arthritis, suggests that in vivo each pathway exerts distinct
effects. In autoantibody-induced inflammatory arthritis, neutrophil recruitment into the joint is
choreographed via multiple chemoattractant receptors, including the leukotriene B4 (LTB4) recep-
tor BLT1 and the chemokine receptors CCR1 and CXCR2. Once in the joint, neutrophils perpetu-
ate their own recruitment by releasing LTB4 and IL-1β. The molecular mechanisms regulating neu-
trophil recruitment by neutrophils, however, have remained elusive. Here we show that in this model,
C5aR and FcγRs are both required to enable neutrophils to orchestrate their own recruitment into
peripheral tissues with each exerting unique effects on neutrophils. Specifically, C5aR activation of
neutrophils is required for LTB4 release and early neutrophil recruitment, while FcγR engagement
upon neutrophils induces IL-1β release and subsequent neutrophil-active chemokine production,
amplifying neutrophil recruitment. Thus, C5aR and FcγRs work in sequence to initiate and sustain
neutrophil recruitment. These findings support the concept that immune complex-induced leuko-
cyte recruitment in vivo is not composed of redundant pathways, but of elements each serving dis-
tinct and critical functions culminating in tissue inflammation. These new insights will be instru-
mental for the development of new therapeutic strategies in the treatment of immune
complex-induced diseases.
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Establishment of novel ELISA using full-length recombinant human collagen XVII
K Izumi, W Nishie, H Ujiie and H Shimizu Department of Dermatology, Hokkaido University
Graduate School of Medicine, Sapporo, Japan
Bullous pemphigoid (BP), the most common autoimmune blistering disorder, is caused by autoan-
tibodies (autoAbs) to collagen XVII (COL17). A commercial ELISA which detects autoAbs to the non-
collagenous 16A domain (NC16A) is widely used to diagnose BP and assess its clinical severity,
based on the fact that autoAbs in a majority of BP patients recognize the NC16A domain. However,
it is well known that autoAbs of BP can react with parts of COL17 other than the NC16A domain.
Thus, such autoAbs cannot be detected by the commercial ELISA using bacterial recombinant NC16A.
Furthermore, in mucous membrane pemphigoid (MMP), a related membrane-dominated pemphigoid
disease, autoAbs preferentially react with the C-terminal domain of COL17. Therefore, MMP autoAbs
reacting to COL17 also cannot be detected by the commercial ELISA. To overcome these limita-
tions, we established a novel ELISA to detect autoAbs against all the epitopes on COL17. We first
produced highly purified full-length recombinant human COL17 from HEK293 cells stably express-
ing human COL17 cDNA. Using the recombinant full-length COL17 as a substrate, we performed
ELISA using 73 sera from BP patients and 49 sera from controls (other bullous disease patients and
normal healthy individuals). The ELISA’s sensitivity was 71.2% and specificity was 100%. Using our
novel ELISA, we next assessed the reactivity of IgG autoAbs from 9 BP patients in which no IgG
autoAbs could be detected by the commercial ELISA reacting with NC16A. The experiment found
that IgG autoAbs from 2 of the 9 BP patients reacted with the full-length recombinant human COL17,
suggesting that a small proportion of BP patients may develop the disease by autoAbs to COL17
other than the NC16A domain. The novel ELISA demonstrated that IgG autoAbs from 6 of 8 MMP
patients reacted with the full-length COL17. This novel ELISA, which can detect autoAbs to full-
length COL17, is a potential tool not only for diagnosing BP but also for elucidating its pathome-
chanism.
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T cells with an autoreactive phenotype and a deregulated production of reactive oxygen
species occur as a feature of immunosenescence in old mice
S Koellner, J Scheuermann, S Vander Beeken, JM Weiss, A Sindrilaru, K Scharffetter-Kochanek and
T Peters Dermatology, Ulm University, Ulm, Germany
Aging of the immune system, termed “immunosenescence”, is characterized by a functional decline
leading to an onward immunodeficiency. As regulatory mechanisms also decline, this altogether
results in infection, tumor and autoimmune disease with high prevalence in the elderly. We here
characterize distinct age-dependent T cell subpopulations showing a profile of dysfunctional and/or
autoreactive T cells in peripheral lymphoid organs of young, adult and old mice (3-6, 9-12 and 18-
24 months-old C57BL/6, n>5). The majority of the CD4 T cell subset showed an age-related reduc-
tion of CD27 and the CD28 costimulatory receptor and down-regulation of CD5. Only a minority
of the CD4 T cell subset showed a CD27lo CD28hi CD5hi phenotype indicating homeostatic expan-
sion, which typically occurs due to a reduced thymic T cell output with age. Also CD8 T cells and
CD4- CD8- DN T cells had this age-related CD27lo CD28hi CD5hi phenotype suggesting these
cells have an age-related increase in self reactivity. Recent reports indicate that imbalanced levels
of reactive oxygen species (ROS) contribute critically to driving chronic inflammation and immunose-
nescence. Therefore, we used high-throughput six-channel fluorescence FACS to further analyze the
age-dependent CD27lo CD28hi CD5hi T cells regarding their ability of ROS induction in a next
step. As a result, CD27lo CD28hi CD5hi T cells showed a markedly increased ROS response to the
mitochondrial electron chain complex inhibitor rotenone ex vivo measuring increased O2- radi-
cals and H2O2 as compared to phenotypically normal naïve and antigen-experienced control T
cells. In summary, our data reveal a substantial increase of pathogenic T cell subsets in old mice
leading to dysfunction and autoreactivity. This is further supported by a T cell phenotype-depend-
ent altered ROS profile. Our data may contribute to clarify important aspects of an age-associated
dysfunction of T cells in an aging immune system.
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The atopic skin microenvironment modulates the phenotype and T cell polarising capacity of
myeloid dendritic cells as determined by laser scanning cytometry
G Nagy,1,2 A Kapitány,1,2 D Minh,3 K Gáspár,1,2 G Mócsai,1,2 Z Bacsó,3 T Bíró,4 ÉVA Remenyik1 and
A Szegedi1,2 1 Department of Dermatology, University of Debrecen, MHSC, Debrecen,
Hungary, 2 Department of Dermatological Allergology, University of Debrecen, MHSC,
Debrecen, Hungary, 3 Department of Biophysics and Cell Biology, University of Debrecen,
MHSC, Debrecen, Hungary and 4 DE-MTA “Lendület” Cellular Physiology Research Group,
University of Debrecen, MHSC, Debrecen, Hungary
It is not known exactly when or where circulating myeloid dendritic cells (mDCs) acquire their
ability to polarise T cells towards characteristic subtypes in atopic diseases. We aimed to investi-
gate whether isolated peripheral blood mDCs from atopic dermatitis (AD) patients and from con-
trols differ in their cytokine expression profile de novo and after stimulation. In our experimental
model system for the stimulation we created an AD-specific tissue microenvironment by culturing
isolated mDCs with thymic stromal lymphopoietin (TSLP) and Staphylococcus enterotoxin B (SEB).
We also aimed to identify phenotypically these “resting” and activated mDCs according to their
supposed expression of the cell surface markers of inflammatory epidermal DC (IDEC). Because of
the low number of mDCs in the peripheral blood and the limited blood sample volume available,
it is challenging to directly investigate the phenotype and function of mDCs from patients. Using
multiparametric laser scanning cytometry (LSC) we managed to determine the T cell polarising
cytokine profile (IL-12 indicating Th1 polarisation, IL-2, IL-4, and CCL17 indicating Th2 polarisa-
tion, IL-6 and TNFα indicating Th22 polarisation,TGFβ1, IL-23, and IL-6 indicating Th17 polarisa-
tion and TGFβ1 and IL-10 indicating Treg polarisation) and other cellular aspects of mDCs in sam-
ples from AD patients. IDEC-like phenotype were identified according to CD11c, CD1a, CD1c,
CD207, CD206 and FcεRI expression using multicolor flow cytometry. According to our results the
surrounding skin microenvironment is essential for the manifestation of the AD-specific distinctive
polarity of mDCs (Th2-Th22 bias) and also for the expression of the specific IDEC-like features.
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The effect of hydroxychloroquine on the lupus erythematosus-like skin lesions in MRL/lpr
mice
T Shimomatsu,1,2 H Li,1 T Ikeda,1 N Kanazawa1 and F Furukawa1 1 Department of Dermatology,
Wakayama Medical University, Wakayama city, Japan and 2 Department of Dermatology,
Wakayama Rosai Hospital, Wakayama city, Japan
Hydroxychloroquine (HCQ) is an antimalarial drug which has been used for the treatment of inflam-
matory disorders, including arthropathy of rheumatoid arthritis, arthropathy and cutaneous symp-
toms of systemic lupus erythematosus (SLE), and cutaneous LE (CLE). Although this drug has been
long applied for clinical use in most of the European and Asian countries, the phase 3 randomized
double-blind placebo-controlled study is underway for the treatment of SLE and CLE in Japan. As
underlying mechanisms for these clinical effects of HCQ, it has been shown that HCQ can sup-
press the production of prostaglandins and inflammatory cytokines and regulate the innate immune
system. Furthermore, in SLE, HCQ is reportedly associated with impaired interferon-alpha (IFN-α)
and tumor necrosis factor-alpha (TNF-α) production by plasmacytoid dendritic cells. However, the
precise mechanisms by which HCQ exerts its effect on CLE, especially in vivo, still remain to be
defined. Therefore, in this study, we administered HCQ to MRL/lpr mice, well-known model mice
for SLE which occasionally present LE-like skin lesions, for 4 months since 3 months of age, and
examined its safety and effect on LE-like lesions. As a result, 6 among 13 mice in the group given
drinking water, 3 among 11 mice in the group administered low-dose HCQ (4 mg/kg/day), and 2
among 11 mice in the group administered high-dose HCQ (40 mg/kg/day) presented the skin lesions.
Mortality rate was 24% in the group of water, 8% in the group of low-dose HCQ (4 mg/kg/day), and
8% in the group of high-dose HCQ (40 mg/kg/day). Mean body weight gain was 4.6g, 8g, and 5.1g,
respectively. Thus, HCQ showed a tendency to reduce the appearance of LE-like lesions and there
were no differences among three groups, regarding the survival rate and weight loss. These results
suggested that HCQ had therapeutic effects on LE-like skin lesions without adverse effects.
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A GWAS analysis identifies non-HLA genes within the MHC locus as associated with pem-
phigus vulgaris
O Sarig,1 D Vodo,1 S Rosset,2 S Bercovici,9 L Zoller,3 I Goldberg,1 M Indelman,4 S Baum,5
A Barzilai,5 H Trau,5 E Avitan-Hersh,4 M Hertl,10 S Rosenberg,6 M Noethen,7 K Skorecki,4
E Schmidt,8 D Zillikens,8 A Darvasi,6 D Geiger,9 S Ibrahim8 and E Sprecher1 1 Tel Aviv Medical
Center, Tel Aviv, Israel, 2 Tel Aviv University, Tel Aviv, Israel, 3 Maccabi Health Care Services,
Tel Aviv, Israel, 4 Rambam Medical Center, Haifa, Israel, 5 Sheba Medical Center, Tel Aviv,
Israel, 6 Hebrew university, Jerusalem, Israel, 7 University of Bonn, Bonn, Germany, 8
University of Luebeck, Luebeck, Germany, 9 Technion, Haifa, Israel and 10 Philipps-University
Marburg, Marburg, Germany
Pemphigus vulgaris (PV) is a rare autoimmune disease, particularly prevalent in Jewish popula-
tions. PV has been shown to be associated with various HLA class II alleles. Using a GWAS design
in a Jewish cohort of PV patients and controls (n = 497), we identified significant associations between
PV and 69 markers clustered within three peaks across the MHC locus, which were replicated in
an independent cohort (n = 411): P1: rs2244839-rs2246618 (max corrected p-value (mcPval): 8.98e-
15, replication Pval < 3e-5), P2: rs1980495-rs9275312 and P3: rs9275312-rs3916765 (mcPval:
2.12e-19, replication Pval < 0.002). P1 harbors two non-HLA genes, HCG26 and MICB while P2
contains the BTNL2 gene. Both MICB and BTNL2 have been repeatedly identified in previous asso-
ciation studies of auto-inflammatory disorders. To establish the specificity of the association between
PV and these genes, and to rule out the possibility that they were related to neighboring HLA sus-
ceptibility alleles, we calculated LD values for a series of SNPs tagged to relevant HLA alleles. No
associated HLA alleles were found within the P1 region. P2 which contains the DRB1 and BTNL2
loci was remarkably associated with the DRB1*0401 allele but not with the DRB1*0402 allele,
which has been previously shown to be associated with PV in Jewish patients, supporting an asso-
ciation with BTNL2. And finally, as expected, P3 was found to be associated with the DQB1*0302
allele previously shown to be associated with PV in Jewish populations. In summary, our results sug-
gest associations between PV and previously unreported non-HLA genes across the MHC locus.
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High throughput screening of small molecule libraries identifies histone deacetylases as new
therapeutic targets in psoriasis
L Magal,1 N Sagiv,1 J Nousbeck,1 M Pavlovsky,1 D Tyomkin,2 V Shoshan-Barmatz,2 D Fuchs-
Telem,1 O Sarig1 and E Sprecher1 1 Tel Aviv Medical Center, Tel Aviv, Israel and 2 Ben Gourion
University, Beer Sheva, Israel
IGFBP7 was recently shown to regulate keratinocyte proliferation, differentiation and apoptotic activ-
ity, which are typically abnormal in psoriasis, suggesting that IGFBP7 may contribute to the disease
pathogenesis. Accordingly, IGFBP7 is deficient in the psoriatic epidermis and recombinant IGFBP7
was found to cure psoriasis in a humanized mouse model. As administration of recombinant IGFBP7
is associated with costs and delivery obstacles, we sought to identify small inducers of IGFBP7
transcriptional activity, to be used as novel therapeutics in psoriasis. We used a cell line constitu-
tively expressing a luciferase reporter gene under the regulation of IGFBP7 promoter and screened
1496 compounds. Among several significant hits, vorinostat, a histone deacetylase inhibitor, was
found to reproducibly induce IGFBP7 promoter activity and to induce endogenous IGFBP7 expres-
sion in a time- and dose-dependent manner. Pathway analysis revealed that among the biological
networks most significantly associated with vorinostat treatment were the IGF1- and IL-17 signal-
ing pathways, of direct relevance to psoriasis. Similar to IGFBP7, vorinostat inhibited proliferation
and promoted differentiation of keratinocytes. Using cell lines in which IGFBP7 was stably knocked
down, we found out that vorinostat induces keratinocyte differentiation in an IGFBP7-dependent
manner. Moreover, decreased IGFBP7 expression promoted vorinostat-induced G2/M arrest effect.
Finally, in a preliminary set of experiments, we demonstrated that systemic (i.p.) administration of
vorinostat to chimeric mice carrying human psoriatic skin resulted in an increase in IGFBP7 expres-
sion followed by significant decrease in epidermal thickness and inhibition of epidermal prolifera-
tion. Thus, the present data suggest that histone deacetylase inhibitors may be of potential use in
the treatment of psoriasis and other hyperproliferative skin disorders.
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Adiponectin deficiency exacerbates psoriasiform skin inflammation by promoting IL-17 pro-
duction from γδ T cells
S Shibata,1 Y Tada,1 Y Asano,1 M Sugaya,1 T Kadono,1 T Yamauchi,2 N Kubota,2 T Kadowaki2 and
S Sato1 1 Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan and 2
Metabolic Disease, Faculty of Medicine, University of Tokyo, Tokyo, Japan
Accumulating evidence has revealed that metabolic syndrome, including obesity, diabetic melli-
tus, hypertension and dyslipidemia, is associated with an increasing risk of psoriasis. Adiponectin,
one of the representative adipocyte-derived adipokines, was primarily recognized as a metabolic
mediator of insulin sensitivity. Recent reports have increasingly demonstrated that adiponectin also
regulates immune responses in various inflammatory diseases. We have previously reported that
adiponectin in vitro exerts anti-inflammatory effects on normal human keratinocytes and THP-1
cells. In this study, to further investigate the potential role of adiponectin in the pathogensis of pso-
riasis, we induced psoriasis-like skin inflammation triggered by topical application of the TLR7/8
agonist, imiquimod, on adiponetin-deficient and wild-type mice. Here, we showed that adiponectin-
deficient mice exhibited disease exacerbation with severe inflammatory cell infiltrates and epider-
mal hyperplasia, compared with wild-type mice. In the analysis of skin mRNA expression, imiquimod
treatment resulted in a significant upregulation of Th17 cytokines, IL-17A/IL-17F/IL-22, and the
absence of adiponectin strongly induced further upregulation of these cytokines. Flow cytometric
analysis of lymph nodes revealed that γδ T cells were the major source of IL-17A, and adiponectin
deficiency increased the number of IL-17-producing γδ T cells. Furthermore, adiponetin in vitro
directly suppressed IL-17 production from γδ T cells in a dose-dependent manner. Accordingly,
adiponectin-deficient mice needed a further dose of anti-IL-17 antibody than wild-type mice to
prevent psoriasiform dermatitis in vivo. Collectively, these results suggest that adiponectin deficiency
exacerbates psoriasiform skin inflammation by promoting the recruitment and induction of IL-17-
producing γδ T cells, and plays immunomodulatory roles during the psoriatic pathophysiology.
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Human CD141+ dermal dendritic cells (DCs) and vitamin D3 induced CD141hi DCs are
defined by common molecular signatures
N Ali,1,2 C Ainali,3,1 B Flutter,1 C Chu,1 G Barinaga,1 I Tosi,1 K Grys,1 E Sharif-Paghaleh,2 S Tsoka,3
G Lombardi2 and FO Nestle1 1 NIHR, St Johns Institute of Dermatology, King’s College London,
London, United Kingdom, 2 MRC Centre for Transplantation, King’s College London, London,
United Kingdom and 3 Dept of Informatics, King’s College London, London, United Kingdom
he dermis of human skin contains a complex network of dendritic cells (DCs) and other immune
cells. We have recently identified a tissue-resident CD14+CD141+ dermal DC (CD141+ DDCs)
with potent immunoregulatory ability in vitro and in vivo (Chu et al J Exp Med 2012), thus playing
an important role in maintaining tissue immune homeostasis. Exposure of blood monocyte-derived
DCs (MoDCs) to vitamin D3 induces a CD14+CD141hi population (CD141hi VitD3 MoDCs) resem-
bling CD141+ DDCs in both phenotype and function. Transcriptome analysis of CD141+ DDCs
and CD141hi VitD3 MoDCs identified a common molecular signature, including a core module of
20 genes related to intracellular calcium signaling and neuro-immunological pathways. To analyse
functional similarity between DC subsets, we used principle component analysis (PCA) and hier-
archial clustering to show that CD141+ DDCs and CD141hi VitD3 MoDCs cluster together. Like-
wise, the opposing DC populations, CD1c+ DDCs and CD141lo VitD3 MoDCs, also cluster together.
These results suggest that CD141+ DDCs and CD141hi VitD3 MoDCs are functionally related DC
populations and that ultraviolet B (UVB)-derived VitD3 can induce tissue-resident CD141+ DDCs
from blood MoDCs. Therefore, CD141+ DCs are likely to play an essential role in UVB mediated
skin immunoregulation under both normal and pathological conditions.
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Epigenetic modifications and altered mRNA stability cause a restricted expression of SOCS3
in human keratinocytes
J Zeitvogel,1 M Wittmann2 and T Werfel1 1 Department of Dermatology and Allergy, Hannover
Medical School, Hannover, Germany and 2 Leeds Institute of Molecular Medicine, University
of Leeds, Leeds, United Kingdom
As shown recently by us human keratinocytes display a restricted ability to up-regulate SOCS3 in
response to STAT3 activating cytokines like IL-27. It was the aim of the current study to investigate
whether keratinocytes have a generally disturbed induction of important feedback mechanism of
SOCS3. T cell derived cytokines and other cytokines involved in inflammatory skin diseases (like
IL-1β, IL-18, TNFα, OSM, IL-27) were analyzed by qRT-PCR and Western blot in regard to their
potential to up regulate SOCS3 in keratinocytes as compared to macrophages. Furthermore, a SOCS3
promoter reporter assay was done to analyze the capacity of keratinocytes to activate SOC3 pro-
moter dependent transcription. Using a demethylation assay we subsequently checked for epige-
netic based alterations in SOCS3 expression. In keratinocytes only IFNγ was able to induce SOCS3
mRNA but - of note - no significant protein induction was found. In contrast macrophages also
respond to IL-27, OSM and TNFα with increased SOCS3 mRNA and protein levels. Interestingly,
the promoter reporter assay revealed that in macrophages the detected promoter activity was in
line with our data obtained for SOCS3 mRNA whereas in keratinocytes SOCS3 promoter activation
was not in accordance with the data found for SOCS3 mRNA: keratinocytes showed high basal
activation of the SOCS3 promoter construct but stimulation with IFNγ or STAT3 activating cytokines
did not result in an increase of promoter activity. Of interest, keratinocytes treated with a demethy-
lation reagent showed significantly higher SOCS3 mRNA levels upon stimulation as compared to
the control. Therefore, we conclude that in keratinocytes SOCS3 expression is regulated by mRNA
stability and epigenetic modifications. The mechanisms of SOCS3 regulation in keratinocytes which
are different to those in inflammatory cells such as macrophages may contribute to chronicity of
inflammatory skin diseases.
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A Vγ4+ subset of IL-17-precommited dermal γδT cells contributes to skin inflammation in a
murine model of psoriasis
F Ramirez-Valle,1,2,3 EE Gray2,3 and J Cyster2,3 1 Dermatology, University of California San
Francisco, San Francisco, CA, 2 Microbiology and Immunology, University of California San
Francisco, San Francisco, CA and 3 Howard Hughes Medical Institute, University of California
San Francisco, San Francisco, CA
Interleukin-23 (IL-23) and IL-17 are important in the pathogenesis of psoriasis. CD4+ T helper 17
(Th17) cells have been considered the main source of IL-17 in psoriatic skin, but recently IL-17-
committed dermal γδT (γδT17) cells have been shown to play a role in murine models of psoriasis-
like dermatitis including IL-23 injection and imiquimod treatment. Further, an increase in γδT cells
has been noted in human psoriatic skin lesions. Several distinct subsets of γδT cells can be distin-
guished in murine skin, and whether some or all of these subtypes contribute to psoriasis-like skin
inflammation is unknown. Here, we show that a Vγ4+ subset of dermal γδT17 cells contributes to
skin inflammation in response to topical imiquimod application. Mice lacking Vγ4+ γδT17 cells
demonstrate decreased ear swelling, reduced neutrophil recruitment, and lower expression of inflam-
matory cytokines such as IL-17A and IL-17F and anti-microbial peptides after imiquimod treatment
of ear skin. Vγ4+ γδT17 cells expand markedly and selectively in the draining lymph nodes and their
frequency increases in the blood of imiquimod-treated mice. These expanded cells home effi-
ciently to inflamed skin where they aggravate the response to imiquimod. Thus, targeting the acti-
vation or migratory properties of IL-17 committed γδT cells could have therapeutic applications for
inflammatory skin disorders such as psoriasis.
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Inhibitory effect of mesenchymal stem cells on IL-23-induced psoriasis-like skin inflamma-
tion
Y Lee and T Kim Dermatology, The Catholic University of Korea, Seoul, Republic of Korea
It has been known that mesenchymal stem cells (MSCs) have activity to inhibit the proliferation or
activation of lymphocytes and their inhibitory effects do not require HLA-matching because MSCs
express low level of HLA molecule. Therefore, it seems that MSCs have activity to regulate immune
responses. In this study, we determined whether MSCs could inhibit IL-23-induced psoriasis-like
skin inflammation. 2X106 MSCs were injected subcutaneously on day -1 and day 13, and IL-23
was injected intradermaly every other day until day 14. Mouse ears were collected on day 15, and
H&E staining and real time PCR were performed to investigate whether MSCs could inhibit IL-23-
induced skin inflammation. IL-23-induced skin inflammation was inhibited when MSCs were injected
on day -1 and day 13 even though a one-time injection of MSCs did not affect IL-23-induced skin
inflammation. The expression of proinflammatory cytokines, such as IL-1 beta, IL-6, IL-17 and TNF-
alpha was also inhibited by MSC injection on day -1 and day 13. Chemokines are also important
factors for skin inflammation, such as psoriasis. Thus, expression levels of chemokines in mouse ear
were determined. Two-time injections of MSCs on day -1 and day 13 decreased expressions of
CCL17, CCL20, and CCL27. Interestingly, a one-time injection of MSCs on day -1 or day 13 also
inhibited the chemokine expressions. In vitro experiments also showed anti-inflammatory effect of
MSCs. Treatment of conditioned media from MSC cultures suppressed IL-6 expression from IFN-
gamma/TNF-alpha stimulated HaCaT cell line. These results suggest that MSCs could be useful in
treating IL-23-mediated skin inflammation.
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Lack of skin Th17/Th22 CD4+ T cells and antimicrobial peptides in lesions of hidradenitis sup-
purativa leads to a vicious circle perpetuating chronic inflammation
C Hotz,1 A Guguin,1 M Surenaud,1 M Boniotto,1 N Ortonne,2 R Bosc,2 O Chosidow,2
P Wolkenstein,2 Y Lévy1,2 and S Hüe1,2 1 INSERM U955, Créteil, France and 2 Henri-Mondor
Hospital, Créteil, France
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease. Although, remissions of dis-
ease have been reported in patients treated with antibiotics or immunosuppressors, the phys-
iopathogenesis of HS remains largely unknown. We hypothesized a dysregulation of the balance
between inflammatory and protective T cell responses leading to an impaired antimicrobial defence
in the skin. We used a systems biology approach to study phenotype and functional profiles of T
cells from HS and healthy donors (HDs) using a large array of ex vivo, in vitro tests following stim-
ulation of PBMCs with various bacterial products and in situ analysis. Results showed: i) in the blood,
HS patients exhibited a higher frequency of CD4+IL-17A+(2.1%) and CD4+IL-22+(1.3%) as com-
pared to HDs (1.2% and 0.5%, respectively) (P<0.05) whereas no difference in the frequency of
Treg or CD4+ T cells expressing skin homing receptors CCR6 or CCR10 were found; ii) stimulation
of PBMC from HS with flagelline or Staphylococcus aureus led to a higher production in super-
natants of IL-17, IL-22 and IFN-γ as compared to HDs; iii) in the skin, as compared to HDs (n=12)
expression of IL-22 and RORγt RNAs was decreased in HS (n=6) contrasting with a higher expres-
sion of Foxp3 RNA. HIC confirmed an infiltration of Treg but not Th17 cells in HS. Accordingly, a
low expression of Anti-Microbial Peptides mRNAs (LL-37, hBD2, PS100A7) was found in skin
biopsies surrounding HS lesions. In conclusion, HS patients are characterized by a high frequency
in the blood of functional Th17/Th22 T cells responding to bacterial products. However, despite
expressing skin homing receptors these cells are rare at the sites of skin inflammation. Local pro-
duction of AMP remains low in active HS skin lesions. Likely, this lack of AMP production, key trig-
ger of T cell homing, results in a lack of Th17/Th22 T cells. Thus, our results point out a vicious cir-
cle perpetuating chronic inflammation in HS.
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Novel isonahocol E3 exhibits anti-inflammatory and anti-angiogenic effect in endothelin-1-
stimulated human keratinocytes
SK Sah and T Kim Dermatology, The Catholic University of Korea, Seoul, Republic of Korea
Endothelin-1 (ET-1) is reported to be a potent mitogenic and pro-angiogenic factor that plays a vital
role in both physiological and patho-physiological processes. In skin, ET-1 is implicated in prolif-
eration of dermal cells and various skin related disorders, such as psoriasis and atopic dermatitis.
ET-1 and its receptor A (ET-A) and B (ET-B), could be a potential target for developing specific ther-
apeutics to treat such disorders. Here, we first report that the brown algae, Sargassum siliquastrum,
produced an isonahocol member named [2, 5-dihydroxy-3-(13-hydroxy-3, 7, 11, 15-tetramethyl-
12-oxo-hexadeca-2, 6, 14-trienyl)-phenyl]- acetic acid methyl ester (commonly known as Ison-
ahocol E3), which have functional antagonistic activities against ET-1-induced inflammatory and
pro-angiogenic effects. Isonahocol E3 significantly inhibited ET-1-induced cell proliferation as well
as inflammatory mediators, such as IL-6, TNF-alpha, IL-8 and pro-angiogenic factors like metallo-
proteinases in immortalized keratinocytes, HaCaT. We also found that isonahocol E3 suppressed
the expression of ET-A and ET-B and phosphorylation of ERK1/2 induced by ET-1. These results indi-
cated that the activities of isonahocol E3 were similar to or more than those of BQ123 and BQ788,
known as inhibitors to ET-1. Taken together, this study suggests that isonahocol E3 has anti-inflam-
matory and anti-angiogenic activities against ET-1 by regulating the expression of its receptor and
activation of ERK signaling pathway.
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Increased frequency of skin-infiltrating Th17 cells is associated with interstitial lung disease
and hyperkeratotic eruptions in dermatomyositis patients
T Fujiyama, H Hashizume, T Ito, S Hirakawa and Y Tokura Dermatology, Hamamatsu University
School of Medicine, Hamamatsu, Japan
Dermatomyositis (DM) is an autoimmune disorder clinically characterized by skin eruptions, mus-
cle weakness, autoantibodies, and occasional interstitial lung disease (ILD) and internal malignancy.
Recently, DM has been reclassified into several subtypes according to the autoantibodies. ILD fre-
quently occurs in the anti-aminoacyl-tRNA synthetase (ARS) antibody+ type and anti-CADM-140
antibody+ type. Meanwhile, the pathogenesis of skin eruptions in DM remains unfully elucidated.
We sought to investigate the association of the eruptions with ILD, focusing on the skin-infiltrating
T cells. Fourteen newly diagnosed DM patients were enrolled in this study, and skin biopsies were
taken from markedly erythematous lesions. Eight patients had active ILD with elevated serum KL-6
levels (≥500 U/ml), while 6 had no detectable ILD with normal KL-6 levels (<500 U/ml). By immuno-
fluorescence staining of the affected lesional skin, IL-17+ cells were observed in the majority of
cases at various frequencies. We expanded skin-infiltrating T cells with IL-2 and anti-CD3/CD28
antibody-coated microbeads. T cells from DM patients with ILD produced significantly higher
amounts of IL-17 in the culture supernatants than did those from DM patients without ILD (P=0.036).
Flow cytometric analysis of the expanded T cells showed that they were positive for CD4 and CCR6,
indicating Th17 cells. We found that this Th17 population was increased in skin-infiltrating cells
from DM patients with ILD (mean, 1.9%) compared to those without ILD (mean, 0.2%). When the
skin lesions were clinically divided into 4 grades in hyperkeratosis intensity, the patients with ILD
exhibited significantly marked hyperkeratosis (top 2 grades, 7/8) and mimicked psoriasis as com-
pared to those without ILD (2/7). Our study suggests that the frequency of skin-infiltrating Th17
cells and their cytokine production are increased in DM patients with ILD, and they preferentially
manifest hyperkeratotic psoriasiform skin eruptions.
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Carbamazepine-induced bullous pemphigoid with elevated IgE and peripheral eosinophilia
J Hooten and AG Cardones Dermatology, Duke University, Durham, NC
The exact role by which IgE participates in the pathogenesis of bullous pemphigoid remains to be
elucidated. We present a case of carbamazepine-induced BP associated with profound eosinophilia
and elevated circulating IgE. A 55 y.o. African American woman with multiple sclerosis, quadri-
plegia and seizure disorder presented with a generalized pruritic eruption following hospitalization
for status epilepticus and a urinary tract infection. Her seizure disorder had previously been well
controlled for 20 years on carbamazepine. Physical examination revealed diffuse skin involvement
with numerous tense bullae and hyperpigmented, dusky annular plaques. Direct immunofluores-
cence revealed linear IgG and C3 at the DEJ, which localized to the epidermal side on split skin.
Circulating IgG antibodies against BP2, but not BP1 antigen were detected. Peripheral eosinophil
count was normal. After she stabilized on oral prednisone, carbamazepine, which had been dis-
continued along with all her other medications when her rash developed, was re-introduced. This
was followed by a rapid exacerbation of her blistering disease, progressive eosinophilia, profound
leukocytosis, a markedly elevated serum IgE level and increasing anti-BP2 antibody titers. Her
eosinophil count and IgE level peaked at 16.32 x 109 (48%) and 13,900 IU/ml, respectively and
her highest anti-BP2 antigen IgG titer reached 9789 U. Carbamazepine was subsequently discon-
tinued and replaced with levetiracetam. Her cutaneous lesions improved, she was able to tolerate
a slow taper of prednisone during the following three months, and has so far not required steroid
sparing agents. Furthermore, her eosinophil count returned to normal. While cases of drug-induced
bullous pemphigoid have been reported, to our knowledge, this is the first case of carbamazepine-
induced BP in the setting of long-standing carbamazepine therapy and resultant marked peripheral
eosinophilia and elevated IgE levels despite systemic steroids.
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Genome wide association mapping of alopecia areata in 5 inbred strains of mice identifies
novel and currently known genes for this disease
JP Sundberg,1,2 KA Silva,1 VE Kennedy,1 LE King2 and A Berndt3 1 The Jackson Laboratory, Bar
Harbor, ME, 2 Vanderbilt University, Nashville, TN and 3 University of Pitsburgh, Pittsburgh,
PA
Alopecia areata (AA) is a cell mediated autoimmune disease directed against anagen stage hair fol-
licles in mammals including humans. All the C3H substrains and A/J strain of mice are well known
to develop adult onset AA that is very similar to that in humans. In a large scale aging study of 31
inbred strains, AA was confirmed in these strains as well as MRL/MpJ, SJL/J, and SWR/J. Using
genome-wide association mapping methods, candidate genes were identified in Alaa1, 2, and 4
but not Alaa3 of the C3B6F2 quantitative trait loci (QTLs). Tap2 was confirmed in Alaa1, confirm-
ing earlier haplotype mapping studies. Additional candidate genes were identified on mouse Chro-
mosomes 1, 2, 3, 5, 11, 12, and 18 confirming the complex genetic basis of AA. Many of these
genes have been found in human AA genetic studies as well.
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In vitro study of the effect of cutaneous sensory innervation in a tissue-engineered psoriatic
skin
J Ringuet, R Pouliot and F Berthod LOEX/CMDGT, Centre de recherche du CHU de Québec,
Université Laval, Quebec, QC, Canada
Psoriasis is a complex multifactorial inflammatory disease that affects 2% of the population world-
wide. It is characterized by the hyperproliferation of keratinocytes, an infiltration of lymphocytes
and an increased vascularisation. Even though its origin is still misunderstood, the latest studies tend
to point toward an autoimmune cause but the role of cutaneous innervation in this process has not
been clarified yet. The release by sensory neurons of neuropeptides like substance P, calcitonin gene-
related peptide, vasoactive intestinal peptide and pituitary adenylate cyclase activating polypep-
tide plays a key role in this neurogenic inflammation. Psoriatic skin is known to contain increased
number of nerve fibers and high concentrations of neuropeptides. We hypothesized that neuropeptides
can induce keratinocytes to release increased amounts of nerve growth factor, enhance keratinocyte
proliferation and be at least in part responsible for abnormal vascularisation. Therefore, the objec-
tive of this study was to investigate the impact of the neuropeptides and their receptors on a tissue-
engineered skin. Our psoriatic model is based on a reconstructed skin made of a collagen-chitosan
sponge cultured with fibroblasts, endothelial cells and sensory neurons. The epidermal layer is com-
posed of healthy, lesional or non-lesional psoriatic keratinocytes. We first showed that lesional pso-
riatic keratinocytes secreted more NGF than non-lesional and healthy keratinocytes in our model.
This secretion was increased in the presence of sensory neurons. The epidermal layers under the
stratum corneum were thicker in the psoriatic model and were even thicker in presence of the sen-
sory neurons. Furthermore, the addition of K252a, a potent inhibitor of the NGF receptors, resulted
in a decreased epidermal thickness. Thus, this tissue-engineered innervated and endothelialized
psoriatic skin provides a unique model to further evaluate the interaction between the cutaneous
sensory innervation, the microvasculature and lesional keratinocytes involved in the pathogenesis
psoriasis.
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Involvement of necroptosis in the development of imiquimod-induced psoriasis-like dermatitis
T Honda, T Murata, Y Ueharaguchi, N Ishizawa, Y Miyachi and K Kabashima Dermatology, Kyoto
University, Kyoto, Japan
Necroptosis is recently identified as a form of programed cell death, in which receptor-interacting
protein (RIP)1 and subsequent RIP3 kinase activation is a central pathway for its development.
Necroptotic cells induce inflammation through the release of various cytokines or necrotic danger-
associated molecular patterns. Recent reports indicated that mice with keratinocyte-specific necrop-
totic cell death exhibit severe chronic skin inflammation, which suggests the involvement of necrop-
tosis in the pathogenesis of chronic skin inflammatory diseases, such as psoriasis. In this study, we
investigated the involvement of necroptosis in the pathogenesis of psoriasis using an imiquimod
(IMQ)-induced mouse psoriasis model. Daily application of IMQ to the ear skin caused skin inflam-
mation with psoriariform scaly erythema accompanied with epidermal and dermal thickening. In
this model, we detected the positive signals of TUNEL both in the epidermis and dermis, suggest-
ing the induction of programmed cell death in skin by IMQ application. In addition, RIP3 expres-
sion was significantly upregulated both in mRNA and protein level in the skin lesions. Administra-
tion of necrostatin-1, a specific inhibitor of RIP1 kinase, significantly reduced the severity of
IMQ-induced psoriasis-like dermatitis. In line with the above findings, immunohistochemical analy-
sis revealed positive signals for RIP3 in the human psoriasis skin lesion. This is the first observation
indicating that necroptosis is involved in the pathogenesis of psoriasis.
214
Prevalence and co-occurrence of autoantibodies in healthy blood donors
W Jung*,1,2 J Prüssmann*,1,2 A Recke,1,2 K Rentzsch,3 D Juhl,4 R Henschler,5 S Müller,1,2
P Lamprecht,2,6 E Schmidt,1,2,7 E Csernok,6 S Görg,4 W Stöcker,3 D Zillikens,1,2 SM Ibrahim*1,2 and
RJ Ludwig*1,2 1 Dermatology, University of Lübeck, Lübeck, Germany, 2 Excellence Cluster
“Inflammation at Interfaces”, Schleswig-Holstein, Germany, 3 Euroimmun AG, Lübeck,
Germany, 4 Transfusion Medicine, University Hospital of Schleswig-Holstein, Lübeck/Kiel,
Germany, 5 Transfusion Medicine, Cellular Therapeutics & Hemostaseology, Ludwig-
Maximilians-University, Munich, Germany, 6 Rheumatology, Universitiy of Lübeck, Lübeck,
Germany and 7 Comprehensive Center of Inflammation Medicine, University of Lübeck,
Lübeck, Germany
Clinical observations show a rising incidence of autoimmune diseases, their co-occurence as well
as patients who develop antibodies (Ab) to additional autoantigens that are primarily unrelated to
their autoimmune disease. It is unclear, if different auto-Ab co-occur in healthy individuals; this
would imply shared mechanisms that induce loss of tolerance. To address this question, prevalence
of different auto-Ab (antinuclear antibodies (ANA), anti-CCP, -TPO, -PCA, -BP180/BP230, -Dsg1/3,
ANCA) was determined in healthy blood donors and tested for co-occurrence. ANA associated
with SLE were detected by indirect immunofluorescence and antigen-specific assays in 6,454
blood donors. ANA prevalence ranged from 0.02% (1:10,000) to 5.62% (1:100). Overall prevalence
of Ab against CCP amounted to 1.3%, TPO to 4.6%, PCA to 1.1%, BP180/BP230 to 0.6%, Dsg1/3
to 0.1% and ANCA to 0.3%. Most auto-Ab were detected more frequently (>24-fold) than reported
prevalence of associated diseases. Contrary, anti-CCP Ab have only a 2-3 fold higher prevalence
than rheumatoid arthritis (RA). In ANA positive samples (≥1:320), anti-CCP (p<0.05), -TPO (p<0.05)
and -Dsg1/3 Ab (p<0.01) were significantly more frequent. Thus, ANA co-occur with auto-Ab that
target antigens apparently not related to SLE; other auto-Ab (e.g. ANCA) were not concurrently
present. While loss of tolerance to self-antigens may be induced by shared mechanisms, the spe-
cific set of auto-Ab seems to be controlled independently. Differences in auto-Ab and disease preva-
lence suggest that additional events are required for clinical disease manifestation. *equal contrib-
utors
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Integrative approach combining human xenograft model with advanced computational analy-
sis identifies PIM1 as a critical checkpoint in inflammation
E Semenova*,1 GK Perera*,1 C Ainali*,1 C Hundhausen,1 G Barinaga,1 D Kassen,1 AE Williams,1
MM Mirza,2 M Balazs,3 R Sanchez-Rodriguez,1 J Barker,1 R Trembath,1 S Tsoka,4 W Ouyang3 and
FO Nestle1 1 Division of Genetics and Molecular Medicine, Guy’s, King’s and St. Thomas’
School of Medicine, King’s College London, London, United Kingdom, 2 Genomics Core
Facility Biomedical Research Centre, Guy’s and St. Thomas’ Hospital, London, United
Kingdom, 3 Department of Immunology, Genentech Inc., South San Francisco, CA and 4
Department of Informatics, School of Natural and Mathematical Sciences, King’s College
London, London, United Kingdom
We combined advanced computational analysis with the use of clinically relevant in vivo models
with the aim to dissect molecular mechanisms downstream of IL22 signaling. IL-22 is a key cytokine
at sites of peripheral tissues, providing a link between the immune system and the epithelium. Injec-
tion of IL22 into human skin xenograft model resulted in a striking psoriasiform pathology with asso-
ciated vascular remodeling, supporting the critical role of IL-22 in the development and progres-
sion of human psoriasis. Integrative biology analysis identified a set of novel anti-IL-22 therapeutic
response genes. One of the genes, PIM1, has been previously implicated in vascular remodeling,
but had no direct association with psoriasis. PIM1 was expressed in normal epidermis and dermis.
Importantly, PIM1 protein levels were strongly elevated specifically in the blood vessels of psori-
atic patients as compared to the vessels within healthy skin. To test PIM1 relevance in an in vivo
setting, we utilised an established model of imiquimod-induced psoriasiform inflammation that has
been reported to be dependent on IL22. Mice were treated with topical imiquimod in the presence
or absence of PIM kinase small molecule inhibitor. Inhibition of Pim-1 resulted in a striking reduc-
tion of acanthosis and a significant reduction in the number and thickness of dermal vessels. Thus
our integrative approach has identified a novel checkpoint in inflammation downstream of IL22
signalling.
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Determination of cutaneous dermatomyositis severity using the cutaneous dermatomyositis
disease area and severity index 
CO Anyanwu,1,2 KJ Propert3 and VP Werth1,2 1 Department of Dermatology, Philadelphia
Veterans Affairs Medical Center, Philadelphia, PA, 2 Department of Dermatology, University of
Pennsylvania, Philadelphia, PA and 3 Department of Biostatistics and Epidemiology,
University of Pennsylvania, Philadelphia, PA
Optimal clinical management and development of novel therapies for Dermatomyositis (DM) neces-
sitate outcome measures that reliably assess disease progression and treatment efficacy. The Cuta-
neous Dermatomyositis Disease Area and Severity Index (CDASI), a skin-based outcome measure,
was developed to systematically and quantitatively assess DM severity. We aim to classify DM sever-
ity using CDASI activity scores of adult DM patients in a prospective observational database study.
Patient information was collected using questionnaires completed by the patient and principal inves-
tigator during office visits. Of 105 patients in the database, 11 were lost to follow-up and 3 had
incomplete visits resulting in the inclusion of 91 patients in the analysis. Subjects were representa-
tive of all three subtypes of DM including 52% with classic DM, 43% with amyopathic DM and
5% with hypomyopathic DM. At each initial patient encounter cutaneous DM was scored by the
principal investigator using the CDASI and a 5-point Likert scale. On the Likert scale, 65% of patients
had none or mild disease, 31% had moderate disease and 4% had severe disease. The median CDASI
activity scores for mild, moderate and severe disease were 13, 27 and 35 respectively, and thus
increased with disease severity, confirming the construct validity of this instrument. A receiver-oper-
ating characteristic curve generated via logistic regression indicates that a cut-off of approximately
20 out of 100 points on the CDASI best distinguishes subjects with none to mild disease from those
with moderate or severe disease (sensitivity, 88%; specificity 86%, area under the ROC curve
92%). This study contributes to continued efforts to validate the CDASI.
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Antibodies from patients with bullous pemphigoid and neurological disease bind to murine
cortical and hippocampal neurons
K Taghipour,1 C Chi,2 B Bhogal,3 RW Groves,1,3 VA Venning4 and F Wojnarowska5 1 Genetics and
Molecular Medicine, King’s College London, London, United Kingdom, 2 College of Medicine,
Chang Gung University, Taoyuan, Taiwan, 3 Immunodermatology, St John’s Institute of
Dermatology, London, United Kingdom, 4 Oxford University Hospitals, Oxford, United
Kingdom and 5 Nuffield Department of Clinical Medicine, Oxford University, Oxford, United
Kingdom
Evidence links bullous pemphigoid (BP) with some neurological diseases (ND) but the mechanism
behind this is unknown. The discovery of BP antigens in the central nervous system prompted a
hypothesis of cross-reactivity. The aim of this work was to (i) study the reactivity of BP sera to neu-
ronal antigens and (ii) elucidate the relation between serum reactivity and presence of ND. Target
antigens were identified in 108 BP patients (BP+ND, n=58 and BP-ND, n=50) by ELISA and
immunoblotting. Indirect immunofluorescence using mouse brain as substrate (BrIF) was performed
on all BP and 20 control sera, and the results were scored by intensity. There was no association
between the target antigens (BP180 and/or BP230) and presence of ND. Positive BrIF was seen in
56 BP and 13 controls with varying grades and patterns. There was a significant difference in grades
suggesting a stronger staining in BP+N (P=0.025, Kruskal-Wallis). The difference in grades increased
when positive responses were compared, with the strongest staining in BP+N, followed by BP-N
and controls (P=0.007, Kruskal-Wallis). The fluorescence uptake was chiefly in cortical neurons
although some BP sera exhibited a striking hippocampus staining. The white matter did not stain at
all. Positive BrIF was not associated with gender or any specific autoantibody in BP groups. There
was no relation between the pattern/grade of staining and presence of ND. None of the control sera
showed strong staining or labeled the hippocampal cells, although moderate and weak stainings
were noted. These data suggest that neurons are recognized by circulating IgG and both BP180 and
BP230 are of importance in the link with ND. It is not clear whether these neuron-binding anti-
bodies are those that also bind to skin or whether other IgG antibodies play a role.
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The role of interleukin 17- induced receptor-interacting protein-4 in human keratinocytes
H Bae, Y Park, S Jeong, Y Jang, H Kim, W Ryu, J Kim, H Lee and S Son Laboratory of Cell Signaling
and Nanomedicine, Department of Dermatology and Division of Brain Korea 21 Project for
Biomedical Science, Korea University College of Medicine, Seoul, Republic of Korea
The receptor-interacting protein-4 (RIP4) was identified as a serine/threonine kinase in development
of the epidermis and cutaneous inflammation. But, the regulatory mechanisms of IL-17-induced
RIP4 expression have not been characterized. In this study, we investigated the regulatory mecha-
nism of IL-17-induced RIP4 expression and it’s physiological role in human keratinocytes. After treat-
ment of IL-17to human keratinocytes, RIP4 mRNA and protein levels increased in a time-depend-
ent manner. Also, IL-17 upregulated the activity of RIP4 promoter in a dose-dependent manner. By
ChIP assay and luciferase assay using various RIP4 promoter fragments with single mutated Egr-1
binding site, Egr-1 activated the transcriptional expression of RIP4 by binding to the Egr-1 binding
element in the RIP4 proximal promoter. These observations suggest that Egr-1 could be a regulator
of RIP4 expression. To understand the functional role of RIP4 in keratinocyte and to investigate the
genes regulated by RIP4, RNA-based micro-array analysis was performed. Expression of immune
response-related genes including CCL20, IL-8, S100A7 and CXCR7 were significantly changed by
RIP4. To identify the interacting protein with RIP4, the immunoprecipitation assay was performed.
As a result, STAT-3 was identified as a new protein interacting with RIP4. The interaction with RIP4
was increased by Egr-1 and STAT-3 enhanced STAT-3 activation. Taken together, these findings from
the present studies indicate that IL-17-induced Egr-1 activates the transcriptional expression of RIP4.
Increased RIP4 elicts STAT-3 phosphorylation by directly interacts with STAT-3. Thus, activation of
RIP4-mediated signaling pathway may contribute to IL-17-induced inflammation in human ker-
atinocytes.
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The development and validation of the TABQOL, a tool to measure the quality of life impacts
of treatments used in patients with autoimmune blistering disease
A Tjokrowidjaja,1,2 BS Daniel,1 JW Frew,1 DF Sebaratnam,1 A Hanna,1,2 S Chee,1,2 A Dermawan,1,2
C Wang,1,2 C Lim,1,2 SS Venugopal,1 LM Rhodes,3 J Cochrane,3 B Welsh,4 T Nijsten5 and
DF Murrell1,2 1 Department of Dermatology, St George Hospital, Gray St, Kogarah, Sydney,
NSW, Australia, 2 University of New South Wales, Sydney, NSW, Australia, 3 Premier
Specialists Research and Development, Sydney, NSW, Australia, 4 Department of
Dermatology, St Vincent’s Hospital, Melbourne, VIC, Australia and 5 Department of
Dermatology, Erasmus MC, Rotterdam, Netherlands
Aim: The development of a quality of life instrument specific to the effects of treatments used in
patients with autoimmune bullous disease (AIBD). Methods: Patients with histologically diagnosed
AIBD in an Australian outpatient setting were recruited for this study. A comprehensive item gen-
eration process was used to build a 45-item pilot Autoimmune Bullous Disease Quality of Life
(ABQOL) questionnaire, distributed to 70 AIBD patients. Questions pertaining to the treatment effects
were selected for inclusion in the treatment-specific questionnaire (TABQOL). This pilot TABQOL
was administered to 70 AIBD patients and the results were subjected to factor analysis to reduce
the questionnaire to 17 items. The questionnaire was then evaluated for validity and reliability.
Results: Face and content validity were established through the comprehensive patient interview
process, expert review and summaries of treatments used. In terms of convergent and discriminant
validity it was found to have appropriate correlation with the DLQI (R=0.64) and level of treat-
ments used (p<0.01), and was found to be responsive to overall variations in treatment burden. The
TABQOL was also found to be a reliable instrument evaluated by internal consistency (Cronbach
alpha coefficient =0.892) and test re-test reliability (R=0.98). Conclusion: The TABQOL has been
shown to be a valid and reliable instrument which may to be used to measure treatment burden
and serve as an end-point in clinical trials.
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CD11a, CD11c and CD18 gene polymorphisms and susceptibility to Behçet’s disease in Korea
S Park,1 K Park,1 Y Park,2 D Bang3 and E Lee2 1 Biology, School of Biological Science and
Chemistry, Sungshin Women’s University, Seoul, Republic of Korea, 2 Dermatology, Ajou
University School of Medicine, Suwon, Republic of Korea and 3 Dermatology, Yonsei
University College of Medicine, Seoul, Republic of Korea
Lesions of Behçet’s disease (BD) show vascular infiltrates of immune cells which highly express inte-
grins. β2 integrins CD11/CD18 play a major role in cell migration to inflammatory lesions and
induce inflammatory cytokine production. Genetic polymorphisms might alter the conformation
and expression of CD11/CD18, which may contribute to the pathogenesis of BD. 9 single nucleotide
polymorphisms (SNPs) of CD11a, CD11c, and CD18 were genotyped using PCR-RFLP and haplo-
type analysis in 305 BD patients and 266 healthy controls. The frequencies of genotype rs11574944
CC, haplotype rs11574944C rs2230433G rs8058823A were significantly lower in BD patients, but
the frequency of haplotype TGA in CD11a was higher in BD patients (p = 0.026, OR = 0.7, per-
mutation p = 0.011, and p = 0.026, respectively). The frequencies of genotype rs2230429 CC and
rs2929 GG, C and G allele, and haplotype rs2230429C rs2929G in CD11c were higher in BD
patients (p = 0.0004; OR = 1.8, p = 0.021; OR = 1.5, p < .0001; OR = 1.7, p = 0.013; OR = 1.4,
and permutation p = 0.001, respectively). The frequencies of genotype rs235326 CC, C allele, and
haplotype rs2070946A rs235326T rs760456C rs684G in CD18 were higher in BD patients (p =
0.002; OR = 1.7, p = 0.001; OR = 1.6, and permutation p = 0.012, respectively). Other SNPs were
not significantly associated with susceptibility to BD. In conclusion, the major genotype and hap-
lotype of LFA-1 (CD11a/CD18) seems to decrease risk of BD, whereas major genotype and haplo-
type of CR4 (CD11c/CD18) may increase the risk. The changes in immune cell migration and cytokine
production resulting from protein changes due to genetic variations of β2 integrins might be a pos-
sible mechanism explaining these results.
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Resveratrol and benzoyl peroxide activity against propionibacterium acnes
EJ Taylor,1,2 J Champer3 and J Kim1,2 1 Medicine, Division of Dermatology, UCLA, Los Angeles,
CA, 2 Dermatology, Greater Los Angeles Healthcare System Veteran’s Affairs, Los Angeles, CA
and 3 City of Hope National Medical Center, Duarte, CA
Resveratrol (RES) is an antioxidant that has multiple biologic effects including anti-inflammatory
and antimicrobial properties. Acne vulgaris is a disease of the pilosebaceous unit, characterized by
innate host antimicrobial responses to Propionibacterium acnes, which leads to tissue inflamma-
tion and injury. In this study, we sought to determine whether RES is capable of reducing P. acnes
growth and inhibiting pro-inflammatory cytokines induced by P. acnes. The effect of RES was com-
pared to benzoyl peroxide (BPO), a drug commonly used to treat acne vulgaris. We aimed to study
the antibacterial, anti-inflammatory, and cytotoxic properties of RES and BPO alone and in combi-
nation. Colony forming unit assay, IL-12 ELISA, MTS cytotoxicity assay, and electron microscopy
were performed to evaluate the effects of RES and/or BPO on P. acnes and P. acnes-induced inflam-
mation. RES demonstrated a slow-onset and sustained antibacterial activity against P. acnes over a
10-day period, whereas BPO showed a rapid-onset but short-term bactericidal response that dimin-
ished after 24 hours. Additive antibacterial activity was observed when RES and BPO were com-
bined in comparison to either compound alone. P. acnes induction of IL-12 production in primary
human monocytes was decreased in the presence of both RES and BPO and this response was not
due to toxicity as RES was significantly less toxic to human monocytes and keratinocytes than BPO.
Finally, electron microscopy suggested a mechanism of action for RES induced killing as P. acnes
treated with RES demonstrated altered bacterial morphology consistent with intramembranous
edema. In conclusion, RES and BPO demonstrate unique antibacterial kinetics in vitro, and their
enhanced activity together in addition to RES’s anti-inflammatory effect on P. acnes induced pro-
inflammatory cytokine suggest a novel therapy in the treatment of acne vulgaris in vivo.
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Psoriasin (S100A7) promote angiogenesis in psoriasis
J Vegfors, A Ekman, C Bivik and C Enerbäck Ingrid Asp Psoriasis Research Center, Department
of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
The S100 calcium-binding protein family is involved in a number of cellular processes such as cell
cycle progression, energy metabolism and cellular differentiation. Psoriasin, S100A7, was initially
identified as a gene highly expressed in psoriasis. We have previously shown that psoriasin is induced
by reactive oxygen species (ROS) and that the downregulation of endogenous psoriasin expression
in a cancer cell line inhibited tumor growth in vivo. In accordance with these results, the down-
regulation of vascular endothelial growth factor (VEGF) in cells with reduced psoriasin levels was
demonstrated. These findings raised the hypothesis that psoriasin may promote angiogenesis. Vas-
cular modifications occur early in the development of psoriasis, suggesting that angiogenesis is one
of the key features in the pathogenesis of psoriasis. We recently showed that psoriasin interacts
with the multiligand receptor for advanced glycation end products (RAGE) providing endothelial
cell proliferation. The purpose of this study was to investigate the role of psoriasin in the mediation
of angiogenesis in psoriasis. We show that psoriasin induces human dermal microvascular endothe-
lial cell (HMVEC-d) proliferation, migration and tube formation, demonstrated by in vitro angio-
genesis assays. IL-17, a key cytokine in psoriasis that has previously been shown to have a role in
mediating angiogenesis and generating ROS and VEGF, strongly induces psoriasin. We demon-
strate that inhibition of the IL-17-activated PI3K and NF-κB signalling pathways in HMVEC sup-
presses the psoriasin-induced migration. In conclusion, we show that psoriasin, like IL-17 and VEGF,
mediates endothelial cell proliferation, migration and tube formation. In addition, psoriasin-induced
HMVEC migration is mediated by the same signalling pathways as IL-17 and VEGF. Psoriasin may
therefore play a role in psoriasis by promoting oxidative stress response and angiogenesis.
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Diagnostic criteria for erosive lichen planus affecting the vulva: An electronic-delphi con-
sensus exercise
RC Simpson,1 KS Thomas,1 P Leighton2 and R Murphy3 1 Centre of Evidence Based
Dermatology, University of Nottingham, Nottingham, United Kingdom, 2 University of
Nottingham, Nottingham, United Kingdom and 3 Nottingham University Hospitals NHS
Trust, Nottingham, United Kingdom
The erosive subset of lichen planus (ELP) is a chronic, relapsing condition. There is no defined set
of criteria for diagnosing ELP affecting the vulva (ELPV). We performed a three-stage international
electronic-Delphi exercise to reach consensus on a clinico-pathological diagnostic dataset for ELPV.
A total of 73 experts from 14 countries participated; 69 (95%) completed all three rounds. Partici-
pants represented dermatology, gynecology, histopathology and venerology. In the first two rounds
participants were asked to rate the importance of selected clinical and pathological criteria on a
five-point scale. Responses from Round 1 were presented in Round 2, along with additional diag-
nostic criteria suggested by participants. In Round 3 participants were asked to rate the diagnostic
features as ‘essential’ or ‘supportive’. We defined consensus as being where 75% participants agreed
on the importance of an item. Of the items that were considered important, no item reached con-
sensus as an ‘essential’ diagnostic criteria. Consensus was achieved for the following as ‘support-
ive’ diagnostic criteria: i) Scarring/loss of normal architecture; ii) the presence of a hyperkeratotic
border to lesions or Wickham’s striae in surrounding skin; iii) involvement of other mucosal sur-
faces; iv) well demarcated erosions/erythematous areas at the vaginal introitus; v) symptoms of
pain/burning; vi) presence of vaginal inflammation; vii) presence of a well-defined inflammatory
band involving the dermo-epidermo junction consisting predominantly of lymphocytes; viii) signs
of basal layer degeneration. It was recognised that 3 or more supportive features should be present
to make a diagnosis of ELPV. Most participants agreed that histological confirmation was not required
if sufficient clinical features were present. This consensus exercise has developed an internation-
ally agreed diagnostic dataset for ELPV for adoption into clinical practice and in clinical trials.
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Calcipotriol counteracts betamethasone-induced decrease in biomarkers related to skin atro-
phy
H Norsgaard,1 P Descargues,2 S Kurdykowski,2 T Gonzalez,1 G Duenstl1 and M Røpke1 1 LEO
Pharma, Ballerup, Denmark and 2 GenoSkin, Toulouse, France
The calcipotriol/betamethasone dipropionate two-compound gel is widely used for topical treat-
ment of psoriasis vulgaris. It has been hypothesized that the addition of calcipotriol to the steroid
component may counteract steroid-induced skin atrophy. Decreases in collagen synthesis and degra-
dation (suppression of MMPs), hyaluronic acid (HA) and epidermal thickness have all been associ-
ated with skin atrophy. The aim of this study was to compare the skin atrophogenic potential of the
calcipotriol/betamethasone dipropionate combination with the respective mono-treatments by inves-
tigating their effect on these biomarkers in vitro in fibroblast and keratinocyte cultures, ex vivo in a
new skin explant model (NativeSkinTM) and in vivo in minipigs. Betamethasone mono-treatment
induced a slight but consistent reduction in collagen I synthesis by fibroblasts in vitro and ex vivo.
Secretion of MMP1 and MMP3 from both fibroblasts and keratinocytes was also inhibited by
betamethasone mono-treatment. In contrast to betamethasone, calcipotriol or the combination
increased collagen I synthesis both in vitro and ex vivo. Similarly, an opposing effect of calcipotriol
and betamethasone was also seen on MMP expression. Betamethasone reduced the secretion of HA
in both fibroblast and keratinocyte cultures. Calcipotriol did not affect the secretion of HA in
fibroblast cultures while the combination reduced secreted levels of HA to that obtained by betametha-
sone mono-treatment. However, in keratinocyte cultures calcipotriol enhanced the secretion of HA
and no significant change was seen with the combination treatment. In vivo, treatment with
betamethasone gel significantly decreased epidermal thickness in minipigs compared with the vehi-
cle group. By contrast, treatment with calcipotriol gel or the combination gel did not reduce epi-
dermal thickness in minipigs. In conclusion, these data indicate that the calcipotriol component of
the two-compound gel counteracts the betamethasone-induced decrease in biomarkers related to
skin atrophy.
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Gene mutation analysis of Korean patient with early onset and recalcitrant generalized pus-
tular psoriasis
H Song,1 S Yun,2 S Park,2 Y Juhnn3 and E Lee1 1 Dermatology, Ajou University School of
Medicine, Suwon, Republic of Korea, 2 Microbiology and Immunology, Ajou University
School of Medicine, Suwon, Republic of Korea and 3 Biochemistry and Molecular Biology,
Seoul National University College of Medicine, Seoul, Republic of Korea
Generalized pustular psoriasis (GPP) is a rare and aggressive form of psoriasis characterized by dif-
fuse erythematous disseminated sterile pustules, fever, leukocytosis, and increased acute phase reac-
tants. Some cases are reported as familial GPP exhibiting mutation in the interleukin-36 receptor
antagonist (IL-36Ra) gene in Tunisia and Japan. IL-36Ra gene mutation is suggested to be a cause
of overexpression of proinflammatory cytokines. Herein, we performed mutation analysis of the IL-
36Ra gene in a 17-year old Korean female patient with early onset (age 4) and severe GPP. Genomic
DNA extracted from her peripheral blood mononuclear cells was subjected to polymerase chain
reaction and nucleotide sequencing. The patient turned out to be heterozygous for point mutation
in intron 3, designated as c.115+6T>C leading to skipping of exon 3 at the transcript level and pro-
duction of premature termination codon. Unlike Japanese patients reported to have compound muta-
tions, this Korean patient does not have mutation for c.368C>G or c.28C>T. This is the first report
that a Korean patient with GPP has mutation in the IL-36Ra gene.
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Rituximab treatment for severe pemphigus
K Heelan, S Walsh and NH Shear Division of Dermatology, Sunnybrook Health Sciences
Centre, Toronto, ON, Canada
Rituximab (RTX) induces B cell depletion and has shown efficacy in antibody-mediated autoim-
mune disease. RTX is increasingly being acknowledged as an effective treatment option for pem-
phigus. We sought to evaluate RTX efficacy and safety in comparison with classic immunosup-
pressants for pemphigus and to evaluate the clinical response of pemphigus patients to RTX using
the modified Rheumatoid Arthritis (RA) protocol (1g intravenously (IV) on days 1 and 15, consider
future 500mg IV if clinically warranted) by assessing responses to first and repeated cycles. Con-
secutive patients with a diagnosis of severe pemphigus vulgaris (n=84) and foliaceus (n=8) treated
with RTX (n=92) or systemic corticosteroids alone or combined with immunosuppressants (n=137)
were retrospectively reviewed. Of the 92 patients treated with RTX, mean duration of disease prior
to RTX was 39.5 months. Following cycle 1 all patients had a response, 41 achieving complete
remission (CR) within 6 months. Of the remaining patients 32 achieved CR on adjuvant treatment
and 19 achieved partial remission on or off treatment, thereafter 49 patients relapsed. There was no
statistically significant difference between sex, type of pemphigus or clinical type (mucous, cuta-
neous or mucocutaneus) and time to relapse. Median time to failure was 18 months (95 % confi-
dence interval 12.8-23.2). Relapses were treated with further RTX. Mean follow-up time after RTX
cycle 1 was 26 months. At last follow-up 56 patients had achieved CR and 27 CR on adjuvant treat-
ment. CR rates on or off treatment increased from 79% to 90% with subsequent cycles. Regarding
status of disease, at last follow up there were a significantly higher number of patients with CR in
the RTX group compared with the control group (60% vs. 31%, P<0.001), similarly patients in the
RTX group were less likely to be on steroids (14 % vs. 42%, P<0.001). No severe RTX side effects
occurred. The modified RA protocol for RTX seems to be an effective and well-tolerated treatment
for pemphigus. Patients who fail to achieve remission after 1 cycle or patients who relapse, benefit
from further cycles of RTX.
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Reversal of long-standing alopecia areata in C3H/HeJ mice using topical JAK inhibitors
A Jabbari,1 Z Dai,1 L Xing,3 A de Jong,1 AM Christiano1,4 and R Clynes1,2,3 1 Dermatology,
Columbia University, New York, NY, 2 Medicine, Columbia University, New York, NY, 3
Pathology, Columbia University, New York, NY and 4 Genetics & Development, Columbia
University, New York, NY
Alopecia areata (AA) is one of the most prevalent autoimmune diseases for which no targeted ther-
apy exists. T cells have been previously implicated in the disease process, but the immune activa-
tion pathways and specific T cell types involved have not been identified. Guided by our GWAS
studies implicating NKG2D ligands (NKG2DL) in human AA, here we identify NKG2D-expressing
CD8+ cytolytic T cells (CTLs) as the dominant immune effectors in the C3H/HeJ mouse model, which
were both necessary and sufficient for disease induction. Moreover, we show that the NKG2DLs
Rae-1 and H60 are both upregulated in the AA mouse hair follicle (HF). We interrogated the cytokine
pathways involved in the AA inflammatory response, identifying a dominant IFN-γ signature as well
as IL-15. These two cytokines conspire to induce the pathogenic AA Type 1 cytotoxic T cell inflam-
matory response. IL-15 produced by the HF promotes the activation of “NK-type” IFN-γ producing
CTLs. In turn, IFN-γ produced by alopecic CTLs activates the HF, closing a pathogenic circle, by
upregulating HF IL-15, MHC molecules and NKG2DLs, all of which target the HF for CTL attack.
This type 1 cytotoxic pathway can be interrupted with either anti-cytokine biologics or small mol-
ecule inhibitors of their downstream effector JAK kinases. We demonstrate that both IL-15 blocking
antibodies and systemic JAK inhibition prevent disease induction in grafted AA mice. Importantly,
two recently FDA approved JAK inhibitors, tofacitinib (JAK3i) and ruxolitinib (JAK1/2i), that inhibit
signaling through the IL-15 and IFN-γ receptors respectively, have been topically formulated and
have demonstrated safety and efficacy in human psoriasis. We show that both topical JAK inhibitors
eliminate local CTLs and induce hair regrowth, durably reversing AA in mice with established dis-
ease, thereby providing a strong rationale for their clinical evaluation in human AA.
228
CD4+CD28null cells are not expanded but exhibit a cytotoxic profile in patients with psori-
asis
XT Lima, RF Magalhães, FH Téo, RL Mamoni and MH Blotta University of Campinas, Campinas,
Brazil
We aimed to evaluate the frequency and characteristics of CD4+CD28null T (CD28null) cells in
psoriasis. This uncommon subset is increased in other immune-mediated inflammatory diseases,
such as rheumatoid arthritis and psoriatic arthritis (PsA). Lymphocytes of patients with active mod-
erate to severe plaque-type psoriasis and healthy volunteers were analyzed using flow cytometry to
evaluate the frequency of CD28null cells and their expression of homing and cytotoxic molecules
and inflammatory cytokines (ex-vivo and after stimulation – LPS and anti-CD3 + calcium ionophore).
Serum concentrations of high-sensitivity CRP and TNF-αwere measured by nephelometry and ELISA.
In the analysis of the frequency of CD28null cells, we performed univariable and multivariable
analyses, adjusting for a priori selected (age, gender and dyslipidemia) and confounding variables.
We evaluated 36 patients with psoriasis and 16 controls. Age was similar in both groups. Psoriasis
patients had mean (SD) PASI and BSA of 14.5 (9.0) and 32.4% (26.2%), respectively and 17 patients
(47.2%) had arthritis. Prevalence of diabetes, dyslipidemia and male gender were increased in pso-
riasis group, the latter being statistically significant. In the univariable analysis, there was no differ-
ence in the frequency of CD28null cells between the groups (ex vivo and after stimulation). There
was increased expression of cytotoxic granules in the CD28null cells from ex vivo samples of pso-
riasis patients, but no difference in the expression of homing molecules and cytokines between the
groups. In the multivariable analysis, there was no difference in the frequency of CD28null cells
(0.17, 95% CI -0.86 - 1.21). Psoriasis patients had higher serum concentration of hs-CRP (p=0.22)
and TNF-α (p=0.04). Although psoriasis patients did not have increased frequency of CD28null cells,
they had more cells expressing cytotoxic molecules ex vivo. These cells may be degranulating after
stimulation and may have a role in the immunomodulation of psoriasis.
S38 Journal of Investigative Dermatology (2013), Volume 133
IID13_Abstracts-5  3/25/13  3:00 PM  Page S38
Auto-Immunity & Inflammation | ABSTRACTS
229
IL-4 down-regulation of involucrin expression in atopic dermatitis involves competitive bind-
ing of Stat6 to the coactivator CBP
L Bao,1 J Alexander,1 H Zhang1 and LS Chan1,2,3 1 Dermatology, Univ Illinois, Chicago, IL, 2
Microbiology/Immunology, UIC, Chicago, IL and 3 Jesse Brown VA Med Center, Chicago, IL
Skin barrier defects play an important role in the pathogenesis of atopic dermatitis (AD). Involucrin,
an important barrier protein suppressed in human AD, is down-regulated by IL-4 in keratinocytes.
Decreased involucrin levels in Stat6 transgenic mice suggest a role of Stat6 in the down-regulation.
However, the molecular mechanism for IL-4 down-regulation of involucrin has not been delineated,
and especially how Stat6, a transcriptional activator, represses involucrin expression is totally
unknown. Since Stats usually recruit the coactivator p300/CBP in the general transcription machin-
ery and involucrin regulation involves p300/CBP, we hypothesize that Stat6 activated by IL-4 may
compete with the involucrin transcription factors for p300/CBP binding, thus suppressing involu-
crin transcription. Using IL-4 transgenic mice, an AD mouse model, we find that involucrin expres-
sion is similarly down-regulated as in human AD. In HaCat cells, IL-4 down-regulation of involu-
crin expression is prevented by Jak inhibitors, suggesting that Jak-Stat may be involved in the
regulation. To further investigate IL-4 regulation of involucrin, we transfected HaCat cells with an
involucrin promoter-luciferase reporter and then treated them with IL-4 or vehicle. IL-4 greatly sup-
presses the promoter activity, which is totally abolished by cotransfecting the CBP expression vec-
tor, indicating clearly that IL-4 cannot down-regulate involucrin in the presence of excessive CBP.
In addition, IL-4 fails to suppress involucrin promoter activity in HaCat cells cotransfected with a
dominant negative DN-Stat6 lacking the CBP binding domain. As controls, cotransfection with
DN-Stat3, -Stat5a/5b or empty vector has no effect on IL-4 action. Finally using ChIP assay, we
demonstrate that IL-4 decreases CBP binding to the involucrin transcription machinery. For the first
time, we clearly delineate the molecular mechanism for IL-4 down-regulation of involucrin in AD,
which involves competitive binding of Stat6 to CBP.
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Pharmacokinetic (PK) and pharmacodynamic (PD) correlation in topical drug formulation
J Lenn, H Aloor, J Cote-Sierra, L Santos, S Cook, J Therrien and H Hofland Center for Skin Biology,
Stiefel, a GSK company, RTP, NC
A selective glucocorticoid receptor agonist is under investigation for the treatment of atopic der-
matitis. This study explores the correlation between skin permeation (PK) and target engagement
(PD) of the compound from topically applied suspension based cream formulations versus that in
a solution based formulations. Topical drug permeation studies were performed to assess drug deliv-
ery into and through human skin using flow-through cells. A non-linear dose response with increas-
ing concentration of the compound was observed in the epidermis and dermis for the suspension
based cream formulations. On the other hand, the solution based formulations showed improved
drug delivery into both epidermis and dermis when compared to the suspension based formula-
tions. To assess the drug activity, the solution and suspension based formulations were tested in a
LPS stimulated ex vivo human skin culture and a delayed type contact hypersensitivity mouse model.
Treatment with the solution based cream resulted in more than a 3 fold reduction in IL-8 secretion
compared to the suspension based cream in the LPS stimulated ex vivo model; suggesting the solu-
tion based cream formulation is likely to achieve a greater anti-inflammatory efficacy. Similarly, the
solution based formulations resulted in a greater reduction in ear swelling using the mouse atopic
dermatitis model. These studies demonstrated that formulations with compounds fully solubulized
active pharmaceutical ingredient (API) can result in better drug bioavailability and significantly
improve drug efficacy.
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Psoriasis is associated with DC-HIL+ myeloid-derived suppressor cells that have defective sup-
pressor function
J Chung, K Tamura, K Nezafati, PD Cruz, B Chong and K Ariizumi Dermatology, UT
Southwestern Medical Center, Dallas, TX
Psoriasis is considered to be an autoimmune disease caused by inappropriate activation of T cells
regulated by positive and negative mechanisms, in which the former has been studied much more
compared to the latter. Among the most potent inhibitors of T cell activation are myeloid-derived
suppressor cells (MDSC) whose numbers rise exponentially in both malignant and inflammatory
disorders. Having reported DC-HIL receptor expressed by MDSC in melanoma patients to be the
critical mediator of these cells’ ability to suppress T cell function, we questioned whether a similar
mechanism is true for an inflammatory disease like psoriasis. By FACS analysis, we showed the
MDSC phenotype (CD14+ HLA-DRno/low) within PBMC to be increased significantly in psoriasis
patients (5.7% ± 4; n=7) compared to healthy controls (0.2% ± 0.2; n=12) (p=0.003). Frequencies
of DC-HIL+ cells among MDSC and of DC-HIL+ MDSC among PBMC were also increased in pso-
riasis patients vs. controls: 76% ± 29 vs. 4.2% ± 2; and 3.9% ± 3.5 vs. 0.1% ± 0.1, respectively. We
next examined suppressor function by comparing the ability of MDSC purified from PBMC of pso-
riasis (93-96% DC-HIL+ MDSC; n=3) vs. melanoma patients (90-99% DC-HIL+; n=4) to suppress
IFN-γ production by autologous T cells in the presence of anti-CD3/CD28 Ab at increasing cell
ratios. MDSC from psoriasis patients suppressed IFN-γ production by a puny 20-50% and only at
the high cell-ratio of 1:0.5. This outcome is exceedingly low compared to MDSC from melanoma
patients which caused >90% suppression. Having shown anti-DC-HIL Ab to almost completely
block suppressor function of MDSC from melanoma patients, we probed for a similar result for
MDSC from psoriasis patients, and found no effect. Thus, melanoma and psoriasis patients share
circulating MDSC with high DC-HIL expression, but differ in these cells’ ability to suppress T cell
activation. The relative functional deficiency of DC-HIL+ MDSC in psoriasis may be related to lack
of tolerance for autoreactive T cells in this disease.
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Identification of heterogeneous human Treg cell subsets with implications in the pathogene-
sis of acne inversa
A Heeseler, R Scheer and C Zielinski Department of Dermatology, Charité-Universitätsmedizin
Berlin, Berlin, Germany
Immune responses are tailored to protect against particular types of pathogen encounters. A suc-
cessful immune defense strategy however also requires intricate negative regulation to restrict inflam-
mation induced host damage. FOXP3+ regulatory T (Treg) cells are a broadly acting and potent
anti-inflammatory population of CD4+ T cells essential for maintaining immune homeostasis and
preventing autoimmune inflammation. Although Treg cells are generally considered to be a sepa-
rate lineage of CD4+ T cells, recent murine studies have indicated that they use different transcrip-
tional programs to regulate Th1, Th2, or Th17 responses, and that these are associated with the
expression or activation of specific T helper cell-associated transcription factors. This implicates phe-
notypic and functional heterogeneity within the Treg compartment. We therefore set out to analyze
if Treg cells in humans also display functional specialization. We could demonstrate the existence
of distinct human Treg subsets with different migration capacities that correlated with different
types of immune functions such as cytokine production. These Treg subsets matched their Th1, Th2
and Th17 effector cell counterparts (Tcon), but retained their suppressive function. Treg as compared
to Tcon cells showed a homing bias towards the peripheral body surfaces such as the skin where
they are expected keep microbiota induced immune responses in check. We could also demon-
strate that in inflammatory diseases the relative composition of subsets within the Treg compart-
ment is altered. In Acne inversa, skin homing Tregs are reduced whereas IL-17 producing Treg cells
are increased. Thus, we could demonstrate a so far unrecognized functional heterogeneity within
the human Treg compartment and a correlation with alterations in its relative composition with
inflammatory diseases such as Acne inversa.
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Systemic VEGF inhibition decreases CD4+ T cells and Th17 cytokines improving psoriasis-
like skin inflammation in KC-Tie2 mice
D Diaconu, Y Fritz, SM Dawes, CM Loyd and NL Ward Dermatology, Case Western Reserve
University, Cleveland, OH
Psoriasis is characterized by epidermal hyperplasia, cutaneous inflammatory cell infiltrate and der-
mal angiogenesis, concurrent with increases in VEGF. VEGF is derived from activated keratinocytes,
infiltrating leukocytes and vascular cells; and exerts its effects in an autocrine and paracrine man-
ner on resident skin cells eliciting their proliferation, activation and expression of pro-inflammatory
cytokines. Despite recent reports of a patient experiencing psoriasis remission during bevacizumab
treatment for colon cancer, targeting VEGF has received minimal attention. The KC-Tie2 mouse
model of psoriasiform skin inflammation develops skin disease that phenocopies human psoriasis
including increases in angiogenesis and VEGF expression (~3-fold; P<0.02). To investigate anti-VEGF
treatment in psoriasis, we treated adult KC-Tie2 mice and littermate controls with systemic VEGF-
Trap or control FC protein (25mg/kg; n=8/group) 2x/wk for 4 wks. VEGF-Trap significantly reduced
dermal angiogenesis to control levels in KC-Tie2 mice (P=0.04 vs KC-Tie2+FC protein) with con-
comitant reductions in acanthosis (47%; P=0.03 vs KC-Tie2+FC protein) and decreases in innate
defense genes S100A8/A9 and DefB3 (all P<0.03). Despite significant decreases in cutaneous
CD11b+, CD11c+ and F4/80+ cells in VEGF-Trap treated KC-Tie2 mice (P<0.001 vs KC-Tie2+FC
protein), levels remained significantly increased compared to control littermates (P<0.04). Myeloid
cell-derived cytokines, TNFα IL-1, IL-6 and IL-12 remained elevated following VEGF-Trap treat-
ment whereas IL-23 expression returned to control mouse levels (P=0.02 vs KC-Tie2+FC protein).
Interestingly, CD4+ T cells decreased (63%; P=0.001) in VEGF-Trap treated KC-Tie2 mouse skin,
accompanied by significant reductions in IL-17A, IL-17F and IL-22 (all P<0.007). Taken together,
these data provide in vivo evidence for efficacy of VEGF inhibition for psoriasis and suggest that
disease improvement may occur via VEGF-mediated effects on the IL-23/Th17 axis of inflamma-
tion.
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Development of a mouse model for linear IgA bullous dermatosis
P Geng,1 L Lin,1 M Park,1 N Li,1 K Shumate,1 MP Marinkovich,2 R Hall,3 L Diaz1 and Z Liu1 1
Dermatology, University of North Carolina, Chapel Hill, NC, 2 Dermatology, Stanford
University, Stanford, CA and 3 Dermatology, Duke University, Durham, NC
Linear IgA bullous dermatosis (LABD) is an autoimmune inflammatory blistering disease charac-
terized by the linear IgA deposition of IgA at the basement membrane zone (BMZ) and subepider-
mal bulla with a predominant neutrophilic infiltrate in the dermis. The IgA autoantibodies in LABD
recognize BP180/collagen XVII, a hemidesmosomal protein also identified as the autoantigen in the
autoimmune subepidermal blistering disease, bullous pemphigoid (BP). IgG autoantibodies in BP
and IgA autoantibodies in LABD specifically target the immunodominant region termed NC16A of
BP180. We recently generated a humanized mouse strain, in which the NC16A domain replaces
the counterpart, NC14A domain, of mouse BP180. NC16A humanized mice (NC16A), when injected
with anti-NC16A IgG autoantibodies from BP, develop BP-like skin lesions. Here, we test if LABD
IgA autoantibodies are pathogenic in the humanized BP180 mouse. It is known that mouse neu-
trophils lack IgA receptors for human IgA; therefore, NC16A mice were reconstituted with purified
human neutrophils locally or systemically. NC16A mice without human neutrophil reconstitution
injected with BP180-specific IgA from LABD alone did not show any skin abnormalities. In con-
trast, NC16A mice reconstituted with human neutrophils injected (i.d. or i.p.) with BP180-specific
IgA developed subepidermal blisters 24 h post IgA injection. Neutrophil-reconstituted NC16A
mice injected with control IgA did not develop blisters. The skin of diseased mice exhibited human
IgA deposition at the BMZ and neutrophil infiltration at the lesional/perilesional site. In vitro, LABD
IgA in the presence of recombinant NC16A, activates human neutrophils resulting in the release of
proteolytic enzymes and inflammatory mediators. We conclude that both BP180-specific IgA and
neutrophils are required in experimental LABD.
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Gene expression signature of TRAF3IP2-silenced keratinocytes reveals unexpected effects on
KC differentiation and cytokine responses
S Lambert,1 WR Swindell,1 LC Tsoi,2 BL Drumright,1 SW Stoll,1 RP Nair1 and JT Elder1 1
Dermatology, University of Michigan, Ann Arbor, MI and 2 Biostatistics, University of
Michigan, Ann Arbor, MI
TRAF3IP2 is a susceptibility locus for psoriasis and psoriatic arthritis encoding Act1, an E3 ubiqui-
tin ligase that couples the IL17 receptor to NF-κB and other downstream signaling pathways. To fur-
ther investigate the role of Act1 in KC responses to IL17, we conditionally silenced TRAF3IP2 in N-
TERT-TR keratinocytes using a tetracycline (Tet)-inducible shRNA targeting TRAF3IP2 followed by
high-throughput RNA sequencing to identify differentially expressed genes. Tet exposure for seven
days (to allow KC to attain confluence and achieve effective [>80%] knockdown of Act1 protein)
blocked several known IL17 target gene responses, including VNN3, NFKBIZ, ZC3H12A and VAA1
as well as the synergistic induction of DEFB4A and NOS2 by IL17+TNF. However, exposure to Tet
in the absence of exogenous cytokines resulted in 215 genes with > 2-fold changes in expression
(161 down, 54 up), complicating the analysis of Act1 silencing on other IL17 target genes such as
LCN2, S100A7, IL1F9 and PI3. Gene Ontogeny analysis revealed that genes whose expression is
decreased by TRAF3IP2 silencing alone encode proteins involved in the early phases of epidermal
differentiation (DSG1, DSC1, KRT1, KRT10), which was confirmed by QRT-PCR and Western blot-
ting. Consistent with decreased differentiation, TRAF3IP2 silencing resulted in a 1.8-fold increase
of Ki67+ KC (p=0.036) and markedly decreased c-jun phosphorylation as cultures passed through
confluence. In line with the paradoxical risk-increasing effect of the Act1 D10N variant, gene set
enrichment analysis revealed that genes showing larger fold-change (IL17/control) with TRAF3IP2
silencing overlapped significantly more often than expected with genes overexpressed in psoriasis,
whereas the opposite was observed for genes with lower fold-change after silencing (both p < 0.001).
These results reveal pleiotropic and unexpected effects of Act1 in shaping the abnormal gene expres-
sion profile of psoriatic skin.
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Upregulation of miR-18a is associated with keratinocyte apoptosis in toxic epidermal necrol-
ysis
A Ichihara, M Jinnin, K Sakai, S Masuguchi, S Fukushima and H Ihn Dermatology and Plastic
Surgery, Kumamoto University, Kumamoto, Japan
Toxic epidermal necrolysis (TEN) is severe drug-induced cutaneous reaction. Because of a high mor-
tality rate, it is important to diagnose it in the early stage, predict its severity and treat it intensively.
However, there has been no reliable diagnostic marker or disease activity marker of TEN in clini-
cal use. We investigated the role of microRNAs in the pathogenesis of TEN. MicroRNAs were extracted
from tissues and sera of TEN, Stevens-Johnson syndrome, or erythema multiforme patients and healthy
control subjects. To determine the pathogenic microRNAs, we performed PCR array analysis. The
results were confirmed with quantitative real-time PCR, in situ hybridization, immunohistochem-
istry, transient transfections of siRNA or microRNA mimic into cultured keratinocytes, and flow
cytometry. PCR array analysis and real-time PCR using tissue microRNAs demonstrated miR-18a
level was increased in patients with drug eruptions including TEN (p<0.05) in vivo, correlating with
the disease activity. The transfection of miR-18a mimic into keratinocytes in vitro resulted in the
increase of apoptotic cells. Immunohistochemical analyses revealed protein expression of BCL2L10,
predicted target of miR-18a, was decreased in TEN (p<0.05). Transfection with siRNA for BCL2L10
induced the keratinocyte apoptosis. Immunostaining of caspase 9, which is the key caspase of intrin-
sic apoptosis pathway, showed that caspase 9 was activated in the epidermis of TEN. Furthermore,
we first investigated serum microRNA levels in TEN patients. Serum miR-18a levels tended to be
increased in TEN patients and were correlated with the width of erosion area. Considering that
BCL2L10 is an anti-apoptotic member of the BCL2 family, our results indicate that down-regulated
BCL2L10 caused by miR-18a overexpression induce keratinocyte apoptosis in TEN. Investigation
of the regulatory mechanisms of keratinocyte apoptosis by microRNA may lead to develop new
treatments and new disease marker.
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Topical application of delphinidin reduces psoriasiform lesions in the flaky skin mouse by
inducing epidermal differentiation and inhibiting proliferation and inflammation
HC Pal, CA Elmets and F Afaq Dermatology, University of Alabama at Birmingham,
Birmingham, AL
Psoriasis is a chronic inflammatory skin disease that affects approximately 2-3% of the American
population. Several line of evidence suggests that psoriasis is characterized by hyperproliferation
and aberrant keratinocyte differentiation leading to a disrupted skin barrier with an abnormal stra-
tum corneum. Identification of natural agents that possess the ability to abrogate these effects could
be useful for the treatment of this disease. Delphinidin, present in pigmented fruits and vegetables,
possesses potent antioxidant and anti-inflammatory activities. Earlier studies from our laboratory
have shown that treatment of three-dimensional reconstituted psoriatic human skin with delphini-
din increased the activation of caspase-14 that is involved in terminal differentiation and cornifi-
cation, as well as the expression of other markers of epidermal differentiation. In the present study,
we determined whether topical application of delphinidin can modulate pathological markers of
psoriasiform lesions in the flaky skin mouse and whether this is associated with increased caspase-
14 expression and reduction in cell proliferation and inflammation. Treatment of the flaky skin mouse
with delphinidin (0.5 mg/cm2 and 1 mg/cm2 skin area; five times a week) resulted in increased
expression and processing of caspase-14 protein and mRNA expression. In addition, delphinidin
treatment increased the expression of early (K1 and K10) and late (fillagrin and loricrin) differenti-
ation marker proteins. More importantly, there was a reduction in the pathological markers of pso-
riasiform lesions in mice that received topical delphinidin. There was also a decrease in the expres-
sion of markers for cell proliferation (Ki-67 and PCNA) and inflammation (iNOS). Furthermore,
delphindin treatment resulted in down-regulation of occludin and up-regulation of claudin 1 mem-
bers of tight junction proteins. Based on these findings, we suggest that delphinidin could be a prom-
ising agent for treatment of psoriasis.
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Anti-BP180-type mucous membrane pemphigoid IgG induces endocytosis of BP180/collagen
XVII less frequently than bullous pemphigoid IgG
A Naruse,1 S Hiroyasu,1 H Imanishi,1 H Kobayashi,1 M Ishii,1 H Koga,2 T Hashimoto2 and
D Tsuruta1,2 1 Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan
and 2 Dermatology, Kurume University School of Medicine, and Kurume University Institute
of Cutaneous Cell Biology, Kurume, Japan
Anti-BP180 type mucous membrane pemphigoid (BP180-MMP) is a rare autoimmune subepider-
mal blistering disease, which targets C-terminus of BP180/collagen XVII. Recently, we reported that
bullous pemphigoid (BP) IgG induces internalization of BP180 via macropinocytic pathway, depletes
BP180 and weakens epidermal cell-matrix integrity. In contrast, the pathomechanism of BP180-
MMP is not well understood. To elucidate this mechanism, we followed the fate of BP180 in cul-
tures of normal human keratinocytes, DJM-1 cells and normal human oral mucosal epithelial cells
by either immunocytochemistry or live cell imaging. No difference was found in expression of var-
ious hemidesmosomal proteins among the three cell lines assessed by immunocytochemistry.
Although all seven BP-IgGs induced BP180 internalization into the cytoplasm, only three of 7 BP180-
MMP-IgGs induced BP180 internalization within 30 minutes. The time course of BP180 internal-
ization after BP180-MMP-IgG treatment was comparable to that after BP-IgG treatment. Fewer BP180
particles were present in the cytoplasm after BP180-MMP-IgG treatment, compared to after BP-IgG
treatment. BP180-MMP-IgG internalization occurred simultaneously and colocalized with BP180
internalization. No difference in occurrence of these events induced by BP180-MMP-IgGs was found
between keratinocyte and oral mucosal cell lines. These results may suggest that clinical differ-
ences between BP and BP180-MMP are caused by less frequent endocytosis induced by BP180-
MMP-IgG. In addition, predominant oral mucosal lesions found in BP180-MMP may not be due to
difference in BP180 internalization between oral mucosal epithelial cells and keratinocytes.
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STAT2 expression and activation is increased in psoriatic skin
C Johansen, A Hald and L Iversen Depatment of Dermatology, Aarhus University Hospital,
Aarhus C, Denmark
The cytokine-activated janus kinase (JAK) - signal transducer and activator of transcription (STAT)
pathway is known to play an important role in many inflammatory processes. STAT2 belongs to the
STAT family of proteins and is activated by phosphorylation at tyrosine 690. Psoriasis is a chronic
inflammatory skin disease of unknown etiology characterized by hyperproliferation and an abnor-
mal differentiation of the keratinocytes as well as an aberrant immune response. Previous studies
have demonstrated a role for STAT1 and STAT3 in the pathogenesis of psoriasis; however, the role
of STAT2 is still unknown. Thus, the purpose of this study was to characterize the expression and
activation of STAT2 in psoriatic skin. Keratome and punch biopsies were taken from patients with
plaque-type psoriasis. STAT2 mRNA expression was analysed by quantitative PCR, whereas STAT2
protein was examined by western blotting and immunofluorescence analysis. Cultured normal
human keratinocytes were used for in vitro studies. We demonstrated an increased expression of
STAT2 at both the mRNA and protein level, as well as an increased level of the phosphorylated/acti-
vated form of STAT2(tyr690) in lesional psoriatic skin compared with nonlesional psoriatic skin. In
normal skin as well as nonlesional psoriatic skin STAT2 was found to be localized exclusively in
the basal layer of the epidermis, whereas STAT2 staining was observed throughout the entire epi-
dermis in lesional psoriatic skin. In vitro studies demonstrated that the IFNα-induced phosphoryla-
tion/activation of STAT2(tyr690) was mediated by a PKCδ-dependent, but p38 MAPK-independent,
mechanism in cultured human keratinocytes. Taken together, this study demonstrates a possible role
of STAT2 in the pathogenesis of psoriasis and identifies PKCδ as a key kinase in the phosphoryla-
tion/activation of STAT2 in response to IFNα.
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Associations of pruritus severity, sleep problems, and work productivity in patients with mod-
erate to severe psoriasis
AB Kimball,1 E Edson-Heredia,2 B Zhu,2 J Guo,3 T Maeda-Chubachi2 and W Shen2 1 Harvard
Medical School, Boston, MA, 2 Lilly Research Labs, Indianapolis, IN and 3 Pharmanet-i3,
Indianapolis, IN
Psoriasis is known to be associated with substantial pruritus and work impairment. This post-hoc
analysis used data from a phase 2 clinical trial in patients with moderate to severe plaque psoria-
sis (N=142) treated with either ixekizumab of different dose regimens or placebo to evaluate asso-
ciations between pruritus severity, sleep problems and work productivity. The role of sleep prob-
lems as a possible mediator of the association between pruritus severity and work productivity was
also analyzed. Patients completed a pruritus severity visual analog scale (Itch VAS), the Medical Out-
comes Study Sleep scale (MOS-S), and the Work Productivity and Activity Impairment Question-
naire (WPAI) at baseline and Week 16. Mediating effects were tested in multivariate regressions
comparing the effects of the following change from baseline variables: independent variable (Itch
VAS) on the dependent variable (WPAI) with and without controlling for the mediating variable
(MOS-S) and sobel tests. Multivariate analysis without the mediating MOS-S variable showed that
pruritus was significantly associated with Presenteeism, Work Productivity, and Activity Impair-
ment (p<0.0001). In the multivariate regressions MOS-S Sleep Disturbance and Sleep Indices I and
II became significantly associated with Presenteeism, Work Productivity, and Activity Impairment
and the effect of pruritus decreased. Sobel tests indicated that the Sleep Problem Index I, which
measures s initiation, maintenance, respiratory problems, adequacy, and somnolence had a signif-
icant effect (p<0.05) in mediating the relationship between pruritus severity and Presenteeism, Work
Productivity, and Activity Impairment. Work productivity decrements in patients with moderate to
severe psoriasis are associated with sleep impairment and pruritus. Some domains of sleep medi-
ate the role on the effect of pruritus on work productivity, but both factors appear to have inde-
pendent negative effects on work.
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Interest of I-modulia, Aquaphilus dolomiae extract, in immune inflammatory response of
atopic dermatitis pathology
M Aries, C Vaissière, H Delga, M Lévêque, T Nguyen, S Bessou-Touya and N Castex-Rizzi Dermo
Cosmetic Department, Pierre FABRE R&D Center, Toulouse Oncopole, France
Atopic dermatitis (AD) is a chronic inflammatory skin disease with a complex pathophysiology,
including genetic, immunologic and environmental factors interactions, and characterized by
allergic inflammation, barrier disruption and pruritic lesions. Keratinocytes which are active immuno-
logical cells with major control over AD inflammation by means of cytokine/chemokine produc-
tion contribute to the disease phenotype development. Likewise, TH1, TH2, TH17 cells which are
commonly observed in AD lesions are postulated in the disease process. Emollient application makes
the use of topical potent immune modulatory agents logical therapeutic consideration. The aim of
the present study was to evaluate I-modulia, an original biological extract from culture of Aquaphilus
dolomiae, isolated from Avene Spring Thermal Water microflora, on different immune inflamma-
tory cell models. Firstly, inflammatory mediators gene expression was assessed in Normal Human
Keratinocytes (NHK) stimulated by the association polyI:C+IL4+IL13+TNFα and performed by Q-
PCR 32 genes array. Secondly PAR-2 (Protease-activated receptor-2) activity was assessed in NHK
stimulated by trypsin and performed by Ca2+ flux signals monitoring. Finally TH1, TH2, TH17
cytokines basal production was assessed on CD4+ lymphocytes by 12-plex Luminex technology.
Our results showed that I-modulia inhibited gene expression of numerous mediators including TSLP,
IL18, IFNβ1, RANTES, MCP3, TARC, MIP-3α, MDC, IL4R, and induced involucrin, psoriasin, RNase7
gene expression; I-modulia also inhibited the PAR-2 activation and the TH1, TH2, TH17 cytokines
production (IL2,IFNγ/ IL4,IL5,IL13/ IL17, respectively). Together, the present data support the high
regulator activity of I-modulia, an Aquaphilus Dolomiae extract, on keratinocyte inflammatory and
lymphocyte immune responses, and reveal its powerful interest in topical preparations designed for
the regulation of AD immune inflammatory pathology.
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Bicyclic monoterpene diol modulates Th17 cytokine production in human keratinocytes
S Rivas, Y Ee, SC Geen, W Lee and AR Shalita Dermatology, SUNY Downstate Medical Center,
Brooklyn, NY
Bicyclic monoterpene diol (BMTd) has been implicated in modulating the inflammatory response
induced by the neuropeptides (NP), substance P (SP) and calcitonin-gene related peptide (CGRP),
in human keratinocytes. The purpose of this study is to determine the effects of BMTd on cytokine
production in human keratinocytes. Immortalized human cells (hTERT) and primary human ker-
atinocytes (NHEK) were treated with SP and CGRP, with and without BMTd. The cells were treated
for 48 hours at previously established optimal concentrations. Th1, Th2 and Th17 cytokine profiles
were assessed using multi-panel cytokine antibody arrays. hTERT cells treated with CGRP alone dis-
played significant increases (p<0.05) in Th17-associated cytokines, including IL-6 (5.6-fold), sgp130
(2.3-fold), TGF-β1 (4.4-fold), TGF-β3 (4.2-fold), and IL-1R (1.6-fold); Th1 cytokines IFN-γ and TNF-
α showed similar increases. Th17 cytokine production was significantly increased in hTERT cells
treated with BMTd alone, with similar increases noted in IFN-γ and TNF-α. Interestingly, hTERT cells
treated with both CGRP and BMTd demonstrated modest to dramatic decreases in Th17 cytokine
production [IL-6 (11.0%), sgp130 (25.7%), TGF-β1 (38.2%), TGF-β3 (43.0%) and IL-1R (11.0%)].
As determined by ELISA, treatment with SP or CGRP alone showed slight increases in detectable
levels of IL-1α, IL-1β, TNF-α and TGF-β1 as compared to control. Combination treatment of SP and
BMTd showed notable increases in IL-1α, IL-1β, and TNF-α by 25%, 50%, and 45%, respectively,
whereas CGRP and BMTd showed increased levels of TGF-β1 by 74%. Thus, BMTd modulates
neuropeptide-induced cytokine levels in human keratinocytes. These results further indicate that
BMTd may alter NP-induced inflammation in human keratinocytes by modulating Th17 and possi-
bly Th1 cytokine production. Our data suggests that BMTd may play a role in modulating cytokine
levels by working in conjunction with NPs such as SP and CGRP in the skin. Additional studies are
needed to further characterize the effects of BMTd on neuropeptide-induced inflammation.
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Cell permeable peptide-conjugated methotrexate attenuates imiquimod-induced psoriasiform
dermatitis via decreasing IL-17 producing gamma delta T cells
D Byamba,1,2 D Kim,1 D Kim,1 H Jee,1 S Kim,1 S Kim,3 J Baek,4 S Lee5 and M Lee1 1 Department
of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of
Medicine, Seoul, Republic of Korea, 2 Brain Korea 21 Project for Medical Science, Yonsei
University College of Medicine, Seoul, Republic of Korea, 3 Department of Dermatology,
National Health Insurance Corporation Ilsan Hospital, Goyang, Republic of Korea, 4
Department of Dermatology, Gil Medical Center, Gachon University, Goyang, Republic of
Korea and 5 Department of Biotechnology, Yonsei University College of Life Science and
Biotechnology, Seoul, Republic of Korea
Interleukin (IL)-23/IL-17 axis and their related cytokines such as IL-17A, IL-17F, IL-22, IL-21 and IL-
26 play essential roles in a variety of autoimmune or chronic inflammatory diseases, including pso-
riasis. Recently IL-17 is known to be produced mainly by both T helper (Th) 17 cell and gamma
delta (γδ) T cells in psoriasis. In mouse psoriasis-like skin inflammation induced by imiquimod (IQM),
γ δT cells were suggested to be the main producers of IL-17. Our study demonstrated that increased
γδ T cells (including IL-17A producing γδ T cells) and other immune cells such as epidermal and
dermal I-A/I-E+ cells, CD11c+ cells and CD4+ cells in IQM-applied mouse were normalized by an
application of a protein transduction domain conjugated, cell permeable methotrexate (MTX). Also
increased levels of IL-23, IL-17A and IL-22 in IQM-applied mouse skin were reduced by the cell
permeable MTX. Moreover the cell permeable MTX had little toxic effect on liver, kidney and bone
marrow cells unlike intraperitoneal injection of MTX. In conclusion, the IL-17 producing γδT cells,
main pathogenic cellular subsets in psoriasis, are reduced by topically applied, cell permeable MTX,
which leads to the amelioration of psoriasis-like skin inflammation without systemic toxic effects.
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Mechanisms of itch: Proteases activate Mas-related G-protein coupled receptors
VB Reddy, SB Elmariah, E Azimi, T Luo and EA Lerner Dermatology, Massachusetts General
Hospital, Charlestown, MA
Peripheral sensory neurons detect itch stimuli through their peripheral axons in the skin. Signals are
transmitted to the spinal cord via their central projections. Members of the orphan receptor family
of Mas-related G protein coupled receptors (Mrgs) are expressed by small-diameter sensory neu-
rons in DRGs and have been shown to contribute to the generation of itch. In this study, we describe
cleavage and activation of Mrgs by cathepsin S (cat S). Cathepsin S, an endogenous cysteine pro-
tease, has been shown previously to activate protease-activated receptor (PAR) 2 and to induce itch
in humans. Following treatment with cat S, HeLa cells transfected with MRGC11 demonstrate cal-
cium transients as determined by ratiometric calcium imaging and an increase in phosphorylated
PKC expression as detected by Western blot analysis. To determine whether receptor cleavage
occurred, we attached a luciferase tag at the N-terminus of MrgC11. When HeLa cells transfected
with luciferase-tagged receptors were treated with cat S, this released the luciferease as detected by
luminescence and Western blot analysis. Receptor cleavage was blocked when transfected HeLa
cells were pretreated with the protease inhibitor E64. Neither activation nor cleavage occurred when
certain N-terminal receptor leucine residues were mutated to isoleucine, suggesting that these
residues are critical for activity. Because PARs are activated by ‘tethered’ peptides, we examined
this possibility for MrgC11. A series of potential ‘tethered’ peptides 6 to 10 amino acids long were
generated based on the predicted cat S cleavage sites of the MrgC11 N-terminus. These hexa- and
deca- peptides failed to induce calcium signaling in cells expressing wild type MrgC11. These data
suggest that cleavage is required for protease activation. These results indicate that Mrgs can be
activated by cat S and suggest an additional cascade by which cat S signaling contributes to itch
and cutaneous inflammation.
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Opposing effects of the IL12B and IL23R psoriasis associated risk alleles on Th1 and Th17
responses in psoriatic skin
X Xing, A Johnston, WR Swindell, PR Stuart, RP Nair, JJ Voorhees, JT Elder and JE Gudjonsson
Dermatology, Univ. of Michigan, Ann Arbor, MI
Three genes involved in the biology of IL-12 and IL-23 are associated with psoriasis: IL12B, encod-
ing the p40 subunit of IL-12 and IL-23, IL23A, encoding the p19 subunit of IL-23 and IL23R encod-
ing the IL-23 receptor. However, the role of these genes in IL-12/Th1 and IL-23/Th17 biology in
psoriasis is unclear. Our work has focused on the pathologic effect of risk alleles of two of these
genes, IL12B (rs6887695G/rs3212227A haplotype), and IL23R (by rs11209026G allele) compared
to non-risk carriers. The IL12B risk haplotype led to a 12-fold increase in expression of IL12B in
IFN-γ primed dendritic cells (p<0.01, n=43), and affected IL12B risk carriers had increased serum
levels of IFN-γ (6.9-fold, p<0.0001), CXCL10 (2-fold, p<0.01) and IL-12 (6-fold, p=0.1), but decreased
IL-23 (0.7-fold, p<0.01) (n=202 vs. 17). The IL12B risk haplotype showed a shift in the cytokine
environment in psoriatic skin, with 356 genes being elevated in carriers compared to non-carriers
(p<0.05, n=53). These genes overlapped significantly with genes most strongly induced by IFN-γ in
keratinocytes (p<0.001) whereas genes induced by IL-17 and IL-22 had significantly decreased over-
lap (p<0.001). In contrast, we found IL23R expression increased in psoriatic skin (2-fold, p<0.05)
and primarily localized to CD3+ T-cells. Carriage of the IL23R risk allele was accompanied by ele-
vated serum levels of IL-17 (p<0.01, n=101 vs. 5) in affected carriers, resulting in a shift in the
cytokine environment in psoriatic skin towards IL-17, IL-22 and TNF-induced genes (p<0.001, n=58).
Taken together, our results indicate that these two variants amplify different arms of the T-cell responses
that co-exist in psoriatic skin, with the IL12B risk variant amplifying Th1 responses, and the IL23R
risk variant expanding Th17 responses. These results emphasize psoriasis as a mixed Th1/Th17 dis-
ease and may have implications for future treatments.
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Molceular identification and characterization of rosacea as a Th1- and Th17-dominated dis-
ease
J Buddenkotte,1,2 F Cevikbas,1 P Novak,2 J Aubert,3 I Carlavan,3 C Kempkes,1 T Buhl,1 S Déret,3
P Reiniche,3 M Sulk,1 J Voegel3 and M Steinhoff1 1 Depts. of Dermatology and Surgery,
University of California San Francisco, San Francisco, CA, 2 Dept of Dermatology, University
Hospital Münster, Münster, Germany and 3 Galderma R&D, Sophia Antipolis, France
Rosacea is a frequent chronic inflammatory skin disease with a high impact on patient’s quality of
life and a poorly understood pathophysiology. Rosacea is characterized by neurovascular changes,
skin barrier dysfunction, and a lymphomonocytic infiltrate that is poorly characterised on a molec-
ular/cellular level. In particular, the exact composition of the inflammatory T cell infiltrate and its
differences with respect to the cytokine/chemokine profile in the various subtypes of rosacea is
unknown. Therefore, we performed gene array studies in patients with rosacea subtypes 1 to 3, fol-
lowed by real-time PCR analysis and quantitative immunohistochemistry and double-immunoflu-
orescence. Our results show that in all stages, rosacea is a disease predominant of TH1 helper cells
and TH17 cells, but not TH2 cells. Gene array along with qRT PCR data and immunohistochem-
istry confirm upregulation of selective genes that are involved in T cell recruitment and TH1- or
TH17 activation, such as IL-6, -17, -22, IFN-γ, CCL20, CXCL9,-10, and -11, for example. Of note,
STAT-4 gene was upregulated in rosacea tissue as compared to acne tissue indicating different sig-
nalling pathways dominant in rosacea and acne. We also identified cytokine and chemokine recep-
tors that are differentially regulated among the different subtypes of rosacea and as compared to
healthy skin. Thus, TH1 and TH17 cells may play an important role in the pathophysiology of rosacea.
Because TH17 cells are involved in autoimmune and infectious diseases, these results shed new
light on the pathobiological mechanisms involved in rosacea. Drugs that modulate TH17 function
may be beneficial for the treatment of rosacea.
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CCL7 (macrophage chemotactic protein-3, MCP-3) is upregulated in lesional psoriatic skin
dependent on TNF-alpha activity
PM Brunner, B Reininger, I Klein, F Koszik and G Stingl Dpt. of Dermatology, Div. of
Immunology, Allergy and Infectious Diseases, Vienna, Austria
Chemokines are small chemotactic proteins that have a crucial role in leukocyte recruitment into
inflamed tissue. Targeting these mediators has been suggested as a potential therapeutic option in
inflammatory skin diseases. In skin of psoriatic patients, we performed a comprehensive screen of
proinflammatory mediators commonly involved in immune regulation. We found that CCL7 (mono-
cyte chemotactic protein-3, MCP-3), a chemokine ligand known to interact with multiple C-C
chemokine receptors, was markedly increased in lesional as compared to nonlesional and normal
control skin (40.2 and 63.6 fold increase, respectively; p<0.001). Surprisingly, its expression out-
numbered mRNA levels of other C-C chemokines known to be increased in lesional psoriatic skin,
namely CCL2 (MCP-1), CCL3 (MIP-1A), CCL5 (RANTES), CCL11 (Eotaxin-1), CCL19 (MIP-3B), CCL20
(MIP-3A) and CCL22. CCL7 mRNA levels were also slightly elevated in biopsies taken from patients
with atopic dermatitis or lichen planus in comparison to normal controls. However, this increase
was far less pronounced than that seen in lesional skin of patients suffering from chronic plaque-
type psoriasis or guttate psoriasis. In search of factors responsible for this upregulation, we found
that CCL7 protein production was induced in cultured human keratinocytes by TNF-alpha, but not
by other proinflammatory mediators such as IL-6 or IL-1beta. Consistently, CCL7 mRNA expression
in lesional psoriatic skin was decreased to levels found in nonlesional psoriatic skin already 16 hours
after the intravenous infusion of the TNF-alpha-blocker infliximab. In sum, our data suggest a
pathophysiological role of CCL7 (MCP-3) in the development and maintenance of psoriatic skin dis-
ease.
248
Dysregulated production of IL-23 and IL-10 by Langerhans cells in psoriasis
CM Sweeney,1 K Adamzik,2 A Tobin,3,2 G Kelly1,2,3 and B Kirby1 1 Dermatology Research, St.
Vincent’s University Hospital, University College Dublin D, Dublin, Ireland, 2 Dermatology,
St. Vincent’s University Hospital, Dublin, Ireland and 3 Dermatology, Adelaide and Meath
Hospital, Dublin, Ireland
Psoriasis is an immune-mediated inflammatory skin disorder. IL-23 plays a central role in psoriasis
by directing the development of T helper (h) 17 cells which substantially contribute to disease. The
active form of vitamin D3, 1,25-dihydroxyvitamin D3 (1,25 (OH)2 D3) exerts a variety of immunoreg-
ulatory functions and is protective in several inflammatory disease models. This study examined the
effect of 1,25 (OH)2 D3 on the function of epidermal and monocyte-derived Langerhans cells (LC).
1,25 (OH)2 D3 suppressed zymosan-induced IL-23 production but enhanced IL-10 production by
LC from healthy controls (p<0.01). The effect of 1,25 (OH)2 D3 was mediated via IL-10 since neu-
tralization of IL-10 reversed the suppressive effect of 1,25 (OH)2 D3 on IL-23 production (p<0.05).
LC from psoriasis patients produced significantly more IL-23 following zymosan stimulation com-
pared with LC from healthy controls (p<0.01). In contrast to healthy controls, IL-23 production by
LC from psoriasis patients was not regulated by 1,25 (OH)2 D3. 1,25 (OH)2 D3 failed to enhance
IL-10 production by LC from psoriasis patients and did not affect the expression of IL-23 by LC from
psoriasis patients. Moreover, recombinant β-defensin-3 abrogated the suppressive effect of 1,25
(OH)2 D3 and enhanced the production of IL-23 by LC from healthy controls (p<0.05). In contrast,
recombinant IL-10 enhanced the ability of 1,25 (OH)2 D3 to regulate IL-23 production by LC from
psoriasis patients (p<0.01). This study demonstrates that vitamin D3 suppresses IL-23 production via
IL-10 in healthy individuals and demonstrates dysregulated IL-23 production by LC in psoriasis via
β-defensin-3.
249
Immune complexes recruit slanDCs and NK cells to the vascular interface
T Döbel, A Lonsdorf, A Kunze, A Enk and K Schäkel Department of Dermatology, Heidelberg
University Hospital, Heidelberg, Germany
The formation and deposition of autoantibodies or immune complexes (ICs) in the vascular bed or
tissues is a pathogenic event of several autoimmunity-driven inflammatory diseases. Fc receptor-
dependent recognition of these ICs by immune cells mediates dysfunctional effector mechanisms
leading to IC-triggered inflammation and tissue damage. In a flow chamber-based approach cou-
pled with time-lapse video microscopy we measured the arrest function of blood leukocytes to small
immobilized ICs. Under conditions of physiological shear stress (up to 2 dynes/cm2) we observed
the arrest of Fc gamma R III (CD16) positive dendritic cells (slanDCs) and NK cells, two potent
effectors of antibody-dependent cell-mediated cytotoxicity. Other human blood DCs (plasmacy-
toid DCs and CD1c+ DCs) or T cells completely failed to adhere. Using blocking antibodies with
high selectivity we show that shear-resistant attachment to ICs depends on CD16a but is largely
independent of Fc gamma R II (CD32). Concordantly, mature slanDCs that have proteolytically
downregulated CD16 failed to attach. Testing various human IgG subtypes we found that only human
IgG3 was capable to promote the firm arrest of slanDCs, again in a largely CD16a-dependent man-
ner. We further corroborate our findings by showing enhanced arrest of slanDCs on monolayers of
human dermal microvascular endothelial cells pre-incubated with IgG-anti-endothelial cell anti-
bodies. Immunohistochemical detection of slanDCs in early skin lesions of allergic vasculitis also
lends support to the existence of a CD16a/IC-mediated recruitment at the endothelial interface.
Taken together, we have shown that CD16a mediates an efficient shear-stress-resistant adhesion of
circulating slanDCs and NK cells to immobilized ICs. These data provide evidence for a novel con-
duit of rapid FcR-dependent recruitment of immune cells in IC-mediated tissue inflammation.
250
Mice with heterozygous deficiency of manganese superoxide dismutase (SOD2) show fea-
tures of inflamm-aging
J Scheurmann, N Treiber, C Weber, AC Renkl, D Frenzel, F Buback, A Ruess, G Schulz,
K Scharffetter-Kochanek and JM Weiss Dermatology and Allergology, Ulm University, Ulm,
Germany
Immunosenescence is associated with a chronic inflammatory state. Dendritic cells (DC) are cen-
tral in regulating skin immunity. However, little is known about the contribution of DC to “inflamm-
aging”. We determined Langerhans cells (LC) numbers in aged epidermis and found a 60% reduc-
tion of LC, confirming previous findings. Reactive oxygen species have been linked with aging. The
mitochondrial manganese superoxide dismutase (SOD2) is in the first line of antioxidant defence.
Recently an accelerated aging phenotype in mice with conditional deficiency for SOD2 in the con-
nective tissue has been described. We investigated the function of DC from SOD2 heterozygous
mice (SOD2+/-) and found that at 4 months of age LC numbers are not altered, but activated LC
have moderately impaired expression of MHC-II and CD86. Immature SOD2+/- DC produced
increased proinflammatory IL-6 and chemokines CXCL1 and CXCL2. Upon challenge SOD2+/-
DC accumulated ROS. When activating SOD2+/- DC by LPS they less efficiently upregulated MHC-
II and CD86. Surprisingly, in vivo contact hypersensitivity (CHS) was enhanced in SOD2+/- mice
although SOD2+/- DC were less potent in stimulating wild type T cells. However, SOD2+/- T cells
showed increased proliferation, even when stimulated with SOD2+/- DC, possibly explaining the
increased CHS. Our findings suggest that SOD2 is a molecular candidate in the regulation of
“inflamm-aging” conveying both immunosuppressive and proinflammatory signals through alter-
ation of DC and T cell functions.
251
Different mRNA expression profiles in subcutaneous adipose tissue derived from body areas
with and without psoriatic skin manifestations
A Langkilde-Lauesen Nielsen, L Raaby, C Johansen and L Iversen Department of Dermatology,
Aarhus University Hospital, Aarhus, Denmark
Adipose tissue may play a role in the pathogenesis of psoriasis. A high Body Mass Index (BMI) is
associated with severe psoriasis and increased expression of resistin and leptin has been found in
serum from psoriatic patients compared to healthy controls. Furthermore, adipose derived cytokines
have been shown to be associated with increased inflammation. The purpose of this study was to
investigate the mRNA expression profile in subcutaneous adipose tissue in body areas with psori-
asis compared to body areas with no psoriasis in the same patient. A microArray analysing 28,869
mRNAs was conducted on excision biopsies from 3 psoriatic patients (males, age: 25-45 years;
Psoriasis Area and Severity Index (PASI): 17-23; BMI: 28.5-39.1). The biopsies were divided into
subcutaneous adipose tissue and epidermal/dermal tissue. 574 differently expressed mRNAs between
subcutaneous adipose tissue derived from body areas with and without psoriatic skin manifestations
were found. 56 of these mRNAs had more than 2-fold higher expression in the subcutaneous adi-
pose tissue than in the epidermal/dermal tissue suggesting that these mRNAs may be more related
to adipose tissue than to epidermal/dermal tissue. A literature search conducted on the 56 mRNAs
revealed that 15 of these were described as related to inflammation, 10 to differentiation, 18 to pro-
liferation, 18 to cancer, 9 to obesity and 5 had no previously functional description. This study sug-
gests that the subcutaneous adipose tissue plays an active role in the pathogenesis of psoriasis but
in order to describe the precise mechanism, further studies are needed.
252
K14-directed Hoxb13 transgenic mice develop phorbol-induced and age-related hyperpro-
liferative skin lesions characterized by enhanced inflammation and angiogenesis
JA Mack1,2 and EV Maytin1,2 1 Biomedical Engineering, Cleveland Clinic, Cleveland, OH and 2
Dermatology, Cleveland Clinic, Cleveland, OH
The function of Hox genes in embryonic development is well established, but their potential roles
in adult tissue maintenance and disease is poorly understood. This is especially true for the skin
where approximately 30 of the 39 known Hox genes, including Hoxb13, are reportedly expressed.
To illuminate possible functions for Hoxb13 in skin, we generated transgenic (TR) mice overex-
pressing Hoxb13 in the basal layer of the epidermis, driven by the K14 promoter (K14-Hoxb13 TR
mice). In two independent TR lines (K14-Hoxb13 TR3 and K14-Hoxb13 TR6), pruritic skin lesions
develop spontaneously as the mice age (beginning at ≈ 5 months). The lesions in aging mice are
characterized by 1) epidermal hyperplasia, 2) a striking increase in neutrophils, macrophages, and
mast cells (p>0.0001 for all three cell types), 3) an increased number of blood vessels (p>0.0001),
and 4) increased expression of TNF-α and VEGF. In addition, normal K14-Hoxb13 TR skin shows
high levels of pSmad2, an effector of TGF-β signaling. Interestingly, young K14-Hoxb13 TR mice
when subjected to short-term topical application of the phorbol ester 12-O-tetradecanoylphorbol-
13-acetate (TPA), develop skin lesions remarkably similar to those in the aging mice. TPA is an agent
thought to exert its major effects in part through PKC activation, and PKC signaling has been shown
by others to promote inflammation, promote angiogenesis, and modulate TGF-β activity. A prelim-
inary examination of protein isolated from TPA-treated mouse skin with a pan antibody against p-
PKC indicates that one or more PKC isoforms may be upregulated in K14-Hoxb13 transgenic mice
compared to wild-type. Together, our results suggest that Hoxb13 functions as a regulator of inflam-
matory and angiogenic processes and may accomplish this in part through regulation of PKC and/or
TGF-β signaling.
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ΔNp63 is a key driver of inflammatory signaling in atopic dermatitis
R Romano,1 E Guttman-Yassky2 and S Sinha1 1 Biochemistry, State University of New York at
Buffalo, Buffalo, NY and 2 Dermatology, Rockefeller University, New York, NY
Atopic Dermatitis (AD) is a chronic relapsing inflammatory skin disease, whose underlying patho-
genetic basis and molecular attributes remains complex and elusive. Our recent genomic profiling
experiments on skin lesions of human AD patients revealed a dramatic up-regulation of the tran-
scription factor p63. p63, specifically the ΔNp63 isoforms, play an indispensable role in skin epithe-
lial development, differentiation and homeostasis. However, the role of this regulator in the etiol-
ogy of AD has not been examined. To investigate the contribution of ΔNp63 to the pathogenesis of
AD, we have utilized a mouse model with targeted overexpression of ΔNp63 to the basal layer of
the epidermis. Overexpression of ΔNp63 in adult mice results in a skin phenotype that shares many
of the key histological, pathological and molecular features associated with human AD skin lesions.
More specifically, these animals develop pruritic skin lesions accompanied by epidermal hyper-
plasia and aberrant cellular differentiation. Furthermore, ΔNp63 transgenic skin exhibit a chronic
and reactive inflammatory microenvironment marked by macrophage and mast cell infiltrations and
the polarization of T-helper subset 2 (Th2) cells. Consistent with these changes, global transcriptome
profiling shows a marked increase in many pro-inflammatory cytokines/chemokines in the ΔNp63
mouse skin. This includes expression of high levels of Th2 cytokines including IL4, IL5 and IL10, as
well as predominant activation of the IL-33 signaling pathway- all factors known to contribute to
AD. Interestingly, ChIP experiments show that a large number of these pro-inflammatory
cytokines/chemokines to be under the direct transcriptional control of ΔNp63. Together, our data
suggests that elevated levels of ΔNp63 unleashes a distinct pro-inflammatory trigger which influ-
ences the broader skin microenvironment. The discovery of ΔNp63 as an important contributor to
AD pathophysiology can be harnessed for a better understanding and effective treatment of this dis-
ease.
255
A PASI ≥90 response is associated with improved patient reported outcomes: Results from a
phase 2 study in patients with psoriasis treated with ixekizumab
E Edson-Heredia,1 S Banerjee,1 B Zhu,1 T Maeda-Chubachi,1 G Cameron,1 W Shen,1 K Gordon2
and C Leonardi3 1 Lilly Research Labs, Indianapolis, IN, 2 Northwestern University Feinberg
School of Medicine, Chicago, IL and 3 St. Louis University School of Medicine, St. Louis, MO
The objective of this analysis was to determine whether greater improvement in Psoriasis Area and
Severity Index (PASI) was associated with larger improvements in Dermatology Life Quality Index
(DLQI) and pruritus severity (Itch VAS) in patients with moderate to severe plaque psoriasis. Data
were from a randomized, double-blind, placebo-controlled phase 2 clinical trial in psoriasis patients
(N=142) treated with multiple doses of ixekizumab SC (10, 25, 75, 150 mg dose groups) or placebo.
All treatment groups were combined for the analysis. PASI improvement from baseline to Week 16
was divided into PASI<75 (N=63), PASI75-<90 (N=15), PASI90-<100 (N=29), and PASI100 (N=32)
groups. Changes in DLQI and Itch VAS scores from baseline to Week 16 were compared between
PASI groups using ANCOVA. Logistic models were used to compare those who achieved a DLQI
score of 0 between PASI groups. Significantly greater improvements in Itch VAS and DLQI mean
score were observed between groups (p<0.05, all comparisons). Achieving PASI100 and PASI90-
<100 at Week 16 was associated with 50.8 and 53.8 point decreases in Itch VAS, respectively, as
compared with the 27.1 point decrease for the PASI75-<90 and the 5.1 point decrease for the PASI<75
group. Similarly, DLQI scores decreased by 9.8 and 9.3 points,, for the PASI100 and PASI90-<100
groups, respectively, compared with the 6.9 point decrease for the PASI75-<90 group and 2.9 point
decrease for the PASI<75 group. Greater than 50% of patients in both the PASI100 and PASI90-
<100 groups reached DLQI of 0 at Week 16 compared to 6.7% for the PASI75-<90 group and
1.6% for the PASI<75 group. These results suggest that patients with ≥90% PASI improvements may
achieve significantly higher improvements in quality of life and symptom relief than patients with
lesser PASI improvements.
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Bullous pemphigoid eosinophils express FcεRI and exhibit an immunoregulatory degranula-
tion profile
HM Holahan,2 KA Messingham,2 JW Wang2 and JA Fairley1,2 1 Dermatology, VA Medical Center,
Iowa City, IA and 2 Univ of Iowa, Iowa City, IA
Bullous pemphigoid (BP) is an autoimmune blistering disease triggered by IgE and IgG autoanti-
bodies targeting the hemidesmosomal protein BP180 (type XVII collagen). Peripheral and tissue
eosinophilia is highly characteristic of untreated BP and recent data suggests eosinophils are criti-
cal in the induction and persistence of some immune reactions. We evaluated expression of the
high affinity IgE receptor, FcεRI, on eosinophils to enhance understanding of their role in BP. FcεRI
expression was evaluated on circulating and tissue eosinophils by double label immunofluores-
cence on cryosections or cytospins respectively, utilizing antibodies against major basic protein
(MBP) and the α chain of FcεRI. Examination of BP biopsies (n=4) revealed many FcεRI+ /MBP+
cells, which were not observed in normal skin (n=3). Similarly, a higher frequency of peripheral
MBP+ cells from BP patients (n=13) expressed the FcεRI (~50%) compared to controls (<5%; n=13)
(p=0.008). Flow cytometry (CD16-CD49d+) was used to confirm surface expression of FcεRI. Addi-
tionally, 3 patients who were followed longitudinally lost surface FcεRI expression on circulating
eos with disease treatment/remission. Since IL-4 and IL-5 are potent regulators of eosinophil home-
ostasis (IL-4, IL-5) and FcεRI expression (IL-4), these cytokines were evaluated in serum and blister
fluid by ELISA. Both cytokines were elevated BP sera (n=13; p<0.05), while only IL-4 was elevated
in BP blister fluid (p<0.05; n=8). As an index of degranulation, eosinophil derived neurotoxin (EDN),
major basic protein (MBP) and eosinophil chemotactic protein (ECP) were measured in the serum
and blister fluid of untreated BP patients or controls. EDN levels were significantly elevated in BP
sera (n=11) compared to controls (n=11), while EDN and ECP were significantly elevated in BP
blister fluid (n=4-8) compared control blister fluid (n=4). Differential release of eosinophil contents
suggests piecemeal type of degranulation, which is associated with immunoregulation.
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Increased proportion of regulatory B cells after rituximab therapy for autoimmune blistering
skin diseases (AIBD): A potential mechanism for disease control 
A Chen,1 A Yoshizaki,2 T Miyagaki,2 RD Streilein,1 TF Tedder2 and RP Hall1,2 1 Dermatology,
Duke, Durham, NC and 2 Immunology, Duke, Durham, NC
Regulatory B (B10) cells have been detected in humans and are increased in subjects with AIBD.
Rituximab has been shown to have clinical benefit for patients with AIBD, even after B cell recov-
ery. We hypothesized that the prolonged clinical remission after rituximab therapy may result from
an increase in the proportion of regulatory B cells; B10 + B10 progenitor(B10pro). Peripheral blood
B cells from 32 patients with AIBD were analyzed for B10 and B10pro cell frequencies.24 subjects
were treated with prednisone(Pred) and/or conventional steroid sparing drugs(SSD) while 8 subjects
were treated with rituximab as well as Pred and/or SSD. B10+B10pro cells were identified as pub-
lished (Blood 117:530, 2011) and expressed as the % of total B cells that expressed IL-10 after cul-
ture in the presence of CD40L and either LPS or CpG. Median B10+B10pro cell frequencies for sub-
jects never treated with rituximab were 1.6 % and 4.6% of the total B cell population after CD40/LPS
and CD40L/CpG stimulation, respectively, similar to the median B10+B10pro cells of AIBD sub-
jects before rituximab therapy (1.1% CD40L/LPS ;7.7% CD40L/CpG). After rituximab therapy (median
368 days) median B10+B10pro cell frequencies increased to 9.4% (CD40/LPS; p = 0.03 and 11.6%
(CD40L/CpG;NS). Subjects treated with Pred and/or SSD, who had tapered to <10 mg Pred/day
and had no significant active disease had median B10+B10pro cell frequencies of 3.7%(CD40L/LPS)
and 8.4%(CD40L/CpG) which was less than for rituximab-treated subjects in remission on no pred-
nisone (9.4% and 11.6%). After treatment with rituximab, subjects with ABID had an increase in
the proportion of B10+B10pro cells, greater than the frequencies observed before rituximab treat-
ment and the frequency in subjects in remission after treatment with Pred and /or SSD. These data
suggest that regulatory B cells may play a unique role in therapeutic responses to rituximab ther-
apy that is different from that seen after conventional therapy.
254
Relationship of patient reported outcome measures to changes in clinical status in patients
with moderate to severe psoriasis
P Wang,1 E Edson-Heredia,1 B Zhu,1 W Shen,1 S Banerjee1 and C Leonardi2 1 Lilly Research Labs,
Indianapolis, IN and 2 St. Louis University School of Medicine, St. Louis, MO
The objective of this post hoc analysis was to examine the association between patient reported out-
come (PRO) measures and Psoriasis Area and Severity Index (PASI) changes in patients with mod-
erate to severe plaque psoriasis. Data were from a randomized, double-blind, placebo-controlled
Phase 2 clinical trial in patients (N=142) treated with either ixekizumab (different dose regimens)
or placebo. All treatments were combined for this analysis. The associations were determined through
two approaches: 1) Spearman correlations between changes in PASI score and PRO measures from
baseline to Week 16 and 2) comparison of PRO measure changes from baseline between PASI75
responders and non-responders using ANCOVA. PRO measures in this study included: Dermatol-
ogy Life Quality Index (DLQI), Quick Inventory of Depressive Symptoms (QIDS), Medical Outcomes
Study Short-Form 36 (SF36), Work Productivity and Activity Impairment questionnaire (WPAI) and
a pruritus severity item (Itch VAS). Changes in PASI score had moderate (0.3-0.5) to high (>0.5) cor-
relations with changes in Itch VAS, DLQI total score, and DLQI subscales of as Symptoms and Feel-
ings, Daily Activities, Work and School, and Personal Relationships (p<.001). There were moderate
to low (0.1-0.3) correlations with changes in SF36 Physical Component Summary (PCS) and the
WPAI scores of Presenteeism, Work Productivity Loss, Activity Impairment (p<0.05). Significant
differences in changes of DLQI, Itch VAS, QIDS, SF36 PCS, and Presenteeism, Work Productivity
Loss, and Daily Activity Impairment scores from baseline to Week 16 were observed between groups
who achieved PASI75 response and those who did not (p<0.05). The results of the current analysis
suggested that outcomes of dermatology-specific quality of life and psoriasis symptom severity are
more highly associated with changes in psoriasis clinical status relative to outcomes such as work
productivity or general health status.
258
Reversible Th22 dysfunction and persistent loss of Th17 responses in patients with L-CTCL
R Watanabe, E Guenova, A Gehad, J Teague, N Adams, AA Dorosario, R Glinert, M Tawa,
JB Carter, KA Chaney, DC Fisher, TS Kupper and RA Clark Dana Farber/Brigham and Women’s
Cancer Center, Boston, MA
Patients with leukemic CTCL (L-CTCL) have an average survival of 3 years and most commonly die
from infections. IL-17 producing Th17 cells protect against extracellular pathogens. IL-22 promotes
barrier function and protects against bacterial pathogens in the gut. We investigated IL-17 and IL-
22 production in patients with L-CTCL. In agreement with prior studies, malignant T cells in 15/15
L-CTCL patients produced Th2 cytokines but did not produce IL-17 or IL-22. To examine Th17 and
Th22 function in non-malignant CD4 T cells, we stimulated blood T cells with anti-CD3 beads for
four days and assayed for cytokine production. Blood Th17 and Th22 responses were significantly
reduced in patients with L-CTCL as compared to healthy controls (Th17: 0.44% vs. 2.9%, p<0.01,
Th22: 0.90% vs. 3.1%, p<0.05), as was production of IFNγ. Th17 and Th22 cells were similarly
reduced in L-CTCL skin lesions as compared to healthy controls (Th17: 3.2% vs. 22.7%, 22 pts,
p<0.001; Th22: 2.9% vs. 13.2%, 22 pts, p<0.01). As we previously reported, IL-4 and IL-13 pro-
duction were markedly increased in lesional skin T cells. In vitro culture of normal blood T cells
with L-CTCL T cells decreased production of IFNγ, IL-17 and IL-22 in the normal T cells. Neutral-
ization of IL-4 and IL-13 restored IFNγ production but production of IL-17 and IL-22 remained sup-
pressed. We next studied patients in clinical remission following a variety of therapies and found
that, although Th1 and Th22 responses recovered in the blood and skin of patients with L-CTCL,
Th17 responses were persistently reduced (blood: 0.75%, skin: 2.93%). Our results suggest that
Th17 and Th22 responses are reduced in both the blood and skin of patients with L-CTCL and that
although Th22 responses improve after therapy, Th17 function remains suppressed. Reduced Th17
function may contribute to the susceptibility of L-CTCL patients to extracellular pathogens.
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Defective expression of class I antigen presentation pathway members in Merkel cell carci-
noma may underlie low MHC I expression and contribute to immune evasion
V Huang,1 M Dowlatshahi,1 DB Keskin,1 B Reinhold,1 TC Mayo,2 J Teague,1 A Gehad,1
EL Reinherz,1 M Shuda,2 JA DeCaprio,1 M Thakuria,1 AA Dorosario1 and R Clark1 1 Dana
Farber/Brigham and Women’s Cancer Center, Boston, MA and 2 Cancer Virology Program,
University of Pittsburgh, Pittburgh, PA
Merkel cell carcinoma (MCC) is a highly malignant skin cancer associated with a novel polyomavirus.
Down-regulation of class I MHC has been reported and may impair immune recognition. We con-
firmed MHC I expression was markedly reduced in primary tumors and in 3 validated MCC cell
lines. Mass spectrometry analysis of peptides eluted from 1/2 HLA-A2 MCC cell lines demonstrated
markedly reduced peptide presentation, with an absence of even ubiquitous peptides including
GILT. RT-PCR analysis of MCC tumors demonstrated defective expression of the Class I presenta-
tion pathway members TAP-1, TAP-2 and tapasin in 3/3 MCC cell lines with decreased MHC I expres-
sion whereas levels of calnexin, calreticulin and PD1A3 were comparable to those observed in
human PBMC. Interferons, though not an effective systemic therapy for MCC, up regulate MCC
MHC I in vitro and after intralesional injection. 3/3 MCC cell lines treated in vitro with IFNγ showed
marked upregulation of surface MHC I but in only 1 cell line was transcription of MHC I genes them-
selves induced. Instead, IFNγ treatment normalized expression of TAP-1, TAP-2 and tapasin in 3/3
cell lines. Abnormal expression of multiple members of the class I presentation pathway suggested
that epigenetic changes may underlie defective expression, as opposed to mutations of the genes
themselves. We treated MCC cell lines with the HDAC inhibitor vorinostat and observed increased
expression of TAP-1, TAP-2 and tapasin and increased expression of surface MHC I on 3/3 cell lines
tested. Our results suggest that epigenetic suppression of multiple members of the Class I presen-
tation pathway may underlie defective expression of MHC I in MCC. Medications such as vorino-
stat that restore MHC I expression have the potential to enhance immune responses to this highly
malignant, virally mediated skin cancer.
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Non-selective β-blocker increases the expression of CCL20 in HaCaT cells stimulated with
TNF-α: A possible mechanism in exacerbation of psoriasis
H Kim, S Kim, D Kim, D Kim, D Byamba, H Jee and M Lee Dermatology, Department of
Dermatology, Severance Hospital, Cutaneous Biology Research Institute, Yonsei University
College of Medicine, Seoul, Korea, Seoul, Republic of Korea
Both cardioselective and non-cardioselective β-blockers are known as drugs that aggravate or induce
psoriasis. A possible mechanism is that the decrease of cyclic adenosine monophosphate induced
by β-blockers leads to a decrease in intracellular calcium, which consequently increases cellular
proliferation and lack of differentiation, as seen in psoriasis. However, the immunologic roles of
non-selective β-blocker (NSBB) on the epidermis of psoriasis hasn’t been investigated in depth. An
effort to elucidate these effects of NSBB was made using the HaCaT keratinocytes in vitro. To
induce psoriatic keratinocytes, HaCaT cells were stimulated with TNF-α and IL-23, fundamental
cytokines previously noted for their elementary roles in psoriatic skin. After 24 hours of incubation,
NSBB was added to each TNF-α- and IL-23-treated HaCaT keratinocytes. Via ELISA, CCL20 expres-
sion was shown to be increased in TNF-α-treated HaCaT keratinocytes with NSBB, when com-
pared to the other pre-treatment groups (p<0.05), whereas the expression of CCL20 of IL-23-treated
HaCaT keratinocytes remained unchanged indifferent to the addition of NSBB. Meanwhile, up-reg-
ulation of IL-1β was observed in TNF-α-stimulated keratinocytes regardless of NSBB with no sig-
nificant difference between the groups. ELISA results of CXCL8 NSBB in TNF-α-treated keratinocytes
showed an additive effect, though there were no significant statistical differences between the
other pre-treatment groups. Confocal laser microscopy revealed that NSBB induced significant
translocations of NF-kB p65 into the nuclei in TNF-α stimulated keratinocytes. In conclusion, although
we did not find definitive evidence as to whether NSBB may induce psoriatic keratinocytes by
itself, it was observed that NSBB may increase CCL20 expression in psoriatic keratinocytes stimu-
lated with TNF-α. Furthermore, it seems that NSBB may exacerbate psoriasis through the control of
the transcription of DNA.
261
Atopic dermatitis in adults: Augmented circulating IgG4 and IgE antibodies against Staphy-
lococcus aureus enterotoxin B
RL Orfali, MN Sato, VG Dos Santos, TO Titz, AS Duarte, R Takaoka and V Aoki Dermatology,
University of Sao Paulo School of Medicine, Sao Paulo, Brazil
The aim of this study was to evaluate the profile of anti-Staphylococcus aureus enterotoxin B (SEB)
antibody (Ab) response in adults with AD. We selected 38 patients diagnosed as AD (Hanifin &
Rajka’s criteria), aged between 18 and 65, and 26 healthy controls (HC), aged between 20 and 47
years. Severity of the disease was established according to EASI (Eczema Area and Severity Index)
and patients were graded as mild (28%), moderate (58%) and severe (14%). Sera were assessed for
IgG subclasses, IgA, IgM and IgE against SEB by ELISA. The humoral response in AD patients to SEB
showed elevated circulating IgE and IgG4 levels (p < 0.05 and p ≤ 0.001, respectively), and decreased
IgA and IgM levels (p < 0.05). Severity of atopic dermatitis was related with low IgG1 and IgG3 lev-
els (p < 0.05), and high IgE antibody response (p < 0.05) to SEB. Interestingly, absence of IgE and
IgG1 response to SEB was seen in some AD patients (26.3% and 18.4% respectively). In AD, the
immunoglobulin-related subtype Th2 lymphocytes, such as IgE and IgG4, appear to be relevant in
the response to superantigens. These results emphasize an altered pattern of Ab response to SEB in
AD, which is impaired according the disease severity.
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A non-infectious sand fly salivary gland protein is likely involved in the development and
clonal selection of anti-Dsg1 autoantibodies in Fogo Selvagem
Y Qian,1 JS Jeong,1 JG Valenzuela,2 F Evangelista,1 V Aoki,3 G Hans,4 EA Rivitti3 and LA Diaz1 1
Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2 Vector Molecular
Biology Section, Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, MD, 3
Dermatology, University of Sao Paulo, Sao Paulo, Brazil and 4 Dermatology, University of
Mato Grosso do Sul, Campo Grande, Brazil
We have recently demonstrated that IgG4 anti-Dsg1 antibodies cross-react with LJM11, a major
immunogenic salivary gland protein of Lutzomyia longipalpis, a sand fly that infests endemic areas
of Fogo Selvagem (FS). In addition, serum IgG4 anti-Dsg1 and IgG4 anti-LJM11 correlate in FS
patients. This evidence suggests that LJM11 could be an environmental antigen that drives the devel-
opment of IgG4 anti-Dsg1 response in FS susceptible individuals. Thus, in this study we isolated a
panel of IgG4 monoclonal antibodies using a modified antibody phage display and hybridoma meth-
ods using FS B cells to determine the cross-reactivity of these monoclonal antibodies to Dsg1 and
LJM11. Monoclonal IgG4 antibodies were selected against Dsg1 only, LJM11 only, and both Dsg1
and LJM11. Surprisingly, all selected antibodies react with both Dsg1 and LJM11. We then chose
two of the cross-reactive IgG4 monoclonal antibodies with V gene sequences showing clear evi-
dence of antigen selection and reverted their H and L chain genes to the germline sequences. These
two revertant monoclonal antibodies also bind both Dsg1 and LJM11, strongly suggesting that both
Dsg1 and LJM11 are the selecting antigens for the development of autoantibodies in FS. Our find-
ings suggest that the LJM11 antigen from sand fly is likely to be one of the antigens that stimulates
naïve B cells in those individuals genetically at risk and triggers the autoantibody response that
finally leads to FS.
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Dermatologists’ knowledge of and preferences regarding topical steroids
LF Sandoval,1 SA Davis1 and SR Feldman1,2,3 1 Dermatology, Center for Dermatology Research,
Wake Forest School of Medicine, Winston Salem, NC, 2 Pathology, Wake Forest School of
Medicine, Winston Salem, NC and 3 Public Health Sciences, Wake Forest School of Medicine,
Winston Salem, NC
Topical corticosteroids are the standard-of-care treatment for dermatitis, mild psoriasis, and other
inflammatory skin diseases. Prescribing practices rely on knowledge of topical corticosteroid potency,
as well as potential side effects including steroid allergies. The primary aim of this study is to deter-
mine how dermatologists classify particular topical corticosteroids according to potency, and which
products they prefer in cases when allergenicity is a concern. The data were collected and ana-
lyzed from 105 US-based dermatologists surveyed at the 2011 Summer American Academy of Der-
matology meeting. The majority of dermatologists were in agreement on the potency ranking of
many commonly prescribed topical corticosteroids. Two thirds of the surveyed dermatologists
expressed concern about allergy to topical corticosteroids. In cases of a suspected allergy, des-
oximetasone was the leading product dermatologists would choose to prescribe. Limitations to this
study include that the survey was limited to attendees of an educational conference, possibly lead-
ing to an overestimation of dermatologist knowledge of topical steroids. This study shows that der-
matologists are generally knowledgeable about group classifications of corticosteroids in terms of
potency and that they can appropriately select a topical product with low potential for allergy.
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CD146 expression identifies Th17 and Tc17 subsets in psoriatic blood and skin
NN Mehta, PK Dagur, E Stansky, S Rose, A Biancotto, K Sonti, M Playford and JP McCoy National
Institutes of Health, Bethesda, MD
Psoriasis (PSO) is associated with cardiovascular diseases (CVD), however the link remains poorly
understood. Helper T-cells (Th)17 (CD4+IL17A+ Tcells) and cytotoxic T-cells (Tc)17 (CD8+IL17A+
Tcells) are important mediators of inflammation via interleukin (IL)17 secretion. CD146, also called
melanoma cell adhesion molecule (MCAM) is an endothelial adhesion molecule present in low
frequency on circulating Tcells and facilitates binding of lymphocytes to endothelium. Therefore,
characterizing CD146+ Tcells in PSO may better define a potential link between PSO and CVD.
We performed multiparameter flow cytometry (LSR-II) to study CD146+ Tcell subsets in PSO sub-
jects’ (median BSA 4%, interquartile range 1.1-7% mostly on only topical therapy) blood and
lesional/non lesional (NL) skin. Production of IL-17A was studied after giving PMA+Ionomycin+Brefel-
dinA cocktail for 3hrs then staining for CD3, CD4, CD8, CD146 and intracellular IL17A. The fre-
quency of CD146+Tcells was elevated (p=0.02) in psoriatic blood (4.2%±2.5%, n=21) compared
to non-PSO (2.8%±1.4%, n=71). Within psoriatic circulating T cell pool compared to non-PSO,
CD146 expression was elevated in CD4+ Tcells (6.2%±3.0% vs. 3.5%±1.8%; p<0.001) and in CD8+
Tcells (3.1%±2.7% vs2.1%±1.6%; p<0.001). In psoriatic lesional skin biopsies, CD146 expression
strikingly increased to 40%±20.0% from CD4+Tcells and 40.0%±14.9% of the CD8+Tcells, not
observed in NL skin. Intracellular flow cytometry revealed that 20% of the IL17A+ producing Tcells
co-expressed CD146 in the blood and 90% in lesional skin. CD146+ Tcells are expressed in higher
frequency in PSO blood, and in even higher frequency within lesional skin suggesting that CD146
might play a role in the migration of these cells from the blood to the skin. Furthermore, a high pro-
portion of IL17A+ Tcells express CD146 in blood and skin demonstrating these cells may be a major
source of IL17A in PSO. Larger studies are needed to determine whether CD146 can be used as a
potential biomarker for disease progression and provide a link between PSO and CVD.
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Three IL-17 ligands contribute to psoriasis: Blockade of IL-17RA signaling with brodalumab
JE Towne,2 J Bigler,1 Y Zhang,2 K Kerkof,1 M Timour,1 H Rand,1 P Klekotka,2 DA Martin,1
D Salinger3 and CB Russell1 1 Medical Sciences, Amgen, Seattle, WA, 2 Inflammation, Amgen,
Seattle, WA and 3 PKDM, Amgen, Seattle, WA
IL-17A, IL-17C, and IL-17F are members of the IL-17 family of innate pro-inflammatory cytokines
implicated in pathogenesis of several autoimmune diseases including psoriasis. All three ligands are
highly overexpressed in lesional skin, generate similar responses in keratinocytes, and act through
IL-17 receptor complexes that require the IL-17RA subunit. IL-17C is expressed by keratinocytes,
while IL-17A and IL-17F are produced by Th17 and other lymphoid cells. We examined a mouse
skin inflammation model using antibodies directed against the IL-17 ligands or the IL-17RA subunit
and monitored effects by mRNA profiling and histology. In both aspects, blockade of IL-17RA was
more effective than blockade of individual ligands, suggesting inflammatory contributions from mul-
tiple ligands. Brodalumab antagonizes signaling by competing with the IL-17 ligands for binding to
the IL-17RA subunit. In human disease, single 700mg i.v. doses of brodalumab resulted in near-
complete transcriptional normalization to the non-lesional level within two weeks. The response
included substantial suppression of IL17C mRNA within 1 week, and IL17A and IL17F mRNA over
6 weeks. With lower s.c. doses, a few individuals with low brodalumab exposure demonstrated only
modest molecular responses, although other individuals with similar exposure demonstrated near-
complete responses. Less responsive individuals all had high levels of IL17 ligand mRNAs main-
tained over the first two weeks. These data are consistent with high levels of overexpressed IL-17
ligands competing with low levels of blocking antibody to maintain IL-17 signaling. No single IL-
17 ligand was dominant in the effect. These data suggest that IL-17A, IL-17C, and IL-17F may all
contribute to driving the inflammatory processes of psoriasis. Blockade of signaling by multiple IL-
17 ligands at the IL-17RA and subsequent decreases in ligand expression may both contribute to
the rapid improvement in psoriasis seen following treatment with brodalumab.
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Expression of chemokine receptor D6 in human psoriatic skin is modulated by cutaneous
trauma and microRNAs
K Shams,2 M Singh,2 S Holmes,1 D Burden,1 V King,2 CS McKimmie2 and GJ Graham2 1 Alan Lyell
Centre for Dermatology, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom and 2
Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United
Kingdom
Chemokines are important therapeutic targets and there is a need to better understand the mecha-
nism of their differential regulation. Chemokines play a pivotal role in inflammatory skin responses,
such as psoriasis, by recruiting inflammatory leukocytes and thus initiating and perpetuating inflam-
mation. The atypical chemokine receptor D6 scavenges and internalises chemokines and thereby
plays a role in the resolution of inflammation. In the absence of D6 inflammatory responses are
exaggerated, which can lead to the development of a psoriasis-like pathology in mouse models.
The mechanism by which psoriatic plaques develop at specific sites, adjacent to apparently normal
skin, has hitherto been poorly understood. We have explored the association between D6 expres-
sion and the distribution of plaques in psoriatic skin. D6 expression was significantly elevated in
unaffected skin (7.6-fold, p=0.02, n=9). However, D6 expression in lesional skin was significantly
reduced in comparison (4.4-fold, p=0.03, n=10). Skin trauma can give rise to new psoriatic lesions.
To determine how D6 expression is modulated in response to trauma, unaffected skin of patients
with psoriasis was traumatised by means of tape stripping, which induced a significant down-reg-
ulation of D6 levels (1.5-fold, p=0.03, n=3). Localisation of psoriatic plaques may be explained at
least in part by a reduced expression of D6, with trauma being one trigger for its reduced expres-
sion. To determine the molecular mechanisms that control D6 expression, we have identified sev-
eral miRNAs that both modulate D6 expression and are differentially regulated in psoriasis. Trans-
fection of lymphatic endothelial cells and keratinocytes with specific miRNAs down-regulated D6
expression. Novel modulators of chemokine system such as these miRNAs constitute an exciting
new class of molecules that can be targets for new therapies and/or biomarkers.
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Epitope mapping of anti-type VII collagen antibodies in the patients with recessive dystrophic
epidermolysis bullosa
J Cogan, XY Wang, YP Hou, M Khilili, DT Woodley and M Chen Dermatology, University of
Southern California, Los Angeles, CA
Type VII collagen (C7), the major component of anchoring fibrils, maintains adhesion of the epi-
dermis to the dermis. Mutations in the gene encoding for C7 (COL7A1) cause an inherited skin dis-
ease DEB, while autoantibodies to C7 are associated with an acquired autoimmune disease, epi-
dermolysis bullosa acquisita (EBA). We and others have previously reported the presence of anti-C7
antibodies in patients with recessive DEB (RDEB). It is known that EBA autoantibodies recognize
five major epitopes predominately within the N-terminal noncollagenous 1 domain (NC1) and fewer,
minor epitopes within the triple-helical (TH) and the NC2 domains. However, there have been no
attempts to map the C7 epitopes targeted by the anti-C7 antibodies in RDEB patients. In this study,
we screened 22 patients with RDEB and evaluated their serum for the presence of circulating anti-
C7 antibodies by ELISA and immunoblot analysis using recombinant full length NC1, subdomains
of NC1 and full length C7. In both assays, 8 out of 22 sera from RDEB patients reacted with the five
major antigenic epitopes confined to the CMP, FNIII and VWF-A subdomains of NC1 while none
of the control sera from normal human subjects did. Interestingly, 4 of 22 RDEB sera recognized
exclusively the TH domain of C7. The presence of anti-C7 antibodies did not correlate with the
expression of C7 in the patients’ skin or the position of the COL7A1 mutations. However, none of
these anti-C7 antibodies from RDEB patients bound to the dermal-epidermal junction of human skin
by IIF on salt-split and normal human skin substrate. Additionally, direct immunofluorscence stain-
ing of RDEB patients’ skin did not detect any anti-C7 antibody deposits in their skin and no patients
developed EBA. We conclude that sera from RDEB and EBA patients recognize common epitopes
within the NC1 or TH domain of C7. These data should be taken into consideration when selecting
and monitoring RDEB patients involved in protein replacement clinical trials.
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The effect of Shikonin on monocyte-derived DCs phenotype and IL-23 secretion
Y Wang, J Zhao and P Li Beijing Insitut of Troditional Chinese Medicine, Beijing, China
Objective To invesetigate the effect of Shikonin on cell phenotype and IL-23 secretion of mono-
cyte-derived DCs.Methods Peripheral blood mononuclear cell( PMBC) were purified from buffy
coats from healthy donors,selected the adherent cells after overnight culture,cells were matured
with several pro-inflammatory cytokines or combinations of pro-inflammatory cytokines. Flow
cytometery was used to analyse the effect of Shikonin with different concentration on inflammatory
DCs phenotype,the mixed lymphocyte reaction were tested by Cell counting kit-8,IL-23 secretion
were analyse by ELISA Kit.Results TNF-α25ng/ml induce a high expression of the activation mark-
ers CD80 and CD86;DCs treated with TNF-α25ng/ml stimulate allogeneic T-cell proliferation;
100μg/ml Shikonin suppress the expression of CD80 and CD86,while 50μg/ml Shikonin only sup-
press the expression of CD86;both 100μg/ml Shikonin and 50μg/ml Shikonin suppress the secre-
tion of IL-23 from DCs stimulated with LPS and INF-γ. Conclusion Shikonin suppress the matura-
tion of DCs and reduce the IL-23 secretion from DCs to some extend.
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Human type VII collagen harbors multiple pathogenically relevant epitopes
A Vorobyev,1 H Ujiie,2 A Recke,1 JA Buijsrogge,3 MF Jonkman,3 T Hashimoto,4 SC Kim,5 JH Kim,5
R Groves,6 E Schmidt,1 D Zillikens,1 H Shimizu2 and RJ Ludwig1 1 Dermatology, University of
Lübeck, Lübeck, Germany, 2 Dermatology, Hokkaido University Graduate School of
Medicine, Sapporo, Japan, 3 Dermatology, University Medical Center Groningen, University
of Groningen, Groningen, Netherlands, 4 Dermatology, Kurume University School of
Medicine, Fukuoka, Japan, 5 Dermatology and Cutaneous Biology Research Institute,
Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of
Korea and 6 Immunodermatology, St John’s Institute of Dermatology, St Thomas’ Hospital,
London, United Kingdom
Epidermolysis bullosa acquisita (EBA) is an autoimmune bullous dermatosis, characterized by autoan-
tibodies against type VII collagen (COL7). Several EBA clinical phenotypes are described, includ-
ing mechano-bullous and inflammatory variants. Most EBA patients’ sera react with the non-col-
lagenous (NC)-1 domain of COL7. It remained unclear, if binding to only certain epitopes induces
EBA, and if binding to specific epitopes within NC1 causes different EBA phenotypes.We generated
10 recombinant proteins covering the entire NC1. 69 EBA patients’ sera were analyzed for IgG reac-
tivity with these proteins. Most sera recognized clusters of epitopes throughout NC1. No correla-
tion was detected between antibody specificity and clinical phenotype, but a dependency of epi-
tope distribution on gender and age was noticed. To study pathogenicity, rabbit antibodies to these
epitopes were generated. All antibodies caused dermal-epidermal separation ex vivo. Antibodies
against 2 of these epitopes were affinity-purified and injected into mice carrying the homozygous
null mutations of mouse Col7a1 and the human COL7A1 transgene. Both antibodies caused spe-
cific clinical and histological changes in mice. These observations add to our understanding of the
autoimmune response in EBA and document pathogenic effects of autoantibodies directed to sev-
eral epitopes within the NC1 domain. In addition, the results suggest the dependency of different
clinical variants of EBA on the ability to mount an inflammatory response after IgG binding to the
dermal-epidermal junction, but not on antibody specificity.
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GTW reduced imiquimod-induced skin lesions by a mechanism involving inhibition of STAT3
phospharylation in Th17 cells
Z Jingxia and P Li Beijing Institute of Traditional Chinese Medicine, Beijing, China
Multi-glycoside of Tripterygium wilfordii Hook f. (GTW), an active component of extracts derived
from Tripterygium wilfordii Hook f., has been shown to have anti-inflammatory and immunosup-
pressive activities and used for treatment of psoriasis clinically for many years in China. But its
exact immunological mechanisms of GTW in psoriasis treatment are poorly understood. T helper
cell (Th17) response is considered to play a major role in pathogenesis of psoriasis. It was reported
that imiquimod, used to treat benign skin abnormalities, triggered psoriasis-like disease in humans
and mice and implicated that Th17 cells also play roles in disease development. Using this mouse
model, we demonstrated that GTW protected mice from development of psoriasis-like lesion induced
by imiquimod (IMQ), the protection achieved by GTW treatment in imiquimod-induced psoriasi-
form mice is most likely due to its ability to inhibit immune response of Th17 cells, not Th1, Th2 or
Treg. This study showed GTW suppressed Th17 function through inhibition of STAT3 phosphoryla-
tion, These results could support the use of GTW as a agent to treat psoriasis.
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Decreased A20 can be overcome with an external NF-KB inhibitor in a mouse model of plaque
psoriasis
B Poligone,1 K Gillespie,1 I Strickland2 and S Ghosh2 1 Dermatology, University of Rochester
School of Medicine, Rochester, NY and 2 Department of Microbiology & Immunology,
Columbia University, New York, NY
Psoriasis is a common, immune-mediated disease that usually affects the skin. Psoriasis is gener-
ally characterized by clinical and histologic findings. The clinical findings include thickened red
plaques with pin-point bleeding and a silvery scale. Among the histologic findings are epidermal
acanthosis, neutrophilic abscesses, dilated capillary loops, and elongated rete ridges. The skin dis-
ease has been associated in genetic and molecular studies with a Th17-mediated inflammation.
The initial part of this projecte focused on establishing a mouse model of psoriasis, called the
Rochester mouse. Through breeding schemes, an existing genetic mouse model with an estab-
lished Th17-mediated inflammation was utilized to produce a model with more consistent skin
lesions that present earlier in life. It was discovered that the overproduction of the vascular endothe-
lial growth factor (VEGF) leads to a decrease in the native NF-KB inhibitor, TNFAIP3 (also known
as, A20). This decrease in A20 protein was associated with an increase in several NF-KB depend-
ent genes, including CCL-20 and IL-6. A20 is known to be transcriptionally regulated by NF-KB.
The decrease in A20 in the Rochester mouse did not interfere with the ability of NF-KB to induce
A20. The decrease in A20 protein levels was only present prior to significant skin inflammation. The
addition of the external NF-KB inhibitor, the Nemo Binding Domain (NBD) peptide, was able to
prevent the development of skin lesions in the Rochester mouse. These findings suggest that NF-KB
inhibitors, including the NBD peptide, may be useful in the prevention of psoriasis. Moreover a
closer examination of A20 and other native NF-KB inhibitors in humans, may help to identify patients
susceptible to the development of psoriasis.
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Evaluation of itch-inducing mediators in cutaneous T cell lymphoma
ES Gilmore,1 L Chen1 and B Poligone1,2 1 Department of Dermatology, University of Rochester
School of Medicine, Rochester, NY and 2 Wilmot Cancer Center, University of Rochester
School of Medicine, Rochester, NY
Chronic pruritus is a common symptom affecting many individuals with lymphoma, particularly
those with cutaneous T cell lymphoma and Sezary syndrome. Effective control of pruritus in those
patients is often difficult to achieve as antihistamines may show little benefit. Newer therapies such
as aprepitant, among others, have been proposed as effective measures, working outside of the
classical histamine pathway. However, the identification and characterization of non-histaminergic
pathways relevant to itch have not been defined. Nociceptors in the skin (dorsal root ganglion neu-
rons) have been identified as the relevant pathway carrying messages of itch and pain to the brain.
Measurement of neuronal activity can be assessed in vitro through electrophysiologic patch clamp
and current clamp studies using primary dorsal root ganglion (DRG) neurons from mice. Stimula-
tion of particular subsets of ion channels (TRP, transient receptor potential channels) causes neu-
ronal activation and action potential generation. Here we evaluate the distribution and activity of
candidate TRP-family ion channels in mouse skin and DRG neurons. Additionally, the effects of
non-histaminergic pathways leading to nociceptor activation were investigated, including relevant
itch-associated cytokines.
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A short peptide overlapping the RAL motif of desmoglein 1 contains the conformational epi-
tope for pathogenic IgG4 autoantibodies in fogo selvagem 
F Evangelista,1 A Roth,2 K Shumate,1 P Prisayanh,1 Z Liu,1 V Aoki,3 G Hans,3 E Rivitti3 and L Diaz1
1 Dermatology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2 Kidney Center,
University of North Carolina at Chapel Hill, Chapel Hill, NC and 3 Dermatology, University
of Sao Paulo, Sao Paulo, Brazil
Fogo Selvagem (FS) is an autoimmune skin disease mediated by pathogenic, predominantly IgG4
subclass autoantibodies against Desmoglein-1 (Dsg1). Subclass switching and intramolecular epi-
tope spreading within the Dsg1 ectodomain is linked to the development of FS. Although patho-
genic FS IgG autoantibodies are known to target mainly the N-terminal region of Dsg1, the fine epi-
tope specificity of these anti-Dsg1 IgG4 autoantibodies is not defined. In this study, we used highly
purified IgG4 fractions (97% purity) from 20 FS sera to identify the epitopes recognized by anti-
Dsg1 autoantibodies using Epitope Excision and Matrix Assisted Laser Desorption/Ionization Mass
Spectrometry (MALDI-MS/MS). Ninety five percent of FS sera recognized a peptide within the EC1
domain of Dsg1 (ALNSMGQDLERPLELR) that overlaps the adhesion motif RAL of Dsg1. A second
epitope located in the EC2 domain (QEPSDSPMFIINR) was recognized by 85% of the sera tested.
Mutations of residues M133 and Q135 in EC1 of Dsg1 dramatically reduced the binding of patho-
genic IgG4 autoantibodies to Dsg1 as determined by ELISA (77 % inhibition) and immunoprecipi-
tation, indicating that both residues are required to achieve the proper conformation of the epitope
recognized by pathogenic IgG4 autoantibodies in FS. Mutations of residues D205, S206 and I211
of the EC2 domain did not impair significantly the binding of IgG4 autoantibodies (13% inhibition).
Our results put forward the intriguing possibility that binding of FS IgG4 autoantibodies to the
adhesive site of Dsg1 may directly interfere with the function of this molecule and lead to acan-
tholysis. Hence, these novel findings will have an impact on the development of epitope-specific
immunoassays, provide new insights into the molecular mechanisms and/or environmental trig-
gers(s) of FS and generate potential therapeutic strategies.
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Defining unique B cell signatures in patients with autoimmune blistering diseases
RJ Feldman,1 C Wei,2 BE Neary2 and I Sanz2 1 Dermatology, Emory University, Atlanta, GA and
2 Rheumatology, Emory University, Atlanta, GA
Autoimmune blistering diseases (AIBD) are an uncommon group of immunologically mediated dis-
eases which can affect both skin and mucous membranes, resulting from pathogenic B cell pro-
duction of autoantibodies directed against cellular adhesion proteins in skin. The importance of B
cells in development and perpetuation of AIBD has been demonstrated in recent studies using the
B cell depletion therapy, rituximab. We sought to describe human B cell subsets in patients with
AIBD, with the goal of developing possible disease associated B cell signatures. Multi-chromatic
flow cytometry was performed to evaluate surface phenotype of B cells in patients with pemphigus
and pemphigoid, including bullous pemphigoid and mucous membrane pemphigoid. The B cell
panel included IgD, CD19, CD21, CD23, CD24, CD27, CD38, and CD95, thus dividing B cells
into naïve, memory, and plasmablast subsets, and providing a measurement of cell activation within
the naïve and memory compartments. Memory subsets were further divided into switched mem-
ory, CD19+ IgD- CD27+; non-switched memory, CD19+ IgD+ CD27+; and double negative mem-
ory, CD19+ IgD- CD27-. The early B cell subsets were subdivided into transitional, T1/T2, T3 and
mature naïve B cells based on surface phenotype and an additional mitochondrial dye extrusion
step. Both pemphigus and pemphigoid patients were found to have expanded switched CD19+ IgD-
CD27+ memory B cells compared to healthy controls. Furthermore, pemphigus and pemphigoid
patients have a greatly contracted naïve subset and early transitional T1/T2 B cells with large expan-
sion of transitional T3 B cells. These T3 B cells were found to express an activated phenotype in sev-
eral pemphigoid patients based on decreased cell surface expression of CD21, and increased expres-
sion of CD95. These data suggest that patients with AIBD have definable B cell signatures including
changes in switched memory and late transitional T3 B cell populations which may present unique
future targets for specific B cell directed therapies.
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Neem and turmeric inhibit Propionibacterium acnes induced lipid synthesis and inflamma-
tory response of human sebocytes
J Ornelas,1 RM Dasu,1 R Zackria,1 RR Isseroff1,2 and RK Sivamani1 1 Dermatology, UC Davis
School of Medicine, Sacramento, CA and 2 VA Mather, Mather, CA
Neem and turmeric botanical extracts contain multiple constituent phytochemicals that exhibit
antioxidant and anti-inflammatory properties, and have been used in alternative medical systems
for the treatment of acne. However, more mechanistic study of their effects on acne is needed. We
used aqueous extracts of neem and turmeric to treat human sebocytes as an in vitro model for
acne. Lipid production was examined with Nile Red staining and qRT-PCR analysis for stearoyl-CoA
desaturase-1 (SCD1), the enzyme responsible for the synthesis of inflammatory monounsaturated
fatty acids. The inflammatory response was assessed by qRT-PCR analysis for production of IL-6 and
TLR2 mRNA. Heat-killed Propionibacterium acnes (HKPA) induced a 10% increase (p=0.02) while
exposure to Pseudomonas aeruginosa yielded no relative increase in lipid production compared to
controls. Exposure to neem and turmeric extracts decreased HKPA induced lipid synthesis by 25%
(p<0.001) and 23% (p=0.002), respectively. HKPA induced a 2.5-fold increase in SCD1 mRNA,
and exposure to neem extract mitigated this effect. Compared to control, HKPA induced 5-fold and
2.5-fold increases in IL-6 and TLR2 expression, respectively. However, co-incubation with neem
extract reduced the IL-6 to a 3.5-fold increase over control and reduced TLR2 mRNA expression to
below control. To further assess how prototypical categories of phytochemicals may affect lipid
synthesis, we evaluated the effects of ellagic acid (polyphenol), epigallocatechin gallate (EGCG,
polyphenol), and D-limonene (terpene). We found that only EGCG reduced sebocyte lipid synthe-
sis by 8% (p=0.04) compared to P.acnes exposed controls. Our results demonstrate that neem and
turmeric mitigate the immune and lipid synthesis response induced by HKPA in human sebocytes.
The modulation of lipid synthesis by the polyphenol EGCG prompts continued investigation to iden-
tify the active polyphenols in the neem and turmeric extracts.
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Attenuated regulatory function of IL-10-producing B cells in psoriasis
W Li, M Wan, J Ren, J Gao and Y Liu Dermatology, Xijing Hospital, Xi’an, China
Recent studies revealed that a subset of B cells, regulatory B cells (Bregs), can negatively regulate
T-cell mediated immune response by producing IL-10. It has been found that Bregs are involved in
many T-cell-mediated skin diseases, such as systemic lupus erythema and multiple sclerosis. How-
ever, if and how Bregs participate in the pathogenesis of psoriasis is not clear yet. In the present
study, PBMC of psoriasis patients were cultured in vitro, and the number and phenotype of IL-10
producing B cells were analyzed by FACS after stimulating with LPS, PMA, ionomycin and mon-
ensin. Then the cytokines produced by CD4+ T cells in culture in the presence or absence of sorted
CD19+CD24hiCD38hi B cells from the same psoriasis patient were compared. Results showed
that the percentage of IL-10 producing B cells in psoriasis patient was a little bit higher than that of
control in 5h culture, while in 48h culture, the percentage of IL-10 producing B cells in psoriasis
patient was much lower than that of control, indicating that the ability of Bregs progenitor to dif-
ferentiate into Bregs was attenuated in psoriasis patient. The IL-10 producing B cells in human PMBC
are mostly CD19+CD24hiCD38hi B cells. There were higher level of TNF-α and IFN-γ in the cul-
ture of CD4+ T cells with CD19+CD24hiCD38hi B cells from psoriasis patients than that from nor-
mal controls. These data indicate that the regulatory function of Bregs from psoriasis patients is
weaker than that of controls. Thus our conclusion is that differentiation and function of Bregs are
attenuated in psoriasis patients, and Bregs may be involved in the pathogenesis of psoriasis.
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mRNA regulation is prior to miRNA regulation in psoriatic skin during treatment with Adal-
imumab
L Raaby, A Langkilde, C Johansen and L Iversen Department of Dermatology, Aarhus University
Hospital, Aarhus, Denmark
Anti-TNF-α therapies are well established for severe psoriasis. An inhibition of the mRNA level of
specific inflammatory cytokines are seen as early as 4 days after the first injection with Adalimumab.
MicroRNAs (miRNAs) are small, non-coding RNAs that regulate gene expression by targeting mRNAs.
They are known to play a role in the pathogenesis of psoriasis. However, the regulation in psoriatic
skin during treatment has never been investigated. The aim of this study was to investigate changes
in the miRNA profile in psoriatic skin before and 4 and 14 days after treatment with anti-TNF-α
trerapies and compare the changes to mRNA changes. Biopsies from patients with severe psoriasis
were collected before (n=10) and 4 (n=10) and 14 days (n=6) after treatment. Additionally, biop-
sies from 6 normal healthy volunteers were collected. A miRCURY LNA™ microRNA Array and a
microArray analysing 28,000 mRNAs were used to analyse the samples. The results showed that 4
days after the first injection with Adalimumab 10 mRNA had ≥1.5 fold up- or downregulation, when
comparing lesional skin with day 0. None of the miRNA had a 1.5 fold regulation and only two
miRNA had a fold change above 1.25 up- or downregulation. A larger regulation was seen at day
14 where 175 mRNAs and 16 miRNA were up- or downregulated ≥1.5 fold. When comparing
lesional and nonlesional skin before treatment 42 miRNAs and 1948 mRNAs were up- or down-
regulated (≥1.5 fold). In nonlesional psoriatic skin compared with skin from healthy normal volun-
teers 3 miRNAs were ≥1.5 fold up- or downregulated. This study demonstrates that no miRNAs are
regulated in lesional skin 4 days after treatment and only a very limited number are regulated
within the first two weeks. When comparing miRNA and mRNA an earlier regulation is seen at
mRNA level after treatment with Adalimumab. The sparse regulation of miRNA seen during treat-
ment indicates that the early changes in inflammatory cytokine expression seen in psoriatic skin is
not based on miRNA changes.
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Development of full-thickness skin equivalents including immunological cell types
S Kurdyn,1 S Mielke,2 J Nickel1 and H Walles1 1 Department for Tissue Engineering and
Regenerative Medicine, University Hospital, Würzburg, Germany and 2 Department of
Internal Medicine II, University Hospital, Würzburg, Germany
Besides the goal of developing skin grafts, the use of artificial skin equivalents (SEs) as in vitro test
systems for medical investigations of skin-related issues is also of increasing dermatological rele-
vance, particularly in regard to the 7th Cosmetic Directive in 2009 and the EU directive REACH.
The last years, enormous progress was made in the creation of SEs using primary skin cells in com-
bination with dermal scaffolds, especially in the development of full-thickness SEs (fSEs). However,
currently available SEs are just simplified models as they’re lacking crucial and characteristic struc-
tures like hair follicles and sweat glands. So far, no validated SE contains cells of the immune sys-
tem, even though inflammation and allergic reactions are important mechanisms of the barrier func-
tion of human skin. We developed methods to integrate either lymphocytes or macrophages into
fSEs. Keratinocytes and fibroblasts were isolated from human skin biopsies. Immune cells from other
sources were isolated from buffy coats using ficoll gradient centrifugation and macrophages further
purified by plastic adherence. Fibroblasts mixed with immune cells were integrated into dermal col-
lagen-based matrices with consistent cell distribution. After overlaying these matrices first with
fibronectin and finally with keratinocytes, the SEs were cultured under submersed conditions for 7
days, followed by 14 days at an air-liquid interface to allow an epidermal differentiation and devel-
opment of stratified layers. SEs including immunological cell types were histologically and immunhis-
tologically characterized by HE- and IF-staining using various tissue- and cell-specific markers.
Further optimization of the co-culture methods are under investigation and molecular technologies
as qPCR and in-situ hybridization will be standardized to characterize the “immune-competent”
SEs. Such a model would provide a powerful tool for the investigation of chronic wounds and
immune-inflammatory infections in skin.
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Dimethylfumarate impairs neutrophil functions
S Müller,1 M Behnen,2 S Möller,2 L Hellberg,2,3 M Hänsel,1 D Zillikens,1 W Solbach,2 T Laskay2
and RJ Ludwig1 1 Dermatology, University of Lübeck, Lübeck, Germany, 2 Medical
Microbiology and Hygiene, University of Lübeck, Lübeck, Germany and 3 Euroimmun
Medizinische Labordiagnostika AG, Euroimmun, Lübeck, Germany
Effective host defense against pathogens relies on granulocyte activation. Neutrophilic granulo-
cytes represent a significant portion of infiltrating cells in different chronic inflammatory diseases,
for example psoriasis and multiple sclerosis, and fumarates have been used to improve these dis-
eases. However, the current understanding attributes this effect of fumarates to their modulatory
effects on lymphocytes and dendritic cells. In the present study, we addressed the effect of dimethyl
fumarate (DMF) on neutrophil functions. In vitro, DMF dose-dependently inhibited neutrophil acti-
vation, including activation-induced changes of surface marker expression (CD62L, CD11b and
CD66b), reactive oxygen species (ROS) production, formation of neutrophil extracellular traps (NETs),
neutrophil migration and their capacity to phagocytise. Ex vivo, autoantibody-induced, neutrophil-
dependent tissue injury was impaired by DMF. To confirm these findings in vivo, mouse models of
epidermolysis bullosa acquisita (EBA), a bullous disease induced by autoantibodies to type VII col-
lagen (COL7), were employed. Anti-COL7 antibodies (IgG) lead to neutrophil-dependent skin tis-
sue injury, and in the presence of dimethyl fumarate, induction of skin blistering by anti-COL7 was
significantly reduced. Moreover, therapy with DMF of mice with already established immunization-
induced EBA resulted in a significant reduction of disease severity. Here, we show that DMF impairs
neutrophil functions in vitro, ex vivo and in vivo.
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Fluorescence overlay antigen mapping using laser scanning confocal microscopy differenti-
ates linear IgA bullous dermatosis from epidermolysis bullosa acquisita mediated by IgA
K Wozniak,1 C Kowalewski,1 T Hashimoto,2 N Ishii2 and H Koga2 1 Department of Dermatology,
Medical University of Warsaw, Poland, Warsaw, Poland and 2 Department of Dermatology,
Kurume University School of Medicine, Kurume, Japan
Linear IgA bullous dermatosis (LABD) and epidermolysis bullosa acquisita (EBA) mediated by IgA
antibodies belong to the group of autoimmune subepidermal bullous diseases mediated by IgA
autoantibodies. The aim of the study was to determine whether fluorescence overlay antigen map-
ping using laser scanning confocal microscopy (FOAM-LSCM) is helpful in differentiation among
these diseases. Most importantly, early and correct diagnosis is crucial, because management and
prognosis in both diseases are different. FOAM-LSCM and immunoblot studies were performed in
19 patients with disseminated tense blisters who presented in vivo bound and circulating IgA anti-
basement membrane zone (BMZ) antibodies by immunofluorescence. In results, by FOAM-LSCM,
14 of 19 cases showed in vivo bound IgA above type IV collagen, which is characteristic for LABD,
whereas 5 of 19 cases showed IgA deposits below type IV collagen, typical for EBA. Immunoblot
studies disclosed that IgA antibodies in 11 of the 14 patients with deposits above type IV collagen
reacted with different epitopes on BP180, mainly with LAD-1, which is target antigen in LABD.
Among the 5 patients with deposits below type IV collagen, one patient showed IgA antibodies to
the 200 kDa laminin gamma-1 and another patient to the 290 kDa type VII collagen, EBA antigen.
Additionally, ELISA with recombinant type VII collagen was positive in 3 of 5 cases who presented
IgA deposits below type IV collagen in FOAM-LSCM. As a conclusions, FOAM-LSCM results were
consistent to these in immunoblotting. FOAM-LSCM is useful in routine diagnostics in cases with
undetectable circulating anti-BMZ antibodies, and can differentiating LABD from IgA-EBA: the for-
mer with in vivo bound IgA above type IV collagen and the latter with IgA deposits below type IV
collagen.
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Expression and function of non-neuronal transient receptor potential (TRPA1) ion channel in
mastocytosis
J Buddenkotte,1,2 B Meyerknecht,2 M Sulk,1 S Seeliger,3 C Kempkes,1 F Cevikbas1 and M Steinhoff1
1 University of California San Francisco, San Francisco, CA, 2 University Hospital Münster,
Münster, Germany and 3 University of Göttingen, Göttingen, Germany
Mastocytosis represents a heterogeneous group of disorders with various clinical presentations char-
acterized by aberrant growth and accumulation of tissue mast cells. Etiopathological factors dis-
cussed for the development of mastocytosis variants are the occurrence of an activating mutation
in the gene for KIT, a transmembrane tyrosine kinase growth receptor expressed on mast cells and
dysfunction or dysregulation of the cytokines IL-4, IL-5Rα and IL-6. To date the role of keratinocyte
function in the pathogenesis of mastocytosis is almost entirely not studied. Atoyan et al recently
reported non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin.
However, although TRPA1 activation alters the epidermal cytokine pattern, its function has not been
investigated regarding involvement in cutaneous disease states. Here, we analysed the expression
and distribution of TRPA1 receptors in the various types of inflamed skin on non-neuronal cells using
immunohistochemistry and morphometry, as compared to healthy skin. Our results show that der-
mal immunolabelling of TRPA1 is significantly upregulated in mastocytosis. To confirm expression
of functional TRPA1 on skin cells, primary human keratinocytes were stimulated with mustard oil,
a potent TRPA1/TRPV1 agonist. Application of the TRPA1 agonist led to a significant intracellular
Ca2+ mobilization suggesting a functional expression of the receptor. Furthermore, agonist incu-
bation increased IL-6 concentration in keratinocyte supernatants while the presence of HC030031,
a specific TRPA1 inhibitor, ameliorated the IL-6 upregulating effect of MO. Our results for the first
time indicate that activation of TRPA1 might contribute to the pathogenesis of mastocytosis in humans
by regulating the pro-inflammatory epidermal cytokine pattern.
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An evaluation of early and late onset psoriasis
E Theodorakopoulou,1 L Chularojanamontri,1 M Gittins,2 RB Warren1 and CM Griffiths1 1
Dermatology Centre, University of Manchester, Manchester, United Kingdom and 2 Centre of
Biostatistics, University of Manchester, Manchester, United Kingdom
Henseler and Christophers seminal 1985 paper drew attention to 2 distinct ages of onset for psori-
asis. Early-onset psoriasis (EOP; presenting < 40 y) and late onset psoriasis (LOP; presenting >40 y).
It is well accepted that EOP,but not LOP,is associated with HLA-Cw6. To further investigate differ-
ences between EOP and LOP, we compared clinical and demographic characteristics in a total of
508 subjects(351 psoriasis patients;112 recruited prospectively and 239 retrospectively) and 157
controls. Information on family history (FH) of psoriasis, clinical features, treatment and associated
co-morbidities were recorded. The main analysis composed of 342 psoriasis patients (278 EOP;
mean age of onset 20.6±9.9y and 64 LOP; mean age of onset 54.4±7.6y) and 157 controls (mean
age 69.5±12.5). In line with previous reports, EOP had a more severe disease compared to LOP
patients(x2, P=0.002), with more frequent flares, following upper respiratory tract infections (x2,
P=0.049), whereas, onycholysis and subungual hyperkeratosis were more frequently seen in LOP
(x2, P=0.02). LOP patients had a lower likelihood of having a positive FH of psoriasis (62% of EOP
versus 39.1% of LOP patients; x2, P=0.001). Patients with EOP parents were 91% less likely to
develop LOP than EOP(OR=0.087, P=0.021, 95% CI 0.01-0.69). After stratification for age (>50y)
and accounting for confounders (gender, BMI, disease duration, hypertension, dyslipidemia), LOP
subjects were ∼3 times more likely to develop type 2 Diabetes Mellitus (T2DM), compared to con-
trols (OR=2.56, P=0.05, 95% CI 1.01-6.53), while, in the EOP group, this likelihood was insignif-
icant. EOP subjects were 98% less likely to develop autoimmune thyroiditis (AT) compared to con-
trols (OR=0.025, P=0.02, 95% CI 0.01-0.55). This, however, was insignificant in LOP subjects. These
data indicate differences in clinical presentation, hereditability and co-morbidities between EOP
and LOP and suggest that EOP and LOP may be different diseases.
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Abnormal IL-10 production in skin and blood in hidradenitis suppurativa [HS] patients
G Kelly,1 CM Sweeney,1 R Fitzgerald,2 A Lally,1 AM Tobin2 and B Kirby1 1 Dermatology Research
Group, St. Vincent’s University Hospital, Dublin, Ireland and 2 Tallaght Hospital, Dublin,
Ireland
HS is a chronic relapsing, inflammatory disease characterised by double comedones, recurrent nod-
ules and abscesses in the axillary, inguinal and perineal areas. Recent studies suggest a pathogenic
role for immune dysregulation. IL-1β, IL-10 and TNF-α expression may be enhanced in HS patients
and TNF-α antibodies are effective in the treatment of HS. We examined the expression of cytokines
and inflammatory markers in the skin and peripheral blood of 10 HS patients focusing specifically
on the production of IL-1β, IL-10, TNF-α and T helper cell cytokines. Following ethical approval,
skin biopsies and blood samples were taken from HS patients [age 24-64 years, disease duration 4-
32 years, M:F 3:7, Hurley stage II/III]. T helper lymphocyte (CD4 cell) cytokine expression was
assessed by flow cytometry. Peripheral blood mononuclear cells (PBMC) were isolated and stimu-
lated with Toll-like receptor agonists (LPS and zymosan). Levels of highly sensitive C reactive pro-
tein (hsCRP) were measured and cytokine production was analysed by ELISA. The expression of IL-
10 and highly sensitive CRP were elevated in the serum of 10 HS patients compared with 10
healthy controls [p<0.05]. PBMC from HS patients tended to produce more IL-10 in response to
TLR-agonist stimulation than controls. There was no significant difference in levels of IL-1β and TNF-
α. HS skin biopsy-conditioned media enhanced in-vitro IL-1β and IL-10 production by dendritic
cells isolated from healthy controls. Up to 40% of CD4 cells from HS lesional biopsies produced
IL-10. CD4 cells that produced IFN- γ and IL-17 also produced IL-10. This study shows a marked
increase in IL-10 production both in skin and peripheral blood of HS patients compared to con-
trols. Increased levels of IL-10 may play a direct role in HS pathogenesis by promoting defective
cutaneous immune responses to infection. This combined with marked increase in hsCRP is indica-
tive of significant immune dysregulation in HS.
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Regulation of IFNλ production and response in the skin compartment
A Alase,1 M Stacey,4 R Doble,4 M Goodfield5 and M Wittmann3,1,2 1 Centre for Skin Sciences,
University of Bradford, Bradford, United Kingdom, 2 Dermatology, Bradford Teaching
Hospitals NHS Foundation Trust, Bradford, United Kingdom, 3 Division of Rheumatic and
Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, 4 School of Molecular
and Cellular Biology, University of Leeds, Leeds, United Kingdom and 5 Dermatology,
University of Leeds, Leeds, United Kingdom
IFNλ1 is a type III IFN expressed by skin epithelial cells. It shares the functional anti-viral activities
with type I IFN in susceptible cells, including keratinocytes. Although IFNλ1 has been shown to be
highly expressed in inflammatory skin diseases such as cutaneous lupus erythematosus the role of
IFNλ1 within the skin cytokine network is still not well understood. The aim of this study was to
better understand how IFNλ1 production and responsiveness are regulated in the skin compartment.
Human primary keratinocytes and dermal fibroblasts were stimulated with cytokines or nucleic
acids. Protein expression was determined using ELISA, western blotting and flow cytometry while
mRNA expression was evaluated using qRT-PCR. Our results show that IFNλ1 is induced in ker-
atinocytes by both TLR3 and RIGI/AIM2 ligands. IFNγ but not IFNα or TNFα markedly enhanced
nucleic acid induced IFNλ1 production in keratinocytes. Unexpectedly, dermal fibroblasts were
found to constitutively produce IFNλ1 which was upregulated upon stimulation with IFNα or poly
dA:dT. However, their maximal production was found to be much lower than that of keratinocytes.
In fibroblasts, TNFα markedly suppressed IFNλ1 production. In keratinocytes, TNFα was found to
downregulate the expression of IFNλ-receptor (IFNλR1) and to alter the functional response to IFNλ1
(expression of CXCL10, MxA, IFI16 and GBP-1 to IFNλ1). Our results highlight that TNFα and IFNγ
are important regulators of IFNλ1 production and responsiveness in the skin compartment. These
findings may help to better understand cutaneous side effects associated with anti-TNFα therapy.
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An autocrine regulatory loop in fibroblasts between the keratinocyte growth factor (KGF) and
the extradomain-A fibronectin (EDA+FN) may contribute to psoriasis pathomechanism
B Gubán Konczné,1 K Vas,1 B Kormos,2 A Bebes,1 A Göblös,1 M Széll,1 L Kemény1,2 and Z Bata-
Csörgö1,2 1 Department of Dermatology and Allergology, University of Szeged, Szeged,
Hungary and 2 Dermatological Research Group of the Hungarian Academy of Sciences,
University of Szeged, Szeged, Hungary
In our previous work we showed that the fibronectin splice variant extradomain-A, also known as
oncofoetal fibronectin (EDA+FN), its receptor the alpha5-integrin, the keratinocyte growth factor
(KGF), and its receptor (KGFR) are overexpressed in psoriatic uninvolved skin, compared to normal
skin. EDA+FN and KGF both stimulate keratinocyte proliferation, moreover KGF is also known to
induce alpha5-integrin expression in keratinocytes. In the present work we aimed to measure the
effect of exogenous KGF on the EDA+FN production of fibroblasts. Cultured normal human fibrob-
lasts were incubated with different concentrations of human recombinant KGF. We carried out
real-time RT-PCR, immunocytochemistry and flow cytometric analysis of EDA+FN 24 hours after
exogen KGF treatment. At 25 ng/ml KGF concentration EDA+FN protein and mRNA expressions
increased significantly (n=4, p<0.01). This increase could be inhibited with a specific MEK1 inhibitor,
indicating that MEK1 activation is essential for the effect. Silencing the EDA+FN gene with Ori-
Gene Trilencer-27 siRNA in normal human fibroblasts resulted in increased KGF and KGFR protein
expressions (n=2), with no changes in the mRNA expressions (n=3). These data indicate the exis-
tence of a previously unknown autocrine regulatory network in fibroblasts between KGF and EDA+FN,
which may be relevant to psoriasis pathomechanism.
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Increased th17 inflammatory response to streptococcus and decreased expression of Filag-
grin and Loricrin in vitro in HLA-Cw*0602 positive psoriatic patients compared to HLA-
Cw*0602 negative
ER Ruiz,1 M Ferran,2 M Sacrista,2 A Celada,1 AM Giménez-Arnau,2 RM Pujol2 and LF Santamaria-
Babí1,2 1 Department de Fisiologia i Immunologia, University of Barcelona, Barcelona, Spain
and 2 Department of Dermatology, IMAS, Barcelona, Spain
HLA-Cw*0602 positive psoriatic patients present a more severe clinical disease than HLA-Cw*0602
negative; however the pathological mechanisms behind those differences are not well character-
ized. We are exploring how a clinically relevant innate stimulus, such as Streptococcus (strep),
induces psoriatic immune response in ex vivo cultures with circulating effector/memory CLA+/CLA-
T cells and epidermal cells. In a study with 30 psoriatic patients and 10 controls, the condition of
CLA+ T cells and epidermal cells activated with Strep presented the highest IL-17A and IL-6 pro-
duction (ng/ml) in HLA-Cw*0602+ patients with guttate psoriasis, strep-induced flare, and ASLO>250
compared to the rest of psoriatic patients (16.5 and 1.05 vs 0.7 and 0.06), (p<0.06 and p<0.006),
respectively. Cells from controls and CLA-negative T cells induce a minor and non-significant acti-
vation in the coculture. The effector function of those supernatants on keratinocytes was also eval-
uated in an attempt to explore how psoriatic lesion spreads to neighbour non-lesional. Five day
culture supernatants of strep-activated CLA+T cells with epidermal cells from HLA-Cw*0602+
patients with guttate psoriasis, strep-induced flare, ASLO>250 induced significantly the highest
mRNA expression for beta defensin-2 (p<0.01). Surprisingly, only in this group of patients a signif-
icant reduction in the mRNA expression for Filaggrin, Filaggrin-2 and Loricrin was found compared
to non-activated keratinocytes (-60%) (p<0.01). Our results suggest that a stronger innate-induced
inflammatory Th17 response associated with decreased skin barrier function in HLA-Cw*0602+
patients could explain the more severe clinical picture observed in such patients in comparison to
HLA-Cw*0602 negative.
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Broad spectrum and anti oxidant activities of a vitis vinifera shoot extract
F Pellicier, P Schaeffer, J Cauchard, C Heusele, J Franchi and S Schnebert LVMH-Research, Saint
Jean de Braye, France
Reactive oxygen species (ROS) generated in the skin under UV exposure and by oxidant chemicals
are greatly involved in skin inflammation and aging. Their toxicity is due to their chemical reactiv-
ity and their ability to interfere with transcription factors involved in inflammatory and aging process
such as NF-kB. ROS are not only deleterious in the epidermis and dermis but also at the hypoder-
mal level closely associated with metabolic disorders. We investigated the efficacy of a specific
Vitis vinifera shoot extract against the oxidative stress with three complementary methods. A new
method of detection of the oxidative stress by flow cytometry was developed on normal human
keratinocytes (NHK). Hydrogen peroxide level was quantified after UVA irradiation using an intra-
cellular green fluorescent stain, dihydrorhodamine 123. Keratinocytes irradiated with UVA treated
for a 24hour period with the shoot extract showed a 26% decrease of Rhodamine123 green fluo-
rescence when compared to control cells. Effect of the shoot extract on NF-kB activation by UVB
was evaluated on NHK by Electrophoretic Mobility Shift Assay (EMSA) which quantifies DNA fixa-
tion of NF-kB leading to activation of inflammatory and senescence genes. EMSA showed that in
KHN treated by shoot extract NF-kB binding to DNA induced by UVB was highly reduced rela-
tively to non treated cells. Level of oxidative stress on adipocytes was quantified by image analysis
of ROS with a new method adapted from Image-iT™ LIVE Green Reactive Oxygen Species Detec-
tion Kit for microscopy. The oxidative stress was generated by a tert-butyl hydroperoxyde. Treat-
ment of adipocytes for a 24 hour period with shoot extract decreased the ROS production between
70% and 90% depending of the dose. Vitis vinifera shoot extract was shown to have a broad range
of antioxidant activities such as inhibition of ROS formation and transcription factor NF-kB bind-
ing on DNA. This shoot extract is well adapted for anti-aging topical products for face and body.
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Vasoactive intestinal peptide receptor (VPAC)1 expression is upregulated in psoriatic skin and
decreases during plaque resolution
AJ Onderdijk,1,2 EF Florencia,1,2 T Wabeke,2 M Kant1,2 and EP Prens1,2 1 Dermatology, Erasmus
University Medical Center, Rotterdam, Netherlands and 2 Immunology, Erasmus University
Medical Center, Rotterdam, Netherlands
Psoriatic lesions are characterized by an increased density of nerve fibers and elevated neuropep-
tide levels. Vasoactive Intestinal Peptide (VIP) is a neuropeptide that is increased in lesional skin.
VIP can be secreted by many different cell types including T cells, mast cells and macrophages. The
biological effects of VIP are mediated through its receptors: VPAC1 and VPAC2. These receptors are
present on many different cell types including keratinocytes. VIP is capable of modifying the pro-
liferation, differentiation and activation of macrophages and T cells. In vitro studies have shown
that the result of VIP signaling depends on the VPAC1 and VPAC1 ratio present on responder cells.
VPAC1 is important for VIP mediated Th17 differentiation. In several inflammatory disorders includ-
ing atopic dermatitis, significant changes in the receptor expression were reported. However, the
exact role of VIP and its receptors in the pathophysiology of psoriasis is not clear. We hypothesized
that not the only the levels of VIP, but also the differential expression of the receptor subtypes is
important for psoriasis inflammation. We therefore investigated the expression of VIP and its recep-
tor in lesional and non-lesional skin by RT-PCR and monitored the receptor expression during plaque
clearance. The mRNA expression of VIP was not increased in psoriatic skin. However the expres-
sion of VPAC1 but not VPAC2 was significantly increased in lesional skin. Interestingly, during suc-
cessful treatment of patients with psoriasis, the VPAC1 expression decreased, while VPAC2 expres-
sion did not change. These results indicate that the differential expression of VIP receptor subtypes
are important in psoriasis. Targeting the VPAC1 receptor could be an interesting target in the treat-
ment of psoriasis.
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Substance P and neurokinin 1 receptor expression in atopic dermatitis in relation to anxiety
traits and depression
L Lönndahl,1 H El-Nour,1 B Johansson,2 M Holst,3 S Lonne-Rahm,1 A Rasul1 and K Nordlind1 1
Dermatology and venereology unit, Department of Medicine, Solna, Karolinska Institutet,
Stockholm, Sweden, 2 Department of Molecular Medicine and Surgery, Karolinska Institutet,
Stockholm, Sweden and 3 Department of Woman and Child Health, Pediatric Endocrinology
Unit, Karolinska Institutet, Stockholm, Sweden
Atopic dermatitis (AD) is an often severely itching, chronic, inflammatory skin disorder. AD may
worsen due to stress and anxiety. Different neuromediators have been suggested to influence the
level of inflammation as well as being involved in stress and anxiety, one important being sub-
stance P and its receptor (R) neurokinin (NK)-1. Twenty-eight patients (18 females and 10 males)
with AD were examined. The extent of the disease was assessed using SCORAD, and the degree of
subjective pruritus using a visual analogue scale (VAS). The level of chronic stress was determined
using the salivary cortisol test, anxiety traits using the Swedish Universities Scales of Personality
(SSP), and depression using Montgomery-Åsberg Depression Rating Scale-Self assessment (MADRS-
S). Biopsies were taken from lesional (elbow) and non-lesional (sacral area) skin, and stained using
a biotinylated-streptavidine method. The numbers of substance P positive nerve fibres in the epi-
dermis and papillary dermis, and substance P- and NK-1R positive cells in the papillary dermis were
determined. There was a correlation between the level of pruritus, and somatic trait anxiety (STA)
and stress susceptibility (SS), respectively. The number of substance P positive nerve fibers and cells
was higher in lesional compared to non-lesional skin, while there was no difference for NK-1R pos-
itive cells. There was a reverse correlation in the non-lesional skin between the number of substance
P positive fibres, and STA, psychic trait anxiety (PsTA) and SS, respectively. In the lesional skin there
was a reverse correlation between the substance P positive cells, and STA, SS and degree of depres-
sion. Substance P and its NK-1R are likely to have a complex role in AD, worsened by anxiety and
depression.
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Thymosin beta-4 plays important roles in skin cell anti-Inflammation response
Y Chen, K Cintron, Q Zheng, J Lyga and R Wyborski Avon Products. Inc, Suffern, NY
Thymosin beta 4 (Tβ4) is a ubiquitous 4.9 kD polypeptide, which can be found in a variety of mam-
malian tissues and cell types. Recent research has revealed its diverse functions including actin
sequestration, angiogenesis, cell differentiation, wound repair and anti-inflammation in various tis-
sues, especially in cardiac cells. In human skin, inflammation occurs when skin is exposed to UV,
allergens, or irritants. Chronic inflammation can lead to premature skin aging by increasing neu-
trophil infiltration and activating matrix degrading metalloproteases. In this study we investigated
the role of Tβ4 in the anti-inflammatory response in human skin cells to explore its potential as a
skin anti-aging target. Commercially obtained human dermal fibroblasts were treated with tumor
necrosis factor alpha (TNFα) to induce inflammation. Cells were either pre-treated with recombi-
nant Tβ4 or control media to assess its anti-inflammatory effect. Cell lysates and media were col-
lected and qPCR and Elisa were performed to assess inflammation marker interlukin-8 (IL-8) gene
and protein expression. Human cytokines and chemokines PCR array was also performed to inves-
tigate the impact of Tβ4 on the expression profile of key secreted proteins in the inflammation path-
way. We found that Tβ4 significantly suppressed IL-8 gene expression and protein secretion caused
by TNFα stimulation. Tβ4 also significantly regulates a variety of key cytokines and chemokines
genes to play important roles in skin cell inflammation response. Therefore, modulating endoge-
nous Tβ4 could be adopted as an avenue to battle inflammatory damage during skin aging and
photoaging.
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Prodifferentiation and anti -inflammatory and -hyperproliferative effects of delphinidin, a
dietary anthocyanidin, in a three dimensional psoriatic skin equivalent model
J Chamcheu, IA Siddiqui, DN Syed, VM Adhami, BT Boylan and H Mukhtar Dermatology,
University of Wisconsin-Madison, Madison, WI
We previously reported that delphinidin, a dietary anthocyanidin, induces epidermal differentia-
tion and modulates critical stages of keratinocyte maturation program and suggested its use for the
treatment of hyperproliferative dermatoses such as psoriasis. Psoriasis is a chronic inflammatory skin
disease with discernible intrinsic alterations of epidermal homeostasis resulting in hyperprolifera-
tion, inflammation and aberrant keratinization. Therefore, development of agents such as delphini-
din that possess the ability to abrogate these effects could be promising for the management of pso-
riasis. We investigated the effects of delphinidin,10 and 20 micromolar for 5 days, treatment in a
three dimensional psoriatic skin equivalent model (3D PsoEpi) by immunohistochemistry and west-
ern blot analysis and observed that delphinidin alone or in combination with retinoic acid (RA) or
vitamin D3 (vitD3) induced differentiation (increased caspase-14 and filaggrin) and decreased hyper-
proliferation (decrease in Ki67 and PCNA levels) and inflammation (decreased iNOS and STAT-3).
The expression of “alarmins”, the antimicrobial peptides psoriasin/S100A7 and koebnerisin/S100A15
are increased in psoriasis. By qPCR analysis, we observed that delphinidin treatment decreased gene
expression of both alarmins. Increased alarmins also synergize and prime keratinocytes for pro-
duction of cytokines that further exacerbate the inflammatory response. Muti-Analyte ELISArray
cytokine analysis of 3D-PsoEpi culture supernatants showed that delphinidin significantly decreased
the release of IL-1A (7 fold), IL-2 (2.2 fold), IL-6 (5 fold), IL-8 (3 fold), IL-10 (4 fold) and IFNγ (2 fold)
compared to untreated controls, and its combination with vitD3 and RA, in general decreased IL-
2, 4 and 10. These observations suggest that delphinidin could be developed either alone or in com-
bination with other anti-psoriatic agents for the management of psoriasis.
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cAMP regulates IL-12 production through Cox-2 and p38MAPKin human 6-sulpho LacNAc
(slan) dendritic cells
H Prakash,1 K Anja,1 O Stephanie,1 G Thomas2 and S Knut1 1 Dermatology, Heidelberg
University, Heidelberg, Germany and 2 Imstitute of Immunology, Heidelberg University,
Heidelberg, Germany
Slan-dendritic cells (DCs) are a population of Fc gammaRIII (CD16) expressing human blood and
dermal DCs. We have previously demonstrated their proinflammatory role in psoriasis and lupus
erythrematosus. In contrast to conventional DCs (CD1c+ DCs), slanDCs undergo a rapid and spon-
taneous maturation which enables them to produce copious amounts of IL-12 and TNF-α upon stim-
ulation with LPS/IFN-gamma. Here we studied signaling mechanisms that control the IL-12 pro-
ducing capacity of slanDCs. We observed that the cAMP elevating agents dibutyryl-cAMP, forskolin
or phosphodiesterase 4 (PDE4) inhibitors strongly inhibited LPS/IFN-gamma induced IL-12- and
TNF-α production and induced a concurrent elevation of IL-10, IL-1β and IL-23. We next asked for
a potential mechanism of cAMP mediated inhibition of IL-12- and TNF-α production. Here we iden-
tified that blocking of COX-2 rescued the cAMP mediated inhibition of cytokine production. COX-
2 is known to induce the generation of prostaglandine E2 (PGE2). Indeed, priming of slanDCs with
PGE2 completely blocked the LPS/IFN-gamma driven production of IL-12- and TNF-α production.
Therefore, in human skin the function of dermal slanDCs may well be controlled by inducing
increased levels cAMP via triggering of G-protein coupled receptors or by pharmacologic blocking
of PDE4 in slanDCs. Thereby, COX-2 can be activated to induce PGE2 production which than con-
trols the proinflammatory capacity of slanDCs.
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Desmoglein 1 is depleted from desmosomes and internalized into large vacuoles in pemphi-
gus foliaceus patient skin 
AM Poot,1 D Kramer,1 R Kalicharan,2 J Kuipers,2 A Ishida-Yamamoto,3 MF Jonkman,1
BN Giepmans2 and HH Pas1 1 Dermatology, University Medical Center Groningen, University
of Groningen, Groningen, Netherlands, 2 Cell Biology, University Medical Center Groningen,
Groningen, Netherlands and 3 Dermatology, Asahikawa Medical University, Asahikawa, Japan
Pemphigus foliaceus (PF) is characterized by intra-epidermal acantholysis and anti-desmoglein 1
(Dsg1) antibodies. We have shown by immunofluorescence (IF) that in skin of PF patients IgG induces
clustering of Dsg1 with plakoglobin. In higher layers, endosomes are present that contain IgG,
Dsg1 and plakoglobin. In the present study we investigated the fate of Dsg1 at the ultrastructural
level. Skin sections from 3 PF patients and 2 healthy controls were stained for Dsg1 by post-embed-
ding immunogold-labeling and visualized by electron microscopy. The number of Dsg1 labels per
desmosome was decreased in PF skin compared to healthy skin. This was most apparent in the lower
epidermal layers, with 1 to 3 labels per desmosome in PF skin versus 6 to 12 labels per desmosome
in healthy skin. The regions containing Dsg1-depleted desmosomes corresponded with clustering
of Dsg1 as shown by IF. In these regions prominent labelling was present along membranous struc-
tures that lacked desmosomes, and that resembled invaginations of neighbouring keratinocytes
into each other. Here we also found curvicircular structures: double membrane structures with 40
nm space between the membranes. Analysis of serially cut sections suggested that these structures
represent cross sections of invaginations. In the upper epidermal layers, where we found endosomes
by IF, large cytoplasmic Dsg1-labeled double membrane vacuolar structures were present that meas-
ured up to 3 μm in diameter. The space between these double membranes was 20 to 25 nm. We
conclude that in PF patient skin, desmosomes are depleted of Dsg1, fitting the desmoglein non-
assembly depletion hypothesis. The IgG-bound clustered non-desmosomal Dsg1 is internalized
through a currently unknown mechanism involving invaginations of cells into each other and in a
later phase the appearance of large vacuoles.
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Oxidative stress induces demethylation of PP2A catalytic subunit in human primary fibrob-
lasts
JB Stock,1 X Li,1 S Zhang,1 A Iinishi,2 M Stock2 and E Perez2 1 Molecular Biology, Princeton
University, Princeton, NJ and 2 Signum Dermalogix, Monmouth Junction, NJ
Oxidative stress is a major cause of skin aging. Protein phosphatase 2A (PP2A) is an important pro-
tein serine/threonine phosphatase in mammalian cells and has been previously linked to Alzheimer’s
Disease and aging. Methylation of the C-terminal leucine residue of the PP2A catalytic subunit
(PP2Ac) plays a crucial role in regulating PP2A function. To better understand the molecular mech-
anisms underlying this process in skin, we investigated the effects of oxidative stress on posttrans-
lational modification of PP2Ac in primary human dermal fibroblasts. Hydrogen peroxide (H2O2)
and Ultraviolet A (UVA) dramatically increased PP2A demethylation. Methylation turnover studies
with [3H]-methyl-labeling indicated that the effect of oxidative stress on methylation is primarily
due to an increase in activity of the PP2A demethylating enzyme, PME. Moreover, a PME-specific
inhibitor (ABL-127) protects PP2A against oxidative stress-induced demethylation. Anti-oxidants
such as N-acetyl cysteine (NAC) and α-tocopherol (VitE) protected PP2A from demethylation. Whereas
NAC acts by reducing levels of reactive oxygen species, VitE protects by binding directly to PP2A
and inhibiting its interaction with PME. Ceramide affords similar protection by binding to PP2A at
a site that appears to overlap the VitE binding site. This study provides insights into the signal-trans-
duction mechanisms that underlie oxidative stress responses in the dermis and provide a path for
the development of novel tocopherol and ceramide anti-aging therapeutics.
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Chronic mild stress modulates the 5-HT1A and 5-HT2A receptor expression in the cerebel-
lar cortex of NC/Nga atopic–like mice
A Rasul,1,4 B Johansson,2 S Lonne-Rahm,1 K Nordlind,1 E Theodorsson3 and H El-Nour1 1
Dermatology and Venereology Unit, Department of Medicine, Karolinska University Hospital,
Solna, Karolinska Institutet, Stockholm, Sweden, 2 Department of Molecular Medicine and
Surgery, CMM, Karolinska Institutet, Stockholm, Sweden, 3 IBK/Clinical Chemistry, Linköping
University Hospital, Linköping, Sweden and 4 Department of Dermatology and Venereology,
Gävle Hospital, Gävle, Sweden
Atopic eczema may worsen due to stress. Cerebellum becomes activated during itch and scratch-
ing, and also shows profound changes in neuromediator expression, including serotonergic changes,
during chronic stress. In the present study the cerebellar cortex of the atopic-like mouse NC/Nga
was studied regarding the effect of chronic mild stress on expression of two well characterized
serotonergic receptors (R), 5-HT1A and 5-HT2A. In total 24 mice were used. Sixteen of these mice
were subjected to unpredictable stressors for 8 weeks, and 8 mice used as controls. In order to evoke
an eczema, 16 of the mice were then painted with a mite antigen for an additional 4 week period.
Thus, three groups of mice, stressed eczematous (SE), non-stressed eczematous (NSE) and stressed
control (SC), were obtained. The expression of the serotonergic receptors was studied using a biotiny-
lated-streptavidin technique. An image analysis program was used to detect 5-HT1AR positive sig-
nal and the area fraction was determined. For 5-HT2AR a semiquantitative technique was used, the
immunoreactive surface area and signal intensity being measured. The highest value for 5-HT1AR
expression was found in the NSE group, while the lowest in the SC group. This value differed (p <
0.05) between the groups. The highest value for 5-HT2AR immunoreactive surface area was found
in the SE group, while the lowest in the SC group, also here a difference (p < 0.001) was found
between the groups. In addition, the signal intensity was highest in the SE group, with a difference
(p < 0.01) compared to the other groups. In conclusion, chronic mild stress modulates serotonin
receptors 1A and 2A in the cerebellar cortex of atopic-like mice.
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Cytokine profile before and after hematopoietic stem cell transplantation in severe diffuse
systemic sclerosis
J Barault,1 L Michel,1 D Farge,2 Z Marjanovic,2 F Jean-Louis,1 R Porcher,3 S Hadj-Khelifa,2
F Verrecchia1 and J Van Laar4 1 Dermatology. AP-HP Hôpital Saint-Louis, Inserm, Paris, France,
2 Internal Medicine, AP-HP Hôpital Saint-Louis, Paris, France, 3 Biostatistics, Univ Paris
Diderot, Paris, France and 4 Internal Medicine, Institute of Cellular Medicine, Newcastle,
United Kingdom
Objective: Systemic sclerosis (SSc) is a heterogeneous auto-immune disease characterized by exces-
sive fibrosis in skin and internal organs which has been related to high Th2-cytokines in the serum.
Autologous hematopoietic stem cell transplantation (aHSCT) for severe diffuse cutaneous SSc (dcSSc)
appears as a promising treatment, allowing rapid regression of skin and lung fibrosis with improved
functional status. This study was designed to evaluate the cytokine profiles in dcSSc patients before
and up to 4 years after aHSCT. Methods: Serum levels of cytokines (IL2,IL-4,IL-6,IL-8,IFN-g,IL-10),
pro-fibrotic markers (VEGF,TGFb,PDGF), endothelial markers (E-selectin,P-selectin), and the MCP-
1 chemokine were measured in 20 dcSSc patients before aHSCT (M0), and then quaterly during the
1styear and yearly until the 4thyear following aHSCT, as compared to 18 healthy controls. SSc skin
fibrosis was assessed by mRSS repeated measures. Results: Autologous HSCT induced sustained
reduction of the mRSS throughout follow-up (p<0.001). Before aHSCT, IL-6, IL-8, MCP-1, IL-10
and IFN-γ serum levels were significantly higher in dcSSc versus controls, while IL-2 and VEGF lev-
els were increased but not significantly. Six months after aHSCT and up to 4 years, IL-8, MCP-1,
PDGF and VEGF levels decreased progressively, whereas IL-6, IL-10 and IFN-γ cytokine levels did
not vary. TGF-b levels were similar in dcSSc and controls before aHSCT, and decreased signifi-
cantly at M6 to return to initial values at M48. Conclusion: We first report that the increase in pro-
fibrotic and Th2-cytokines serum levels in severe SSc patients can be partly reversed after aHSCT,
in parallel with effective regression of skin fibrosis.
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Multiple roles of polyunsaturated fatty acids in sebocytes. Relevance in acne pathogenesis
E Camera,1 W Chen,2 T Alestas,2 E Makrantonaki,2 H Seltmann,2 K Müller-Decker,3 M Ludovici,1
O Ottaviani,1 M Picardo1 and CC Zouboulis2 1 Cutaneous Physiopahology/CIRM, San
Gallicano Institute of Dermatology (IRCCS), Rome, Italy, 2 Departments of Dermatology,
Venereology, Allergology and Immunology, Dessau Medical Center, Dessau, Germany and 3
Deutsches Krebsforschungszentrum, Heidelberg, Germany
The polyunsaturated fatty acids (PUFA) linoleate (LA) and arachidonate (AA) are constituents of seba-
ceous lipids and key players of the inflammatory processes occurring in the pilosebaceous unit.
Sebocytes are competent for AA biotransformation into eicosanoids and leukotrienes (LT). AA trig-
gers the LT inflammatory signalling in sebocytes, suggesting advantages of 5-LOX inhibitors in acne
therapy. AA, LA, and their byproducts are ligands of the γ and α isoforms of peroxisome prolifera-
tor-activated receptors (PPARs), expressed in sebocytes. PPARs control differentiation, lipid biosyn-
thesis, and inflammation in sebocytes. We observed that AA and LA and derivatives induced sebo-
cyte enlargement and lipid droplets accumulation. Testosterone co-administration slightly enhanced
the PUFA-induced sebogenesis. AA stimulated the production of prostaglandins (PG) E2 and
15deoxyΔ12,14-PGJ2, a natural PPARγ ligand. 17β-Estradiol proved to induce 15deoxyΔ12,14-PGJ2
and IGF-I synthesis and to down-regulate IGF-IR expression. Normal sebaceous glands expressed
cytokines and chemokines, known triggers of the keratinocyte phospholipase A2. Released PUFA,
in turn, led to cytokine and chemokine synthesis. We investigated the biotransformation of AA and
LA (100 μM) in sebocytes. Intact sebaceous lipids such as acylglycerols, wax and cholesteryl esters,
and AA and LA-derived PUFA were profiled with lipidomics tools. Exogenous PUFA underwent mul-
tiple metabolic processes, such as desaturation, oxidation, and elongation. Supplied and newly
formed PUFA were incorporated into neutral lipids and contributed to the variety of acyl-lipids syn-
thesized de-novo. Our results highlighted multiple functions of AA and LA in sebocytes proving
them substrates of sebogenesis, mediators of inflammation, and targets of hormones activity.
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Prevage® blend of cosmetic functional ingredients counteracts skin aging by providing anti-
oxidant and anti-inflammatory protection
L Popescu,1 JR Fernandez,2 JB Stock,3 M Stock,2 A Felix,1 A Pellegrino1 and E Perez2 1 Elizabeth
Arden, New York, NY, 2 Signum Dermalogix, Monmouth Junction, NJ and 3 Princeton
University, Princeton, NJ
The skin is under constant attack from a variety of environmental stressors and undergoes aging as
a consequence of environmental damage. The primary factor for skin aging is ultraviolet (UV) radi-
ation, which results in reactive oxygen species (ROS), DNA damage and chronic inflammation.
Idebenone, the main cosmetic functional ingredient in Prevage® has previously been shown to be
a powerful anti-oxidant protecting against skin aging. Similarly, ergothioneine demonstrates excel-
lent free radical scavenging capacity. Arazine™ (N-acetyl-farnesyl-cysteine) has been shown to
exhibit anti-inflammatory properties inhibiting the release of pro-inflammatory mediators, and the
migration and of inflammatory cells. Together these 3 cosmetic functional ingredients comprise the
Prevage® blend. In this study we investigated the anti-oxidant potential of the Prevage® blend and
other commonly used anti-aging ingredients using the five environmental protection factor (EPF)
assays (D. H. McDaniel et al. 2005 JCD, 4:10-17). In addition, we broadened the scope of the EPF
to measure the inflammatory protection factor (IPF). Cultured primary normal human keratinocytes
(NHEKs) and human dermal fibroblasts (HDFs) exposed to UVA and UVB upregulated the produc-
tion of IL-6, TNFα and pro-MMP-1. Using a 180 point scoring system (20 points for each endpoint
measured), results demonstrate that Prevage® blend at 168 is superior to all other ingredients
tested in providing anti-oxidant protection and mitigating UV induced pro-inflammatory cytokines
and MMP production. Other ingredients tested included ferulic acid (135), ubiquinone (98), kinetin
(93), tocopherol (92), lipoic acid (83) and ascorbic acid (76). Given its strong anti-inflammatory
and anti-oxidant properties, Prevage® provides the optimal blend of ingredients to protect against
skin aging caused by environmental damage.
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Atypical pemphigus
L Venegoni, D Fanoni, F Vaira, E Berti and S Muratori Dermatology, Fondazione IRCCS Ca’
Granda, Milan, Italy
We diagnosed 300 new cases of pemphigus vulgaris (PV) and foliaceus (PF) in the last 10 years. In
all cases we collected clinical data, skin and blood serum for diagnosis. Methods used were direct
immunofluorescence (DIF); indirect IF (IIF) on monkey oesophagus (OE), normal human skin (NHS)
and sodium salt split (SS) skin; ELISA for BP 180-230, C-VII and Desmoglein (DSG) 1-3; transfected
cells for DSG1-3 and BP230, biochips for BP180 and western blot. Atypical clinical presentations
were observed in case of herpetiform pemphigus (HP). Atypical HP demonstrated IgA IC deposits,
anti DSG3, anti BP180 (confirmed by SS) or IC staining in absence of DSG1-3 reactivity (Desmo-
collin+). Concurrent neoplasia were detected in 2 HP patients. Localized oral pemphigus vulgaris
(OPV) were also observed, IgA and IgG IC mucosal deposits were demonstrated in 2 cases (1 case
associated with thyroid neoplasia). In 2 exceptional cases OPV and PF firstly occurred during preg-
nancy. Patients affected by chronic lymphatic leukemia showed aggressive paraneoplastic pem-
phigus or a more common OPV. In children PV, PF and a rare case of IgA pemphigus were observed.
Typical cases of subcorneal pustolosis like IgA pemphigus were also observed in adults. Looking at
serology anti DSG1-3 and anti BP180-230 were simultaneously detected by ELISA in some patients
(more aggressive cases?) and complete clinical remission may be observed also in patients with
persistent high titre of antibodies, but IIF tests are usually negative. Interestingly IIF on NHS, in
patients showing specific DSG1 or DSG3 ELISA positivity, stained lower part of epidermis (DSG3+)
or upper part of epidermis (DSG1+). The specificity of cells transfected by DSG1-3 and BP230 was
also confirmed in all cases analyzed. In conclusion even if majority of pemphigus cases should be
identify and classify by new technologies, the immunological and clinical profile of some rare
cases of PV or PF have to be better determined.
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Atypical pemphigoid
S Muratori, L Venegoni, D Fanoni, M Riboldi and E Berti Fondazione IRCCS Ca’ Granda, Milan,
Italy
We analyzed dermoepidermal blistering disorders (DEBD) such as bullous pemphigoid (BP) and
acquired epidermolysis bullosa (EBA). We observed cases of BP and IgA linear dermatosis in chil-
dren and adults; cases of mucosal BP with concurrent deposits of IgA and IgG and several cases
with IgE dermo-epidermal linear deposit by direct and indirect immunofluorescence (DIF and IIF).
IgE deposits were detected in mucosal BP in association with IgA and IgG. In case of trauma-induced
blistering lesions, simulating EBA, the negativity of anti C-VII ELISA suggested BP. In some cases we
detected by IIF positivity of both floor and roof of sodium salt split skin (SS), indicating the presence
of additional antigenic determinants. In one exceptional case associated with chronic lymphatic
leukemia we found high titre of ANA by IgM on HEP-2 slides, in vivo positivity (DIF) of nuclei and
basal lamina and IgA linear deposition. Positivity of the basal lamina, vessels (C-IV?) and nuclei on
normal human skin (NHS) and of the floor, both for IgM and IgA was confirmed by IIF. Another case
with psoriasiform features from the infancy, skin fragility and blistering appeared in 1990 and low
titre of IgG anti BP180 was demonstrated; IIF on SS clearly stained both roof and floor by anti-IgG
and roof by anti-IgE. High titre of serum IgE was present in absence of eosinophilia. The lesions
resolved and recurred for years, not responsive to therapies, as in congenital blistering disorders.
The histology showed dermo-epidermal and acantholytic features in the same blister. In several
cases you can find ELISA positivity for BP180-230, but also for DSG1-3, the last not confirmed by
IIF on NHS and transfected cells. We observed 10 cases of EBA confirmed by ELISA for C-VII or by
immunomapping. Aggressive cases, showed cutaneous and mucosal involvement. In conclusion
also if it is true that DEBD should be identify and classify by new technologies, immunological and
clinical profile of some cases have to be better determined.
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Topical formulation of an effective, oral pain drug, ARRY-797, provides high local concetra-
tions in porcine knee
L Burgess, D Corson, C Mannila, J Pheneger, S Andrews and J Neale Array BioPharma, Boulder,
CO
ARRY-797 is a potent, selective p38 MAP kinase inhibitor that has demonstrated significant pain
relief in osteoarthritis (OA) patients that was both rapid and sustained when delivered orally. ARRY-
797 also reduced circulating biomarkers of bone resorption and cartilage degradation, suggesting
the potential for disease-modifying activity. However, transient increases in creatine kinase and mild
prolongations in the QTc interval were also observed in clinical studies. Topical delivery could
enhance the utility of ARRY-797. We explored various topical vehicles in live pigs and evaluated
tissue-plasma ratios. We conclude that topical delivery of ARRY-797 can provide high local con-
centrations in the knee of pigs with concomitant low systemic exposure. ARRY-797 was formulated
at various strengths in several vehicles and then dosed topically on the knees or back of pigs. Oral
dosing of ARRY-797 was also performed as a control. Serial plasma, cartilage tissue, meniscus tis-
sue and synovial tissue samples were collected and analyzed for parent drug and the major metabo-
lite. From these data tissue-plasma ratios that ranged from 3.0 to 923.6 were obtained. Compared
to oral dosing, topical dosing of ARRY-797 consistently provided higher tissue-plasma ratios despite
high variability. In some instances, extremely high concentrations of the drug were detected in
knee tissues after topical dosing. For example, applying 3% ARRY-797 in vehicle #3 to pig knees
resulted in a cartilage/plasma ratio of 923.6, a meniscus/plasma ratio of 104.2 and a synovial tis-
sue/plasma ratio of 717.8 when measured at one hour post dose. If the pig is a reasonable dermal
model for human, then it may be feasible to formulate ARRY-797 for transdermal delivery to
osteoarthritis patients to provide pain relief while avoiding elevated plasma concentrations. In this
way, the utility of this effective pain drug could be expanded.
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Decreased fibrinolytic potential in transglutaminase 3 antibody positive dermatitis herpeti-
formis patients
A Görög,1 P Silló,1 L Szabó,3 K Kolev2 and S Kárpáti1 1 Department of Dermatology, Venerology
and Dermatooncology, Semmelweis University, Budapest, Hungary, 2 Department of Medical
Biochemistry, Semmelweis University, Budapest, Hungary and 3 Institute of Materials and
Environmental Chemistry, Research Centre for Natural Sciences, Hungarian Academy of
Sciences, Budapest, Hungary
Our aim was to compare the rates of fibrinolysis and the fibrin structure of plasma clots in der-
matitis herpetiformis (DH) patients and controls, while circulating IgA epidermal transglutaminase
(TG3) antibody positivity and dapsone treatment have been also analized. Fresh plasma and serum
samples from 18 DH patients and 6 healthy controls were clotted with thrombin, lysis was initiated
with tissue-type plasminogen activator (tPA) and the turbidity of the clots was continuously moni-
tored (its maximal value was used as an indicator of fibrin structure, the time to reach half-maxi-
mal turbidity was defined as lysis time). The fibrin network structure in plasma clots was directly
evaluated using scanning electron microscopy (SEM). The plasma lysis time of DH patients was
prolonged (p=0.0259), the maximum turbidity was higher (p=0.0098) compared to the control group.
In the sera there was no significant difference between these groups. The maximal turbidity of plasma
clots in the subgroup of TG3 positive patients was increased (p=0.0024), the lysis-time was longer
(p=0.0270) than the values measured in healthy subjects, similarly to the subgroup non-treated with
dapsone. We did not find any significant difference between the maximum turbidity and the lysis-
time of TG3 negative patients on gluten-free diet and dapsone-treated patients compared to control
group. SEM showed an increased fiber diameter in DH plasma clots. Our data indicate, that the
decreased fibrinolytic potential, the high maximal turbidity and the altered fibrin structure in TG3-
IgA antibody positive DH patients might contribute to skin symptom development, while the favor-
able effect of dapsone treatment to the fibrinolytic capacity is in line with its therapeutic effective-
ness.
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Keratinocyte-derived over-expression of protease-activated receptor-2 (PAR-2) results in epi-
dermal-neuronal communication with pruritus and atopic dermatiti
F Cevikbas,1 A Ikoma,1 C Kempkes,1 T Akiyama,2 T Buhl,1 M Langner,1 E Camerer,3 E Carstens,2
SR Coughlin4 and M Steinhoff1 1 Depts. of Dermatology and Surgery, University of California
San Francisco, San Francisco, CA, 2 Dept. of Neurobiology, University of California Davis,
Davis, CA, 3 Cardiovascular Research Center, INSERM, Paris, France and 4 Cardiovascular
Research Institute, University of California San Francisco, San Francisco, CA
Neuronal activation of protease-activated receptor-2 (PAR2) has been implicated in the pathophys-
iology of pruritus, atopic dermatitis, Netherton syndrome as well as skin barrier regulation. How-
ever, high PAR2 expression on keratinocytes (KC) indicates an additional role of PAR2 in diseased
skin and KC-neuronal communication. Therefore, we developed a mouse overexpressing PAR2 in
KC (KC-PAR2OE). Those mice developed severe pruritus, dry skin and eczematous skin lesions
with characteristic atopic-like dermatitis. Topical application of house dust mite (HDM) allergens
aggravated the pathological phenotype in KC-PAR2OE mice (increased pruritus, TEWL and skin
lesions). Spontaneous and HDM-treated KC-PAR2OE developed increased hyperkeratosis and an
atopic-like cell infiltrate (T cells, mast cells, macrophages, eosinophils). Our electrophysiological,
morphological and molecular studies show that KC-PAR2OE mice have an increased density of
unmyelinated nerve fibers and NGF expression levels in the skin, which explains higher suscepti-
bility of these mice to pruritogens (e.g. histamine, SLIGRL, 5-HT) and the development of sponta-
neously increased pruritus. Naltrexone reduced spontaneous scratching in those mice indicating
the involvement of mu-opioids in PAR2 mediated itch. In sum, our results suggest that proteases and
KC-PAR2 are critically involved in the pathophysiology of pruritus and atopic dermatitis. The con-
tribution to nerve elongation and neurotrophin release suggest that KC-PAR2 is an important link
in neuro-epidermal communication with the KC protease-PAR2 system as a forefront of sensory
signalling and neuro-immune communication in skin diseases such as atopic dermatitis.
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Molecular identification and characterization of rosacea as a Th1- and Th17-dominated dis-
ease
C Kempkes,1 J Buddenkotte,2,1 F Cevikbas,1 P Novak,2 J Aubert,3 I Carlavan,3 T Buhl,1 S Déret,3
P Reiniche,3 M Sulk,1,2 J Voegel3 and M Steinhoff1 1 Depts. of Dermatology and Surgery,
University of California San Francisco, San Francisco, CA, 2 Dept. of Dermatology, University
Hospital Muenster, Muenster, Germany and 3 Galderma R&D, Galderma R&D, Sophia
Antipolis, France
Rosacea is a frequent chronic inflammatory skin disease with a high impact on patient’s quality of
life and a poorly understood pathophysiology. Rosacea is characterized by neurovascular changes,
skin barrier dysfunction, and a lymphomonocytic infiltrate that is poorly characterised on a molec-
ular/ cellular level. In particular, the exact composition of the inflammatory T cell infiltrate and its
differences with respect to the cytokine/chemokine profile in the various subtypes of rosacea is
unknown. Therefore, we performed gene array studies in patients with rosacea subtypes 1 to 3, fol-
lowed by real-time PCR analysis and quantitative immunohistochemistry and double-immunoflu-
orescence. Our results show that in all stages, rosacea is a disease predominant of TH1 helper cells
and TH17 cells, but not TH2 cells. Gene array along with qRT PCR data and immunohistochem-
istry confirm upregulation of selective genes that are involved in T cell recruitment and TH1- or
TH17 activation, such as IL-6, -17, -22, Ifn-g, CCL20, CXCL9,-10, and -11, for example. Of note,
STAT-4 gene was upregulated in rosacea tissue as compared to acne tissue indicating different sig-
nalling pathways dominant in rosacea and acne. We also identified cytokine and chemokine recep-
tors that are differentially regulated among the different subtypes of rosacea and as compared to
healthy skin. Thus, TH1 and TH17 cells may play an important role in the pathophysiology of rosacea.
Because TH17 cells are involved in autoimmune and infectious diseases, these results shed new
light on the pathobiological mechanisms involved in rosacea. Drugs that modulate TH17 function
may be beneficial for the treatment of rosacea.
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Anti-desmoglein 1 antibodies are present in a high percentage of Brazilian but not Iranian
patients with cutaneous leishmaniasis
LN Maehara,1,2 TM de Vries,1 J Tomimori,2 AM Porro,2 S Ura,3 F Jaffary,4 GH Diercks,1
MF Jonkman1 and HH Pas1 1 Dermatology, University Medical Center Groningen, University of
Groningen, Groningen, Netherlands, 2 Dermatology, Federal University of São Paulo, Brazil,
São Paulo, Brazil, 3 Dermatology, Lauro de Souza Lima Institute, Bauru, Brazil and 4
Dermatology, Dermatology and Skin Disease and Leishmaniasis Research Centre, Isfahan
University of Medical Sciences, Isfahan, Islamic Republic of Iran
The most prevalent theory for the origin of endemic pemphigus foliaceus (PF) is that anti-desmoglein
1 (Dsg1) antibodies are induced by hematophagous insect bites. In leishmaniasis, which is trans-
mitted by sand fly bites, up to 73% of Brazilian patients are also reported to have anti-Dsg1 anti-
bodies. To evaluate the role of sand flies in triggering antibody production, we determined anti-Dsg1
titers in the sera of patients with cutaneous leishmaniasis in two different countries: Brazil, includ-
ing areas endemic for PF, and in a non-endemic area in Iran. None of the patients had clinical signs
of pemphigus. Fifteen of 41 Brazilian sera (37%) tested positive for anti-Dsg antibodies (4 only anti-
Dsg1, 5 only anti-Dsg3 and 6 both anti-Dsg1 and 3). Anti-Dsg1 indexes were over 19. Nine of
these 15 samples (60%) were positive by indirect immunofluorescence using monkey esophagus
as substrate. Of 61 Iranian patients, only 3 tested positive (5%): one had only anti-Dsg3 antibodies
and two had both anti-Dsg1 and 3, but indirect immunofluorescence was negative. Based on these
data, we suggest that sand flies may induce anti-Dsg antibodies but if so, that Lutzomyia genus
from Brazil seems to be much more potent in inducing these antibodies as the Phlebotomus genus
from Iran. Alternatively, other insects in the Brazilian environment, as Simulium nigrimanum which
is held responsible for inducing endemic Brazilian PF, may also underlie anti-Dsg antibody forma-
tion in Brazilian leishmaniasis. In contrast to previous studies, we found a high percentage of bind-
ing to epithelium suggesting that the epitope may not be located in the Dsg1 precursor proprotein
or on ectodomain 5.
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A new role for mast cells in rosacea
Y Muto, Z Wang, RL Gallo and A Di Nardo Medicine-Dermatology, university of California San
Diego, La Jolla, CA
Rosacea is a chronic inflammatory skin disease whose pathogenesis is still unclear. Recent discov-
eries have indicated that an alteration in the metabolism of LL-37 Cathelicidin (Cath LL-37) antimi-
crobial peptide, by KLKs and MMPs activity, is present in the human inflammatory process that leads
to Rosacea. Mast cells (MCs) are one of the primary sources of Cath LL-37 and proteases in the skin
and are increased within the skin of Rosacea patients. MC proteases are not only able to recruit
other immune cells and amplify the inflammation, but also cause vasodilation and angiogenesis;
moreover, MCs play an important role in mediating signals between the sensory nerve ending and
the dermis. In a mouse model of Rosacea, we demonstrate that MC proteases (chymase and tryptase)
and matrix metalloproteinases (MMPs) are essential in the development of LL-37 mediated rosacea
inflammation. After injection of LL-37, we found 3.1 fold increase of chymase (p<0.001), 11.7 fold
increase of tryptase (p<0.01), 12 fold increase of MMP-9 (p<0.01) and 100 fold of increase of IL-6
for each mRNA expression over baseline in skin wild type (WT) mouse. These increases correlate
with the observed clinical score of skin inflammation. None of the observed changes were present
in MC deficient mouse (KitW-sh/W-sh mouse); they did not develop rosacea-like features with LL-
37 injection into the dermis. Cromolyn (a MC stabilizer) treatment blocked the LL-37 induced mRNA
expression of MMP-9, and MIP-2 which causes rosacea inflammation and angiogenesis. Immedi-
ate degranulation of mouse MCs and increased MMP activity was confirmed by LL-37 challenge in
vitro. We also confirmed that neuropeptides (NPs) strongly induced proteases release and pro-inflam-
matory cytokines production in WT mouse skin. LL-37 and NPs have synergic effect on MCs degran-
ulation and protease release. In conclusion, MCs play a key role in rosacea pathogenesis. Down
regulation of activated mast cells will be a critical mechanism for rosacea therapy.
308
Absolute levels of the novel anti-IL-17A antibody, secukinumab, in skin can be quantified by
dermal open flow microperfusion (dOFM)
G Bruin,1 C Dragatin,2 B Aigner,3 F Polus,1 C Calonder,1 C Froeliger,1 K Tiffner,2 M Bodenlenz,2
J Mader,4 S Korsatko,4 M Ratzer,2 TR Pieber,2,4 C Loesche1 and F Sinner2,4 1 Novartis Institutes for
BioMedical Research (NIBR), Basel, Switzerland, 2 HEALTH—Institute for Biomedicine and
Health Sciences, JOANNEUM RESEARCH Forschungsgesellschaft m.b.H., Graz, Austria, 3
Department of General Dermatology, Medical University, Graz, Austria and 4 Division of
Endocrinology and Metabolism, Department of Internal Medicine, Medical University, Graz,
Austria
Secukinumab (AIN457) is a new monoclonal antibody (mAB) targeting IL-17A for the treatment of
inflammatory diseases, including skin diseases such as psoriasis. To gain insight into the mecha-
nism of action in the target tissue, we investigated the distribution of secukinumab in dermal inter-
stitial fluid (ISF) and in serum by measuring its absolute concentration after a single s.c. adminis-
tration. Eight healthy subjects (19-38 years old) received a single s.c. dose of secukinumab (300
mg) on day 1. Secukinumab levels were quantified in dermal ISF on day 15 using dermal open flow
microperfusion (dOFM) combined with no-net-flux calibration. A specific dOFM probe with 100
μm pores was used for dermal sampling. The concentration of sinistrin, administered i.v. over 12 h
as reference, was also measured in the dermal ISF samples to verify the stability of the dOFM sam-
pling recovery and to verify sinistrin as a calibrator for secukinumab. Serum secukinumab concen-
tration on day 15 was 34.9 +/- 10.5 μg/ml, as expected, while the corresponding mean dOFM-
derived concentration in dermal ISF was 23.5 % of that measured in the serum. The dOFM sampling
recovery of sinistrin was stable over 12 h, was reproducible between probes and subjects, and could
be used for secukinumab calibration. The study demonstrated significant levels of secukinumab in
the skin after s.c. administration suggesting the potential for a local, as well as a systemic, mecha-
nism of action targeting dermal upregulation of IL-17A, an important mediator of psoriasis. In addi-
tion, dOFM is a promising technique for investigating the distribution of secukinumab in dermal
ISF.
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The comorbidities associated with serum vitamin D deficiency in veteran psoriasis and effect
of antioxidant therapy
CN Young,2,1 W Nasir,1,2 R Jackson,1,2 R Kakar1,2 and L Savoy2,1 1 Dermatology, Wayne State
University, Detroit, MI and 2 Dermatology, John D Dingell Veterans Affairs Medical Center,
Detroit, MI
The objective of this study is to assess serum vitamin D levels in veteran patients with psoriasis and
to identify associations between vitamin D status, key clinical factors and disease severity, and
comorbidities. The effect of oral supplemental vitamin D3 on serum 25(OH) vitamin D levels in pso-
riasis patients was studied. In addition, the effect of antioxidant therapy on comorbidities associ-
ated with psoriasis was also assessed. The health benefits of antioxidant oral supplements on meta-
bolic syndrome associated with psoriasis were elucidated and discussed. The study was a randomized
controlled trial conducted at John D Dingell VAl center in Detroit Michigan. Data were drawn from
120 psoriatic patients seen in VA outpatient clinic. 25(OH) vitamin D levels were evaluated along
with markers of disease activity, physician and patient global assessments and PASI score calcu-
lated. Psoriasis patients with hypovitaminosis D received oral vitamin D3 (cholecalciferol) therapy
at a dose of 5000 IU daily for 26 weeks. Patients with more than one metabolic syndrome were ran-
domly divided into four groups, each group received a different oral antioxidant or combination of
these four antioxidant pills daily respectively. Blood samples were drawn at week 0, at the week 26
at week 52. Serum measurements of 25(OH)D, ESR, HbA1c, Lipid Profile, Comprehensive meta-
bolic panel and homocysteine and C-reactive protein were assessed. RESULTS: Blood 25(OH) Vita-
min D level from the patients with hypovitaminosis D increased significantly after the week 26
receiving vitamin D3 supplement at doses of 5000 IU daily. No direct correlation was observed
between PASI score improvement and vitamin D treatment. Serum inflammatory markers CRP, homo-
cysteine, ESR also decreased in all four patients groups receiving antioxidant pill. But the better
profile of these inflammatory makers was obtained in the patients group receiving combination of
these four antioxidant pills daily.
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IL-17 mediated responses have a role in ultraviolet irradiation-induced immunosuppression
in skin
HA Li, M Vaid, CA Elmets, SK Katiyar and H Xu University of Alabama at Birmingham,
Birmingham, AL
This study has examined the role of IL-17 in ultraviolet (UV) irradiation-induced immunosuppres-
sion in skin and mechanisms for suppressive effects. In the study, wild type B6 and IL-17 receptor
A deficient (IL-17R-/-) mice were irradiated with UV. Effects on contact hypersensitivity (CHS)
responses to allergens in the skin and leukocyte functions of UV-irradiated mice in the induction of
T cell proliferation were determined. Results showed that UV irradiation significantly (P<0.01) sup-
pressed CHS responses in wild type mice whereas it did not show a significant effect (P>0.05) on
the responses in IL-17R-/- mice. Analysis of skin tissues showed that UV irradiation induced high
levels of inflammatory cytokines and chemokines in wild type mice whereas the effects were sig-
nificantly diminished in IL-17R-/- mice. Accordingly, infiltration levels of granulocytes and mono-
cytes in the UV-irradiated skin of IL-17R-/- mice were significantly lower than those in UV-irradi-
ated wild type mice. Importantly, spleen cells from UV irradiated wild type mice had decreased
ability to induce the proliferation of antigen specific T cells compared to those from naïve untreated
mice. Depletion of CD11b+ or CD4+ cells from spleen cells of UV-irradiated wild type mice could
significantly restore their ability to induce T cell proliferation. In contrast, spleen cells from UV-irra-
diated and naïve untreated IL-17R-/- mice showed similar ability to stimulate the proliferation of
antigen specific T cells. These results suggest that UV-induced inflammation in the skin is regulated
by IL-17. A deficiency in IL-17 diminishes UV-induced immunosuppression which is related with
a reduced level of inflammation and leukocyte infiltration in the UV-irradiated skin. UV-induced
regulatory cells are composed of CD11b+ myeloid cells and CD4+ T cells. This study indicates a
novel role of IL-17 in UV-induced immunosuppression in the skin. Further studies are required to
elucidate mechanisms by which IL-17 regulates the development of UV-induced suppressor cells.
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Anti-inflammatory activity of clotrimazole on TPA-induced ear swelling in mice
O Brandt, D Spazierer, C Schuster, L El-Housseiny and G Stingl Division of Immunology, Allergy
and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna,
Vienna, Austria
Fungal infections are frequently accompanied by inflammation of the affected regions. Imidazole
drugs are not only effective in eliminating fungal infections, but also in rapidly reducing the con-
comitant inflammation, presumably by down-modulating the expression of proinflammatory
cytokines. The imidazole derivate clotrimazole (CLT) has been in clinical use for more than 25
years and has been demonstrated to inhibit trinitrobenzene sulfonic acid (TNBS)-induced colitis in
rats and tumor necrosis factor (TNF)-alpha-induced adhesion molecule expression in vitro. We aimed
to investigate the anti-inflammatory potency of CLT in two acute inflammation models. Therefore,
skin inflammation was induced in female BALB/c mice by topically application of 12-O-tetrade-
canoylphorbol acetate (TPA) and oxazolone (OXA) on one ear, respectively. 15 min. thereafter, CLT
in various concentrations was applied and the resulting ear edema was quantified by measuring the
increase of ear thickness after 24 hours. While CLT had no significant impact on OXA-induced ear
inflammation, it reduced the TPA-induced ear swelling dose-dependently and significantly up to
43.6% (CLT 2%). Moreover, even at concentrations below 0.1% a significant reduction in ear edema
could be observed. Accordingly, our observations suggest that CLT possesses pronounced anti-inflam-
matory activities and selectively suppresses inflammatory pathways that may also be relevant for
the concomitant inflammation commonly seen in fungal skin infections.
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Cellular expression of the alarmin IL-33 in acute skin inflammation
O Sundnes, D Khnykin and G Haraldsen Pathology, Oslo University Hospital, Oslo, Norway
Interleukin-33, a recently described member of the IL-1-family, is an important player in a variety
of inflammatory settings and is thought to be released from damaged or necrotic cells. Little work
has so far been published on the cellular expression and regulation of IL-33 in inflammatory lesions.
In normal mouse skin IL-33 showed a nuclear expression in non-proliferating keratinocytes (Ki67-
) and periglandular myoepithelial cells. After injection with Staphylococcus aureus (6h i.d.) we
observed that nuclear IL-33 disappeared from keratinocytes in the center of the lesion and instead
appeared in fibroblasts at the periphery. The keratinocyte layer remained intact and expressed nuclear
HMGB1, revealing no evidence of overt necrosis at this time point, thus indicating possible secre-
tion. Wound lesions of the ear showed a similar picture at the margins. At later time points IL-33
reappeared in keratinocytes, initially in a hyperproliferative, multilayer structure in which IL33 and
Ki-67 remained minimally co-localized. Similarly, in cultured human keratinocytes there was con-
stitutive expression of nuclear IL-33 in non-proliferating cells and in contrast to endothelial cells,
expression levels appeared unaffected by cell density or pro-inflammatory activation (TNF-α or
IL1β). We conclude that the regulation of IL-33 in keratinocytes appears to involve molecular sig-
nals different from the regulation seen in vascular endothelial cells and deserves further investiga-
tion.
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Ultraviolet radiation-induced migration of skin dendritic cell subsets requires transforming
growth factor type-β signaling
A Glick, A Ravindran, J Mohammed and A Gunderson Pennsylvania State University, University
Park, PA
Ultraviolet radiation (UVB) is the leading cause of skin cancer worldwide and modulates inflam-
mation driven cutaneous pathologies such as delayed type hypersensitivity and contact hypersen-
sitivity through actions on skin resident dendritic cell (DC) subsets. Transforming Growth Factor-β1
(TGF-β1) is a potent cytokine in the skin that regulates DC function. To test the role of TGF-β1 in
DC responses to UV we irradiated SKH1 mice with UVB in the presence or absence of topical
SB431542 (SB), a small molecule inhibitor of the TGF-β type I receptor, and measured lymph node
migration of skin DC subsets. As early as 2 hrs post UVB irradiation at a minimal erythema dose
there was an increase in Smad2 and Smad3 phosphorylation in whole skin protein extracts that was
blocked by SB. SB431542 treatment suppressed UVB-induced migration of skin DC subsets, pri-
marily CD103+ CD207+ and CD207- DC populations to the lymph node 2.5 and 1.75 fold, respec-
tively, p<.05, and suppressed UVB-induced migration of these subsets in an ex vivo ear explant
assay. Topical SB also suppressed the number of UVB-induced Interferon-γ secreting CD4+ and
CD8+ T cells 2-fold, effector differentiation of CD4+ and CD8+ lymph node T cells 5 and 2.5-fold
p<.05, and the UVB-induced increase in percentage of Interferon-γ producing skin infiltrating CD4+
and CD8+ T cells 3-fold, p<.05. Significantly, expression of a dominant negative Type II receptor in
CD11c+ dendritic cells (CD11c-TβRII DNR) suppressed UVB-induced lymph node migration of
CD103+ CD207+ and CD207- DC subsets as well as migration from ear explants cultures to a sim-
ilar extent. These results directly link TGF-β signaling in dermal DC to their UVB-induced activa-
tion and migration and subsequent initiation of cutaneous inflammatory responses.
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Live cell imaging of desmosomal proteins in pemphigus foliaceus
E Sokol,1,2 KA Sjollema,1 MA Baird,3 MW Davidson,3 MF Jonkman,2 HH Pas2 and BN Giepmans1
1 Department of Cell Biology, UMCG, Groningen, Netherlands, 2 Department of
Dermatology, UMCG, Groningen, Netherlands and 3 National High Magnetic Field
Laboratory, The Florida State University, Tallahassee, FL
Autoimmune blistering skin disease pemphigus foliaceus (PF) is characterized by auto-immune IgG
antibodies that bind to the desmosomal component desmoglein 1 (Dsg1). In skin these antibodies
change Dsg1 distribution by crosslinking this desmosomal protein into large aggregates containing
Dsg1, plakoglobin (PG) and IgG. The desmoglein non-assembly depletion hypothesis explains acan-
tholysis as loss of cell-cell adhesion through depletion of Dsg1 in the subcorneal layers of PF
patient skin. To investigate this pathomechanism we aim at imaging desmosomal proteins in a time
dependent manner during PF IgG induced acantholysis. Plasmids encoding desmosomal proteins
Dsg1 and PG fused to fluorescent proteins (FP) were constructed and PF patient IgG was covalently
labeled with distinct fluorescent dyes. Dsg1 tagged FP was expressed in an epithelial cell line and
the effect of PF IgG on this protein was followed in real time using two photon microscopy. PF IgG
bound to the cells immediately after addition and induced clustering both of Dsg1 tagged FP and
endogenously expressed Dsg1 followed by internalization of PF IgG and colocalization with Dsg1.
Clusters of PF IgG and Dsg1 appeared as dynamic structures that enlarged during time and remained
on the cell membranes during cell division. Our results reveal that IgG induces clustering of Dsg1
and that this remodeling is similar as seen in pemphigus patient skin. The correct localization of FP-
chimaeras and their shift in localization when contacting PF IgG shows that they are feasible reagents
for studying pemphigus acantholysis by multispectral two-photon microscopy. In combination with
our recent successful transfection of ex-vivo human skin by particle bombardment method they form
an attractive basis for studying the molecular PF pathomechanism.
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Epidermal RelA specifically restricts contact allergen induced inflammation and apoptosis in
skin
S Kumari, T Krieg and I Haase Dept. Dermatology, University of Cologne, Cologne, Germany
Contributions of skin resident non- immune cells to the regulation of skin inflammation have not
been thoroughly investigated. Both forced activation or inhibition of NFκB signaling in the epider-
mis can lead to inflammatory skin phenotypes in mice. We have asked whether partial functional
inhibition of NFκB signaling in epidermal keratinocytes can modulate inflammatory responses of
the skin. To address this we deleted exons 7- 10 of the rela gene specifically in epidermal ker-
atinocytes to produce a truncated, non functional RelA protein (RelAEKO mice). These mice do not
show a spontaneous inflammatory skin phenotype. Induction of contact allergy against dinitroflu-
orobenzene (DNFB) resulted in significantly stronger ear swelling and increased epidermal thick-
ness in RelAEKO mice as compared to control mice. This enhanced response was specific for the
delayed type hypersensitivity (DTH) response, since it was not observed in irritant contact dermatitis
following application of croton oil. Epidermal hyperproliferation in RelAEKO mice was non- cell
autonomous, since functional impairment of RelA inhibited proliferation of primary epidermal ker-
atinocytes in culture. Comparative protein expression analysis of DNFB treated ears of RelAEKO
and control mice revealed increased expression of calgranulins A and B (S100A8/ A9) in inflamed
skin of RelAEKO mice. This was not observed in croton oil treated ears. These results demonstrate
that epidermal RelA specifically regulates DTH induced skin inflammation by restricting expres-
sion of inflammatory mediators such as S100 proteins. In addition, we here describe an essential
but non specific function of RelA in the protection of epidermal keratinocytes from apoptosis. Our
study identifies new functions of NFκB signaling in the epidermis and corroborates a specific role
of epidermal keratinocytes in the regulation of skin inflammation.
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Pemphigus vulgaris mimicking toxic epidermal necrolysis
K Drenovska,1 S Vassileva,1 J Kazandjieva,1 K Manuelyan,1 O Hadjiiski,2 M Balabanova1 and
S Marina1 1 Department of Dermatology, University Hospital “Alexandrovska”, Sofia, Bulgaria
and 2 Department of burns and plastic surgery, UMHATEM “N.I. Pirogov”, Sofia, Bulgaria
Pemphigus is an autoimmune bullous disease mediated by autoantibodies against desmosomal anti-
gens. Pemphigus vulgaris is characterized by severe mucocutaneous involvement and life-threat-
ening potential due to the denudation of vast skin or mucosal surfaces which may resemble toxic
epidermal necrolysis (TEN, Lyell’s syndrome). A 24-years old man presented in the Department of
Dermatology-Sofia with vesiculo-bullous eruption initially involving the trunk and further affecting
the mucous membranes and large skin areas, including the palms and soles. The clinical diagnosis
of pemphigus vulgaris was confirmed histologically and by means of immunofluorescent tests and
ELISA-Dsg1 and 3. Systemic treatment with corticosteroids, azathioprine and antibiotics resulted in
slight improvement. Soon after discharge from hospital patient’s general and skin condition aggra-
vated significantly. He was readmitted with sloughing of large skin areas of the trunk and extremi-
ties, bilateral erosive conjunctivitis, and involvement of the nasal and entire oral mucosa resem-
bling the clinical picture of TEN. The patient was transferred to Department of burns and plastic
surgery of Pirogov University Emergency Hospital. Immunofluorescence and ELISA tests again sub-
stantiated pemphigus while histological findings could be interpreted in the spectrum of TEN. The
patient received pulse corticosteroid therapy and high doses IVIg along with adequate reanimation
care with good results. The massive mucocutaneous involvement in the presented patient could not
distinct between severe pemphigus vulgaris or association pemphigus-Lyell’s syndrome. The term
“Lyellisation” or “secondary epidermal necrolysis” has been introduced for similar cases of pem-
phigus, acute generalized pustular psoriasis Von Zumbusch, burns, etc., which may be included in
the spectrum of the “scalded skin syndrome” along with the drug-induced cases of TEN and staphy-
lococcal scalded skin syndrome (SSSS).
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Establishment of a humanized model of skin immunity to investigate human skin-resident
immune responses to pathogens
P Agarwal,1 G Vladimer,1 WJ Racki,2 A Cuthbert,2 E Lien,1 MS Brehm,2 DL Greiner,2 JE Harris1 and
L Shultz3 1 Medicine, University of Massachusetts Medical School, Worcester, MA, 2
Molecular Medicine, University of Massachusetts Medical School, Worcester, MA and 3
Jackson Laboratories, Bar Harbor, ME
The goal of this study was to determine whether a functional human skin graft with skin-resident
immune cells could be established in a severely immunocompromised mouse strain, resulting in a
humanized mouse model of inflammatory skin diseases. While animal models of human disease
facilitate the study of basic mechanisms, many do not fully reflect human disease, and numerous
therapies developed in animals have not been successfully translated to humans. The NOD-scid-
IL2rnull (NSG) is a unique strain of mice that accepts most human tissues, including skin, tumors,
thymus, liver, etc., as well as human T cells. Our study uses NSG mice and discarded human skin
from panniculectomy surgery to investigate skin-resident immune responses in human skin. We
report that NSG mice engraft with human skin, which heals within 3 weeks of grafting. Human
skin-resident T cells are present within fresh skin, and are maintained throughout healing of the skin.
Surprisingly, while skin-resident dendritic cells and macrophages are also present in freshly iso-
lated skin, they disappear from the graft shortly after transplantation, reappearing 4-6 weeks later,
suggesting that this would be the optimal time frame in which to study skin-resident immune
responses. Further, we demonstrate successful infection with relevant skin pathogens, including vac-
cinia virus (the smallpox vaccine) and Yersinia pestis (the plague). Future studies will aim to char-
acterize human skin-resident immune responses to human skin pathogens, as well as the contri-
butions of individual cell types to that response.
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Type I cytokines and chemokines are targetable immune pathways in alopecia areata
Z Dai,1 L Xing,2 A Jabbari,1 A de Jong,1 AM Christiano1,3 and R Clynes1,2,4 1 Dermatology,
Columbia University, New York, NY, 2 Pathology, Columbia University, New York, NY, 3
Genetics & Development, Columbia University, New York, NY and 4 Medicine, Columbia
University, New York, NY
Alopecia areata (AA) is pathologically characterized as a “swarm of bees,” comprised of T cells
around and invading the hair follicle. We recently defined the phenotype of these cells in the C3H/HeJ
alopecic mouse. These IFN-γ producing “NK-type” CD8 killer T cells infiltrate the hair follicle, are
massively expanded in the cutaneous lymph node and are necessary and sufficient for disease trans-
fer in adoptive recipients. In alopecic mice, the inflammatory signature is dominated by the Type I
response, and the CXCL9-11 chemokines are amongst the most highly upregulated genes in lesional
skin. The FDA-approved small molecule JAK1 inhibitor ruxolitinib, which blocks IFN signaling, elim-
inated the Type I cytokine signature and durably reversed AA development in mice with established
disease when given topically. Interestingly, the CXCR3 receptor, known to bind these IFN-inducible
chemokines, is upregulated on the key pathogenic alopecic CTL effectors. To demonstrate whether
CXCL9-11 chemokines were pathogenically required, we treated mice with blocking antibodies to
CXCR3. Importantly CXCR3 blockade prevented AA development in the AA graft model and notably
abrogated the expansion of CXCR3+ alopecic killer T cells in the skin and cutaneous lymph node.
We show here using transcriptional profiling of human and mouse alopecic skin that the IFN path-
way is the dominant signaling pathway involved in AA. Transcriptional profiles of 12 AA patients
and 6 normal controls, show that IFN-inducible chemokines (CXCL9-11) are massively transcrip-
tionally upregulated in the skin of human AA lesions. Taken together, these data demonstrate proof-
of-principle of interfering with the Type I response in human AA, via blockade of IFN-inducible
chemokines. CXCR3 blockade could be approached clinically with either antibody or small mole-
cule blockade, the latter being particularly intriguing as a topical therapeutic.
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Injection of immunocytes into non-lesional skin grafts from psoriatic patients induces psori-
asis-like lesions
J Wegner-Kops, E von Stebut-Borschitz and RE Schopf Dermatology, Johannes Gutenberg Univ.,
Mainz, Germany
Psoriasis is a clinically well-defined skin condition that can be treated by immunosuppressive agents
including cyclosporine and biologics directed against TNF, IL12/IL23 and IL17. Pathogenesis still is
not completely understood. Mouse models with distinct immuno-deficient properties are being
sought to study pathogenesis of psoriasis. Our present study intends to establish a model for in vivo
analysis of psoriasis by transfer of human PBMCs into NOD-SCID (lacking T and B cells) and NOD-
SCID gamma-chain-/- mice (lacking T/B cells and NK cells). For this purpose, we obtained non-
lesional and lesional skin from psoriatic patients. The skin grafts were transplanted between the
scapulae of the mice. Weekly, the transplants were examined clinically and documented photo-
graphically in order to monitor the time kinetics regarding the start of symptoms and alterations of
skin over time. After 10 weeks, biopsies of the skin grafts were obtained and examined histologi-
cally. 12 weeks after xeno-transplantion of human skin, 1-3x106 PBMC from autologous psoriatic
patients (skin donors) were activated by stimulation with IL-2 and staphylococcal enterotoxin B (SEB)
and transferred intradermally into skin grafts of the immunodeficient mice. At week 17 the skin grafts
were re-biopsied. Cell proliferation was visualized by expression of Ki67, immature psoriatic ker-
atinization by cytokeratin 16. We found a markedly increased Ki67 expression of epidermal and
dermal cells, both in lesional and uninvolved grafted skin from psoriatic patients after intradermal
transfer of activated autologous PBMCs at the end of the experiment (week 17) We also detected
an increased epidermal expression of cytokeratin 16, which is an important marker of psoriasis, in
non-lesional skin, independent of the mouse stain. These findings indicate the development of pso-
riasis after 17 weeks in xeno-transplants from non-lesional psoriatic skin in the presence of acti-
vated autologous PBMCs. Our results indicate that the xeno-transplant models employed are suited
to study pathogenesis of psoriasis.
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CD4+ T cells regulate disease severity in a mouse model of vitiligo
J Harris, P Agarwal, M Rashighi and K Essien University of Massachusetts Medical School,
Worcester, MA
In this study we explored the role of CD4+ T lymphocytes in the pathogenesis of vitiligo. Vitiligo is
an autoimmune disease characterized by melanocyte death and subsequent depigmentation of the
epidermis, mediated by auto-reactive, melanocyte specific CD8+ T lymphocytes. Since CD4+ T
lymphocytes are present in lesional skin from vitiligo patients, and subsets of these cells are known
to interact with CD8+ T cells to either promote or suppress their activity, we hypothesized that CD4+
T cells are key players in the progression of vitiligo. To test this hypothesis, we used a mouse model
where melanocyte specific CD8+ T cells, are adoptively transferred into mice with black skin. In
this model, depigmentation of the ears, nose, feet, and tail appears 4-6 weeks following treatment.
To examine the role of CD4+ T cells in vitiligo, mice were treated with CD4 depleting antibody,
which resulted in efficient depletion of CD4 T cells in spleen, lymph nodes, and skin, as well as a
greater than 4-fold increase in the severity of disease (p<0.0001). Further analysis revealed a 20 –
80 fold increase in the number of CD8+ T cells in the skin of vitiligo mice that were depleted of
CD4+ T cells, compared to non-depleted mice with vitiligo. Preliminary data suggest that this increase
is not a result of T cell proliferation within the skin. Additional studies revealed a similar effect
using CD25-depleting antibody, suggesting that T regulatory cells were responsible for control of
depigmentation. This assertion is consistent with the high prevalence of T regulatory cells in the
skin as 50% of all CD4+ T cells in the skin are also FoxP3+. In summary, our data support an impor-
tant role for CD4+ T cells in regulating the severity of vitiligo, but not for providing help to CD8+
T cells during disease.
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Increased circulating Th17 cells and elevated serum levels of TGF-beta and IL-21 invovled in
human non-segmental vitiligo development
L Zhou,1,2 Y Shi,1,2 K Li,1,2,3 I Hamzavi,2 T Gao,3 H Lim1,2 and Q Mi1,2 1 Immunology Program,
Henry Ford health System, Detroit, MI, 2 Dermatology, Henry Ford Health System, Detroit,
MI and 3 Xijing Hospital, Xian, China
Although it is widely believed that non-segmental vitiligo (NSV) results from the autoimmune destruc-
tion of melanocytes, the detailed immune mechanisms remain poorly understood. Th17 cells, a sub-
set of CD4+ helper T cells, have been identified to be implicated in a variety of human autoim-
mune diseases. To comprehensively evaluate the role of Th17 cells and the pathways driving these
T cell differentiations in NSV, we had compared the frequencies of peripheral blood Th17 cells and
other IL-17 producing T cells by flow cytometry between 42 active NSV patients with 45 race-, gen-
der- and age-matched healthy control subjects. Serum levels of IL-17A and Th17 cell differentiation
related cytokines including TGF-beta1, IL-6, IL-23, IL-22 and IL-21 were detected by ELISA. Our
results showed the increased circulating Th17 cell frequencies and elevated serum IL-17A, TGF-
beta1 and IL-21 levels in NSV patients. Further more, the increased Th17 cell frequencies are pos-
itively correlated with serum TGF-beta1 levels and the body surface area (BSA) in NSV patients.
These results indicate the involvement of Th17 cells in the development and progression of NSV,
and more importantly, our data highly suggest that elevated serum TGF-beta and IL-21 could con-
tribute to enhanced Th17 cell differentiation in NSV.
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Chemical inducers of depigmentation in vitiligo
ML Frisoli, M Rashighi, P Agarwal, KI Essien and JE Harris Medicine, University of Massachusetts
Medical School, Worcester, MA
Our goal in this study was to identify chemicals that worsen or induce vitiligo, and to characterize
their mechanism of melanocyte toxicity. Emerging data support a role for both T cell-mediated
autoimmunity and melanocyte stress in vitiligo, yet how these two systems interact to cause skin
depigmentation is still a mystery. In addition, a number of chemicals have been implicated in vitiligo
induction, a process previously referred to as “chemical leukoderma,” and those may promote vitiligo
by inducing melanocyte stress. Monobenzyl ether of hydroquinone (MBEH), historically used in
rubber production, was the first to be implicated in this process. We initially optimized in vitro assays
using human melanocytes to detect induced cellular stress. Using these tools, we screened chem-
icals commonly used in household skin products, identifying those with an increased risk of exac-
erbating vitiligo. Next, we tested MBEH in vivo to determine its pro-inflammatory effects within the
skin. Preliminary data reveal a significant infiltration of innate cell populations following MBEH
treatment, prior to clinical changes. Further characterization of this innate immune response may
help elucidate early events preceding an autoreactive, T cell-mediated response in chemical-induced
vitiligo. Further testing of common chemical agents capable of causing chemical leukoderma will
help to promote safer industry standards that decrease the risk of vitiligo, and assist counseling of
vitiligo patients to make safer choices in their use of commercial products.
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Fumaric acid esters: The future of psoriasis therapy?
I Helwa2,3 and WB Bollag2,3,1 1 Oral Biology, Georgia Health Sciences University, Augusta, GA,
2 Physiology, Georgia Health Sciences University, Augusta, GA and 3 Charlie Norwood
VAMC, Augusta, GA
Psoriasis is a common immune-mediated inflammatory hyperproliferative disorder affecting skin,
nails and joints. The histologic hallmarks of skin lesions include thickening of the epidermis with
abnormal differentiation, exaggerated vascularity and a dermal immune cell infiltrate. These hall-
marks reflect the interplay between 3 major cell types; keratinocytes, endothelial cells and immune
cells. The exact etiology of psoriasis is still a major unresolved issue, and treatment is a major chal-
lenge. In Germany, the drug Fumaderm® is licensed for the treatment of psoriasis. However, a poor
understanding of its mechanism is a major barrier to its approval in many countries. The goal of our
research is to understand the mechanism of action of monomethylfumarate (MMF), regarded as the
active ingredient of Fumaderm®. Our preliminary data have shown that MMF has an anti-prolifer-
ative, pro-differentiative effect on mouse and human keratinocytes. It has similar anti-proliferative
effects on human endothelial cells. Our data also show that dimethylfumarate (DMF), which is the
major constituent of the drug Fumaderm® and a prodrug of MMF, has anti-proliferative, pro-differ-
entiative effects on mouse keratinocytes between 10 and 100μM concentration. Recent studies
suggest that MMF may function by binding to the receptor GPR109A. Our results, consistent with
other reports, have shown that mouse keratinocytes express GPR109A. Treatment of GPR109A knock-
out keratinocytes with MMF does not yield the same degree of reduction in proliferation as com-
pared to wild-type cells. Therefore, MMF may be partially functioning through GPR109A. In sum-
mary, keratinocytes express GPR109A, and both MMF and DMF have anti-proliferative,
pro-differentiative effects on keratinocytes. Published data showed an anti-proliferative effect of
DMF on human endothelial cells; our data show a similar effect for MMF. This suggests that MMF,
or a derivative thereof, might be an ideal agent for treating psoriasis by targeting the major con-
tributing players in the disease process.
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25-Hydroxyvitamin D3 rescues mice from the toxic effects of nitrogen mustard
L Au and KQ Lu Dermatology, Case Western Reserve University, Cleveland, OH
Mustards are powerful alkylating agents that have detrimental effects on the skin when used in chem-
ical warfare. However, they can be beneficial when used as chemotherapies against cutaneous lym-
phomas but are often limited by dose toxicity. Exposure to mustard results in epithelial injury fol-
lowed by induction of massive inflammation. Macrophages are key cell mediators in the latter
process and via production of inflammatory factors iNOS and TNF-α, they further exacerbate mus-
tard-related skin injury. Recent reports of macrophage intracellular conversion of 25-hydroxyvita-
min D3 (25(OH)D) to calcitriol leading to auto-suppression of inflammation led us to hypothesize
that 25(OH)D could attenuate tissue destruction following exposure to topical nitrogen mustard
(NM). We observe that a single intraperitoneal (i.p.) dose of 25(OH)D given 1 hour after NM expo-
sure rescues mice from NM-related toxicities. These animals remained healthy with rapid skin wound
recovery (n=5). In contrast, the NM only group had non-healing wounds, became visibly weak, with
mean survival of 7-9 days (n=5). Histopathological analysis of the NM-applied skin area reveals full
thickness necrosis with fat degeneration, massive edema, and brisk inflammation. qRT-PCR reveals
a 20-fold increase in iNOS and TNF-α compared to null (n=7; p<0.0004 and p<0.0002, respec-
tively). In contrast, the 25(OH)D cohort had minimal inflammatory cells and few foci of epidermal
necrosis with a 5-fold increase of iNOS and TNF-α (n=7; p<0.0027 and p<0.0037, respectively).
Blood smears show marked leukopenia and anemia in NM-exposed mice at days 7-9 and is the
main identified mortality factor. The 25(OH)D cohort had unremarkable blood smears. Consistent
with mouse skin findings, analysis of skin from CTCL patients treated with topical carmustine (NM-
related) show a 3-fold increase of iNOS expressing macrophages by confocal microscopy (n=3,
p=0.05). In conclusion, 25(OH)D attenuates the toxic effects following exposure to NM and may
represent a potential countermeasure against chemical threats and a drug to alleviate toxic effects
associated with chemotherapy.
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Microenvironmental abnormalities in the lesional and nonlesional skin of patients with vitiligo
M Su,1 R Yu1 and Y Zhou1,2 1 Dermatology and Skin Science, University of British Columbia,
Vancouver, BC, Canada and 2 Institute of Dermatology, Anhui Medical University, Hefei,
China
Vitiligo is characterized by the death of melanocytes in the skin. The purpose of this study is to sys-
tematically characterize the molecular and cellular characteristics of the lesional and non-lesional
skin of vitiligo patients. Twenty-three subjects with vitiligo vulgaris and sixteen healthy volunteers
were recruited for this study. Paired lesional and non-lesional skin biopsies from vitiligo patients,
and normal skin biopsies were obtained from healthy volunteers with informed consent. The fol-
lowing aspects were analyzed: (1) transcriptome changes present in vitiligo skin using DNA microar-
rays and qRT-PCR; (2) abnormal cellular infiltrates in vitiligo skin explant cultures using flow cytom-
etry; and (3) distribution of the abnormal cellular infiltrates in vitiligo skin using immunofluorescence
microscopy. Compared with normal skin, vitiligo lesional skin contained 17 genes (mostly
melanocyte-specific genes) whose expression was decreased or absent. In contrast, the relative
expression of 13 genes was up-regulated. The up-regulated genes point to aberrant activity of the
innate immune system, especially natural killer cells in vitiligo. Strikingly, the markers of height-
ened innate immune responses were also found to be up-regulated in the non-lesional skin of vitiligo
patients. In conclusion, this study revealed previously unknown molecular markers that strongly
suggest aberrant innate immune activation in the microenvironment of vitiligo skin, not only in the
lesional skin but also in the non-lesional skin. Therefore therapies targeting the entire skin surface
may improve treatment outcomes.
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